SUDDEN DEATH in EPILEPSY FORENSIC AND CLINICAL ISSUES
SUDDEN DEATH in EPILEPSY FORENSIC AND CLINICAL ISSUES EDITED BY...
86 downloads
674 Views
11MB Size
Report
This content was uploaded by our users and we assume good faith they have the permission to share this book. If you own the copyright to this book and it is wrongfully on our website, we offer a simple DMCA procedure to remove your content from our site. Start by pressing the button below!
Report copyright / DMCA form
SUDDEN DEATH in EPILEPSY FORENSIC AND CLINICAL ISSUES
SUDDEN DEATH in EPILEPSY FORENSIC AND CLINICAL ISSUES EDITED BY
CLAIRE M. LATHERS PAUL L. SCHR AEDER MICHAEL W. BUNGO JAN E. LEESTMA
Boca Raton London New York
CRC Press is an imprint of the Taylor & Francis Group, an informa business
CRC Press Taylor & Francis Group 6000 Broken Sound Parkway NW, Suite 300 Boca Raton, FL 33487-2742 © 2011 by Taylor and Francis Group, LLC CRC Press is an imprint of Taylor & Francis Group, an Informa business No claim to original U.S. Government works Printed in the United States of America on acid-free paper 10 9 8 7 6 5 4 3 2 1 International Standard Book Number-13: 978-1-4398-0223-6 (Ebook-PDF) This book contains information obtained from authentic and highly regarded sources. Reasonable efforts have been made to publish reliable data and information, but the author and publisher cannot assume responsibility for the validity of all materials or the consequences of their use. The authors and publishers have attempted to trace the copyright holders of all material reproduced in this publication and apologize to copyright holders if permission to publish in this form has not been obtained. If any copyright material has not been acknowledged please write and let us know so we may rectify in any future reprint. Except as permitted under U.S. Copyright Law, no part of this book may be reprinted, reproduced, transmitted, or utilized in any form by any electronic, mechanical, or other means, now known or hereafter invented, including photocopying, microfilming, and recording, or in any information storage or retrieval system, without written permission from the publishers. For permission to photocopy or use material electronically from this work, please access www.copyright.com (http:// www.copyright.com/) or contact the Copyright Clearance Center, Inc. (CCC), 222 Rosewood Drive, Danvers, MA 01923, 978-750-8400. CCC is a not-for-profit organization that provides licenses and registration for a variety of users. For organizations that have been granted a photocopy license by the CCC, a separate system of payment has been arranged. Trademark Notice: Product or corporate names may be trademarks or registered trademarks, and are used only for identification and explanation without intent to infringe. Visit the Taylor & Francis Web site at http://www.taylorandfrancis.com and the CRC Press Web site at http://www.crcpress.com
To (DS) a 4-year old boy with a history of nocturnal seizures who found hidden Christmas presents, including the one he wanted most of all, a remote control car two weeks before Christmas. The next morning he was found dead in bed. He and other victims of SUDEP challenge all of us to find preventive measures as quickly as possible. (CML) To Carol and Richard Lathers and to Marcel J. Lajoy for their love, support, and words of wisdom while completing this endeavor. (CML) To two university students (MB) and (AG) who were victims of SUDEP and to their courageous families who helped to found Epilepsy Bereaved in the United Kingdom. (PLS) To my patient wife Barbara and daughters Maria and Ellen who dealt with my many hours of editorial distraction with forbearance, encouragement and love. (PLS) To my grandson, Lucas, who missed quality time, so that this endeavor could be completed. (MWB)
Table of Contents
Foreword by Samuels Foreword by Schachter Preface Acknowledgments Editors Contributors
xv xvii xxi xxv xxvii xxxi
Section I Forensics of Sudden Death
1
Neurocardiologic Mechanistic Risk Factors in Sudden Unexpected Death in Epilepsy
3
Claire M. Lathers, Paul L. Schraeder, and Michael W. Bungo
2
Forensic Considerations and Sudden Unexpected Death in Epilepsy
37
Jan E. Leestma
3
Omega-3 Fatty Acids in Sudden Unexpected Death in€Epilepsy: Guardian of the Brain–Heart Connection
57
Fulvio A. Scorza, Esper A. Cavalheiro, Ricardo M. Arida, Vera C. Terra, Carla A. Scorza, Eliza Y. F. Sonoda, and Roberta M. Cysneiros
4
Unanswered Questions: SUDEP Studies Needed
67
Claire M. Lathers, Paul L. Schraeder, and Michael W. Bungo
5
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome: Implications in SUDEP David S. Paterson
vii
77
viii Table of Contents
6
Forensic Case Identification
95
Paul L. Schraeder, Elson L. So, and Claire M. Lathers
7
Sudden Unexpected Death in Epilepsy: Future Research Directions
109
Simona Parvulescu-Codrea
8
Forensic Postmortem Examination of Victims of Sudden Unexpected Death in Epilepsy
131
Claire M. Lathers, Paul L. Schraeder, Steven A. Koehler, and Cyril H. Wecht
9
One-Year Postmortem Forensic Analysis of Deaths in Persons with Epilepsy
145
Steven A. Koehler, Paul L. Schraeder, Claire M. Lathers, and Cyril H. Wecht
10
Drug Abuse and SUDEP
159
Steven B. Karch
11
Cocaine-Induced Seizures, Arrhythmias, and Sudden Death
169
Claire M. Lathers, Michelle M. Spino, Isha Agarwal, Laurie S. Y. Tyau, and Wallace B. Pickworth
12
Risk Factors for Sudden Death in Epilepsy
187
Thaddeus S. Walczak
13
EEG Findings in SUDEP
201
Maromi Nei and Nicole Simpkins
14
Severity of Seizures as a Forensic Risk and Case Reports
209
Edward H. Maa, Michael P. Earnest, Mark C. Spitz, and Jacquelyn Bainbridge
15
Intractable Epilepsy in the Setting of Malformations of Cortical Development as a Mechanism for SUDEP
221
Lara Jehi and Imad Najm
16
Neurogenic Cardiac Arrhythmias Howan Leung and Anne Y. Y. Chan
235
Table of Contents
17
Stress and SUDEP
ix
253
Claire M. Lathers and Paul L. Schraeder
18
Genetics of Sudden Death in Epilepsy
267
Neeti Ghali and Lina Nashef
19
Cardiac Channelopathies and Sudden Death
285
Benito Herreros
20
Sodium Channel Dysfunction: Common Physiopathologic Mechanism Associated with Sudden Death ECG Abnormalities in Brugada Syndrome and Some Types of€Epilepsy: Case Histories
303
Claire M. Lathers, Paul L. Schraeder, and Michael W. Bungo
21
Not Seizure but Syncope
311
Saumya Sharma, Trieu Ho, and Bharat K. Kantharia
22
Syncope, Seizures, and SUDEP: Case Histories
325
Claire M. Lathers, Paul L. Schraeder, and Michael W. Bungo
23
Sudden Death in Epilepsy: Relationship to the Sleep–Wake Circadian Cycle and Fractal Physiology
333
John D. Hughes and Susumu Sato
24
SUDEP: Medicolegal and Clinical Experiences
347
Braxton B. Wannamaker
Section II SUDEP Animal Models: MECHANISMS OF RISKS
25
Sudden Death: Animal Models to Study Nervous System Sites of Action for Disease and Pharmacological Intervention Claire M. Lathers
363
x Table of Contents
26
Synaptic Plasticity of Autonomic Ganglia: Role of Chronic Stress and Implication in Cardiovascular Diseases and Sudden Death
395
Karim A. Alkadhi and Karem H. Alzoubi
27
Animal Model for Sudden Cardiac Death: Autonomic Cardiac Sympathetic Nonuniform Neural Discharge
427
Claire M. Lathers
28
Animal Model for Sudden Unexpected Death in Persons with Epilepsy
437
Claire M. Lathers and Paul L. Schraeder
29
A Characterization of the Lockstep Phenomenon in Phenobarbital-Pretreated Cats
465
Jeffrey M. Dodd-O and Claire M. Lathers
30
Relationship of the Lockstep Phenomenon and Precipitous Changes in Blood Pressure
481
Amy Z. Stauffer, Jeffrey M. Dodd-O, and Claire M. Lathers
31
Interspike Interval Histogram Characterization of€Synchronized Cardiac Sympathetic Neural Discharge and€Epileptogenic Activity in the Electrocorticogram of€the€Cat
495
Daniel K. O’Rourke and Claire M. Lathers
32
Power Spectral Analysis: A Procedure for Assessing Autonomic Activity Related to€Risk Factors for Sudden and Unexplained Death in€Epilepsy
513
Animal Model for Sudden Cardiac Death: Sympathetic Innervation and Myocardial Beta-Receptor Densities
539
Stephen R. Quint, John A. Messenheimer, and Michael B. Tennison
33
Claire M. Lathers and Robert M. Levin
34
Antiepileptic Activity of Beta-Blocking Agents
551
Claire M. Lathers, Kam F. Jim, William H. Spivey, Claire Kahn, Kathleen Dolce, and William D. Matthews
Table of Contents
35
Arrhythmias Associated with Epileptogenic Activity Elicited by Penicillin
xi
567
Claire M. Lathers and Paul L. Schraeder
36
Role of Neuropeptides in the Production of Epileptogenic€Activity and Arrhythmias
577
Claire M. Lathers
37
Sudden Epileptic Death in Experimental Animal Models
591
Ombretta Mameli and Marcello Alessandro Caria
38
Sympathetic Nervous System Dysregulation of Cardiac Function and Myocyte Potassium Channel Remodeling in Rodent Seizure Models: Candidate Mechanisms for SUDEP 615 Steven L. Bealer, Cameron S. Metcalf, Jason G. Little, Matteo Vatta, Amy Brewster, and Anne E. Anderson
39
The Urethane/Kainate Seizure Model as a Tool to Explore€Physiology and Death Associated with Seizures
627
Mark Stewart
40
Acute Cardiovascular Response during Kindled Seizures
645
Jeffrey H. Goodman, Richard W. Homan, and IsAac L. Crawford
41
DBA Mice as Models of Sudden Unexpected Death in€Epilepsy
659
Carl L. Faingold, Srinivasan Tupal, Yashanad Mhaskar, and Victor V. Uteshev
Section III Clinical Issues of Sudden Death
42
Cardiac and Pulmonary Risk Factors and Pathomechanisms€of Sudden Unexplained Death in Epilepsy€Patients Josef Finsterer and Claudia Stöllberger
679
xii Table of Contents
43
Neurocardiac Interactions in Sudden Unexpected Death in€Epilepsy: Can Ambulatory Electrocardiogram-Based Assessment of Autonomic Function and T-Wave Alternans Help to Evaluate Risk?
693
Richard L. Verrier and Steven C. Schachter
44
Arrhythmogenic, Respiratory, and Psychological Risk Factors for Sudden Unexpected Death and Epilepsy: Case Histories
711
Claire M. Lathers
45
Sudden Arrhythmic Death Syndrome: Underlying Cardiac Etiologies, Their Implications, and the Overlap with SUDEP
721
Paramdeep S. Dhillon and Elijah R. Behr
46
Odds Ratios Study of Antiepileptic Drugs: A Possible Approach to SUDEP Prevention?
743
Claire M. Lathers, Paul L. Schraeder, and H. Gregg Claycamp
47
Antiepileptic Drugs Benefit/Risk Clinical Pharmacology: Possible Role in Cause and/or Prevention of SUDEP
755
Claire M. Lathers and Paul L. Schraeder
48
Clinical Pharmacology and SUDEP
789
Claire M. Lathers and Paul L. Schraeder
49
Experience-Based Teaching of Therapeutics and Clinical€Pharmacology of Antiepileptic Drugs: Sudden Unexplained Death in Epilepsy: Do Antiepileptic Drugs Have a Role?
801
Claire M. Lathers and Paul L. Schraeder
50
Clinical Pharmacology of Antiepileptic Drug Use: Clinical Pearls about the Perils of Patty
827
Paul L. Schraeder and Claire M. Lathers
51
Compliance with Antiepileptic Drug Treatment and the€Risk of Sudden Unexpected Death in Epilepsy Torbjörn Tomson
845
Table of Contents
52
SUDEP Clinical Case Histories: Typical and Atypical
xiii
853
Paul L. Schraeder
53
Cardiac Antiarrhythmic Agents: Pharmacological Basis for Their Antiarrhythmic and Proarrhythmic Effects
861
Saumya Sharma, Trieu Ho, and Bharat K. Kantharia
54
Could Beta–Blocker Antiarrhythmic and Antiseizure Activity Help Prevent SUDEP?
877
Claire M. Lathers
55
Decision Analysis and Risk Management
887
H. Gregg Claycamp
56
Epilepsy Surgery and the Prevention of SUDEP
905
Ryan S. Hays and Michael R. Sperling
57
Challenges in Overcoming Ethical, Legal, and Communication Barriers in SUDEP
915
Jane Hanna and Rosemary Panelli
58
Bereavement and Sudden Unexpected Death in Epilepsy
937
Lina Nashef and Lene Sahlholdt
59
SUDEP: A Clinical and Communicative Conundrum
943
Paul L. Schraeder and Claire M. Lathers
60
Epilepsy and SUDEP: Lessons Learned: Scientific and Clinical Experience
953
Claire M. Lathers and Paul L. Schraeder
61
SUDEP: A Mystery Yet to Be Solved
967
Claire M. Lathers and Paul L. Schraeder
62
Forensic Evidence and Expert Witnesses: Scientific Evidence: Getting It in and Keeping It Out
973
Thomas L. Bohan
Index
983
Foreword by Samuels
Epilepsy is one of the most prevalent neurological diseases in the world. Known for ages and clearly described in some of the oldest medical treatises, it was greatly feared in the ancient world because of the belief that it could cause sudden death. As reasonable treatments arose—ἀrst bromides, then phenobarbital, and, in the mid-twentieth century, phenytoin, the ἀrst modern antiepileptic drug—the mainstream of the medical community came to believe that epileptic seizures themselves were relatively harmless. During my own training in internal medicine in the 1970s, it was widely taught that the best treatment for a convulsion was to simply place the patient in a safe environment and let the seizure take its course. With the development of newer, safer treatments that include drugs and nonpharmacological approaches such as surgery and, more recently, vagal and deep brain stimulation, it became progressively more apparent that the ancients were, in fact, correct. Epilepsy, a state of recurrent unprovoked seizures, itself indeed carried with it an increased risk for sudden unexpected death and the term SUDEP (sudden unexpected death in epilepsy) was born. SUDEP now joins a long list of sudden death syndromes, including sudden death in middle aged men, sudden unexpected nocturnal death syndrome (SUNDS), sudden death from fright, sudden infant death syndrome (SIDS), sudden death in young athletes, sudden death associated with drug use, sudden death from heart disease, sudden death during sedative drug (including alcohol) withdrawal, sudden death during delirium, sudden death from stroke (including subarachnoid hemorrhage), and sudden death from head injury. With the advent of long-term monitoring of various physiological parameters, including the electrocardiogram, arterial oxygen saturation, and the electroencephalogram, it became apparent that some of these sudden death syndromes had in common a capacity to produce malignant cardiac arrhythmias, respiratory arrest, or both. In his landmark paper of 1942, “Voodoo” Death, the eminent physiologist Walter B. Cannon recounted stories of sudden death from the anthropological literature and posited an autonomic storm as the unifying hypothesis. In the past half-century, much has been learned about the capacity of the brain to damage the visceral organs, but many features of SUDEP remain an enigma. Despite all of the advances in the diagnosis and treatment of seizure disorders, the threat of sudden death still hovers over the epileptic patient, much as it did in ancient times. In Sudden Death in Epilepsy: Forensic and Clinical Issues, four of the most eminent experts in SUDEP, Claire Lathers, Paul Schraeder, Michael Bungo, and Jan Leestma, have put together an impressive tome representing the state of this art and science. The book’s three sections, Forensics of Sudden Death, SUDEP Animal Models: Mechanisms of Risk, and Clinical Issues in Sudden Death, are written by a veritable who’s who in the ἀeld. The interested reader can ἀnd chapters on the history, diagnosis, phenomenology, mechanisms, genetics, animal models, pathology, physiology, and even the social repercussions of this devastating phenomenon. Books written by so many authors inevitably create a challenge with regard to organization and thematic coherence, but the four editors, themselves xv
xvi
Foreword by Samuels
each major contributors to the literature on SUDEP, have done an admirable job pulling together the disparate array of experts into a volume that holds together and is readable. Sudden Death in Epilepsy: Forensic and Clinical Issues should be of great interest to neurologists, psychiatrists, neurosurgeons, internists, cardiologists, neuroscientists, and cardiovascular specialists. Epileptologists and their trainees will ἀnd the content invaluable in their day-to-day lives of counseling and treating people with epilepsy. Taken as a whole, the content acts as a roadmap to those who hope to someday fully understand and prevent this dramatic and tragic event. Martin A. Samuels, MD, FAAN, MACP, DSc (hon) Chairman, Department of Neurology Brigham and Women’s Hospital and Professor of Neurology Harvard Medical School Boston, Massachusetts
Foreword by Schachter
If sudden death in epilepsy is the most feared and serious consequence of epilepsy, why is it seldom discussed and woefully under-researched? The editors point to many reasons for this in the Preface—inadequate animal models and basic understanding, lack of clinical recognition from treating physicians and medical examiners, inability to eliminate the possibility of sudden death in the nearly one in three patients with epilepsy whose seizures are drug-resistant, and continuing reluctance among physicians to discuss sudden death with patients and their families. Compounding these issues is the silo-style infrastructure of academic medicine, which creates intrinsic barriers to establishing clinical and research collaborations across relevant disciplines, such as epidemiology, neurology, cardiology and pulmonology, as well as between physicians and applied scientists, including electrical, mechanical, and computer engineers. Despite these and other problems, there are reasons to be optimistic that research will begin to solve the mysteries posed by Drs. Lathers and Schraeder at the end of this book. First, creative and passionate researchers are dedicated to eradicating sudden death in epilepsy, perhaps most of all the editors of this volume, who have put together the most comprehensive and current treatise on the topic. The like-minded authors span numerous disciplines and their chapters challenge current paradigms and suggest new ways of thinking about sudden death in epilepsy. Second, the National Institute of Neurological Disorders and Stroke (NINDS) is actively engaged. Curing Epilepsy 2007: Translating Discoveries into Therapies, organized by the NINDS, and attended by more than 400 researchers, health care professionals, patients, and family members, affirmed sudden death in epilepsy as a major target for research, with the development and validation of at least one prevention strategy to decrease its occurrence as a short-term goal, and identiἀcation of the responsible mechanisms, including effects of seizures on autonomic functioning, particularly cardiac and respiratory, as a longer-term goal. The NINDS also sponsored a workshop on sudden death in epilepsy, held in November, 2008, which brought together researchers, clinicians, and patient advocacy groups to discuss strategies and to make plans for research and outreach. Third, professional epilepsy societies have recently established committees and taskforces with patient advocacy organizations, and have committed resources to work together to educate epilepsy professionals, doctors in training, and patients and families about sudden unexpected death in epilepsy (SUDEP), and to chart research agendas. The recommendations of one such task force include “convening a multidisciplinary workshop to reἀne current lines of investigation and to identify additional areas of research for mechanisms underlying SUDEP; performing a survey of patients and their families and caregivers to identify effective means of education that will enhance participation in SUDEP research; conducting a campaign aimed at patients, families, caregivers, coroners, and medical examiners that emphasizes the need for complete autopsy examinations for patients with suspected SUDEP; and securing infrastructure grants to fund a consortium xvii
xviii
Foreword by Schachter
of centers that will conduct prospective clinical and basic research studies to identify preventable risk factors and mechanisms underlying SUDEP” [1]. Fourth, numerous patient advocacy groups and family survivors are talking openly and urgently about sudden death in epilepsy at conferences and on Web sites. In addition, these groups are aggressively funding research projects with the hope of uncovering answers that will move the ἀeld forward. Indeed, these and other developments will likely enable critically important progress to be made in the understanding of sudden death in epilepsy and its prevention. These answers cannot come soon enough. And yet answers alone are not sufficient. If lack of seizure control is a signiἀcant risk factor for sudden death in epilepsy, then we must also urgently address the treatment gap in epilepsy, both by making treatments available to the tens of millions of persons with epilepsy in developing countries who currently have no access to anticonvulsants, and by ensuring that all patients everywhere with epilepsy have access to state-of-the-art care, including the full range of pharmacological and nonpharmacological treatment options. Even if researchers identify the underlying mechanism(s) of sudden death in epilepsy and patients have full access to comprehensive care, there will still remain one major barrier—lack of effective communication between physicians and their patients. Here are the agonizing reflections of a physician about whether to inform patients about sudden death€[2]: As a doctor and an epileptologist, I experience the deepest frustration when I am notiἀed of the sudden and unexpected death of one of my patients. Often these patients have been found dead in bed, lying dead on the floor of their apartment, or drowned in the bathtub. They are invariably young and are often at the beginning of their lives. I never forget them, and I feel that I have truly and ultimately failed them. . . . one of my young patients, a 25-year-old man, died last year while in bed. His parents had encouraged him to live alone so that his life would be as normal as possible. They had visited him that evening and had eaten dinner with him. He had a girlfriend, but she had not been there that night. The next morning he was found lying face down on his bed, fully dressed. No one was sure whether or not he had experienced a seizure. When his parents called me, we talked about the problem of sudden death and epilepsy. They wondered why his other doctors and I had not told them or their son that this could occur. I asked them if they thought he would have lived any differently if he had known. If we told every patient with epilepsy about this possibility, some might not dare live independent lives or might be burdened by anxiety, knowing that they might not awake in the morning. To this day, I do not know if my answer was appropriate.
This challenge must be addressed and solved before the discoveries of research can be translated to patient care if we are ever to end the scourge of sudden death. As physicians caring for patients with epilepsy, we should not wait for all the answers. We must accept the imperfect state of knowledge and inform our patients and, where appropriate, their families in a meaningful and compassionate way about sudden death, and work with them as much as possible to reduce the risk factors, especially by completely controlling generalized convulsive seizures. The editors and authors of Sudden Death in Epilepsy: Forensic and Clinical Issues have produced a landmark book that holds extraordinary promise for meaningful progress, bringing us closer to the day when sudden death will be fully preventable. Until then, my
Foreword by Schachter
xix
hope is that this book will inspire researchers, and give some measure of comfort to the bereaved and hope to those living with epilepsy and to their loved ones. Steven C. Schachter, M.D. Departments of Neurology Beth Israel Deaconess Medical Center Harvard Medical School Chief Academic Officer Center for Integration of Medicine and Innovative Technology Boston, Massachusetts
References 1. So EL, Bainbridge J, Buchhalter JR, et al. Report of the American Epilepsy Society and the Epilepsy Foundation Joint Task Force on sudden unexplained death in epilepsy. Epilepsia 2009;50: 917–922. 2. Schachter SC, ed. Epilepsy in our experience: Accounts of health care professionals. Oxford: Oxford University Press; 2008, pp. 7–8.
Preface
This book should be considered a sequel to, rather than a substitute for, the 1990 book Epilepsy and Sudden Death, edited by Lathers and Schraeder. Much of the material in the 1990 book, especially the discussion of animal research data, is still timely, as little additional animal-based work is extant. In addition, the epidemiological, behavioral, and drug-abuse-related data is also currently relevant. This current volume is an expansion rather than an updated sequel to the previous book on sudden unexpected death in epilepsy (SUDEP). These statements are based on our extensive review of the literature for this current book, which indicates that most of the research questions regarding evaluation of mechanisms and prevention of SUDEP have, to date, not been adequately addressed. When the previous book was published, the phenomenon of sudden unexpected/unexplained death in persons with epilepsy was considered to be a controversial topic or a very rare phenomenon by clinicians and pathologists alike. The public had little or no knowledge of the phenomenon. However, one positive consequence of the work done in SUDEP over the ensuing years is that now the phenomenon is widely referred to as SUDEP and it is accepted as a complication of epilepsy worldwide. SUDEP is one of the most common causes of death in young adults with a history of epilepsy, and presents a spectrum of dilemmas to forensic experts, clinicians, and researchers. At a most basic level, as determined in a national survey of coroners and medical examiners and discussed in this book, even in self-evident cases, SUDEP is infrequently used on death certiἀcates as a ἀnal diagnosis or medical cause of death. Ironically, this survey found that the majority of those same coroners and medical examiners who did not routinely use SUDEP on death certiἀcates, nonetheless acknowledged its validity as a diagnosis in a theoretical case in which no cause of death in a person with epilepsy could be found on postmortem examination. This disconnect between intellectual acknowledgment of its existence, and actual use of SUDEP as a death certiἀcate diagnosis, in all likelihood, results in signiἀcant underreporting of the prevalence of this tragic phenomenon. It is hoped that this book will prove to be an important resource to improve the knowledge of coroners and medical examiners about the use of the term SUDEP in appropriate cases. Since a portion of this new book addresses forensic issues, it is intended to be a resource for forensic pathologists, attorneys, coroners, and medical examiners as they struggle to determine the cause of death in persons with epilepsy. Because most other clinical and research aspects of SUDEP are also addressed, neurologists, experts in epilepsy, cardiologists, clinical pharmacologists, pharmacists, nurses, students, and persons with epilepsy or with a family member so diagnosed should all ἀnd sections of interests. Over the past two decades, many more basic and clinical scientists doing research in the ἀeld of epilepsy are focusing on the problem of SUDEP, as it is one of the most common causes of death associated with having epilepsy. However, to date, most research has focused on clinical and epidemiological data, with relatively few investigators using xxi
xxii
Preface
animal models. In addition, there has been little effort to determine whether there are common links between the risk of SUDEP and sudden cardiac deaths. While cardiologists are focusing increasingly on genetic risk factors for potentially life-threatening arrhythmias in young persons without coronary artery disease, there has been little effort to establish collaboration between neuroscience investigators interested in SUDEP and cardiology researchers interested in unraveling the genetically determined risk factors for potentially fatal arrhythmias. This book will be of help in directing neurological and cardiologic investigators to common areas of interest, especially as relates to the unanswered question of why some persons with epilepsy seem to be at risk for neurogenically induced fatal cardiac events. The basic science of epilepsy as relates to SUDEP is updated and expanded in this book. The role of alcohol and other drugs as seizure enhancing or producing conditions are discussed. The role of medication, compliance with prescribed antiepileptic drugs, or lack thereof, is an even more important problem today and is addressed in several chapters. The relevance of epidemiological studies of SUDEP is also presented. Sudden death in the pediatric population is also reviewed. The neurocardiological aspects of SUDEP are addressed in some detail. While SUDEP remains a major unsolved problem, thanks to the efforts of those who have conducted animal and epidemiological studies, what was once denied and called a myth is an acknowledged reality that has to be dealt with as a multidisciplinary issue. To solve the mystery of SUDEP, a global focus is required. Persons at risk must be identiἀed and preventive treatment regimens developed to decrease the occurrence of SUDEP. Clinical chapters emphasize that sophisticated simultaneous ambulatory EKG and EEG telemetry and respiratory function monitoring of patients at risk for sudden death will help identify cardiac, respiratory, and epileptogenic interactions in order to decrease the risk of SUDEP. Basic scientiἀc research programs and clinical and epidemiology studies are needed. Multidisciplinary teams working in clinical settings and with laboratories must address the global issues of SUDEP. Forensic chapters in this book discuss the fact that if the correct term “SUDEP” is used on autopsy reports, and if postmortem verbal autopsies are conducted when needed, the true incidence of SUDEP well may be determined to be much higher than previously thought. Drug development can justify the need for new antiepileptics and drugs in other pharmacological classes that address the reduction of the risk of SUDEP. Animal model chapters discuss new data gleaned by building on the previously utilized models and the lessons learned during the last quarter century. The use of animal models continues to be one of the most useful approaches to better understanding SUDEP. Discussion in various chapters may be summarized by stating that it is important to “think out of the box” when evaluating an established animal model that has the potential, with modiἀcation(s), to investigate possible mechanisms of SUDEP. Various authors of the animal model chapters presented in this book emphasize that multiple models are needed to investigate the pathophysiology of SUDEP, to hypothesize about effective treatments, to develop pilot studies in persons with epilepsy, and to conduct conἀrmatory large-scale clinical trials. The ἀelds of pharmacology, clinical pharmacology, and cardiology have much to offer as we work to improve compliance, develop new antiepileptic drugs, and apply different categories of drugs that hopefully attenuate the chances of occurrence of SUDEP. Authors address the possible overlapping mechanisms that may apply to the risk of sudden
Preface
xxiii
unexpected death occurring in epilepsy and in cardiac disease. Several chapters explore the interaction between the central and peripheral autonomic nervous systems and the cardiopulmonary systems. Included is a discussion of the potential interactive role of genetically determined subtle cardiac risk factors for arrhythmias, with a predisposition for seizurerelated cardiac arrhythmias. The possible mechanisms that are operant in producing both epileptogenic and cardiogenic arrhythmias are addressed. Several chapters examine proposed mechanistic factors in SUDEP, listing risk categories of arrhythmogenic, respiratory, and hypoxia, and psychological factors and discussing mechanisms for risks associated with each category. Several chapters discuss patients with Brugada syndrome and an interesting, interpretive presentation of a hypothesis to explain a common pathophysiologic mechanism associated with sodium channel dysfunction that may be common to clinical electrophysiological abnormalities and some types of epilepsy. Clariἀcation of risk factors and establishment of the mechanism of SUDEP are important to establish preventative measures for SUDEP and emphasize the need to strive for full seizure control. Several chapters discuss the importance of encouraging patients with epilepsy to receive nonmedical, common sense, lifestyle-modifying interventions that have generally accepted public health beneἀts, even though there is as yet no consensus that they may or may not prevent sudden death. Cardiac patients, psychiatric patients, and certain ethnic groups experiencing acute stressful circumstances are at risk for unexpected sudden death. The impact of adverse emotional states on the autonomic control of cardiac rhythm is an established factor leading to cardiac dysrhythmias in humans and other species. Although stress is associated with changes in autonomic neural function, its role as a potential risk factor for SUDEP has not been investigated. The association of epilepsy with depression and anxiety indicates that emotional stress should be evaluated as a potential risk factor for SUDEP. The interactions between emotional factors and the arrythmogenic potential of epileptiform discharges, and the possibility of beneἀt from stress management intervention need investigation. Prospective studies of patients are needed to determine how we can identify which persons with epilepsy are at risk for SUDEP. In a number of chapters, the authors speculate about common potential preventive measures to minimize the risk of both sudden unexpected death in epilepsy and sudden cardiac death. Several chapters address the issue of clinicians who treat persons with epilepsy, manifesting reluctance to discuss the possibility of SUDEP with their patients. This reluctance seems to be the result of concern that even introducing the topic to the patient and family would be stressful for them. However, for the most part, families of SUDEP victims express disappointment that they had not known of this possibility and call for widespread acknowledgment of the potential for occurrence of sudden death in association with epilepsy. Epilepsy Bereaved in the United Kingdom, an organization founded by families of SUDEP victims, has been particularly successful in raising the level of awareness of SUDEP in persons with epilepsy and their families, and within the medical profession and the general public. This kind of advocacy and dissemination of information will serve to increase the availability of resources used to solve the tragic mystery of SUDEP. A primary purpose of this book is to provide clinicians with the knowledge necessary to improve their comfort level in discussing SUDEP with patients and families and thereby to allow for freer dissemination of information about minimizing the known risk factors for SUDEP (e.g., erratic compliance in taking prescribed antiepileptic drugs). Committed investigators in research must solve the mystery of SUDEP using a leadership philosophy foundation that provides innovative vision and approaches for SUDEP
xxiv
Preface
research and teaching programs. The interaction of teaching and research is essential. While a student is learning how to conduct research, that person must simultaneously learn to become a teacher. Academic fellowships and competitions and grant funding for medical students, postdoctoral fellows, residents, and faculty will attract medical and graduate trainees to work on SUDEP and move the SUDEP knowledge base forward. As self-learning exercises, we have incorporated a variety of case studies of sudden death within chapters and as standalone chapters as practical teaching exercises. Clinical and basic science investigators must provide vision and a fertile environment to teach students to become tomorrow’s leaders in the struggle to solve the mystery of SUDEP. Claire M. Lathers Paul L. Schraeder Michael W. Bungo Jan E. Leestma
Acknowledgments
I wish to acknowledge the dedication and hard work of co-editor Claire Lathers. (JEL) We would not have been able to complete this book in a timely manner without the diligent secretarial assistance of Marie Faiola. (CML, PLS, MWB, JEL).
xxv
Editors
Claire M. Lathers, PhD, FCP, has been credentialed as a Senior Biomedical Research Scientist by the U.S. Food and Drug Administration (FDA) for international recognition of her work in the two areas of cardiovascular autonomic dysfunction associated with sudden death in persons with epilepsy and with space flight. The primary focus of her international cardiovascular pharmacology research career has centered on autonomic peripheral and central mechanisms involved in the control and regulation of blood pressure, heart rate and rhythm, and the electroencephalogram. Dr. Lathers and Dr. Schraeder have collaborated and published numerous studies and two books focusing on epilepsy and sudden unexplained death. Dr. Lathers served the FDA for a total of 11 years, including four years as the Senior Advisor for Science to the director in the Center for Veterinary Medicine and director of the Office of New Animal Drug Evaluation and ἀve years in the Center for Drug Evaluation and Research as a pharmacology reviewer. Claire also served as a special government expert for 2 years. Dr. Lathers spent 14 years working as a visiting scientist at NASA/ USRA, collecting data from subjects in ground-based studies and from astronauts and cosmonauts before, during and after space flight. Dr. Lathers earned a BS in pharmacy from Albany College of Pharmacy, Union University and her PhD in pharmacology from the State University of New York at Buffalo School of Medicine. She completed an NIH funded two-year postdoctoral fellowship at the Medical College of Pennsylvania. Her academic faculty experience includes working at the Medical College of Pennsylvania (15 years), Albany College of Pharmacy (two years as president, dean, and tenured professor); Uniformed Services University of the Health Sciences (three years part time); and Gwynedd Mercy College (11 years part time). Dr. Lathers is currently collaborating with a number of academicians on scientiἀc issues of the nexus between human and veterinary medicine clinical pharmacology, antimicrobial resistance, food safety, and biodefense measures. In addition to her academic and government service, Dr. Lathers has worked in the pharmaceutical industry. She served as chief scientiἀc officer of Barr Pharmaceuticals for three years and worked part time with four other pharmaceutical companies during a 15-year period. Dr. Lathers has authored or co-authored over 300 publications and abstracts, has edited three books, and has presented data at over 140 international meetings. She is an emeritus fellow, an honorary member of the Board of Regents, and a past president of the American College of Clinical Pharmacology, having served as regent, treasurer, and president. Dr. Lathers also served as the section editor of the educational series entitled: “Innovative Teaching Methods in Clinical Pharmacology” for the Journal of Clinical Pharmacology for 17 years. Claire served as a member of the Board of the Annapolis Center, charged to evaluate risk assessments, and worked on the epidemiology, toxicology, and food safety workshops and accords. In recognition of her work, Dr. Lathers has been the recipient of numerous awards and honors. xxvii
xxviii Editors
Paul L. Schraeder, MD, FAAN, is professor emeritus of neurology at Drexel University College of Medicine, former chief of neurology at the Medical College of Pennsylvania Hospital, Philadelphia, Pennsylvania and former professor of medicine and neurology at the Robert Wood Johnson School of Medicine in Camden, New Jersey; head of the Division of Neurology at Cooper Hospital/University Medical Center, Camden, New Jersey; and former associate professor of neurology at the Medical College of Pennsylvania. He is a member of the Philadelphia Neurological Society, the American Epilepsy Society, and a fellow of the American Academy of Neurology. He has served on the professional advisory board of the Epilepsy Foundation of Southeastern Pennsylvania and the Epilepsy Foundation of America and as medical advisor to Epilepsy Bereaved, a support organization for surviving friends and family of victims of sudden unexplained death in epileptic persons (SUDEP) in the United Kingdom. Dr. Lathers and Dr. Schraeder co-edited the ἀrst book addressing the topic of Epilepsy and Sudden Death (Marcel Dekker, 1990). Dr. Lathers and he have collaborated for over three decades studying and investigating the mystery of SUDEP and developed the ἀrst experimental animal models of this fatal phenomenon. Dr. Schraeder organized a collaborative nationwide survey of how coroners and medical examiners evaluate the deaths of persons with a history of epilepsy. Dr. Schraeder received the AB€ degree from Bucknell University, Lewisburg, Pennsylvania and the MD degree from€Jefferson Medical€College, Philadelphia, Pennsylvania. He completed his residency in neurology and fellowship in electroencephalography and experimental epilepsy at the University of Wisconsin. Michael W. Bungo, MD, FACC, FACP, has agreed to serve as the third co-editor of this new book. After residency and fellowship training in cardiology at Harvard Medical School programs in Boston, Dr. Bungo worked full time for NASA as director of the Space Biomedical Research Institute at the Johnson Space Center. During his time at NASA, Dr. Bungo ἀrst cataloged arrhythmias occurring in spaceflight crews and hypothesized that the unique physiological and psychological environments of space flight may be arrhythmogenic. The Aerospace Medical Association awarded him the Louis H. Bauer Founders Award and NASA awarded him the NASA Medal for Exceptional Scientiἀc Achievement for his pioneering research work concerning the heart’s adaptation to zero gravity. While at NASA, Dr. Bungo served on the Joint U.S.–U.S.S.R. Working Group that developed the now combined space station science program for these prior competitors. He left NASA to assume the positions of director of the Heart Station, Division of Cardiology and vice chair for Inpatient Affairs, Department of Internal Medicine at the University of Texas Medical Branch in Galveston. Dr. Bungo subsequently moved to the University of Texas Medical School in Houston and served as chief of staff at the LBJ General Hospital, CEO of UT-Physicians, and vice dean for Clinical Affairs. He is currently a professor of medicine in the Division of Cardiology at that same institution. Dr. Bungo’s current research project funded by NASA is entitled “Cardiac Atrophy and Diastolic Dysfunction during and after Long Duration Spaceflight: Functional Consequences for Orthostatic Intolerance, Exercise Capacity, and Risk of Cardiac Arrhythmias.” In addition to numerous publications and presentations, Dr. Bungo and Dr. Lathers have collaborated since 1989 and have co-authored seven published papers. In 2008, Dr. Bungo has co-authored three papers and one book chapter with Drs. Lathers and Schraeder on the mystery of SUDEP. Dr.€Bungo has delivered scientiἀc presentations at three international symposiums organized by Dr.€Lathers.
Editors
xxix
Jan E. Leestma, MD, MM, is the lead author of the second edition of Forensic Neuropathology. He received the MD degree from the University of Michigan School of Medicine in 1964, and a Masters of Management (MM) degree from the J.L. Kellogg Graduate School of Management of Northwestern University, Evanston, Illinois in 1986. He completed residency training in anatomic pathology and neuropathology at the University of Colorado Medical Center, Denver, Colorado and a neuropathology fellowship at the€Albert Einstein College of Medicine, Bronx, New York. He is certiἀed in both anatomic pathology and neuropathology by the American Board of Pathology (1970). He served in the United States Air Force Medical Corps at the Armed Forces Institute of Pathology, Washington, D.C. (1968–1971) and was honorably discharged with the rank of major, USAF MC. He was an assistant and associate professor of pathology and neurology at Northwestern University School of Medicine (1971–1986) and served as chief of neuropathology at both Northwestern Memorial Hospital and the Children’s Memorial Hospitals, Chicago, Illinois. He was professor of pathology and neurology, and dean of students for the Division of the Biological Sciences and the Pritzker School of Medicine at the University of Chicago, Chicago, Illinois (1986–1987). He was an assistant medical examiner and neuropathology consultant to the Office of the Medical Examiner, Cook County, Illinois (1977–1987). He was a guest researcher at the Karolinska Institutet, Huddinge University Hospital, Pathology Institute, Stockholm, Sweden (1981–1982). He was associate medical director and chief of neuropathology at the Chicago Institute of Neurosurgery and Neuroresearch in Chicago (1987–2003). He has had a private consulting practice in forensic neuropathology since the early 1970s which continues to the present time. He has given expert testimony in more than 30 U.S. states, Canada, and the United Kingdom. He is the author of more than 100 professional publications including numerous book chapters in texts. He was the author of Forensic Neuropathology (ἀrst edition), Raven Press, New York, 1988. He is a member of the American Association of Neuropathologists, and of the American Academy of Forensic Sciences. Dr. Leestma wrote some chapters in Epilepsy and Sudden Death, edited by Drs. Lathers and Schraeder. Thus it is a natural extension of this collaboration for these three editors to work with co-editor Dr. Bungo and CRC Press is to expand the focus of forensics and clinical issues. The diverse scientiἀc expertise and endeavors of each of the four editors, working in the different ἀelds of forensics, neurology, cardiology, and clinical pharmacology, have united in this edition to produce a book with a special emphasis on the forensics and clinical issues associated with neurocardiology, epilepsy, arrhythmias, and sudden death.
Contributors
Isha Agarwal
Medical College of Pennsylvania Philadelphia, Pennsylvania
Karim A. Alkadhi, PhD
Department of Pharmacological and Pharmaceutical Sciences University of Houston Houston, Texas
Karem H. Alzoubi
Department of Clinical Pharmacy Jordan University of Science and Technology Irbid, Jordan
Anne E. Anderson, MD
Departments of Pediatrics, Neurology, Neuroscience Baylor College of Medicine Houston, Texas
Ricardo M. Arida
Departamento de Fisiologia Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Jacquelyn Bainbridge, PharmD, FCCP School of Pharmacy University of Colorado Health Sciences Center Denver, Colorado
Steven L. Bealer, PhD
Department of Pharmacology and Toxicology University of Utah Salt Lake City, Utah
Elijah R. Behr, MD
Cardiac and Vascular Division St. George’s University of London London, United Kingdom
Amy Brewster
Department of Pediatrics Baylor College of Medicine Houston, Texas
Michael W. Bungo, MD, FACC, FACP,€CPE
Division of Cardiology University of Texas Medical School at Houston Houston, Texas
Esper A. Calvalheiro
Disciplina de Neurologia Experimental Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Marcello Alessandro Caria
Department of Biomedical Sciences Human Physiology Division Sassari, Italy
Anne Y. Y. Chan
Department of Medicine and Therapeutics Chinese University of Hong Kong and Prince of Wales Hospital Hong Kong SAR, China
H. Gregg Claycamp, PhD
Center for Drug Evaluation and Research Office of Compliance U.S. Food and Drug Administration Silver Spring, Maryland
Isaac L. Crawford
Department of Neurology Southwestern Regional Epilepsy Center Veterans Administration Medical Center University of Texas Southwestern Medical Center Dallas, Texas
Thomas L. Bohan, PhD, JD, F-AAFS, D-IBFES MTC Forensics Peaks Island, Maine
xxxi
xxxii
Roberta M. Cysneiros
Programa de Pós-Graduação em Distúrbios do Desenvolvimento do Centro de Ciências Biológicas e da Saúde da Universidade Presbiteriana€Mackenzie São Paulo, Brasil
Paramdeep S. Dhillon
Cardiac and Vascular Sciences St. George’s University of London London, United Kingdom
Contributors
Benito Herreros, MD, PhD
Cardiology Department Hospital Universitario Rio Hortega Valladolid, Spain
Trieu Ho, MD
Division of Cardiology University of Texas Medical School at Houston Houston, Texas
Richard W. Homan, MD
Department of Physiology Johns Hopkins University Baltimore, Maryland
Department of Neurology University of Texas Southwestern Medical Center Southwestern Regional Epilepsy Center Veterans Administration Medical Center Dallas, Texas
Kathleen Dolce
John D. Hughes, MD
Jeffrey M. Dodd-O, MD
Department of Drug Metabolism Smith Kline & French Laboratories King of Prussia, Pennsylvania
Michael P. Earnest, MD Department of Neurology Denver Health and Hospitals Denver, Colorado
Carl L. Faingold, PhD
Department of Pharmacology Southern Illinois University School of Medicine Springἀeld, Illinois
Josef Finsterer
Krankenanstalt Rudolfstiftung Vienna, Austria
Neeti Ghali
Department of Clinical Genetics Guy’s Hospital London, United Kingdom
Jeffrey H. Goodman, PhD
Department of Physiology and Pharmacology State University of New York Brooklyn, New York
Jane Hanna, OBE, MA, BCL Epilepsy Bereaved Wantage, United Kingdom
Ryan S. Hays
Department of Neurology Thomas Jefferson University Philadelphia, Pennsylvania
National Institute of Neurological Disorders and Stroke National Institutes of Health Bethesda, Maryland
Richard Hughes
Department of Neurology Denver Health and Hospitals Denver, Colorado
Lara Jehi, MD
Department of Neurology Cleveland Clinic Neurological Institute Cleveland, Ohio
Kam F. Jim, PhD
Clinical Documentation Sanoἀ-Aventis Great Valley, Pennsylvania
Claire Kahn, PhD
Department of Drug Metabolism Smith Kline & French Laboratories King of Prussia, Pennsylvania
Bharat K. Kantharia, MD
Division of Cardiology University of Texas Medical School at Houston Houston, Texas
Steven B. Karch, MD, FFFLM, FFDov Berkeley, California
Steven A. Koehler
Office of the Coroner of Allegheny County Pittsburgh, Pennsylvania
Contributors
Claire M. Lathers, PhD, Emeritus FCP Albany, New York
xxxiii
Lina Nashef, MBChB, MD, FRCP
Chicago, Illinois
Departments of Neurology and Clinical Neurosciences King’s College Hospital London, United Kingdom
Howan Leung
Maromi Nei, MD
Robert M. Levin
Daniel K. O’Rourke, MD
Albany College of Pharmacy Albany, New York
Medical College of Pennsylvania Philadelphia, Pennsylvania
Jason G. Little
Rosemary Panelli, PhD
Jan E. Leestma, MD
Department of Medicine and Therapeutics Chinese University of Hong Kong Hong Kong SAR, China
Department of Neurology Jefferson Comprehensive Epilepsy Center Philadelphia, Pennsylvania
Department of Pharmacology and Toxicology University of Utah Salt Lake City, Utah
Joint Epilepsy Council of Australia Seymour, Australia
Edward H. Maa, MD
Graduate School of Nursing University of Virginia Newport News, Virginia
Neurology Denver Health and Hospitals Denver, Colorado
Ombretta Mameli, MD
Department of Biomedical Sciences Human Physiology Division Sassari, Italy
William D. Matthews, PhD
Department of Drug Metabolism Smith Kline & French Laboratories King of Prussia, Pennsylvania
John A. Messenheimer, MD
Department of Neurology University of North Carolina School of Medicine Chapel Hill, North Carolina
Cameron S. Metcalf
Department of Pharmacology and Toxicology University of Utah Salt Lake City, Utah
Yashanad Mhaskar
Department of Pharmacology Southern Illinois University School of Medicine Springἀeld, Illinois
Imad Najm, MD
Department of Neurology Cleveland Clinic Neurological Institute Cleveland, Ohio
Simona Parvulescu-Codrea, MD, PhD
David S. Paterson, PhD Department of Pathology Children’s Hospital Boston Boston, Massachusetts
Wallace B. Pickworth, PhD Addiction Research Center National Institute on Drug Abuse Baltimore, Maryland
Stephen R. Quint, PhD
Department of Neurology University of North Carolina Chapel Hill, North Carolina
Lene Sahlholdt
Danish Epilepsy Centre Dianalund, Denmark
Martin Allen Samuels, MD Brigham and Women’s Hospital Harvard Medical School Boston, Massachusetts
Susumu Sato, MD
Office of Clinical Director National Institute of Neurological Disorders and Stroke Bethesda, Maryland
xxxiv
Steven C. Schachter, MD
Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts
Paul L. Schraeder, MD, FAAN
Department of Neurology (emeritus) Drexel University College of Medicine Philadelphia, Pennsylvania
Carla A. Scorza
Disciplina de Neurologia Experimental Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Fulvio Alexandre Scorza
Disciplina de Neurologia Experimental Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Saumya Sharma, MD
Division of Cardiology University of Texas Medical School at Houston Houston, Texas
Nicole Simpkins
Jefferson Comprehensive Epilepsy Center Thomas Jefferson University Philadelphia, Pennsylvania
Elson L. So, MD
Section of Electroencephalography Mayo Clinic College of Medicine Rochester, Minnesota
Eliza Y. F. Sonoda
Disciplina de Neurologia Experimental Universidade Federal de São Paulo/Escola Paulista de Medicina (UNIFESP/EPM) São Paulo, Brasil
Michael R. Sperling, MD
Jefferson Comprehensive Epilepsy Center Thomas Jefferson University Philadelphia, Pennsylvania
Michele M. Spino
Medical College of Pennsylvania Philadelphia, Pennsylvania
Mark C. Spitz, MD Health Science Center University of Colorado Aurora, Colorado
Contributors
William H. Spivey, MD (deceased) Medical College of Pennsylvania Philadelphia, Pennsylvania
Amy Z. Stauffer, MD
Medical College of Pennsylvania Philadelphia, Pennsylvania
Mark Stewart, MD, PhD
Department of Physiology/Pharmacology and Neurology State University of New York Brooklyn, New York
Claudia Stöllberger
Second Medical Department Krankenanstalt Rudolfstiftung Vienna, Austria
Michael B. Tennison
School of Medicine University of North Carolina Chapel Hill, North Carolina
Vera C. Terra
Departamento de Neurologia, Psiquiatria e Psicologia Médica Universidade de São Paulo. Ribeirão Preto São Paulo, Brasil
Torbjörn Tomson
Department of Neurology Karolinska University Hospital Stockholm, Sweden
Srinivasan Tupal
Department of Pharmacology Southern Illinois University School of Medicine Springἀeld, Illinois
Laurie S. Y. Tyau, MD
Medical College of Pennsylvania Philadelphia, Pennsylvania
Victor V. Uteshev
Department of Pharmacology Southern Illinois University School of Medicine Springἀeld, Illinois
Matteo Vatta
Department of Pediatrics Baylor College of Medicine Houston, Texas
Contributors
Richard L. Verrier, PhD, FACC Beth Israel Deaconess Medical Center Harvard Medical School Boston, Massachusetts
ἀ addeus S. Walczak, MD MINCEP Epilepsy Care Minneapolis, Minnesota
xxxv
Braxton B. Wannamaker, MD Epilepsy Services and Research, Inc. Orangeburg, South Carolina
Cyril H. Wecht, MD, JD
Office of the Coroner of Allegheny County Pittsburgh, Pennsylvania
Forensics of Sudden Death
I
Neurocardiologic Mechanistic Risk Factors in Sudden Unexpected Death in Epilepsy
1
Claire M. Lathers Paul L. Schraeder Michael W. Bungo
Contents 1.1 Introduction 1.2 Risk Factors for SUDEP 1.3 SUDEP Animal Models 1.3.1 Therapies as Factors 1.4 Case of SUDEP with a Premorbid Diagnosis of Nonepileptic Seizures 1.5 Discussion 1.5.1 Future Steps References
3 3 15 24 24 26 26 26
1.1â•…Introduction There are at least three categories of factors that may be operative in the mechanisms for sudden unexpected death in epilepsy (SUDEP) (Lathers et al. 2008a): arrhythmogenic, including changes in autonomic neural and cardiac function, respiratory and hypoxia, and psychological. Each of these main risk factor categories, in all likelihood, includes many subcategories. For example, the arrhythmogenic category includes pharmacological drug effects, genetic ion channelopathies, and acquired heart disease. The psychological factors include stress, anxiety, and depression states. This list of three primary areas of mechanism for SUDEP was expanded to include eight topics (Lathers et al. 2008b, 2008c).
1.2â•…Risk Factors for SUDEP The risk factors for SUDEP are as follows:
1. Pathophysiological mechanisms: cardio/autonomic 2. Respiratory/autonomic factors and hypoxia 3. Syncope 4. Genetic/structural mechanistic factors 5. Risk factors for SUDEP 6. Therapies: increased or decreased risk 7. Psychological factors 8. Unusual factors possibly modifying risk 3
4 Sudden Death in Epilepsy: Forensic and Clinical Issues
The pathophysiological mechanisms of SUDEP are not extant (see Table 1.1). From a cardiac standpoint, there is no question that the sympathetic component of cardiac innervation is involved in the production of potentially fatal tachyarrhythmias. It has also been established that postganglionic cardiac sympathetic innervation is altered in association with temporal lobe epilepsy and may be a pathophysiological risk factor for SUDEP (Druschky et al. 2001). These clinical data correlate with animal studies that found epiÂ� leptiform discharge–related postganglionic cardiac sympathetic abnormalities that were associated with cardiac conduction disturbances and arrhythmias (Lathers and Schraeder 1982, 1987, 1990a; Schraeder and Lathers 1983, 1989; Lathers 2010a, 2010b; Lathers et€al. Table 1.1â•… Pathophysiological Mechanisms Model, Symptoms, and/or Changes Nonuniform autonomic cardiac postganglionic neural discharge associated with coronary occlusion of left anterior descending coronary artery and/or ouabain toxicity in cats.
Arrhythmia monitoring of pacemaker patients. Cardiac beta receptor distribution: Beta receptor density right atria signiἀcantly lower than left atria; right ventricle signiἀcantly lower than left ventricle; density in ventricles higher than atria; beta receptor density of distal distribution of left anterior descending coronary artery signiἀcantly higher than proximal distribution. These regional density differences are related to the cardiac contractile strength of different areas of heart. Regional differences in beta adrenoreceptor densities reflect differences in postganglionic cardiac sympathetic innervation of the myocardium (Randall et al. 1977, 1978, 1984). Regulation of cardiac neural discharge is a new paradigm in the management of sudden cardiac death.
Mechanisms of Sudden Death Nonuniform (increases, decreases, and/or no change) autonomic neural postganglionic cardiac sympathetic discharge traveling through the stellate ganglia causes cardiac€arrhythmias, ventricular ἀbrillation, and/or SUD in the manner described by Han and Moe (i.e., nonuniform recovery of excitability in ventricular muscle). Suggested neural discharge site for drugs to modify occurrence of arrhythmia and death (Lathers et al. 1974a, 1974b, 1977a, 1977b, 1978, 1981, 1988; Lathers 1980, 1981, 1982; Lathers and Roberts 1980, 1985; Spivey and Lathers 1985; Han and Moe 1964). Revealed tachycardias, most likely ventricular tachycardia, related to SUD, give insight into terminal event mechanisms (Wichter et al. 2005; Nagele et al. 2007). A correlation with the release of norepinephrine at sympathetic nerve terminals in the heart in a manner to produce arrhythmia. Innervation density is high in subepicardium and central conduction system. Nonuniform postganglionic cardiac sympathetic cardiac innervation is related to nonuniform beta sympathetic receptor locations in the heart and affects cardiac contractility and development of arrhythmias and/or death. In diseased hearts, cardiac innervation density varies and may lead to sudden cardiac death (Lathers et al. 1986, 1986b, 1988, 1990, 2010a, 2010b, 2010c). These data were conἀrmed by Druschky et al. (2007), Ieda et al. (2006, 2007, 2008), and Kimura et al. (2007). These site differences will vary release of norepinephrine in various sites of the heart. This modiἀes cardiac contractile function and may trigger development of arrhythmias and/or sudden death. Site difference, in part, is one component of the mechanism(s) involved in sudden cardiac death. The heart is extensively innervated and its performance is regulated by the balance of discharges within and between the autonomic nervous system divisions (Ieda et al. 2008; Lathers et al. 1977a, 1977b, 1978; Lathers 1980, 1981). (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
5
Table 1.1â•… Pathophysiological Mechanisms (Continued) Model, Symptoms, and/or Changes Nonuniform autonomic cardiac postganglionic neural discharge associated with pentylenetetrazol-induced interictal epileptogenic activity in cats. Lockstep phenomenon (LSP): Cardiac postganglionic sympathetic and vagal discharges were synchronized one for one with both ictal and interictal discharges and premature ventricular contractions, ST/T changes, and conduction blocks, and precipitous changes in blood pressure occurring concurrent with interictal spikes.
Blockading GABAergic and glycinergic receptors in medulla slices of newborn rats evoked intermittent seizure-like ἀring of cardiac parasympathetic neurons, suggesting the seizure-like pattern of ἀring during an epileptic attack may cause neurogenic ictal bradyarrhythmias, cardiac asystole, or even sudden death in persons with epilepsy (Wang et al. 2006). Cardiac postganglionic denervation in patients with epilepsy examined to evaluate ictal asystole because tachyarrhythmias are common during epileptic seizures, while bradyarrhythmias or asystoles occur less frequently (Kerling et al. 2009).
Chaos science: Simple systems that manifest periodic activity are easily perturbed, and are less able to return to the preperturbed state.
Mechanisms of Sudden Death Nonuniform autonomic neural discharge, autonomic neural imbalance of postganglionic cardiac sympathetic, and vagal discharge causes cardiac arrhythmias, ventricular ἀbrillation, and/or asystole and/or SUDEP (Lathers and Schraeder 1982, 1987; Schraeder and Lathers 1983, 1988; Lathers et al. 1984, 1990, 1993; Carnel et al. 1985; Tumer et al. 1985). Lockstep phenomenon is considered to be one potential mechanism for SUDEP (Lathers et al. 1987; Lathers and Schraeder 1990a, 1990b; Stauffer et al. 1989, 1990; Dodd-O and Lathers 1990; O’Rourke and Lathers 1990). 1. Spatial and temporal summation of neuronal discharges in a subcortical center producing a stimulus strong enough to overcome the cortical and ganglionic threshold (Dodd-O and Lathers 1990). 2. Increased synaptic recruitment, resulting in ampliἀcation of subcortical stimuli along their path, so when reaching the cortex and sympathetic ganglion, they are capable of causing susceptible neurons in these regions to discharge. 3. Increased irritability of all neurons so that subcortical impulses could stimulate cortical and ganglionic neurons (Dodd-O and Lathers 1990). Provides supporting data for the lockstep phenomenon ἀnding of Lathers et al. (1987) and colleagues. It is to be determined if the predisposition of central PNS ἀring correlates with electrical remodeling of myocardium, possibly secondary to epileptogenic activity related cardiac neural discharges (LSP).
Single-photon emission computed tomography examined I-(123)-meta-iodobenzylguanidine as a marker of postganglionic cardiac norepinephrine uptake. Pronounced reduction in cardiac single-photon emission computed tomography uptake in asystolic patients indicated postganglionic cardiac catecholamine disturbance. Impaired sympathetic cardiac innervation limits adjustment and modulation of heart rate and may increase the risk of asystolic events and, eventually, SUDEP (Kerling et al. 2009). Data of Kerling et al. support the ἀndings of Lathers et al. (1986a, 1986b, 1987, 1990), Lathers and Levin (2010), and those of Han and Moe (1964). A periodic rhythm in the brain, where normally rich complexity exists, implies a susceptibility to failure that may result in death (Gleick 1987). (continued)
6 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.1â•… Pathophysiological Mechanisms (Continued) Model, Symptoms, and/or Changes Mode locking: Epileptic focus and medullary cardiac center may be locked one to one during state of LSP in the manner suggested by Gleick (1987).
Power spectral analysis (Quint et al. 1990).
Sympathetic innervation is critical for effective cardiac function (Saffitz 2008). Developmental and regulatory mechanisms determining density and pattern of cardiac sympathetic innervation are unclear, as is role of innervation in arrhythmogenesis. Sema3a establishes cardiac sympathetic innervation patterning. Sema3a is abundantly expressed in the trabecular layer in early-stage embryos but is restricted to Purkinje ἀbers after birth, forming an epicardial-to-endocardial transmural sympathetic innervation pattern. Sema3a(−/−) mice lacked a cardiac sympathetic innervation gradient and exhibited stellate ganglia malformation, leading to marked sinus bradycardia due to sympathetic dysfunction. Sympathetic dysfunction: altered postganglionic cardiac sympathetic innervation found postmortem in patients with chronic temporal lobe epilepsy (Druschky et al. 2001).
Mechanisms of Sudden Death Occurrence of a very regular oscillator in the brain is theoretically dangerous, regardless of mechanism. Fractal processes are ubiquitous in biological systems, include brain electrical depolarizations, and are systems that convey different information. Complexity of a fractal process may at times depreciate into a simple periodic process representing decay of the system and dramatic change (Goldberger et al. 1985; Winfree 1987). Causes of death include failure of the brain and heart. If the brain sends a message to the heart triggering a fatal arrhythmia, or if the heart enters an arrhythmia via its own initiative, sudden death will occur. Perturbations of cardiac electrical depolarization may have several mechanisms, any or several of which may be operations (O’Rourke and Lathers 1990). Time-frequency domain analyses of heart rate variability in patients with epilepsy and time-frequency mapping of R–R intervals during partial seizure may provide procedures to assess autonomic activity related to risk factors for SUDEP (Novak et al. 1999; Everengul et al. 2005; Persson et al. 2007). Cardiac-speciἀc overexpression of Sema3a in transgenic mice (SemaTG) associated with reduced sympathetic innervation and attenuation of the epicardial-to-endocardial innervation gradient. SemaTG mice demonstrated sudden death and susceptibility to ventricular tachycardia, due to catecholamine supersensitivity and prolongation of the action potential duration. Concluded appropriate cardiac Sema3a expression is needed for sympathetic innervation patterning and is critical for heart rate control (Ieda et al. 2007).
Altered postganglionic cardiac sympathetic innervation may increase risk of cardiac abnormalities and/or SUDEP (Lathers et al. 1990, Chapter 22).
(continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
7
Table 1.1â•… Pathophysiological Mechanisms (Continued) Model, Symptoms, and/or Changes Amygdaloid kindled seizure effect on cardiovascular system was examined in rats. An abrupt 50% increase in mean arterial pressure (BP) lasting 20–30 s after initiation of seizure occurred with profound bradycardia, characterized by a rate about half of that recorded before stimulation. Changes in heart rate and BP observed during amygdaloid kindled seizures are similar to those observed during secondary spontaneous seizures. Effects apparently are independent of kindling stimulus because stimulusinduced cardiovascular changes were not present at the beginning of kindling. Use of electrical stimulation as a therapy for epilepsy is currently being studied in experimental animals and in patients with epilepsy. This study examined the effect of preemptive, low-frequency, 1-Hz sine wave stimulation (LFS) on incidence of amygdala kindled seizures in rats. Amygdaloid kindled seizures in unanesthetized rats induced abrupt elevation of blood pressure accompanied by a signiἀcant decrease in heart rate.
Mechanisms of Sudden Death Results suggest the kindling seizure model is useful to study underlying mechanisms of seizure-induced cardiac arrhythmias and possibly the clinical phenomenon of SUDEP (Vindrola et al. 1984; Goodman et al. 2005).
Dramatic decrease in incidence of stage 5 seizures in fully kindled animals after preemptive LFS suggests low-frequency stimulation may be an effective therapy for prevention of seizures in patients with epilepsy (Gary-Bobo and Bonvalette 1977). Muscarinic receptor blockade with atropine (1 mg/kg, i.v. abolished seizure-induced bradycardia. Seizure-induced hypertension was unaffected by beta-adrenergic blockade with timolol (1 mg/kg, i.v.), but reduced by phentolamine (5€mg/kg, s.c., an alpha-adrenergic receptor antagonist). Chemical sympathectomy was induced with 6-hydroxydopamine (100 mg/kg, i.v.), an agent that does not cross the blood–brain barrier, eliminated the pressor response but did not completely block seizure-induced bradycardia. Effectiveness of 6-hydroxydopamine was tested with tyramine (0.5 mg/kg, i.v.), an agent that releases endogenous catecholamines. Results indicate amygdaloid kindled seizures activate both branches of the autonomic nervous system. Bradycardia was mediated by the parasympathetic system; the pressor response was caused by an increase in peripheral resistance due to alpha-adrenergic receptor activation. Findings show kindling is a useful seizure model for future studies on the effect of seizures on cardiovascular function and possible mechanisms of seizure-related sudden unexplained death (Goodman et al. 1989, 1990).
Source: Lathers, C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
8 Sudden Death in Epilepsy: Forensic and Clinical Issues
1986a, 1986b, 1986c, 1987, 1993, 2008a, 2008b, 2008c). In addition to the risk of neurogenically induced arrhythmias, neurogenic apnea could be associated with SUDEP. Table 1.2 summarizes the SUDEP risk factors of respiratory/autonomic changes and hypoxia. Rare clinical case reports describe incidences of apnea associated with epileptiform activity (So et al. 2000). Additionally, a well-known sheep model of epilepsy (Simon et al. 1982; Table 1.2â•…Respiratory Factors and Hypoxia Model, Symptoms, and/or Change Postmortem found multiple areas of pulmonary punctuate hemorrhages and large areas of gross hemorrhage and edema in animals dying after induced epileptogenic activity, asystole, or ventricular ἀbrillation (Lathers and Schraeder 1982; Lathers et al. 1984; Carnel et al. 1985; Schraeder and Lathers 1983). In addition to the general and neurological risk factors, there is increasing evidence that cardiac (Aurlien et al. 2009; Kerling et al. 2009; Pezzella et al. 2009; Strzelczyk et al. 2008) and pulmonary (Scorza et al. 2007; Tavee and Morris 2008) changes additionally predispose a person to SUDEP. As with neurological risk factors, cardiac and pulmonary risk factors have neither been investigated by prospective observational follow-up studies nor by intervention studies. The pathomechanisms are still not established (Johnston and Smith 2007). Finsterer and Stöllberger (2010, this book) discuss recent ἀndings and practical implications concerning potential cardiac and pulmonary risk factors and pathomechanisms of SUDEP.
Changes in cardiac function alter cerebral blood flow, which, in turn, produces central hypoxia resulting in epileptogenic activity.
Mechanisms of Sudden Death Tissue hypoxia, hypercarbia, and alterations in acid–base balance may have contributed to the results in our model of experimental epilepsy. Acid–base balance was maintained only within physiological range before the initiation of epileptogenic activity.
So far, there is minimal evidence that any primary pulmonary disease could be a deἀnite risk factor for SUDEP (Finsterer and Stöllberger, 2010, this book). It is also unknown if patients with muscular respiratory insufficiency are at increased risk not to survive a tonic–clonic seizure. These patients appear particularly endangered because they often also have epilepsy and their epilepsy is often difficult to treat. Despite this uncertainty about pulmonary risk factors, there are frequent reports about patients who develop severe pulmonary problems during or after seizures, such as ictal hypoxemia or hypercapnia (Bateman et al. 2008), apnea (Bell and Sander 2006; Jehi and Najm 2008; Ryvlin et al. 2009), acute neurogenic pulmonary edema (Jehi and Najm 2008), or postictal laryngospasm (Tavee and Morris 2008). In a prospective autopsy series on 52 SUDEP patients, 80% had pulmonary congestion and edema (Leestma et al. 1989). It is uncertain if these abnormalities are due to primary pulmonary, cardiac, or laryngeal mechanisms. It is also unclear if only patients with previous lung disease, as opposed to previously healthy subjects, develop such problems. There is little information available about the effects of generalized tonic–clonic seizures on the respiratory system in general. Do generalized seizures induce bronchospasm or loss of tone of the muscles involved in respiration? Recent investigations have shown that at least the vital capacity, forced vital capacity, and forced expiratory volume within the ἀrst second (FEV1 etc.), are not signiἀcantly different between healthy subjects and epilepsy patients (Scorza et al. 2007) (Finsterer and Stöllberger 2010, this book). Some patients exhibit changes in cardiovascular status preceding the onset of convulsions (Schott et al. 1977; Schraeder et al. 1983). (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
9
Table 1.2â•…Respiratory Factors and Hypoxia (Continued) Model, Symptoms, and/or Change The pulmonary edema model of status epilepticus in unanesthetized, chronically instrumented sheep in which sudden death and pulmonary edema occur.
Audiogenic seizures: respiratory arrest. Central alveolar hypoventilation syndrome (Ondine’s curse). Failure of automatic involuntary respiration with preservation of voluntary respiratory drive (Ondine’s curse) is rare, reported following a variety of morphologic lesions near respiratory centers in the lower brainstem. Risk factors include uncontrolled convulsive seizures, as well as respiratory and cardiac factors relating to treatment and supervision.
Epilepsy-related hypoxia. Ictal apnea. Postictal central apnea appears to be one potential mechanism for SUDEP. A 55-s convulsive seizure occurred in a 20-year-old female as she underwent video-EEG monitoring (So et al. 2000). Persistent apnea then developed. Electrocardiogram monitoring rhythm was not altered for the
Mechanisms of Sudden Death Catecholamine levels and seizure type and duration did not differ between animals dying suddenly or those surviving. Benign arrhythmias were generated in all animals; in no case did an arrhythmia account for death of an animal. Striking hypoventilation demonstrated in sudden death group but not in surviving animals. Differences in peak left atrial and pulmonary artery pressures, and in extravascular lung water; pulmonary edema did not account for the demise of sudden death animals. Thus, this model of epileptic sudden death supports a role of central hypoventilation in etiology of sudden unexpected death and shows an association, albeit not fatal, with pulmonary edema. The importance of arrhythmia in its pathogenesis is not conἀrmed (Simon et al. 1982; Johnston et al. 1995, 1997). Respiratory arrest mechanisms, modulated in part by serotonin, may cause SUDEP (Tupal and Faingold 2006a, 2006b). Central alveolar hypoventilation syndrome causes sudden death in a 39-year-old woman with heterotopia of the inferior olive (Matschke and Laas 2007). Neuropathologic examination disclosed preexisting malformation of the lower brain stem and acute local subarachnoid bleeding. Both respiratory and cardiac mechanisms are important. The apparent protective effect of lay supervision supports a role for respiratory factors, in part amenable to intervention by simple measures. Malignant tachyarrhythmias are rare during seizures and sinus bradycardia/arrest, although infrequent, occurs. Both types of cardiac arrhythmias can have a genetic basis as a contributory factor. Authors explore the potential of coexisting liability to cardiac arrhythmias as a contributory factor, but acknowledge that bridging evidence between inherited cardiac gene determinants and SUDEP is lacking (Terrence et al. 1981; Coulter 1984; Schraeder 1987; Nashef et al. 2007). Central apnea with seizures (Schraeder 1987) and neurogenic pulmonary edema and adult distress syndrome (Terrence et al. 1981). (Penἀeld and Jasper 1954; Bobo and Bonvallet 1975) So et al. (2000) note that although epileptic seizures may be associated with arrhythmogenic actions at the heart, in this patient the mechanism of marked central suppression of respiratory activity after seizures was clearly involved and almost resulted in sudden death. This case and Dr. Schraeder’s (1983) case highlight that both respiratory and cardiac changes do occur in persons with epilepsy. The (continued)
10 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.2â•…Respiratory Factors and Hypoxia (Continued) Model, Symptoms, and/or Change ἀrst 10 s, then it gradually and progressively slowed and stopped 57 s later. Cardiorespiratory resuscitation was successful. No evidence of airway obstruction or pulmonary edema was noted. One previous cardiorespiratory arrest after a complex partial seizure without secondary generalization had been reported for this patient. Postictal respiratory arrest was induced by serotonin receptor inhibition and prevented by selective serotonin reuptake inhibitor drugs (Tupal and Faingold 2006a, 2006b). Audiogenic seizure in mice. Obstructive sleep-apnea–induced cardiovascular complications.
Likely processes of the sudden infant death syndrome (SIDS) are identiἀed (apnea, failed arousal, failed autoresuscitation, etc.). The way in which epidemiological risk factors, genetics, neurotransmitter receptor defects, and neonatal cardiorespiratory reflex responses interact to lead to sudden death during sleep is unclear. 5-HT SIDS: Role of medullary 5-HT abnormalities in pathogenesis of SIDS, putative in utero origin of these abnormalities, and environmental and genetic factors interact to ultimately result in sudden death of the infant (Patterson 2010, this book).
Mechanisms of Sudden Death timing of events such as seizures, respiratory and/or laryngospasm, and cardiac EKG changes do vary in different patients.
The role of serotonin in SUDEP must be examined in future animal studies, including the DBA mice model of SUDEP (Faingold et al. 2010, this book). Suggested for use to study postictal respiratory arrest (So 2008). Implicated in pathogenesis of various cardiovascular diseases, including systemic hypertension, coronary artery disease, congestive heart failure, pulmonary hypertension, stroke, and cardiac arrhythmias. Mechanisms by which obstructive sleep apnea affects the cardiovascular system may involve mechanical effects on intrathoracic pressure, increased sympathetic activation, intermittent hypoxia, and endothelial dysfunction (Malow et al. 2000; Jain 2007). It is hypothesized that the neurophysiological basis of SIDS resides in a persistence of fetal reflex responses into the neonatal period, such as ampliἀcation of inhibitory cardiorespiratory reflex responses and reduced excitatory cardiorespiratory reflex responses. Explores ways in which multiple subtle abnormalities interact to lead to sudden death and emphasizes difficulty of ante-mortem identiἀcation of infants at risk for SIDS (Leiter and Böhm 2007). Underlying vulnerability involves a developmental defect in brainstem serotonergic (5-HT) systems that results in failure of protective cardiorespiratory responses to potentially life-threatening, but normally occurring events (e.g., hypoxia, hypercapnia), in the infant during sleep (Patterson 2010, Chapter 5, this book).
Source: Lathers C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
Johnston et al. 1995, 1997) found that although neurogenic pulmonary edema was commonly observed, the mechanism of death in the animals was central neurogenic hypoventilation. Likewise, syncope is a factor for sudden death (Table 1.3). It is evident that, in all likelihood, there are multiple contributing risk factors that, in unfortuitous combinations (including environmental circumstances) in individuals with epilepsy, may result in unexpected death (Nashef et al. 1998). This chapter consists of summary tables highlighting possible risk categories and mechanisms for risks. The reader is encouraged to use the table
Neurocardiologic Mechanistic Risk Factors in SUDEP
11
Table 1.3â•… Syncope Symptoms and/or Changes Syncope is a transient loss of consciousness and postural tone. Usually due to temporary, self-terminating global cerebral hypoperfusion. Important to differentiate from other nonsyncopal transient loss of consciousness attacks (Chen et al. 2008).
Although arising suddenly from prolonged recumbency or returning from weightlessness to earth’s gravity can result in syncope from orthostatic or vasovagal effects, there are many other possible causes. Cardiac causes are more likely to occur in the elderly; noncardiac causes are more common in the younger population. Cases described illustrate often unexpected mechanisms of syncope in otherwise healthy individuals. Cases of sudden collapse. At times, there are obvious cardiac etiologies or central nervous system etiologies; at other times, there are interactive cause and effects with cardiac disorders leading to central nervous system effects or visa versa. However, all too often there are subtle interplays with genetic predispositions, environmental interaction, therapeutic interventions, or unknown organic disease. As consequences are extreme, a thorough investigation and understanding of the mechanisms leading to syncope are of paramount importance. Psychogenic syncope and psychogenic seizures are common disorders but are difficult to identify. Headupright, tilt-table testing evaluates vasovagally mediated syncope and convulsive syncope. In eight patients with syncope and/or tonic–clonic motor activity, without changes in blood pressure and heart rate, transcranial Doppler cerebral blood flow velocity, and EEG monitoring revealed they were, in all instances, psychogenic or malingering. Combined long term ECG and EEG monitoring. Isolated cardiac rhythm abnormalities were noted in 21 patients, but none were symptomatic and no deἀnitive arrhythmias occurred. Isolated EEG abnormalities were noted in 11 patients, 5 of whom had EEG abnormalities consistent with seizure disorders. Simultaneous EEG and ECG abnormalities were seen in four patients. In two, a previously unsuspected etiology for syncope was found: seizures in one patient with heart disease and sinus pauses in another thought to have a seizure disorder.
Mechanisms of Sudden Death The most important screening tool in identifying mechanism(s) of syncope is a detailed history emphasizing a search for underlying disease, speciἀc associated circumstances, and pre- and post-event symptoms. The type of diagnostic studies (i.e., cardiac or neurologic) undertaken should be based on historical data. Seizures must be considered as a possible mechanism of otherwise unexplained loss of consciousness in nonelderly persons, including air crew members (Schraeder et al. 1994; Williams and Frenneaux 2007). Review recent research relevant to managing syncope in adults: syncope evaluation in the emergency department, effectiveness of a structured and standardized approach to syncope, role of the implantable loop recorder, and efficacy of nonpharmacological physical treatments (Chen et al. 2008; Bungo et al. 2010, this book). Clinical cases briefly explore the interactions of disordered electrical potentials in the brain and disordered electrical potentials in the heart (Lathers et al. 2010b, Chapter 22, this book).
It was concluded that patients who pass out or convulse during head-upright tilt without any change in physiologic parameters can be presumed psychogenic in origin and may be referred for psychiatric evaluation without further expensive diagnostic studies (Grubb et al. 1992). Combined ambulatory EEG/ECG monitoring may prove useful in evaluation of some patients with syncope (Beauregard et al. 1991).
(continued)
12 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.3â•… Syncope (Continued) Symptoms and/or Changes Vasovagal syncope. Much of the natural history is unknown. Study determined whether patients presenting for care had a recent increase in worsened syncope frequency. Insufficient cerebral perfusion is a common cause leading to a loss of consciousness with a critical reduction of blood flow to the reticular activating system. In neurally mediated syncope, a paradoxical reflex can occur that induces an increase in cerebrovascular resistance and contributes to the critical reduction of cerebral blood flow.
Mechanisms of Sudden Death Many syncope patients present for care after a recent worsening of their frequency of syncope (Franco 2007; Sheldon et al. 2007). Outlined anatomic structures involved in cerebral autoregulation, its mechanisms in normal and pathologic conditions, and noninvasive neuroimaging techniques used to study cerebral circulation and autoregulation. Emphasis placed on description of autoregulation pathophysiology in orthostatic and neurally mediated syncope (Franco 2007).
Source: Modiἀed and updated from Lathers C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
of contents of this book to identify which chapters are pertinent to a given topic within each table. The reader is referred especially to chapters in this book discussing risks for SUDEP by Walczak (2010), arrhythmias (Lathers and Schraeder 1982, 1987; Lathers et al. 1987), LSP (Schraeder and Lathers 1983, 1989), respiratory issues (Scorza et al. 2007; Finsterer and Stöllberger 2010; Lathers and Schraeder 1982; Carnel et al. 1985), syncope (Sharma et al. 2010, Chapter 21, this book; Lathers et al. 2010b, Chapter 22, this book), genetics (Herreros 2010), stress (Lathers and Schraeder 2006), therapies (Lathers and Schraeder 2002, 2010; Lathers et al. 2003a, 2003b, 2003c; Tompson 2008, 2010; Ryvlin et al. 2009), and unusual factors that may modify SUDEP risk (Scorza et al. 2008a, 2008b, 2010a, 2010b; Calderazzo et al. 2009; Terra-Bustamante et al. 2009). All are encouraged to read Brodie and Holmes (2008) and the chapter presenting how to educate persons with epilepsy about their risk factors and how to help families and survivors of SUDEP deal with the unexpected loss of a person with epilepsy (Hanna and Panelli, 2010, Chapter 57). There is general agreement that central nervous and autonomic nervous system/cardiorespiratory interactions include arrhythmias and apnea (Tables 1.1 and 1.2). Complicating the nervous system/cardiac relationship are relatively recent discoveries of genetically determined predispositions to arrhythmias that may result in seizure-like events at the time of the acute cardiac dysfunction (Table 1.4). How these genetic cardiac predispositions interact with the central and autonomic nervous systems is not understood. It is generally accepted that certain associated clinical circumstances [e.g., male gender (Table 1.5), poorly controlled generalized tonic clonic seizures, use of multiple antiepileptic drugs, changing doses or drugs, withdrawal of antiepileptic drugs, and poor compliance with antiepileptic drug use] are associated with an increased risk of SUDEP (Table 1.6). That psychogenic factors associated with life stresses are risk factors for cardiac arrhythmias and sudden death is well recognized by cardiologists (Lathers and Schraeder 2006). Also, certain ethnic groups have an increased incidence for stress-related sudden deaths [e.g., bangungut in healthy Filipino men (Table 1.7)]. There has been almost no organized effort to determine the role of stress as a risk factor for SUDEP. The stress response involves acute or chronic increases in sympathetic neural activity. Furthermore, Scorza and colleagues have identiἀed unusual factors that may modify the risk for SUDEP such as ambient temperature, the lunar phases of the moon,
Neurocardiologic Mechanistic Risk Factors in SUDEP
13
Table 1.4â•… Genetic/Structural Mechanistic Factors Associated Changes Four main inherited arrhythmia syndromes that are thought to be responsible for sudden death. Two clinical cases exhibit both Brugada syndrome and epilepsy produced by sodium channel dysfunction (Lathers et al. 2010b, this book). Brugada syndrome is produced by a mutation in gene SCN5A, which encodes the alpha subunit of the cardiac sodium channel (Antzelevitch et al. 2005a, 2005b; Aurlien et al. 2009. Herreros (2010, Chapter 19) note that some epileptic syndromes (Graves 2006) are due to different mutations in genes encoding alpha subunits of neuronal sodium channels (SCN1A, SCN2A) or in the beta subunit (SCN1B), common for both cardiac and neuronal isoforms (Lehmann-Horn and Jurkat-Rott 1999). The long QT syndrome: A genetically transmitted cardiac arrhythmia due to ion channel protein abnormalities, affecting the transport of potassium and sodium ions across the cell membrane. Patients may present with syncope, seizures, or aborted cardiac arrest. Long QT syndrome is an important cause of unexplained sudden cardiac death in the young.
Cardiac hypertrophy: An independent predictor of cardiovascular morbidity and mortality, predisposition to heart failure, QT interval prolongation, and ventricular arrhythmias.
Mechanisms of Sudden Death Four syndromes: long QT syndrome, Brugada syndrome, short QT syndrome, and catecholaminergic polymorphic ventricular tachycardia reviewed by Herreros (2010, Chapter 19, this book). Additional clinical, electrocardiographic, and genetic studies are needed to improve individual risk stratiἀcation and to determine any relationship among sodium channel dysfunction, Brugada ECG, and idiopathic epilepsy. Two patients presented in the cases appear to support the possibility that a common pathophysiologic mechanism associated with sodium channel dysfunction may be common to ECG abnormalities of Brugada syndrome and some types of epilepsy. Many patients must be screened to conἀrm. Risks factors for sudden death must be deἀned and linked with mechanisms for death (Kornick et al. 2003; Lathers et al. 2008a, 2008b, 2008c; Herreros, 2010, Chapter 19; Lathers et al. 2010a, Chapter 20).
Diagnosis of long QT syndrome depends on an ECG showing a prolonged QT interval (Kiehne and Kauferstein 2007). Establishment of a registry and discovery of genetic mutations causing the syndrome contribute greatly to understanding this condition and impetus to understanding other inherited cardiac arrhythmias. Genotype-phenotype correlation studies allow risk stratiἀcation of long QT syndrome patients. Lifestyle modiἀcation to avoid triggers for malignant cardiac arrhythmias, and use of beta blockers, pacemakers, and implantable deἀbrillators may reduce mortality in these patients (Vohra 2007). Mutations of cardiac ion channel genes affecting repolarization cause the majority of congenital cases. Despite detailed molecular characterizations of mutated ion channels, understanding how individual mutations may lead to arrhythmias and sudden death requires study of intact heart and modulation by autonomic nervous system. Studies of molecularly engineered mice with mutations in genes known to cause long QT syndrome in humans and speciἀc to cardiac repolarization in mice are reviewed (Salama and London 2007). Cardiac angiotensin II overproduction leads to long QT syndrome, resulting from IK1 potassium-dependent prolongation of action potential duration via modulation of channel subunit expression (Domenighetti et al. 2007). (continued)
14 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.4â•… Genetic/Structural Mechanistic Factors (Continued) Associated Changes Inherited arrhythmia syndromes, channelopathies.
Short QT syndrome: ECGs show a shortened QT interval and tall and narrow T waves. The cause is mutation of the potassium channel genes. Cardiac hypertrophy: associated with a dramatic change in gene expression proἀle of cardiac myocytes. Many genes important during development of the fetal heart but repressed in adult tissue are reexpressed, resulting in gross physiological changes and arrhythmias, cardiac failure, and sudden death. One transcription factor possibly important in repressing expression of fetal genes in the adult heart is REST (repressor element 1-silencing transcription factor).
Genetic factors in SUDEP: Likely to reflect underlying heterogeneous mechanisms common to the brain and heart, as has been shown to be the case with sudden cardiac death and sudden infant death syndrome (Ghali and Nashef 2010, this book).
Mechanisms of Sudden Death Long QT syndrome (Kiehne and Kauferstein 2007), short QT syndrome, catecholaminergic polymorphic ventricular tachycardia, Brugada syndrome, and overlapping phenotypes; established connections between these syndromes and idiopathic ventricular ἀbrillation (Sarkozy and Brugada 2005). Persons with short QT syndrome have increased familial risk of sudden cardiac death (Gaita et al. 2003, 2004). REST expression prevents increased BNP (Nppb) and ANP (Nppa) gene, encoding brain and atrial natriuretic peptides. Adult rat ventricular myocytes response to endothelin-1 and inhibition of REST results in increased expression of these genes in H9c2 cells. Increased expression of Nppb and Nppa correlates with increased histone H4 acetylation and histone H3 lysine 4 methylation of promoter-proximal regions of these genes. Deletions of individual REST repression domains combined activities of two domains of REST required to efficiently repress transcription of Nppb gene. A single repression domain is sufficient to repress Nppa gene. Data provide insight into molecular mechanisms for changes in gene expression proἀle cardiac hypertrophy (Bingham et al. 2006, 2007). Overlapping mechanisms. The increasing number of mongenically associated epilepsy syndromes raises the question of how epilepsy and arrythmogenic genetic disturbances may be concurrent. The association of uncontrolled epilepsy with risk of SUDEP leads to speculation that in some cases of idiopathic epilepsy, a genetic mutation may also cause a predisposition to fatal cardiac arrhythmias. The recent association of long QT syndrome with epilepsy suggests that ion channel gene mutations may be inherited susceptibility factors for neurogenic cardiac arrhythmia in some persons with epilepsy. Further investigation into overlap of epileptogenic and arrhythmogenic epidemiological and genetic factors is warranted.
and other factors (Table 1.8). As is evident from the listings in the above-mentioned tables, there is a likelihood that common risk factors for SUDEP and arrhythmogenic cardiac disease are related to centrally initiated peripheral autonomic dysfunction in association with epileptiform discharges and stress. Issues that need resolution include a better understanding of the individual risks, the mechanisms of cardiac arrhythmia and arrest in persons without a previously identiἀed structural heart disease, a deἀnition of abnormal interactions between the central nervous system (CNS) and the heart, the role of neurogenic pulmonary edema and central apnea in combination with cardiac autonomic neural and subtle anatomic and genetic factors as risk for SUDEP, and development of primary and secondary preventive measures along with educational programs to disseminate essential information to physicians, patients, and families.
Neurocardiologic Mechanistic Risk Factors in SUDEP
15
Table 1.5â•…Risk Factors for SUDEP SUDEP Risk Factors in a Swedish Population (Nilsson et al. 2001)
Retrospective Study of Risk Factors, United States Reviewed association between several clinical variables and SUDEP to elucidate risk factors. Characteristics of 67 cases correlated with published previous studies. Education of physicians about existence of SUDEP and risk factors is imperative to improving patient education and reduction in mortality (Lear-Kaul et al. 2005). Behavioral Risk Factor Surveillance System Data from South Carolina Compared health insurance coverage, health care visits, health-related behaviors among persons with epilepsy vs. general population (Ferguson et al. 2008).
Position of Patients at Night (Kinney et al. 2009; Monter et al. 2007; McGregor and Wheless 2006).
1. Higher number of seizures per year (relative risk of 10.16 in patients with more than 50 seizures/year compared to no more than 2 years) 2. Increased number of antiepileptic drugs (9.89 for three drugs vs. monotherapy) 3. Early vs. late onset epilepsy (7.72) 4. Frequent changes in antiepileptic drug dosage vs. unchanged dosage (6.08) 5. Risk and early onset and SUDEP risk and seizure frequency was weaker for females 6. Frequent dosage changes had a stronger association in females 7. Early age of onset and male sex 1. Long history of seizure disorder 2. Under medication or poorly controlled seizure activity 3. Male gender 4. Age younger than 40 years 5. Mental or physical stress
Persons with epilepsy: 1. Are more likely to smoke. 2. Have less physical activity. 3. Need better access to health care. 4. Need interventions focused on smoking cessation and increase in physical activity. 5. Lack money to visit a doctor. One-third of respondents with active epilepsy reported in past 12 months needed to see a doctor but could not because of cost. Note: Authors do not relate these behavior risk factors to increased likelihood of SUDEP per se, but one could also consider them to be risk factors for SUDEP. 1. Especially important in persons with uncontrolled epilepsy in institutional settings. 2. Avoid prone position and soft pillows when sleeping. 3. Use respiration monitors during sleep. 4. Train caregivers to be vigilant and to intervene to prevent respiratory compromise for institutionalized and at-home patients.
1.3â•… SUDEP Animal Models The importance of using many different animal models to study SUDEP in order to glean insights into the various mechanisms of risks and their contribution to the initiation of the death event is discussed by Lathers (2010a, Chapter 25) (Table 1.1). So (2008) emphasizes the signiἀcance of using audiogenic seizure mice to study postictal respiratory arrest. Postictal respiratory arrest was induced by serotonin receptor inhibition and prevented by
16 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.6â•… Therapies: Increased or Decreased Risk Symptoms and/or Changes
Mechanisms of Sudden Death
Increased risk SUDEP The putative advantage of new drugs is a smaller spectrum of Antiepileptic drugs—New antiepileptic possible adverse events, such as sedation and some may drugs, e.g., topiramate and lamotrigine, minimize noncompliance by reducing side effects of developed for chronic focal and secondarily lethargy and cognitive impairment. Many new antiepileptic generalized epileptic seizures. Therapeutic drugs do have less frequent interactions, leading to efficacy of these drugs does not seem to be improved tolerability with comedication (Lathers et al. superior to traditional anticonvulsants such 2003a, 2003b, 2003c; Walczak 2003). However, difficulty in as phenobarbital. achieving therapeutic dosage with some of the newer antiepileptic drugs because of side effects makes one question whether some newer agents are better than the older antiepileptic drugs. Suggests SUDEP rates reflect population rates and not a Risk of SUDEP rates in patients on speciἀc drug effect. FDA requires warning labels on the risk lamotrigine, gabapentin, topiramate, of SUDEP in association with use of each of the mentioned tigabine, and zonisamide are similar to drugs (Lathers and Schraeder 2002). those on standard antiepileptic drugs. Compliance with antiepileptic drugs In a coroner’s office review of forensic cases in Allegheny important in prevention of SUDEP. County for the year 2001, Lathers et al. (2003a, 2003b) found low, or no, levels of antiepileptic drugs postmortem in persons with epilepsy who died of SUDEP. Hughes (2009) deemed the most important SUDEP risk Noninterventional, single-arm study (Martin factor to be noncompliance with antiepileptic medication. et al. 2009). Explored the effectiveness and Ryvlin et al. (2009) found the risk of SUDEP is increased in behavioral outcomes in intellectually patients who have poor compliance and exhibit nocturnal disabled patients with topiramate for seizures and generalized tonic–clonic seizures. However, epilepsy. compliance is not the only therapeutic question to ask about victims of SUDEP. Others include: Is the correct dose of the antiepileptic drug being used? Was more than one drug prescribed and were there recent dose drug changes? All agree that maintenance of a stable therapeutic drug levels is crucial to avoid SUDEP. Some improvement in nearly all behavioral aspects was observed under concomitant topiramate therapy. In addition, seizure frequency decreased. Two unexpected deaths in patients taking the antiepileptic drug topiramate were attributed to SUDEP (Martin et al. 2009). A prolonged QT interval leads to increased risk for QT-prolonging drugs and risk of SUD. development of ventricular tachyarrhythmias, particularly Torsades de pointes is associated with early polymorphic ventricular tachycardia (torsades de pointes). cardiac depolarization. Drugs that prolong Polymorphic arrhythmia may rapidly develop into QT interval: class III antiarrhythmic agents, ventricular ἀbrillation and cause sudden death antimicrobial agents (fluoroquinolone and (Reingardiene and Vilcinskaite 2007). macrolide antibiotics), antipsychotic and antidepressant drugs, agents used in general anesthesia, and antimycotics (Reingardiene and Vilcinskaite 2007). Adverse cardiovascular effects of antipsychotic treatment: Cardiovascular Effects of Antipsychotics tachycardia, orthostatic hypotension, and rarely, SUD, Older antipsychotic literature was primarily muscarinic cholinergic antagonism, alpha(1)-adrenergic concerned with physiological consequences antagonism, or receptors associated with cardiac of muscarinic cholinergic antagonism, (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
17
Table 1.6â•… Therapies: Increased or Decreased Risk (Continued) Symptoms and/or Changes
Mechanisms of Sudden Death
Alpha(1)-adrenergic antagonism, or receptors associated with cardiac conduction, but current literature recognizes that, for most antipsychoticexposed patients, the more signiἀcant cardiovascular burden of treatment is mediated by metabolic adverse effects such as weight gain, dyslipidemia, and diabetes mellitus.
conduction, metabolic adverse effects of weight gain, dyslipidemia, and diabetes mellitus (Michelsen and Meyer 2007). High-dose methadone can induce QT prolongation by hERG inhibition, resulting in QT prolongation, but new evidence shows that QT prolongation can occur at much lower doses, even when the drug is not given IV.
Methadone produces QT prolongation, arrhythmias, and sudden death (Karch 2010, this book, Chapter 10).
May be acting directly on myocardial conduction to produce arrhythmia and death (Lathers and Lipka 1986, 1987; Lathers et al. 1986a; Lipka and Lathers 1987; Lipka et al. 1988).
Chlorpromazine or thioridazine do not appear to produce arrhythmia or death via a central locus in an experimental cat model. Decreased risk SUDEP The question must be asked if persons thought to be at risk for SUDEP should be placed on a beta blocker, in addition to the prescribed anticonvulsant(s). Beta blockers are also used to reduce stress and persons with epilepsy generally are stressed by the disease and associated problems (Lathers and Schraeder 2006). Beta blockers produce anticonvulsant activity whether administered via the intraosseous route or intravenously (Jim et al. 1988, 1989; Spivey et al. 1987a, 1987b; Lathers et al. 1989, 1990, 2008). Note the intraosseous and endotracheal routes of administration of antiepileptic drugs may be used when IV access is not available in status epilepticus. These routes are appropriate for emergency room pediatric seizures or cardiac arrest when unable to establish a traditional IV line (Rusli et al. 1987; Jim et al. 1988, 1989; Spivey et al. 1987a, 1987b; Lathers et al. 1989, 1990, 2008). Postmortem found no serious pathology in the tibia bone after intraosseous administration, other than the expected needle track (Lathers et al. 1989). Selective serotonin reuptake inhibitor drugs. Postictal respiratory arrest was induced by serotonin receptor May be protective in some persons at risk inhibition and prevented by selective serotonin reuptake for SUDEP with a component of apnea. inhibitor drugs. The role of serotonin in SUDEP must be examined in future animal studies (Tupal and Faingold 2006). Vagal nerve stimulation may decrease risk of SUDEP by 50% Vagal nerve stimulation may decrease (Annegars et al. 2000). susceptibility to ventricular tachycardias (Verrier et al. 2009; Verrier and Schachter 2010). Beta blockers exhibited anticonvulsant activity.
Source: Lathers C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
18 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.7â•… Psychological Factors Symptoms and/or Changes Scared to death. A 21-year-old student had generalized tonic–clonic seizures induced by mental image of human pain. One ictal event occurred while listening to a description of suffering, as read from Fox’s Book of Martyrs. While again listening to the offending passage during EEG and ECG monitoring, had 25 s of asystole terminating in electrocerebral silence and a generalized tonic, tonic–clonic seizure. A 24-hour ambulatory monitor recorded episodes of progressive sinus bradycardia concomitant with P–R interval prolongation and Wenckebach atrioventricular block. Sinoatrial conduction times and sinus node recovery times were normal on atrial pacing (Schraeder et al. 1983). Emotional trauma and psychological stress. Stress response is associated with increased sympathetic activity and catecholamine levels that may be associated with increased risk of cardiac arrhythmias, especially in context of epileptiform cerebral discharges (Pickworth et al. 1990). Stress is associated with changes in autonomic neural function. Its role as a potential risk factor for SUDEP is not known. Association of epilepsy with cardiac abnormalities, such as neurogenic arrhythmias and microscopic perivascular and interstitial ἀbrosis, and with depression and anxiety indicates emotional stress with related increases in catecholamines should be evaluated as a potential risk factor for SUDEP. Stress and anger. Compare morphology and initiation pattern between ventricular arrhythmias that are triggered by anger and those that are not. At the time of shock, patients with implantable cardioverter-deἀbrillators recorded levels of deἀned mood states preceding the shock in a diary. Stress risk factors and triggers of sudden death. An autopsy proven case-control study (Owada et al. 1999).
Mechanisms of Sudden Death Since implantation of a permanent pacemaker, has been asymptomatic. Patient demonstrates advantages of reproducing the circumstances associated with an unexplained loss of consciousness while monitoring EEG and ECG (Schraeder et al. 1983).
Arrhythmogenic effects of efferent sympathetic drive precipitate cardiac arrhythmia and sudden death. Patients with preexisting heart disease are particularly at risk. Generation of proarrhythmic activity patterns within cerebral autonomic centers may be ampliἀed by afferent feedback from a dysfunctional myocardium (Gray et al. 2007). Impact of adverse emotional states on autonomic control of cardiac rhythm is a known important factor leading to cardiac dysrhythmias in humans and other species. Interaction between emotional factors and arrythmogenic potential of epileptiform discharges and possibility of beneἀt from stress management intervention need to be investigated (Lathers and Schraeder 2006). Ventricular arrhythmias occurring in setting of anger are more likely pause dependent and polymorphic. Suggests that in predisposed populations anger may create an arrhythmogenic substrate susceptible to more disorganized rhythms, a possible mechanism linking emotion and sudden death (Stopper et al. 2006). Identiἀed risk factors and triggers of sudden death in cases where causes of death were deἀnitely proven by autopsy in Japan. Legal and medical records for 4 years were investigated. Of 271 cases, 176 patients, 20 to 59 yrs-old were cases of sudden death in working generations. Of these, 91 cases, 52% could be analyzed by telephone interviews from close family members. One examiner undertook all phone interviews with the case subjects. As control subjects, 1167 employed persons who consulted for a health check. Of sudden death cases, ἀnal diagnosis in 29 cases was coronary artery disease (31.9%), 18 acute cardiac dysfunction (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
19
Table 1.7â•… Psychological Factors (Continued) Symptoms and/or Changes
Retrospective study. Reviewed association between several clinical variables and SUDEP to elucidate risk factors. Characteristics of 67 cases correlated with published ἀndings in previous studies (Lear-Kaul et al. 2005).
Mechanisms of Sudden Death (19.8%), 6 other cardiac diseases (6.6%), 4 acute aortic dissection (4.4%), 4 cerebrovascular disease (4.4%), and 30 other diseases (32.9%). Through conditional logistic analysis, the following risk factors emerged as candidates: Long-term stress, history of heart disease, hypertension, chest symptoms, autonomic disturbance, short-term stress, and a smoking habit. Short-term stress, autonomic disturbance and a smoking habit increased the risk of sudden death due to coronary artery disease. Long-term stress was associated with an increased risk of sudden death due to acute cardiac dysfunction. Demonstrated that autonomic disturbance and stress were closely related to occurrence of sudden death (Owada et al. 1999). Attributes that deἀne an at-risk group of epileptics include: less than 40 years old, male, long history of seizure disorder, under medication or poorly controlled seizure activity, and mental or physical stress. Education of physicians about the existence of SUDEP and risk factors is imperative in improving patient education and reduction in mortality (Lear-Kaul et al. 2005).
Source: Lathers C. M., P. L. Schraeder, M. W. Bungo, in Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Nova Science Publishers, Inc., Hauppauge, NY, 2008. With permission.
selective serotonin reuptake inhibitor drugs. The possible role of serotonin in SUDEP must be examined in future animal studies (Faingold et al. 2010, Chapter 41). The ἀring pattern of cardiac parasympathetic neurons, as well as cardiac sympathetic postganglionic nerves, during an epileptic attack has been shown to change and has been termed the lockstep phenomenon (Lathers et al. 1987; Stauffer et al. 1989, 1990; Dodd-O and Lathers 1990; O’Rourke and Lathers 1990). The observation of autonomic neural discharges time-locked to cortical epileptiform is evidence that epileptogenic activation of the cardiac parasympathetic nerves, revealed by ictal bradyarrhythmias or cardiac asystole, may be one contributing cause of sudden death of patients with epilepsy. Likewise, epileptogenic activation of the cardiac sympathetic nerves may be another contributing cause of SUDEP. An imbalance between the two systems’ (i.e., the cardiac parasympathetic and the cardiac sympathetic) neural discharge patterns may contribute to SUDEP (Lathers and Schraeder 1982, 1986; Schraeder and Lathers 1983, 1989). Wang et al. (2006) provided supporting data for the LSP ἀnding. They examined blockade of inhibitory neurotransmission evoked seizure-like ἀring of cardiac parasympathetic neurons in brainstem slices of newborn rats. Speciἀcally, blockade of GABAergic and glycinergic receptors in medulla slices evoked intermittent seizure-like ἀring of cardiac parasympathetic neurons, suggesting the seizure-like pattern of ἀring during an epileptic attack may cause neurogenic ictal bradyarrhythmias, cardiac asystole, or even sudden death in persons with epilepsy. Nonuniform autonomic cardiac postganglionic neural discharges are associated with coronary occlusion of the left anterior descending coronary artery and/or ouabain toxicity in cats (Lathers et al. 1974a, 1974b, 1977a, 1977b, 1978; Lathers 1980, 1981). Nonuniform
20 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.8â•…Unusual Risk Factors Modify SUDEP Factor Unusual potential risk factors for SUDEP were examined by Scorza and colleagues (2008a, 2008b, 2010a, 2010b), Calderazzo et al. (2009), and Terra-Bustaman et al. (2008).
Physical activity (Scorza et al. 2008a).
SUDEP seems to occur more commonly during sleep (Asadi-Pooya and Sperling 2009). Chronobiology of acute pulmonary edema (Bilora et al. 1998).
Mechanism of Sudden Death Studies are needed to examine the role of unusual factors that are listed below to determine if they are applicable to SUDEP. These include life style modifying interventions with accepted public health beneἀts, but as yet with no consensus that they may or may not prevent sudden death. Animal studies and clinical studies are needed (Lathers et al. 2008b, reply; 2010c, Unanswered question). May modify the role of autonomic effects and cardiorespiratory disturbances. Beneἀts of physical activity may be related to reductions in sympathetic activity. Morbidity and mortality in cardiovascular disease are often associated with elevations in sympathetic activity (Scorza et al. 2008a; Schraeder et al. 1983). Increased physical action does have a beneἀcial cardiovascular effect. The question is, will increased physical activity be of beneἀt if one assumes cardiovascular sympathetic dysfunction or insufficiency in persons with epilepsy? In general, regular exercise does not have a downside, if the patient is cardiovascularly ἀt. The role of regular exercise in prevention of SUDEP is not established (Lathers et al. 2008b reply; 2010c, this book). Autonomic cardiorespiratory disturbances. Alterations in clinical parameters including ECG changes, blood pressure, respiration, and vasomotor tone (Hirsch and Martin 1971; Lathers and Schraeder 1982; Schraeder and Lathers 1983; Wannamaker 1985). ECG changes in experimental epilepsy include heart rate changes, arrhythmias, conduction blocks, altered ECG morphology, and QT interval). See discussion of Bilora et al. (1998) below and Chapter 23 by Hughes and Sato (2010, this book). Found pulmonary edema incidence higher during the night. No signiἀcant weekly or circannual rhythms detected. Examine possible relations with decreased heart output, increased sympathetic tone, or partial baroceptor desensitization occurring at night (Bilora et al. 1998). Evaluation of some cases of SUDEP and ners-SUDEP during long-term electroencephalography monitoring suggest that autonomic instability ending in cardiorespiratory arrest may be triggered by postictal suppression rather than by ictal activation of the autonomic nervous system. More epidemiologic studies on high-risk populations of persons with epilepsy are needed (Schuele 2009). The increase sympathetic tone or desensitization of baroceptors may contribute to occurrence of cardiac autonomic arrhythmias. See discussions of interictal activity and cardiac arrhythmias (continued)
Neurocardiologic Mechanistic Risk Factors in SUDEP
21
Table 1.8â•…Unusual Risk Factors Modify SUDEP (Continued) Factor
Seizure activity and neurogenesis (Scorza et al. 2008b). Omega-3 fatty acid nutritional deἀciency (Scorza et al. 2008a).
Low temperature (Scorza et al. 2008a).
Winter temperatures may lead to cardiac abnormalities and, hence, to sudden death. Are they a risk factor for SUDEP? (Colugnati et al. 2008).
Role of heart rate in rats with epilepsy during low temperature exposure (Sonoda et al. 2008). Minimum external temperature, mean external temperature (Bell et al. 2009). Climate fluctuations (Calderazzo et al. 2009). Sunlight may be a beneἀt in that vitamin D deἀciency may increase risk of SUDEP (Scorza et al. 2010a).
Mechanism of Sudden Death and baroreceptor changes by Lathers (2010a, 2010b) and cardiac and pulmonary risk factors and pathomechanisms of SUDEP by Finisterer and Stollberger (2010, Chapter€42). Aberrant dentate granule cell neurogenesis may influence negatively the cardiovascular system of a patient with epilepsy and lead to cardiac abnormalities and risk of SUDEP. Beneἀcial effect of nutritional aspects of omega-3 fatty acid may decrease cardiac arrhythmias and sudden death (SUD) in patients at risk for cardiac disease. No established answer at this time. See comments by Lathers et al. (2008b). Questions have been raised (Lathers et al. 2008a, 2008b, 2008c, 2010c) that need to be addressed: 1. Exactly how does one deἀne a low temperature? 2. What is the degree range used to deἀne a low temperature? 3. What is the duration at this low degree range? 4. Is there a dose response so that there is an increased risk of sudden death related to the lowest temperature? Mammals hibernate as a strategy to survive cold conditions. Hibernating mammals inherit a stable cardiovascular function. They show resistance to hypothermia at a cellular level, the membrane potential and excitability are more stable in their cardiac cells. Aortic smooth muscle cells maintain ionic gradients upon prolonged exposure to low temperature, cardiac myocytes from the mammals maintain constant levels of intracellular free calcium and forceful contractility at 10°C or lower. Postulate hibernating mammals have cardiovascular particularities that confer heart protection. The relevance to persons with epilepsy is to be determined. Low temperature increased the heart rate of patients with epilepsy. Authors suggest exposure to low temperatures could be a risk factors for cardiovascular abnormalities and, thus, for SUDEP. Found no evidence of association between either mean temperature group or minimum temperature group and SUDEP but there was a slight excess of SUDEP in the coldest (mean temperature) groups. May have an effect on SUDEP occurrence. Some clinical studies suggest low vitamin D levels may be associated with death from heart failure and sudden cardiac death. There also appears to be an association between low vitamin D and seizure occurrence. Scorza et al. suggest vitamin D may exhibit anticonvulsant action. More data are needed. (continued)
22 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 1.8â•…Unusual Risk Factors Modify SUDEP (Continued) Factor The lunar phase (Terra-Bustamante et al. 2009).
Lunar phase, month, season: no association found between these factors and SUDEP (Bell et al. 2009).
Mechanism of Sudden Death An epilepsy unit performed an 8-year analysis, examining possible associations between the phase of the moon and SUDEP. Incidence of SUDEP was highest at full moon (70%), followed by waxing moon (20%), and new moon (10%). No SUDEPs occurred during the waning cycle. Preliminary ἀndings suggest the full moon correlates with occurrence of SUDEP. Dataset of National Sentinel Clinical Audit of EpilepsyRelated Deaths examined all death certiἀcates of those who died in England and Wales between 9/1999 and 8/2000 to see if epilepsy was mentioned. Of 2412 deaths, 409 were identiἀed as probable SUDEP.
(increases, decreases, and/or no change) autonomic neural postganglionic cardiac sympathetic discharge traveling through the stellate ganglia, causes cardiac arrhythmias, ventricular ἀbrillation, and/or sudden cardiac death in the manner described by Han and Moe (1964), i.e., nonuniform recovery of excitability in ventricular muscle. It was suggested that the modiἀcation of neural discharge is a way for drugs to modify the occurrence of arrhythmia and death (Lathers et al. 1974a, 1974b, 1977a, 1977b, 1978; Lathers 1980, 1981; Han and Moe 1964). Nonuniform autonomic cardiac postganglionic neural discharge was also found to be associated with pentylenetetrazol-induced interictal epileptogenic activity in cats. Nonuniform autonomic neural discharge and autonomic neural imbalance of postganglionic cardiac sympathetic and vagal discharge cause cardiac arrhythmias, ventricular ἀbrillation, asystole, and/or SUDEP. Regional differences in the beta adrenoceptor densities reflects differences in postganglionic cardiac sympathetic innervation of the myocardium (Randall 1977, 1984; Randall et al. 1984). These site differences will vary the release of norepinephrine in various sympathetic nerve terminals and sites in the heart to modify cardiac contractile function and may trigger development of arrhythmias and/or sudden death. Innervation density of beta adrenoceptor densities is high in the subepicardium and central conduction system. Nonuniform postganglionic cardiac-sympathetic cardiac innervation is related to the nonuniform beta-sympathetic receptor locations in the heart and affects cardiac contractility and development of arrhythmias and/or death. In diseased hearts, cardiac innervation density varies and may lead to sudden cardiac death (Lathers et al. 1985, 1986a, 1986b, 1988, 1990, 2010; Lathers and Levin 2010, Chapter 33, this book). Seizures exert effects on cardiac function (Schuele, 2009). Since tachyarrhythmias are common during epileptic seizures, whereas bradyarrhythmias or asystoles occur less frequently, Kerling et al. (2009) evaluated cardiac postganglionic denervation in patients with epilepsy to determine if this was responsible for ictal asystole. I-(123)-metaiodobenzylguanidine was used as a marker of postganglionic cardiac norepinephrine uptake, using single-photon emission computed tomography. They concluded that a pronounced reduction in cardiac single-photon emission computed tomography uptake of asystole patients indicates postganglionic cardiac catecholamine disturbance. Impaired sympathetic cardiac innervation limits adjustment and heart-rate modulation and may increase the risk of asystole and, eventually, sudden unexpected death in persons with epilepsy. These data support the ἀnding of Lathers and colleagues described above. The
Neurocardiologic Mechanistic Risk Factors in SUDEP
23
reader is also referred to the chapter by Lathers and Levin (2010) that examines nonuniform sympathetic innervation and beta-sympathetic receptor locations and discusses how these factors affect cardiac contractility and the development of cardiac arrhythmias and/ or sudden death. Cerebral ischemia is associated with neuron degeneration. Accumulation of excess excitatory amino acids in the synaptic clef, activation of excitatory amino acid receptors, and influx of calcium into neurons are involved in the development of ischemia-induced neuronal death. Schwartz et al. (1995) hypothesized that neuroprotection may occur if inhibitory transmission via gamma-aminobutyric acid (GABA) is enhanced to offset excitation. Diazepam, a drug known to increase GABA-induced chloride channel opening, was studied in rats after hippocampal GABA levels had returned to post-transient global ischemia basal levels. The authors concluded that delayed enhancement of GABAergic neurotransmission directly at the site of vulnerability after an ischemic event does protect the vulnerable neurons from death. This model should be adapted to an animal model of seizure activity to study the effect of diazepam on GABA-mediated effects that may prevent ischemia-induced neuronal death, prevent the worsening of central neuronal communication due to epileptogenic activity, and eventually contribute a protective CNS effect that lessens individual at risk for SUDEP. Table 1.2 discusses postmortem multiple areas of punctuate hemorrhages and large areas of gross hemorrhage and edema in animals dying after inducing epileptogenic activity, asystole, or ventricular ἀbrillation (Lathers and Schraeder 1982; Schraeder and Lathers 1983; Lathers et al. 1984; Carnel et al. 1985). Tissue hypoxia, hypercarbia, and alterations in the acid–base balance may have contributed to the results in our model of experimental epilepsy. Acid–base balance was maintained only within physiological range before the initiation of epileptogenic activity (Lathers and Schraeder 1982, 1987; Schraeder and Lathers 1983, 1989; Carnel et al. 1985; Stauffer et al. 1989, 1990). Changes in cardiac function alter cerebral blood flow, which, in turn, produces central hypoxia that results in epileptogenic activity. Some patients exhibit changes in cardiovascular status preceding the onset of convulsions (Schott et al. 1977; Schraeder et al. 1983). So (2008) has emphasized risk factors of postictal apnea and hypoxia, with or without pulmonary congestion, in combination with generalized tonic–clonic seizures and, to a lesser degree, with complex partial seizures and respiratory arrest as a mechanistic cause of SUDEP. So et al. (2000) also noted that, although epileptic seizures may be associated with arrhythmogenic actions of the heart, in their patient, the mechanism of marked central suppression of respiratory activity after seizures was clearly involved and almost always resulted in sudden death. This case, and the case of Schraeder et al. (1983), highlight that both respiratory and cardiac changes do occur in persons with epilepsy. The timing of events such as seizures, respiratory and/or laryngospasm, and cardiac EKG changes does vary in different patients. Ryvlin et al. (2009) note that the pathophysiology of SUDEP is not clear, but postictal central or obstructive apnea is one likely mechanism. However, as noted by Lathers (2010b, Chapter 44, this book): Caution must be exerted when concluding respiratory changes alone are the primary mechanism of death. At the ἀrst onset of the clinical problem cardiac arrhythmias may be felt by the patient but may not be visually detected by a witness. ‘Invisible’ cardiac arrhythmias may be initiated and then followed by ‘visible’ respiratory distress. Therefore, in addition to repositioning of the patient to ensure ease of respiration and/or stimulation of respiration, it is important, if possible, also to simultaneously monitor and medically support cardiac rate and rhythm.
24 Sudden Death in Epilepsy: Forensic and Clinical Issues
The reader is referred to additional discussion of actual case histories focused on arrhythmogenic, respiratory, and psychological risk factors in Chapter 44 of this book (Lathers 2010b). Most likely, different mechanisms and/or a different combination of mechanisms are responsible for death in different persons with epilepsy. 1.3.1â•… Therapies as Factors Data suggest that beta blockers exert a protective effect against seizure induction and/ or the development of cardiac arrhythmias with interictal and ictal activity (Spivey et al. 1987b; Jim et al. 1988, 1989; Lathers et al. 1989a, 1989b, 1990, 2008a) (Table 1.6). The question must be asked whether persons thought to be at risk for SUDEP should be placed on a beta blocker, in addition to the prescribed anticonvulsant(s). Celiker et al. (2008) reported clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia and concluded that medical treatment with propranolol and verapamil may decrease the incidence of arrhythmia. If patients are still refractory, implantation of intracardiac deἀbrillators should be considered. Obviously, a delay in diagnosis or inadequate treatment can result in sudden cardiac death. The same is true for persons at risk for SUDEP. See the case history of SUDEP by Schraeder (2010). Hughes (2009) addressed the issue of how to predict patients at risk for SUDEP by reviewing published reports of such deaths. With a mean incidence of SUDEP at 1.8/1000, a mean standardized mortality ratio of 6.8, and a mean percentage of SUDEP cases among deaths from epilepsy at 16.6%, the problem of SUDEP and risk factors is an important issue to be resolved. Hughes identiἀed 17 risk factors and concluded, just as Lathers et al. (2008a, 2008b, 2008c) stated, that a cardiac or pulmonary problem may be a primary risk factor in different patients. He deemed the most important risk factor to be noncompliance with antiepileptic medication. Maintenance of therapeutic drug levels is crucial to avoid SUDEP. Ryvlin et al. (2009) also found that the risk of SUDEP is increased in patients who have poor compliance, nocturnal seizures, and generalized tonic–clonic seizures. However, compliance is not the only risk factor to be addressed if a person is a victim of SUDEP. There are several postmortem questions to be asked (Lathers and Schraeder 2009) about a patient on an antiepileptic drug that still becomes a SUDEP victim. One must inquire whether the correct dose of the antiepileptic drug was being used to control seizures. Another clinical pharmacology question that must be asked is whether the patient was on the correct antiepileptic drug to control the particular type or mixture of seizures experienced. When evaluating the role of drugs as protectors of life, clinical pharmacologists (Lathers and Schraeder 2002) caution us to remember that the use of all drugs is a risk/beneἀt ratio evaluation (Lathers et al. 2003a, 2003b, 2003c). Thus, the use of antiepileptic drugs may not provide 100% protection to the patient against sudden death.
1.4â•…Case of SUDEP with a Premorbid Diagnosis of Nonepileptic Seizures Table 1.8 discusses unusual risk factors examined by the laboratory of Scorza to determine if they are risk factors for SUDEP and/or have been speculated to be risk factors. This includes asking whether the lunar phase has an effect on SUDEP (Terra-Bustamante et al. 2009). A retrospective examination of the incidence of SUDEP in an epilepsy unit over an
Neurocardiologic Mechanistic Risk Factors in SUDEP
25
A 35-year-old woman was found dead in bed by her parents. She had a longstanding psychiatric history with the occurrence of seizure-like events. On one occasion,€she had a nonepileptic seizure in her neurologist’s office consisting of sliding to the floor with bizarre asynchronous bilateral motor activity without loss of consciousness. This event occurred consequent to an emotionally tense situation at her home. Past observation of another type of event consisting of some automatisms and postÂ� ictal confusion complicated the history. Multiple routine EEGs over the years were unremarkable, save for one that showed unequivocal isolated left temporal interictal discharges. The patient was placed on carbamazepine and found to have consistent therapeutic levels. The patient recognized that the complex partial events were no longer occurring, but that others continued. After the retirement of her neurologist, the patient was seen at another center and subjected to several days of inpatient EEG monitoring, during which multiple clinical events were observed without any epileptiform activity being documented on any of the EEG recordings. As a result, the patient was informed that her seizures were nonepileptic and was advised to taper her antiepileptic medications. Several weeks later her parents notiἀed her former neurologist of her demise. Co mment s by L at hers, Schraeder, and Bung o Persons with only nonepileptic seizures would, by deἀnition, not be at risk for SUDEP. However, the unfortunate reality is that from 10% to 30% of persons who appear to have long-established nonepileptic seizures also have epilepsy (Betts 1997). Thus, although the majority of persons with nonepileptic seizures do not have concurrent epilepsy, in those who also have a bona-ἀde seizure disorder, as demonstrated in this case, there is a risk of SUDEP associated with withdrawal of antiepileptic drugs based on the observation of only nonepileptic events. The physician must consider all aspects of the history and all prior EEG data before having conἀdence that the antiepileptic medication can be safely withdrawn. One should also keep in mind that rapid discontinuation of medication that was at a therapeutic serum level could induce a withdrawal seizure even in a person without epilepsy, further clouding the issue of diagnosis. From Betts, T. 1997. Psychiatric aspects of nonepileptic seizures. In Epilepsy: A Comprehensive Textbook, ed. J. Engel and T. A. Pedley. Philadelphia, PA: LippincottRaven Publishers.
8-year period was reviewed to look for a possible association. The review found the number of SUDEP cases was highest at the time of a full moon (70%), followed by a waxing moon (20%), and a new moon (10%). There were no SUDEP cases during the waning cycle. The authors concluded that a full moon appears to correlate with SUDEP. This same laboratory has examined other factors that may be involved in SUDEP, from regular imbibing of sardines and salmon to the influence of climate fluctuations (Calderazzo et al. 2009). Scorza et al. (2008b) have raised the question of whether seizure activity also influences dentate granule cell neurogenesis, since neurogenesis persists throughout life in adult mammalian dentate gyrus and is regulated by environmental, physiological, and
26 Sudden Death in Epilepsy: Forensic and Clinical Issues
molecular factors. The presence of hilar ectopic dentate granule cells was studied after status-�epilepticus was induced experimentally and it was determined that these cells migrate aberrantly, are abnormally integrated, and that the resulting hyperexcitability may contribute to seizure generation and/or propagation. Since high seizure frequency is a potential risk factor for SUDEP, the authors hypothesize that cardiac arrhythmias during and between seizures or transmission of epileptic activity to the heart via the autonomic nervous system may play a role. Thus, the aberrant neurogenesis may negatively influence the cardiovascular system of the patient with epilepsy and lead to cardiac abnormalities and then to the unwanted event of SUDEP. Studies are needed to examine the role in SUDEP played by these unusual factors to determine if they are risk factors.
1.5â•…Discussion 1.5.1â•… Future Steps The American Epilepsy Society and the Epilepsy Foundation Joint Task Force on SUDEP (So et al. 2008) assessed knowledge about SUDEP and recommended the following steps: 1. Hold a multidisciplinary workshop to reἀne current lines of investigation and identify additional areas of research for mechanism underlying SUDEP. 2. Conduct a survey of patients, families, and caregivers to identify effective means of education to enhance participation in SUDEP research. 3. Campaign for emphasis of the need for complete autopsy examinations for patients with suspected SUDEP. 4. Secure infrastructure grants to fund a consortium of centers to conduct prospective clinical and basic research studies to identify preventable risk factors and mechanisms underlying SUDEP. During the interim before these steps have been achieved, it is most important to provide prompt and optimal control of seizures, especially generalized convulsive seizures, to prevent SUDEP. A global focus is needed to resolve the risk factors for and mechanisms of epilepsy and sudden death (Lathers 2009).
References Annegers, J. F., S. P. Coan, W. A. Hauser, and J. Leestma. J. 2000. Epilepsy, vagal nerve stimulation by the NCP system, all-cause mortality, and sudden, unexpected, unexplained death. Epilepsia 41: 549–553. Antzelevitch, C. 2005a. Cardiac repolarization. The long and short of it. Eurpace 7 (Suppl 2): 3–9. Antzelevitch, C. 2005b. Modulation of transmural repolarization. Ann N Y Acad Sci 1047: 314–323. Asadi-Pooya, A. A., and M. R. Sperling. 2009. Clinical features of sudden unexpected death in epilepsy. J Clin Neurophysiol Aug 24. [Epub ahead of print]. Aurelien, D., T. P. Leren, E. Taubøll, and L. Gjerstad. 2009. New SCN5A mutation in a SUDEP victim with idiopathic epilepsy. Seizure 18: 158–160. Bateman, L. M., C. S. Li, and M. Seyal. 2008. Ictal hypoxemia in localization-related epilepsy: Analysis of incidence, severity and risk factors. Brain 131: 3239–3245.
Neurocardiologic Mechanistic Risk Factors in SUDEP
27
Beauregard, L. A., R. Fabiszewski, C. H. Black et al. 1991. Combined ambulatory electroencephalographic and electrocardiographic recordings for evaluation of syncope. Am J Cardiol 68: 1067–1072. Bell, G. S., and J. W. Sander. 2006. Sudden unexpected death in epilepsy. Risk factors, possible mechanisms and prevention: a reappraisal. Acta Neurol Taiwan 15: 72–83. Bell, G. S., J. L. Peacock, and J. W. Sander. 2009. Seasonality as a risk factor for sudden unexpected death in epilepsy: A study in a large cohort. Epilepsia Oct 27. [Epub ahead of print]. Betts, T. 1997. Psychiatric aspects of nonepileptic seizures. In Epilepsy: A Comprehensive Textbook, ed. J. Engel and T. A. Pedley, Chapter 199. Philadelphia, PA: Lippincott-Raven. Bilora, F., G. Vettore, C. Maifredini, S. Rocco, M. Pastorello, and F. Petrobelli. 1998. Chronobiology of acute pulmonary edema in an emergency service. Cardiologia 43: 303–307. Bingham, A. J., L. Ooi, L. Kozera, E. White, and I. C. Wood. 2007. The repressor element 1-silencing transcription factor regulates heart-speciἀc gene expression using multiple chromatinÂ�modifying complexes. Mol Cell Biol 27: 4082–4092. Bingham, A. J., L. Ooi, and I. C. Wood. 2006. Multiple chromatin modiἀcations important for gene expression changes in cardiac hypertrophy. Biochem Soc Trans 34 (Pt 6): 1138–1140. Bobo, E. G., and M. Bonvallet. 1975. Amygdala and masseteric reflex: I. Facilitation, inhibition and diphasic modiἀcations of the reflex, induced by localized amygdaloid stimulation. Electroencephalogr Clin Neurophysiol 39: 329–339. Brodie, M. J., and G. L. Holmes. 2008. Should all patients be told about sudden unexpected death in epilepsy (SUDEP)? Pros and Cons. Epilepsia 49 (Suppl 9): 99–101. Calderazzo, L., R. M. Arida, R. M. Cysneiros, E. A. Cavalheiro, and F. A. Scorza. 2009. From sardines to salmon: Influence of climate fluctuations on sudden unexpected death in epilepsy. Epilepsy Behav Jan. 20. Carnel, S. B., P. L. Schraeder, and C. M. Lathers. 1985. The effect of phenobarbital pretreatment on cardiac neural discharge and pentylenetetrazolâ•‚induced epileptogenic activity. Pharmacology 20: 225–240. Celiker, A., I. Erdogan, T. Karagoz, and S. Ozer. 2008. Clinical experiences of patients with catecholaminergic polymorphic ventricular tachycardia. Cardiol Young 23: 1–8. Chen, L. Y., D. G. Benditt, and S. Win-Kuang. 2008. Management of syncope in adults: An update. Mayo Clin Proc 83: 1280–1293. Colugnati D. B., R. M. Arida, S. L. Cravo, G. H. Schoorlemmer, A. C. de Almeida, E. A. Cavalheiro, and F. A. Scorza. 2008. Hibernating mammals in sudden cardiac death in epilepsy: What do they tell us? Med Hypotheses 70: 929–932. Coulter, D. L. 1984. Partial seizures with apnea and bradycardia. Arch Neurol 41: 173–174. Di Maio, T. G., and J. V. M. Di Maio, eds. 2006. Excited Delirium Syndrome. Cause of Death and Prevention. Boca Raton, FL: CRC Press. Dodd-O, J. M., and C. M. Lathers. 1990. A characterization of the lock step phenomenon in Phenobarbital treated cats. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 13, 199–220. New York, NY: Marcel Dekker. Domenighetti, A. A., C. Boixel, D. Cefai, H. Abriel, and T. Pedrazzini. 2007. Chronic angiotensin II stimulation in the heart produces an acquired long QT syndrome associated with IK1 potassium current downregulation. J Mol Cell Cardiol 42: 63–70. Druschky, A., M. J. Hiltz, P. Hopp et al. 2001. Interictal cardiac autonomic dysfunction in temporal lobe epilepsy demonstrated by [123I]metaiodobenzylguanidine-SPECT. Brain 124: 372–382. Everengul, H., H. Tanriverdi, D. Dursunoglu et al. 2005. Time frequency domain analyses of heart rate variability in patients with epilepsy. Epilepsy Res 63: 131–139. Faingold, C. L., S. Tupal, Y. Mhaskar, and V. V. Uteshev. 2010. DBA mice as models of sudden unexpected death in epilepsy. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 41. Boca Raton, FL: CRC Press.
28 Sudden Death in Epilepsy: Forensic and Clinical Issues Ferguson, P. L., J. Chiprich, G. Smith et al. 2008. Prevalence of self-reported epilepsy, health care access, and health behaviors among adults in South Carolina. Epilepsy Behav 13: 529–534. Finsterer, J., and C. Stöllberger. 2010. Cardiac and pulmonary risk factors and pathomechanisms of sudden unexplained death in epilepsy patients (SUDEP). In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 42. Boca Raton, FL: CRC Press. Franco, F. A. 2007. Cerebral autoregulation and syncope. Prog Cardiovasc Dis 50: 49–80. Gaita, F., C. Giustetto, F. Bianchi et al. 2003. Short QT syndrome: A familial cause of sudden death. Circulation 108: 965–970. Gaita, F., C. Giustetto, F. Bianchi et al. 2004. Short QT syndrome: Pharmacological treatment. J Am Coll Crdiol 43: 1494–1499. Gary-Bobo, E. G., and M. Bonvalette. 1977. Commissural projection to the amygdala through the ἀmbria fornix system in the cat. Exp Brain Res 27: 61–70. Ghali and Nashef. 2010. Genetics of SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues,€ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 18. Boca Raton, FL: CRC Press. Gleick, J. 1987. Chaos: Making a New Science. New York, NY: Viking Press. Goldberger, A. L., V. Bhargava, and B. J. West. 1985. Nonlinear dynamics of the heart beat. Physica 17D: 207–214. Goodman, J. H., R. W. Homan, and I. L. Crawford. 1989. Kindled seizures activate both branches of the autonomic nervous system. Epilepsy Res 34: 169–176. Goodman, H. J., R. W. Homan, and I. L. Crawford. 1990. Kindled seizures elevate blood pressure and induce cardiac arrhythmias. Epilepsia 31: 489–495. Goodman, J. H., R. E. Berger, and T. K. Tcheng. 2005. Preemptive low-frequency stimulation decreases the incidence of amygdala-kindled seizures. Epilepsia 46: 1–7. Graves, T. D. 2006. Ion channels and epilepsy. Q J Med 99: 201–217. Gray, M. A., P. Taggart, P. M. Sutton et al. 2007. A cortical potential reflecting cardiac function. Proc Natl Acad Sci USA 104: 6818–6823. Grubb, B. P., G. Gerard, D. A. Wolfe et al. 1992. Syncope and seizures of psychogenic origin: identiἀcation with head-upright tilt table testing. Clin Cardiol 15: 839–842. Han, J., and G. K. Moe. 1964. Nonuniform recovery of excitability in ventricular muscle. Circ Res 14: 44–60. Hanna, N. J., and R. J. Panelli. 2010. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma, Chapter 57. Boca Raton, FL: CRC Press. Herreros, B. 2010. Cardiac channelopathies and sudden death. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 19. Boca Raton, FL: CRC Press. Hirsch, C. S., and D. L. Martin. 1971. Unexpected death in young epileptics. Neurology 21: 682–690. Hughes, J. R. 2009. A review of sudden unexpected death in epilepsy: Prediction of patients at risk. Epilepsy Behav 14: 280–287. Ieda, M., H. Kanazawa, Y. Ieda et al. 2006. Nerve growth factor is critical for cardiac sensory innervation and rescues neuropathy in diabetic hearts. Circulation 114: 2351–2363. Ieda, M., H. Kanazawa, K. Kimura et al. 2007. Sema3a maintains normal heart rhythm through sympathetic innervation patterning. Nat Med 13: 604–612. Ieda, M., K. Kimura, H. Kanazawa, and K. Fukuda. 2008. Regulation of cardiac nerves: a new paradigm in the management of sudden cardiac death? Curr Med Chem 15: 1731–1736. Jain, V. 2007. Clinical perspective of obstructive sleep apnea-induced cardiovascular complications. Antioxid Redox Signal 9: 701–710. Jehi, L., and I. M. Najm. 2008. Sudden unexpected death in epilepsy: Impact, mechanisms, and prevention. Clevel Clin J Med 75 (Suppl 2): S66–S70. Jim, K. F., C. M. Lathers, V. L. Farris, L. F. Pratt, and W. H. Spivey. 1989. Suppression of pentylenetetrazol elicited seizure activity by intraosseous lorazepam in pigs. Epilepsia 30: 480–486.
Neurocardiologic Mechanistic Risk Factors in SUDEP
29
Jim, K. F., C. M. Lathers, W. H. Spivey, W. D. Matthews, C. Kahn, and K. Dolce. 1988. Suppression of pentylenetetrazolâ•‚elicited seizure activity by intraosseous propranolol in pigs. J Clin Pharmacol 28: 1106–1111. Johnston, A., and P. Smith. 2007. Sudden unexpected death in epilepsy. Expert Rev Neurother 7: 1751–1761. Johnston, S. C., R. Siedenberg, J. K. Min, E. H. Jerome, and K. D. Laxer. 1997. Central apnea and acute cardiac ischemia in a sheep model of epileptic sudden death. Ann Neurol 42: 588–594. Johnston, S. C., J. K. Horn, J. Valente, and R. P. Simon. 1995. The role of hypoventilation in a sheep model of epileptic sudden death. Ann Neurol 37: 531–537. Karch, S. 2010. Drug abuse and SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 10. Boca Raton, FL: CRC Press. Kerling, F., M. Dutsch, R. Linke, T. Kuwert, H. Stefan, and M. J. Hilz. 2009. Relation between ictal asystole and cardiac sympathetic dysfunctions shown by MIBG-SPECT. Acta Neurol Scand 120: 123–129. Kiehne, N., and S. Kauferstein. 2007. Mutations in the SCN5A gene: Evidence for a link between long TQ syndrome and sudden death? Forensic Sci Int Genet 1: 170–174. Kimura, K. M. Ieda, H. Kanazawa et al. 2007. Cardiac sympathetic rejuvenation: a link between nerve function and cardiac hypertrophy. Circ Res 100 (12): 1755–1764. Kinney, H., A. Chadwick, L. A. Crandall, M. Grafe, D. L. Armstrong, W. J. Kupsky, F. L. Trachtenberg, and H. F. Krous. 2009. Sudden death, febrile seizures, and hippocampal maldevelopment in toddlers: A new entity. Pediatr Dev Pathol Jul 16: 1. [Epub ahead of print]. Kornick, C. A., M. J. Kilborn, J. Santiago-Palmer et al. 2003. QTc interval prolongation associated with intravenous methadone. Pain 105 (3): 499–506. Lathers, C. M. 1980. Effect of timolol on postganglionic cardiac and preganglionic splanchnic sympathetic neural discharge associated with ouabainâ•‚induced arrhythmia. Eur J Pharmacol 64: 95–106. Lathers, C. M. 1981. Carnivores. Induced disease. Myocardial infarction. In Mammalian Models for Research on Aging 224–228. Washington, DC: National Academy Press. Lathers, C. M. 1982. Lack of effect of methylprednisolone on cardiac neural discharge associated with coronary occlusionâ•‚induced arrhythmia and death. Eur J Pharmacol 85: 233–238. Lathers, C. M. 2009. Epilepsy and sudden death: Personal reflections and call for global action. Epilepsy Behav 15 (3): 269–277. Lathers, C. M. 2010a. Sudden death animal models to study nervous system sites of action for disease and pharmacological intervention. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 25. Boca Raton, FL: CRC Press. Lathers, C. M. 2010b. Arrhythmogenic, respiratory, and psychological risk factors for sudden unexpected death and epilepsy. Case histories. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma. Chapter 44. Boca Raton, FL: CRC Press. Lathers, C. M., and R. M. Levin. 2010. Animal model for sudden cardiac death. Sympathetic innervation and myocardial beta receptor densities. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma. Chapter 33. Boca Raton, FL: CRC Press. Lathers, C. M., and P. L. Schraeder. 1982. Autonomic dysfunction in epilepsy. Characterization of autonomic cardiac neural discharge associated with pentylenetetrazolâ•‚induced epileptogenic activity. Epilepsia 23: 633–648. Lathers, C. M., and P. L. Schraeder. 1987. Review of autonomic dysfunction, cardiac arrhythmias, and epileptogenic activity. J Clin Pharmacol 27: 346–356. Lathers, C. M., and P. L. Schraeder. 1990a. Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, 485–505. New York, NY: Marcel Dekker.
30 Sudden Death in Epilepsy: Forensic and Clinical Issues Lathers, C. M., and P. L. Schraeder. 1990b. Synchronized cardiac neural discharge and epileptogenic activity, the Lock Step Phenomenon. Lack of correlation with cardiac arrhythmias. In Epilepsy and Sudden Death, ed. C. M Lathers and P. L. Schraeder, Chapter 12, 187–198. New York, NY: Marcel Dekker. Lathers, C. M., and P. L. Schraeder. 2002. Clinical pharmacology: Drugs as a beneἀt and/or risk in sudden unexpected death in epilepsy? J Clin Pharmacol 42: 123–136. Lathers, C. M., and P. L. Schraeder. 2006. Stress and sudden death. Epilepsy Behav 9: 236–242. Lathers, C. M., and P. L. Schraeder. 2009. Verbal autopsies and SUDEP. Epilepsy Behav 14: 573–576. Lathers, C. M., and P. L. Schraeder. 2010. Antiepileptic drugs beneἀt/risk clinical pharmacology: Possible role in cause and/or prevention of SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma, Chapter 47. Boca Raton, FL: CRC Press. Lathers, C. M., R. F. Flax, and L. J. Lipka. 1986a. The effect of C1 spinal cord transection or bilateral adrenal vein ligation on thioridazineâ•‚induced arrhythmia and death in the cat. J Clin Pharmacol 26: 515–523. Lathers, C. M., R. M. Levin, and W. H. Spivey. 1986b. Regional distribution of myocardial receptors. Eur J Pharmacol 130: 111–117. Lathers, C. M., W. H. Spivey, L. E. Suter, J. P. Lerner, N. Tumer, and R. M. Levin. 1986c. The effect of acute and chronic administration of timolol on cardiac sympathetic neural discharge, arrhythmia, and beta adrenergic receptor density associated with coronary occlusion in the cat. Life Sci 39: 2121–2141. Lathers, C. M., J. L. Gerard-Ciminera, S. I. Baskin, J. C. Krusz, G. J. Kelliher, and J. Roberts. 1981. The action of reserpine, 6-hydroxydopamine, and bretylium on digitalis-induced cardiotoxicity. Eur J Pharmacol 76: 371–379. Lathers, C. M., K. F. Jim, and W. H. Spivey. 1989a. A comparison of intraosseous and intravenous routes of administration for antiseizure agents. Epilepsia 30: 472–479. Lathers, C. M., K. F. Jim, W. High, W. H. Spivey, W. D. Matthews, and T. Ho. 1989b. An investigation of the pathological and physiological effects of intraosseous sodium bicarbonate in pigs. J Clin Pharmacol 29: 354–359. Lathers, C. M., K. F. Jim, W. H. Spivey, C. Kahn, K. Dolce, and W. D. Matthews. 1990. Antiepileptic activity of beta-blocking agents. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 24, 485–505. New York, NY: Marcel Dekker. Lathers, C. M., G. J. Kelliher, and J. Roberts. 1974a. Correlation of ouabainâ•‚induced arrhythmia and nonuniformity in cardiac accelerator nerves. Clin Res 22: 682A. Lathers, C. M., G. J. Kelliher, J. Roberts, and A. B. Beasley. 1978. Nonuniform cardiac sympathetic nerve discharge: Mechanism for coronary occlusion and digitalisâ•‚induced arrhythmia. Circulation 57: 1058–1065. Lathers, C. M., G. J. Kelliher, J. Roberts, and A. B. Beasley. 1977a. Role of the adrenergic nervous system in arrhythmia produced by acute coronary artery occlusion. In Pathophysiology and Therapeutics of Myocardial Ischemia, ed. A. Lefer, G. Kelliher, and M. Rovetto, 123–147. Myocardial Ischemia Symposium, Philadelphia Physiological Society, May 6, 1976. New York, NY: Spectrum Publ. Lathers, C. M., J. Roberts, and G. J. Kelliher. 1977b. Correlation of ouabainâ•‚induced arrhythmia and nonuniformity in the histamineâ•‚evoked discharge of cardiac sympathetic nerves. J Pharmacol Exp Ther 203: 467–479. Lathers, C. M., S. A. Koehler, C. H. Wecht, and P. L. Schraeder. 2003a. Forensic antiepileptic drug levels in 2001 autopsy cases of sudden, unexpected deaths in persons with epilepsy in Allegheny County Pennsylvania. FDA Science Forum, Washington, DC. Lathers, C. M., S. A. Koehler, C. H. Wecht, and P. L. Schraeder. 2003b. Forensic antiepileptic drug levels in 2001 autopsy cases of sudden, unexpected deaths in persons with epilepsy in Allegheny County, Pennsylvania. Annual Meeting of the American College Clinical Pharmacology, Orlando, FL.
Neurocardiologic Mechanistic Risk Factors in SUDEP
31
Lathers, C. M., P. L. Schraeder, and H. G. Claycamp. 2003c. Clinical pharmacology of topirimate vs. lamotrigine vs. Phenobarbital: Comparison of efficacy and side effects using odds ratios. J Clin Pharmacol 43: 491–503. Lathers, C. M., and L. J. Lipka. 1986. Chlorpromazine: Cardiac arrhythmogenicity in the cat. Life Sci 38: 521–538. Lathers, C. M., and L. J. Lipka. 1987. Cardiac arrhythmia, sudden death, and psychoactive agents. J€Clin Pharmacol 27: 1–14. Lathers, C. M., L. J. Lipka, and H. A. Klions. 1988. Digitalis glycosides: A discussion of the similarities and differences in actions and existing controversies. Rev Clin Basic Pharmacol 7: 1–108. Lathers, C. M., and J. Roberts. 1980. Digitalis cardiotoxicity revisited. Life Sci 27: 1713–1733. Lathers, C. M., and J. Roberts. 1985. Are the sympathetic neural effects of digoxin and quinidine involved in their action on cardiac rhythm? J Cardiovasc Pharmacol 7: 350–360. Lathers, C. M., J. Roberts, and G. J. Kelliher. 1974b. Relationship between the effect of ouabain on€ arrhythmia and interspike intervals (ISI) of cardiac accelerator nerves. Pharmacologist 16:€201. Lathers, C. M., P. L. Schraeder, and M. Bungo. 2008a. Mystery of sudden death: Mechanisms for risks. Epilepsy Behav 12: 3–24. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008b. Reply. Epilepsy Behav 13: 265–269. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008c. Sudden death: Neurocardiologic mystery, Chapter 13. In: Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Chapter 13. New York, NY: Nova Science Publishers, Inc. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2010a. Sodium channel dysfunction. Common physiopathologic mechanism associated with sudden death ECG abnormalities in Brugada syndrome and some types of epilepsy. Case histories. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma, Chapter 20, Boca Raton, FL: CRC Press. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2010b. Syncope, seizures and SUDEP. Case histories. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 22. Boca Raton, FL: CRC Press. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2010c. Unanswered questions: SUDEP Clinical studies needed. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P.€L.€Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 4. Boca Raton, FL: CRC Press. Lathers, C. M., P. L. Schraeder, and S. B. Carnel. 1984. Neural mechanisms in cardiac arrhythmias associated with epileptogenic activity: The effect of phenobarbital in the cat. Life Sci 34: 1919–1936. Lathers, C. M., P. L. Schraeder, and N. Tumer. 1993. The effect of phenobarbital on autonomic function and epileptogenic activity induced by the hippocampal injection of penicillin in cats. J Clin Pharmacol 33: 837–844. Lathers, C. M., P. L. Schraeder, and F. L. Weiner. 1987. Synchronization of cardiac autonomic neural discharge with epileptogenic activity: The lock step phenomenon. Electroencephalogr Clin Neurophysiol 67: 247–259. Lathers, C. M., W. H. Spivey, and R. M. Levin. 1988. The effect of chronic timolol in an animal model for myocardial infarction. J Clin Pharmacol 28: 736–745. Lathers, C. M., W. H. Spivey, R. M. Levin, and N. Tumer. 1990. The effect of dilevalol on cardiac autonomic neural discharge, plasma catecholamines, and myocardial beta receptor density associated with coronary occlusion. J Clin Pharmacol 30: 241–253. Lear-Kaul, K. C., L. Coughlin, and M. J. Dobersen. 2005. Sudden unexpected death in epilepsy: a retrospective study. Am J Forensic Med Pathol 26: 11–17. Leestma, J. E., T. Walczak, J. R. Hughes, M. B. Kalelkar, and S. S. Teas. 1989. A prospective study on sudden unexpected death in epilepsy. Ann Neurol 26: 195–203. Lehmann-Horn F., and K. Jurkat-Rott. 1999. Voltage-gated ion channels and hereditary disease. Physiol Rev 79: 1317–1372.
32 Sudden Death in Epilepsy: Forensic and Clinical Issues Leiter, J. C., and I. Böhm. 2007. Mechanisms of pathogenesis in the sudden infant death syndrome. Respir Physiol Neurobiol 159(2): 127–138. Lipka, L. J., and C. M. Lathers. 1987. Psychoactive agents, seizure production, and sudden death in epilepsy. J Clin Pharmacol 27: 169–183. Lipka, L. J., C. M. Lathers, and J. Roberts. 1988. Does chlorpromazine produce cardiac arrhythmia via the central nervous system? J Clin Pharmacol 28: 968–983. Malow, B. A., K. Levy, K. Maturen, and R. Bowes. 2000. Obstructive sleep apnea is common in medically refractory epilepsy patients. Neurology 55: 1002–1007. Martin, P., A. Schreiner, K. Rettig, and B. Schauble. 2009. Topiramate in patients with epilepsy and intellectual disability. Epilepsy Behav 14: 496–502. Matschke, J., and R. Laas. 2007. Central alveolar hypoventilation syndrome causes SUD. Am J Forensic Med Pathol 28: 141–144. Michelsen, J. W., and J. M. Meyer. 2007. Cardiovascular effects of antipsychotics. Expert Rev Neurother 7: 829–839. McGregor, A., and J. Wheless. 2006. Pediatric experience with sudden unexplained death in epilepsy at a tertiary epilepsy center. J Child Neurol 21: 782–787. Monte, C. P., J. B. Arends, I. Y. Tan, A. P. Aldenkamp, M. Limburg, and M. C. de Krom. 2007. Sudden unexpected death in epilepsy patients: Risk factors. A systematic review. Seizure 16: 1–7. Nagele, H., S. Hashagen, M. Azizi, S. Behrens, and M. A. Castel. 2007. Analysis of terminal arrhythmias stored in the memory of pacemakers from patients dying suddenly. Europace 9: 380–384. Nashef, L., S. Garner, J. W. Sander, D. R. Fish, and S. D. Shorvon. 1998. Circumstances of death in sudden death in epilepsy: interviews of bereaved relatives. J Neurol Neurosurg Psychiatry 64: 349–352. Nashef, L., N. Hindocha, and A. Makoff. 2007. Risk factors in sudden death in epilepsy (SUDEP): The quest for mechanisms. Epilepsia 48: 859–871. Nilsson, L., U. Bergman, V. Diwan, B. Y. Farahmand, P. G. Persson, and T. Tomson. 2001. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: A case-control study. Epilepsia 42: 667–673. Novak, V., A. L. Reeves, P. Novak, P. A. Low, and F. W. Sharbrough. 1999. Time-frequency mapping of R–R interval during complex partial seizures of temporal lobe origin. J Auton Nerv Syst 24: 195–202. O’Rourke, K., and C. Lathers. 1990. Interspike interval histogram characterization of synchronized cardiac sympathetic neural discharge and epileptogenic activity in the electrocorticogram of the cat. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 13, 239– 260. New York, NY: Marcel Dekker. Owada, M., Y. Aizawa, K. Kurihara, N. Tanabe, T. Aizaki, and T. Izumi. 1999. Risk factors and triggers of sudden death in the working generation: An autopsy proven case-control study. Tohoku J Exp Med 189: 245–258. Paterson, D. S. 2010. Medullary serotonergic abnormalities in sudden infant death syndrome. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 5. Boca Raton, FL: CRC Press. Penἀeld, W., and H. Jasper. 1954. Summary of clinical analysis and seizure patterns. In Epilepsy and the Functional Anatomy of Human Brain, 830–831. Boston, MA: Little, Brown. Persson, H., E. Kumlien, M. Ericson, and T. Topmson. 2007. Circadian variation in heart-rate variability in localization-related epilepsy. Epilepsia 48: 917–922. Pezzella, M., P. Striano, C. Ciampa, L Errichiello, P. Penza, and S. Striano. 2009. Severe pulmonary congestion in a near-miss at the ἀrst seizure: further evidence for respiratory dysfunction in sudden unexpected death in epilepsy. Epilepsy Behav (in press). Pickworth, W. B., J. Gerard-Ciminera, and C. M. Lathers. 1990. Stress, arrhythmias and seizures. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 22, 417–446. New York, NY: Marcel Dekker.
Neurocardiologic Mechanistic Risk Factors in SUDEP
33
Quint, S. R., J. A. Messenheimer, and M. B. Tennison. 1990. Power spectral analysis: a procedure for assessing autonomic activity related to risk factors for sudden and unexplained death in epilepsy. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 16, 261–291. New York, NY: Marcel Dekker. Randall, W. C. 1977. Neural Regulation of the Heart, 1–440. New York, NY: Oxford University Press. Randall, W. C. 1984. Nervous Control of Cardiovascular Function, 1–476. New York, NY: Oxford University Press. Randall, W. C., J. X. Thomas, D. E. Euler, and G. J. Rozanski. 1978. Cardiac dysrhythmias associated with autonomic nervous system imbalance in the conscious dog. In Perspectives in Cardiovascular Research, Vol. 2, Neural Mechanisms in Cardiac Arrhythmias, ed. P. J. Schwartz, A. M. Brown, A. Malliani, and A. Zanchetti, 123–138. New York, NY: Raven Press. Reingardiene, D., and J. Vilcinskaite. 2007. QTc-prolonging drugs and the risk of sudden death. Medicina (Kaunas) 43: 347–353. Rusli, M., W. H. Spivey, H. Bonner, R. M. McNamara, C. K. Aaron, and C. M. Lathers. 1987. Pathological effects of endotracheal diazepam in cats. Ann Emerg Med 16: 314–318. Ryvlin, P., T. Tomson, and A. Montavont. 2009. Excess mortality and sudden unexpected death in epilepsy. Press Med 38 (6): 905–910. Saffitz, J. E. 2008. Sympathetic neural activity and the pathogenesis of sudden cardiac death. Heart Rhythm 5: 140–141. Salama, G., and B. London. 2007. Mouse models of long QT syndrome. J Physiol 578 (Pt 1): 43–53. Sarkozy, A., and P. Brugada. 2005. Sudden cardiac death: What is inside our genes? Can J Cardiol 21: 1099–1110. Schott, G. D., A. A. McLeod, and D. E. Jewitt. 1977. Cardiac arrhythmias that masquerade as epilepsy. Br Med J 1: 1454–1457. Schraeder, P. L. 1987. Adult respiratory distress syndrome (ARDS) associated with nonconvulsive status epilepticus. Epilepsia 28: 605. Schraeder, P. L. 2010. SUDEP case histories: Typical and atypical. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 52. Boca Raton, FL: CRC Press. Schraeder, P. L., and C. M. Lathers. 1983. Cardiac neural discharge and epileptogenic activity in the cat: An animal model for unexplained death. Life Sci 32: 1371–1382. Schraeder, P. L., and C. M. Lathers. 1989. Paroxysmal autonomic dysfunction, epileptogenic activity and sudden death. Epilepsy Res 3: 55–62. Schraeder, P. L., C. M. Lathers, and J. B. Charles. 1994. The spectrum of syncope. J Clin Pharmacol 34: 454–459. Schraeder, P. L., R. Pontzer, and T. R. Engel. 1983. A case of being scared to death. Arch Intern Med 143: 1793–1794. Schuele, S. U. 2009. Effects of seizures on cardiac function. J Clin Neurophysiol. Sep 11. [Epub ahead of print]. Schwartz, R. D., X. Yu, M. R. Katzman, D. M. Hayden-Hixson, and J. M. Perry. 1995. Diazepam, given postischemia, protects selectively vulnerable neurons in the rat hippocampus and striatum. J Neurosci 15 (1 Pt 2): 529–539. Scorza, F. A., A. M. Abreu, M. Albuquerque et al. 2007. Quantiἀcation of respiratory parameters in patients with temporal lobe epilepsy. Arq Neuropsiquiatr 65: 450–453. Scorza, F. A., M. Albuquerque, R. M. Arida, V. C. Terra, H. R. Machado, and E. A. Cavalheiro. 2010a. Beneἀts of sunlight: Vitamin D deἀciency might increase the risk of sudden unexpected death in epilepsy. Med Hypotheses 74: 158–161. Scorza, F. A., E. A. Cavalheiro, R. M. Arida et al. 2010b. Omega-3 fatty acids in SUDEP: Guardian of the brain-heart connection. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma. Chapter 3. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 22. Boca Raton, FL: CRC Press.
34 Sudden Death in Epilepsy: Forensic and Clinical Issues Scorza, F. A., R. M. Arida, and E. A. Cavalheiro. 2008a. Preventive measures for sudden cardiac death in epilepsy beyond therapies. Epilepsy Behav 13: 263–264. Scorza, F. A., R. M. Cysneiros, and R. M. Arida et al. 2008b. Adult hippocampal neurogenesis and sudden unexpected death in epilepsy: Reality or just an attractive history? Med Hypotheses 71: 914–922. Sharma, S., T. Ho, and B. K. Kantharia. 2010. Not seizure but syncope: Causes and investigations to establish the diagnosis. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, J. E. Leestma, Chapter 21. Boca Raton, FL: CRC Press. Simon, R. P., L. L. Bayne, R. F. Tranbaugh, and F. R. Lewis. 1982. Elevated pulmonary flow and protein content during status epilepticus in sheep. J Appl Physiol 52: 91–95. Sheldon, R. S., A. G. Sheldon, A. Serletis et al. 2007. Investigators of the prevention of syncope study. Worsening of symptoms before presentation with vasovagal syncope. J Cardiovasc Electrophysiol 18: 954–959. So, E. L. 2008. What is known about the mechanisms underlying SUDEP? Epilepsia 49 (Suppl 9): 93–98. So, E. L., J. Brainbridge, and J. R. Buchhalter et al. 2008. Report of the American Epilepsy Society and the Epilepsy Foundation Joint Task Force on sudden unexplained death in epilepsy. Epilepsia 50: 917–922. So, E. L., M. C. Sam, and T. L. Lagerlund. 2000. Postictal central apnea as a cause of SUDEP: Evidence from near-SUDEP incident. Epilepsia 41: 1494–1497. Sonoda E. Y., D. B. Colugnati, C. A. Scorza, R. M. Arida, A. P. Pansani, A. C. de Almeida, E. A. Cavalheiro, and F. A. Scorza. 2008. Is cold the new hot in sudden unexpected death in epilepsy? Effect of low temperature on heart rate of rats with epilepsy. Arq Neuropsiquiatr 66: 848–852. Spivey, W. H., and C. M. Lathers. 1985. Effect of timolol on the sympathetic nervous system in coronary occlusion in cats. Ann Emerg Med 134: 939–944. Spivey, W. H., C. M. Lathers et al. 1985. A comparison of intraosseous, central and peripheral routes of sodium bicarbonate administration during CPR in pigs. Ann Emerg Med 14: 1135–1139. Spivey, W. H., H. D. Unger, R. M. McNamara, M. M. LaManna, T. Ho, and C. M. Lathers. 1987a. The effect of intraosseous sodium bicarbonate on bone in swine. Ann Emerg Med 16: 773–776. Spivey, W. H., H. D. Unger, C. M. Lathers, and R. M. McNamara. 1987b. Intraosseous diazepam suppression of pentylentetetrazol-induced epileptogenic activity in pigs. Ann Emerg Med 16: 56–59. Stauffer, A. Z., J. Doddâ•‚O, and C. M. Lathers. 1989. The relationship of the lock step phenomenon and precipitous changes in mean arterial blood pressure. Electroencephalogr Clin Neurophysiol 72: 340–345. Stauffer, A. Z., J. M. Dodd-O, and C. M. Lathers. 1990. Relationship of the lockstep phenomenon and precipitous changes in blood pressure. In Epilepsy and Sudden Death, ed. C. M. Lathers and P.€L. Schraeder, Chapter 14, 199–220. New York, NY: Marcel Dekker. Strzelczyk, A., S. Bauer, S. Knake, W. H. Oertel, H. M. Hamer, and F. Rosenow. 2008. Ictal asystole in temporal lobe epilepsy before and after pacemaker implantation. Epileptic Disord 10: 39–44. Stopper, M., T. Joska, and M. M. Burg et al. 2006. Electrophysiologic characteristics of anger-Â�triggered arrhythmias. Heart Rhythm 4: 268–273. Tavee, J., and H. Morris 3rd. 2008. Severe postictal laryngospasm as a potential mechanism for sudden unexpected death in epilepsy: a near-miss in an EMU. Epilepsia 49: 2113–2117. Terra-Bustamante, V. C., C. A. Scorza, and M. de Albuquerque et al. 2009. Does the lunar phase have an effect on sudden unexpected death in epilepsy? Epilepsy Behav 14: 404–406. Terrence, C. E., G. R. Rao, and J. A. Perper. 1981. Neurogenic pulmonary edema in unexpected, unexplained death in epileptic patients. Ann Neurol 25: 594–595. Tomson, T. 2010. Compliance with antiepileptic drug treatment and the risk of SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapters 51 and 22. Boca Raton, FL: CRC Press.
Neurocardiologic Mechanistic Risk Factors in SUDEP
35
Tomson, T., L. Nashef, and P. Ryvlin. 2008. Sudden unexpected death in epilepsy: current knowledge and future directions. Lancet Neurol 7: 1021–1031. Tupal, S., and C. L. Faingold. 2006. Evidence supporting a role of serotonin in modulation of sudden death induced by seizures in DBA/2 mice. Epilepsia 47: 21–26. Tupal, S., and C. L. Faingold. 2006. Respiratory arrest mechanisms, modulated in part by serotonin, may cause SUDEP. Epilepsia 47: 21–26. Tumer, N., P. L. Schraeder, and C. M. Lathers. 1985. The effect of phenobarbital upon autonomic function and epileptogenic activity induced by the hippocampal injection of penicillin in cats. Epilepsia 26: 520. Verrier, R. L., K. Kumar, and B. D. Nearing. 2009. Basis for sudden cardiac death prediction by T-wave alternans from an integrative physiology perspective. Heart Rhythm 6 (3): 416–422. Verrier, R. L., and S. C. Schachter. 2010. Neurocardiac interactions in sudden unexpected death in epilepsy: Can ambulatory electrocardiogram-based assessment of autonomic function and T-wave alternans help to evaluate risk? In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo and J. E. Leestma, Chapters 43 and 22. Boca Raton, FL: CRC Press. Vindrola, O., M. Asai, M. Zubieta, E. Talavera, E. Rodriguez, and G. Linares. 1984. Pentylenetetrazol kindling produces a long-lasting elevation of IR-Met-enkephalin but not IR-Leu-enkephalin in rat brain. Brain Res 297: 121–125. Vohra, J. 2007. The Long QT Syndrome. Heart Lung Circ 16 (Suppl 3): S5–S12. Walczak, T. 2003. Do antiepileptic drugs play a role in sudden unexpected death in epilepsy? Drug Saf 26: 673–683. Walczak, T. 2010. Risk factors for SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 12. Boca Raton, FL: CRC Press. Wang, J., Y. Chen, K. Li, and L. Hou. 2006. Blockade of inhibitory neurotransmission evoked seizurelike ἀring of cardiac parasympathetic neurons in brainstem slices of newborn rats: Implications for sudden deaths in patients of epilepsy. Epilepsy Res 70: 172–183. Wannamaker, B. 1985. Autonomic nervous system and epilepsy. Epilepsia 26 (Suppl 1): S31–S39. Wichter, T., T. M. Paul, and L. Eckardt et al. 2005. Arrhythmogenic right ventricular cardiomyopathy. Antiarrhythmic drugs, catheter ablation, or ICD? Herz 30: 91–101. Williams, L., and M. Frenneaux. 2007. Syncope in hypertropic cardiomyopathy mechanism and consequences for treatment. Europace 9 (9): 817–822. Winfree, A. T. 1987. When Time Breaks Down: The Three-Dimensional Dynamics of Electrochemical Waves and Cardiac Arrhythmias. Princeton, NJ: Princeton University Press.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
2
Jan E. Leestma
Contents 2.1 Background of Sudden or Unexpected Deaths 2.2 Forensic Issues Regarding Epilepsy and SUDEP Deaths 2.2.1 Classifying Deaths as SUDEP 2.3 Drowning 2.4 SUDEP Deaths in the Home or Workplace 2.5 SUDEP Deaths Outdoors 2.6 Role of SUDEP in Traffic Deaths 2.7 SUDEP and Deaths in Agitated Delirium or Restraint 2.8 SUDEP in Criminal Cases 2.9 SUDEP and Anticonvulsant Medication References
37 39 39 41 41 42 42 44 48 50 52
2.1â•… Background of Sudden or Unexpected Deaths Sudden and unexpected deaths generally occur outside hospitals, although victims may be brought to an emergency room. In most locales in the United States, and likely in other developed countries, such deaths are usually not attended by a physician and are without detailed historical or medical information. They will usually be brought to the attention of a medical examiner or coroner, who is responsible for determining the cause and manner of death and for generating a death certiἀcate before the remains may be interred or otherwise disposed of. These responsibilities are statutory in most jurisdictions, but how they are discharged varies widely (DiMaio and DiMaio 2001). When a coroner is the responsible party, this individual may be elected or appointed, and may or may not be a medical doctor. A local pathologist (forensically trained or not) will usually be employed to conduct an autopsy or other examination of the body to make the determination of cause and manner of death. When a medical examiner is involved, that individual is almost always a trained forensic pathologist or will employ a staff of forensic pathologists to perform the required examinations to determine the medical cause of the death and its manner, which by convention may be labeled as a homicide (death at the hands of another), suicide (death by one’s own hand), accident, natural (natural disease processes), or “undetermined.” The coroner or medical examiner may direct that an autopsy be performed and that other studies that may include toxicological examinations of tissues or body fluids be undertaken (DiMaio and DiMaio 2001; Knight 1996). 37
38 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 2.1â•… Manner of Death Statistics Manner of Death
Percentage of Death Certiἀcates (%)
Natural diseases Homicide Suicide Accidents Undetermined
64–66 10–11 4–5 20–22 4–5
Sources: Office of the Medical Examiner, Cook County, IL, Annual Report, 1977– 1979, Office of the Medical Examiner, Chicago, IL, 1979; Leestma, J. E., and E. W. Sharp, in Forensic Neuropathology, CRC Press, Boca Raton, FL, 2009. With permission.
So-called sudden deaths may or may not be truly sudden, with many deἀnitions that surround such deaths (Davis and Wright 1980; de la Grandmaison and Durigon 2002; Kuller 1966; Kuller et al. 1966; Luke and Helpern 1968; Moritz 1954). When one refers to sudden deaths, more often than not, one is really referring to the fact that the victim actually died unexpectedly and, perhaps, also suddenly. When such deaths are witnessed, death may be described as having occurred in minutes rather than hours or longer. When a death is not witnessed, but the victim is found in circumstances that indicate death occurred in the course of normal activities and does not suggest a protracted agonal period, the unexpected and sudden quality of the death can be presumed (Haerem 1978). Such circumstances often involve ἀnding the victim dead in bed, in the bathroom (not bathing), or in a den or living room (in a chair or on the floor). When the victim is found in the bath (submerged or not), swimming pool, sauna or Jacuzzi, near electrical equipment or machinery, or in a vehicle (not involved in a crash), interpretations regarding the exitus may become complicated. When death occurs in the context of an apparent accident, with or without trauma, many facts and factors will have to be considered in reaching a proper determination of cause and manner of death (Leestma 1990a) (see Table 2.1). Owing to the variability in coroners’ and medical examiners’ statistics, it is generally recognized that 10–15% of their cases occurred suddenly and/or unexpectedly (see Table 2.2). Not unexpectedly, the majority of these deaths are due to some form of heart attack. Often this cannot be proven anatomically, although it can be inferred (Haerem 1978; Fineschi et al. 2006; Greenberg and Dwyer 1982; Schwartz and Gerrity 1975). Most central nervous system diseases do not kill suddenly, even though they present suddenly
Table 2.2â•… Medical Causes of Death in Sudden and/or Unexpected Deaths Disease Process Heart and great vessels Respiratory system Brain or meninges Digestive or urogenital systems Miscellaneous
Percentage (%) 56.1 (±7.4%) 14.5 (±6.4%) 15.8 (±2.4%) 8 (±1.7%) 9.5 (±8.9%)
Sources: Kuller, L., J Chronic Dis, 19 (11), 1165–1192, 1966; Kuller, L., A. Lilienfeld, and R. Fisher, Circulation, 34 (6), 1056–1068, 1966; Leestma, J. E., in Forensic NeuroÂ� pathology, CRC Press, Boca Raton, FL, 2009. With permission.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
39
and unexpectedly as in strokes (Leestma 2009a). The largest group of CNS-related sudden deaths appear to occur in the context of epilepsy [sudden death in epilepsy (SUDEP)] (Leestma 2009a, 1990b; Lhatoo and Sander 2002). A number of chapters in this volume deal with population statistics for SUDEP and these data will not be repeated here. Suffice it to say that deaths classiἀed as SUDEP—not a cause of death, but a category of death for which no anatomically evident cause is found, much like the label sudden infant death syndrome (SIDS)—forms an important and nonrare problem for forensic pathologists. As noted before in previous publications (Leestma 1990a, 1990b; Leestma et al. 1989, 1997), the apparent incidence of SUDEP cases at a large metropolitan medical examiner’s facility (Chicago-Cook County, IL) is 60–80 cases per year (Leestma et al. 1989). A casual survey of other large metropolitan offices by the author indicates similar numbers of cases in all of them (Los Angeles, Denver, and Miami). Collecting precise and accurate statistics on SUDEP incidence is problematic because there is wide variation in practices among the forensic community on how such cases are labeled on death certiἀcates as Schraeder et al. (2006) have reported. This is a function of the awareness or lack of awareness of the phenomenon and/or philosophical positions on how, presumably, epilepsy-related deaths should be classiἀed or labeled by forensic pathologists. As alluded to earlier, it is the task and responsibility of the forensic pathologist to determine the medical cause and the manner of death if possible. If this is not possible, then, after all the evidence is gathered, the medical cause of death and, sometimes, the manner of death, must remain undeclared (undetermined). This circumstance is certainly intellectually disappointing and frustrating and may lead to unwarranted speculations on the part of family, friends, attorneys, the media, and colleagues. Such cases, whether assigned the SUDEP designation or not, may ἀnd their way into the legal system as civil cases (torts) or even as criminal cases. The following discussion will explore some of these possibilities and, when possible, provide case examples of the issues involved.
2.2â•…Forensic Issues Regarding Epilepsy and SUDEP Deaths 2.2.1â•…Classifying Deaths as SUDEP Which cases are labeled with the designation SUDEP can be difficult and sometimes controversial. An attempt to provide some guidelines was arrived at in conjunction with data collected during the development of lamotrigine (Lamictal) at the behest of the then Burroughs-Wellcome pharmaceutical company, now Glaxo-SmithKline, Inc. In the clinical trial databases that drew upon studies in many countries with 4700 patients (5747 patient years of exposure) over several years, 45 sudden and/or unexpected deaths were discovered in all arms of the study. It was important to evaluate, if possible, if there was a different incidence of SUDEP deaths between the treated and control groups. To this end, a study group of professionals that included epidemiologists, epileptologists, and pathologists was impaneled to review the data and to determine what criteria might be applied to the cases in order to stratify them for analysis (Leestma et al. 1997; Tennis et al. 1995). As might be expected, the quality and quantity of individual case data varied widely. It was not possible to obtain further data beyond that reported. Cases were stratiἀed according to the following classiἀcation (Leestma et al. 1997):
40 Sudden Death in Epilepsy: Forensic and Clinical Issues
• SUDEP (definite or highly probable) The victim suffered from epilepsy as deἀned by Gastaut (1969) and Gastaut and Zifkin (1985) and had been treated with one or more anticonvulsive agents, usually for many years, and died unexpectedly in a reasonable state of health. The fatal attack occurred suddenly, but death might not have occurred for several hours, when it was usually associated with cardiorespiratory arrest, resuscitative efforts, and their complications. The attack occurred during normal activities in benign circumstances. An obvious medical cause of death was not found after autopsy. Cardiac arrhythmia may have been observed after the attack. If the victim was found in the bath but did not show evidence of drowning, the death may be assignable as SUDEP. If status epilepticus or acute neurotrauma occurred during seizure, the case was excluded. • Possible SUDEP These cases met most or all of the SUDEP criteria, but data suggested more than one possible cause of death associated with seizures, such as death while bathing, swimming, or due to aspiration, with or without an observed seizure. • Other non-SUDEP These cases could not be assigned to either of the ἀrst two categories and an obvious or likely cause of death had been established. • Insufficient data These cases could not be interpreted because of lack of information or ambiguous data concerning the circumstances of death or concurrent medical conditions in the victim. There are and were inevitable issues with the above classiἀcations, owing to all the informational problems that are inherent to any patient-based study. A particularly thorny one was the role of possible drowning in some of the victims, which is discussed later. Other confounding variables include the role of concurrent diseases in the victim, especially heart disease in the older victim, as well as conditions related to alcohol and drug abuse. There are a host of issues in infants and children that include possible SIDS-type deaths. Highly important to any death investigation of an individual who apparently dies suddenly and/or unexpectedly is the death scene investigation (DiMaio and DiMaio 2001; Knight 1996; Leestma 2009b). The physical death scene environment must be documented and carefully inspected. It is important to note if the body is in a position or location that would be consistent with normal activity that was interrupted by the fatal attack. The presence of bruises on the face, head, and extremities does not necessarily mean that the victim was assaulted; rather that if a seizure occurred, the victim may have fallen and been injured or become injured during the clonic phase of a seizure. Context and common sense in evaluating the scene is vital. Furthermore, the investigator should search for and collect any pill bottles that are present and any materials that suggest illicit drug use. The pill bottles may indicate the use of anticonvulsant medications and can provide the names of the pharmacies that dispensed the drug and the physician who prescribed it, who may be contacted later for additional information. If the pill bottles have pills in them and the date of prescription is on the label, or if the bottle is empty, one can make a judgment regarding medication compliance by the victim. If other medications are present, this can also give a
Forensic Considerations and Sudden Unexpected Death in Epilepsy
41
clue as to other medical problems the victim may have had and can provide some guidance as to which toxicological examinations may need to be made. If any witnesses to the attack are present, a detailed description of what was seen is vital. If the attack was not witnessed, it may be possible to determine the timeframe of the attack by inference (when the individual was last seen and found). If friends or relatives are available, they may have knowledge about the health status of the decedent and, speciἀcally, if the victim was epileptic. To aid investigators in collecting this vital information, the author has previously described a “check sheet” that can serve as a template for investigators at death scenes where the victim was epileptic and sudden or unexpected death has occurred (Leestma et al. 1989; Leestma 1990b, 2009b).
2.3â•…Drowning Epileptic individuals are frequently found dead in bathtubs, swimming pools, hot tubs, and natural bodies of water in conjunction with swimming. It is a common instruction to epileptic persons not to bathe upon arising or immediately before going to bed, rather to bathe at another time of the day to avoid the increased likelihood of seizures that occur proximate to sleep (Laidlaw and Richens 1982; Engel and Pedley 2008). The postmortem diagnosis of drowning is imprecise and subject to many evidentiary problems that are well-known to any forensic pathologist such as the so-called “wet” and “dry” forms of drowning (DiMaio and DiMaio 2001; Knight 1996); thus, it cannot be known with complete assurance that a victim who was found submerged in the bathtub or swimming pool, and whose lungs did not show evidence of water aspiration, did not drown (laryngospasm), but rather died from the supposed mechanism(s) typical of SUDEP and simply sank into the water after the attack, when the victim was lifeless. If the potential drowning occurred in a natural body of water, such as a stream, lake, or ocean, it may be possible to recover diatoms and other small particles from the water in the lower respiratory passages, which may indicate aspiration. The forensics of this process and its reliability is controversial (Piette and De Letter 2006; Modell et al. 1999; Pachar and Cameron 1993). If the victim is found in the bathtub but the head is not immersed, this does not necessarily mean that drowning did not occur. The onset of rigor mortis may have shifted the position of the body after death, causing the head to rise out of the bath water. A careful examination of the oral cavity at autopsy may reveals bites of the tongue, lips, or buccal mucosa, which is presumptive evidence that a recent seizure occurred but still does not necessarily mean that drowning did not occur (Ulrich and Maxeiner 2003).
2.4â•…SUDEP Deaths in the Home or Workplace The most common location for SUDEP deaths is in the home, in locations that bespeak an attack that took place during normal activity (Leestma et al. 1989; Leestma 1990b). The most common of these is in the bedroom. The victim may be found in bed in a normal position, or one that suggests some movement, as in a seizure with disordered bedding apparent. The victim may also be found on the floor in the bedroom dressed in normal
42 Sudden Death in Epilepsy: Forensic and Clinical Issues
clothing or in bed clothes beside the bed or in another position that suggests that the fatal attack took place proximate to going to bed. The association of SUDEP, and for that matter epileptic seizures in general (Laidlaw and Richens 1982; Engel and Pedley 2008), with sleep is well known and it is also not uncommon to ἀnd SUDEP victims dead in an easy chair in a den or living room, sometimes with the television on, which suggests that the victim may have been sleeping or dozing when the attack occurred. Death in the bathroom, discussed earlier with respect to drowning, may have no connection with bathing when the victim is found dead on the bathroom floor. In such circumstances, various injuries from the impact of the body surfaces with bathroom ἀxtures is common and may confuse the interpretation of the death scene, suggesting a homicidal attack or perhaps a suicide. A careful documentation of the death scene and blood spatter or blood flow (DiMaio and DiMaio 2001; James et al. 2005) as well as the autopsy may clear up suspicion of foul play. The body of a SUDEP victim may be found in other areas of the home, in the garage or workshop area, or in a workplace area that raises the issue of other means of death than a seizure-related cause. A careful scene inspection and investigation will go a long way in ruling in or out electrocution or intoxication, be they accidental or self-inflicted. Deaths may not be discovered immediately in SUDEP victims and the body may have begun to decompose, making interpretations complex and making a proper scene investigation even more germane. The process of decomposition has been the subject of careful study by forensic scientists and there is a large body of literature on the subject (Milroy 1999; Knight 1996). Occasionally, a body that is not immediately found in a home may be subject to predation by insects, rodents, or pets. Most experienced forensic pathologists are familiar with these phenomena and can differentiate marks upon the body from premortem injuries.
2.5╅SUDEP Deaths Outdoors While it is not common, SUDEP victims can experience a fatal attack outdoors with prompt or delayed discovery of the body. Obviously, the longer a body has lain outside, the more decomposition and environmental effects such as insects, vermin, and other animals will complicate examination of determinations on the body. Even in decomposed bodies, it may be possible to glean valuable information that may make a diagnosis of SUDEP practicable (Milroy 1999; Knight 1996). As with an indoor death scene investigation, the outdoor death scene can yield important information about what happened to the victim and rule in or€out foul play, suicide, or accident. The following case example (Case A) is illustrative.
2.6â•…Role of SUDEP in Traffic Deaths A not uncommon type of forensic case is that involving vehicular crashes in which the driver appears to have experienced some sort of attack that rendered that person unable to control the vehicle. These may be single-vehicle or multivehicle incidents. Such cases are often very difficult to evaluate from a pathological point of view, owing to the often overlying trauma to the body and brain caused by the accident, and also the coexistence of other disease processes, the most important and common being cardiovascular disease.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
43
Case A A middle-aged man had been complaining of headaches and “strange” feelings and set out toward his automobile to go to his family physician for an examination. The man’s wife observed the man fall to the ground and apparently jerk beside his car. When she reached her husband, he was apparently dead. Autopsy revealed a 2.5-cm unruptured, encapsulated mass ἀlled with brownish greasy material indenting the right inferior frontal lobe anterior to the amygdala. Microscopic examination revealed the mass to be an epidermoid cyst. The remainder of the autopsy was unremarkable. It appeared that this man died from an attack that represented a generalized convulsion (GTC), apparently his ἀrst and last, from a lesion in a commonly epileptogenic region of the brain. From the standpoint of SUDEP criteria, this man was not known to be epileptic, although it appears that at the time of his death he experienced a GTC event and, thus, it could be argued the death was SUDEP.
A not uncommon cause of vehicular accidents is an epileptic attack that causes the driver-victim to lose control of the vehicle and incur injuries that may or may not prove to be fatal. In the case of fatal accidents, an examination of the vehicle, its contents, and condition may provide important information for the forensic pathologist. As is always the case, witness accounts and a medical history of the victim may point the way for further inquiry, especially if the victim was suffering from epilepsy and did not appear to have died from traumatic injuries. As in other cases of SUDEP, an effort should be made to determine what drugs the victim was taking, who prescribed them, and if the victim was compliant. A thorough autopsy examination will generally reveal if there are signiἀcant traumatic injuries and a similar thorough neuropathological examination will reveal any acute lesions, or chronic lesions in the brain that might have been epileptogenic. Examples of such lesions are old traumatic contusions, vascular anomalies, tumors, and congenital malformations (Leestma et al. 1989; Leestma 2009b). Autopsies of non-SUDEP deaths in epileptic persons generally show a relatively low incidence of structural lesions in the brain (about 10%), whereas SUDEP victims have a much higher incidence, between 50% and 70% (Leestma et al. 1985, 1989; Monte et al. 2007; Shields et al. 2002; Thom et al. 1999). Not all studies have shown signiἀcant neuropathology, however (Morentin and Alcaraz 2002). If there are acute traumatic lesions in the central nervous system, it may still be possible to determine if there are more chronic lesions present. It may, however, be unlikely to determine if the older lesions had anything to do with the vehicle crash, although sometimes collateral information may suggest a causal event. Examination of the oropharynx may reveal tongue, lip, or buccal bites that may indicate a recent seizure (Ulrich and Maxeiner 2003). Toxicological examination will reveal if anticonvulsants were present and if they were within therapeutic range. While many studies of SUDEP victims have shown that they have been or are taking multiple anticonvulsant medications, they are more likely than not to be noncompliant with respect to anticonvulsant medications (Bell and Sander 2006; George and Davis 1998; Langan 2000; Langan et al. 2005; Lear-Kaul et al. 2005; Lund and Gormsen 1985; McKee and Bodἀsh 2000; Monte et al. 2007; Nilsson et al. 1999; Tomson et al. 2005; Vlooswijk et al. 2007; Walczak 2003).
44 Sudden Death in Epilepsy: Forensic and Clinical Issues
Not all studies have shown this (Opeskin et al. 1999, 2000; Schwender and Troncoso 1986; Walczak et al. 2001), and some have suggested that toxicological studies may not truly reflect proper or improper drug levels (McGugan 1999), thus the role of medications on the risk of SUDEP is, at present, suggestive but has not been proven. Some have suggested that carbamazepine may play some role in SUDEP, either by some idiosyncratic reaction or in connection with changes in dosage of this drug (Hitiris et al. 2007; Nilsson et al. 1999, 2001; Timmings 1993; Walczak 2003). A thorough pathological examination of the heart must be performed to deἀne the extent of arteriosclerotic cardiovascular disease, previous areas of myocardial scarring or necrosis, and any other morphological abnormality of the heart or its valves. One inevitably encounters some degree of cardiovascular disease in accident victims and in sudden or unexpected deaths, and it becomes difficult to compare the importance of what is found to the death circumstances (Natelson et al. 1998; Scorza et al. 2007). There is a robust literature on the heart and sudden death (Okada and Kawai 1983; Rossi 1982; Schwartz and Gerrity 1975; Schwartz and Walsh 1971; Fineschi et al. 2006; Greenberg and Dwyer 1982; Bharati and Lev 1990) and on the so-called neurocardiology (Armour and Ardell 1984; Johnson et al. 1984), which cannot be reviewed here but the issue of cardiac dysfunction and pathology is discussed in detail elsewhere in this volume. Since SUDEP deaths are apparently physiological in the sense that the process that leads to SUDEP is electrophysiological and, thus, may or may not have a morphological counterpart such as a conduction system defect in the heart, an ion channelopathy, or some other deἀnable and demonstrable disease process, the science of forensic pathology can only go so far in determining the mechanism of death in some traffic-related deaths.
2.7â•…SUDEP and Deaths in Agitated Delirium or Restraint There is a category of sudden death in which the victim dies suddenly and unexpectedly while in a state of delirium that may involve an arrest or restraint circumstance, during which the victim dies. This problem has been the subject of a robust literature over many years and recent monographs by DiMaio and DiMaio (2006) and by Ross and Chan (2006) review much of it. It is germane to this discussion that some victims are epileptic. A typical restraint death circumstance is one where an individual is involved in an assault, robbery, disturbance, or some other event that may result in law enforcement personnel, emergency personnel, or rescue personnel being summoned to the scene. Once on the scene, there may be an apparent offender who is violent, disoriented, or delusional and may seem to need to be restrained or taken into custody to prevent flight, injury to the offender or to others. In the course of the activity of restraining the individual, many personnel may become involved in trying to subdue the violent person and in so doing may place handcuffs or restraint ties to the person and may place the individual in the prone position, “hog tie” them, and perhaps overlie the individual with several people. In this circumstance, the violent person may suddenly become quiet or complain of not being able to breathe and suffer a cardiorespiratory arrest from which the victim may or may not be able to be resuscitated. Such events almost inevitably result in some form of litigation in which the personnel involved in the restraint are held to account for what actions they may or may not have
Forensic Considerations and Sudden Unexpected Death in Epilepsy
Case B This 29-year-old man had apparently had a seizure disorder since childhood, for which he had been treated with a variety of anticonvulsant medications and a vagal nerve stimulator (about 3 years before this admission) in an effort to suppress his frequent seizures. On a recent occasion, he had been admitted to a hospital after having suffered a seizure. During admission the patient experienced a cardio/pulmonary arrest from which he was successfully resuscitated. The patient had a history of respiratory troubles including asthma. A brain CT on this admission was said to be negative. The shortness of breath the patient had complained of was thought possibly to be due to aspiration. As the patient began to emerge from his postictal state and resuscitation procedures, he was disoriented and agitated, for which he was medicated. He recovered from this episode. Seven months later in the presence of his mother, the patient experienced a seizure event and apparently, while postictal, he became delirious and combative and assaulted his mother, who called for assistance. Police and ἀre department personnel responded and subdued the man by placing him in handcuffs and hobbles in a prone position on a litter. Soon afterward, he became unconscious and pulseless. Immediately after emergency medical personnel arrived, the patient had a heart rate of 140 and a respiratory rate of 28, but then became pulseless. Resuscitative treatment was begun and the man was conveyed to an emergency facility where he was reported to be asystolic on admission. During resuscitation, the patient urinated and vomited. Resuscitation did not succeed and the patient was pronounced dead. The victim was known to be hypertensive and to have had temporal lobe epilepsy for many years. When he was postical, it was not uncommon for him to be delusional and agitated. Autopsy examination reported a body weight of 251 lb and a height of about 72 in. A number of bruises and abrasions to the face, arms, and hands were noted. There were petechial hemorrhages of the lip mucosa and right flank. A subcutaneous hemorrhage was noted near the left occiput. There was evidence of food aspiration. Heart–blood toxicological examination revealed 10 µg/ml barbiturates, <10 µg/ml Lamotrigine, 25 µg/ml Oxcarbazepine, and no Phenytoin. A vagus nerve stimulator was encountered and removed (no testing done). The internal autopsy examination reported no injuries or obstructions to the neck organs. No injury to the lungs was noted and no pneumothorax was noted. The heart weighed 450 g but no obvious atheromata were noted, although abundant epicardial fat that inἀltrated the myocardium and moderately severe myoἀber scarring and hypertrophy were found. The liver was enlarged (2840 g). Neuropathology examination revealed Purkinje cell loss and cortical atrophy of the cerebellum, mild early hypoxic/ischemic changes in neurons, no apparent abnormality of the hippocampal regions beyond extensive corpora amylacea deposition in the subpial region, and no obvious lesion to account for the epilepsy. Microscopically, the heart showed extensive myocardial ἀbrosis. The medical examiner ruled the manner of death a homicide. A succession of lawsuits ensued against the police and ἀre department personnel who had responded in the incident. It was alleged that the man died because of positional asphyxia and compressive forces on the man’s thorax during the restraint.
45
46 Sudden Death in Epilepsy: Forensic and Clinical Issues
Case C This was a 38-year-old white male who apparently suffered an epileptic seizure while at a university campus where he was attending classes. He allegedly exhibited bizarre behavior and began to bang his head and face against a wall and then experienced what was described as a generalized tonic–clonic (GTC) seizure by many observers. After the seizure he became agitated, delusional, and combative. Police were called and they attempted to restrain the man by handcuffing him in a prone position. Emergency medical personnel were called and transported him to hospital, arriving at 1909 hours. While being transported after glucagon was administered (blood sugar found to be 34), he became still and experienced cardiorespiratory arrest. He was cyanotic and pulseless, with ἀxed and dilated pupils. Cardiac monitoring revealed asystole. Resuscitative measures were instituted without success. He was pronounced dead at 1926 hours. The victim’s history was that he had been epileptic since childhood and two craniotomies had been performed on his right temporal region in an attempt to correct his epilepsy. He continued to have seizures that were described as GTC, for which he was treated with carbamazepine. In spite of medication, he would have periodic seizures with an aura, not described. He was somewhat impulsive and apparently either slightly aphasic or dyslexic, which caused him some frustration. He apparently did not use alcohol or drugs. His medical records indicated he had had diabetes insipidus, in conjunction with one of his craniotomies. A history of diabetes mellitus was unsubstantiated. Autopsy revealed evidence of medical treatment, and that he was somewhat plethoric and had a blotchy erythema of the face with several abrasions apparently due to his head-banging and also to efforts to subdue him. There was blood in the mouth and a large tongue bite was found. The autopsy pathologist did not describe petechial hemorrhages in eyes, viscera, or face and discounted the erythema of the skin as being petechial hemorrhages due to suffocation. He had a number of bruises and abrasions of the elbows, knees, etc., due to scuffling. His heart weighed 490 g and showed <30% atheroma of right coronary, left circumflex, but the left anterior descending artery showed 50% occlusion, and the aorta showed moderate atheroma with no obvious infarct. The lungs were 800 and 680 g, congested and wet. No airway obstruction nor injury to neck or hyoid was noted. The liver was 2600 g and congested, as was the spleen (300 g). The brain was 1320 g with evidence of prior surgery in the right temporal side. No subdural hemorrhage was found, and no traumatic injury noted. The case was ἀled as manner of death undetermined with seizure disorder with delirium, coronary artery disease, and positional restraint.
performed. Inevitably, their training and education regarding proper procedures for “take downs” are scrutinized, along with what sort of supervision occurred during the event (Ross and Chan 2006). Death during restraint victims quite frequently are obese, hypertensive, diabetic, or under the influence of substances such as cocaine, amphetamines, phencyclidine (“angel
Forensic Considerations and Sudden Unexpected Death in Epilepsy
47
dust” or PCP), alcohol, cannabis, barbiturates, or opiates, as well as tranquilizers, antipsychotic medication, anticonvulsants, and other drugs (DiMaio and DiMaio 2006). Often, the use of many drugs is demonstrated. Not infrequently, the victims are found to be hyperpyrexic, have cocaine in their blood, and may show myoglobinuria (Ruttenber et al. 1997, 1999; Ross and Chan 2006). Cardiovascular disease demonstrated at autopsy is common. Some victims have a history of epilepsy and may have been apparently postictal when they were in their delirious state. The following are two cases that illustrate the latter, and most of the problems associated with that. This case, like the previous one, was the subject of civil litigation against the responding personnel and their organizations. In both cases, ultimately, either settlements were reached or no judgments were returned against the defendants or their organizations. Both cases illustrate the complexities that may occur when an agitated or delirious epileptic patient needs to be restrained to prevent self-injury or injury to those nearby. It seems painfully obvious that some action on the part of responding personnel, be they police, ἀremen, emergency personnel, or bystanders may be called for in situations like those described above, and also that it seems inevitable when tragedy occurs that they will be blamed, appropriately or not (Ross and Chan 2006). The causal issue of prone restraint, so-called “hog tying,” and overlaying of the agitated and delirious victim is controversial and is still being debated in scientiἀc and forensic circles and in the courts. Other tactics used in restraint of violent persons may involve one or more variants of the chokehold, which may occlude the airway and/or compress the carotid artery and produce death by these means (Vilke 2006, Reay and Holloway 1982; Reay and Eisele 1982). With respect to “hog tying” and prone restraint, Reay et al. (1988, 1992) and O’Halloran et al. (O’Halloran and Lewman 1993; O’Halloran and Frank 2000; O’Halloran 2004) postulated that when in the prone position “hog tied” and when personnel overlay the agitated individual, respiratory function may become impaired and cause death. From a study of restraint deaths, it was common to ἀnd victims to be obese and it was inferred that when placed in the prone position their obesity may impede diaphragmatic movements and respiratory function. The term positional asphyxia has been applied to this and related phenomena. Other reports highlighted not only the position and manner of restraint but the frequent accompanying excited delirium and its physiological effects as causes of death in such cases (Stratton et al. 1995; Pollanen et al. 1998; DiMaio and DiMaio 2006). In experimental studies reported by Chan et al. (1997, 2004), volunteers were placed in the sitting, supine, and prone positions, restrained and loaded after a period of exercise, and their pulmonary function monitored. Chan et al. (1997, 2004) found no evidence that body position while hog-tied or hobbled could in itself cause asphyxiation and that other factors beyond body position were probably more important in restraint deaths. The authors did not rule out that very obese individuals, who were not tested, might have some special risk of asphyxia due to their obesity. Others have expressed concerns that restraint circumstances, including the body habitus of the victim, may produce respiratory embarrassment (Parkes 2008; DiMaio and DiMaio 2006; Pollanen et al. 1998). A factor in the excited and delirious victim deaths is the stressful general physiological state that exists when violent, struggling, and agitated conditions occur. Some have referred to this state as “catecholamine” storm (LaPosata 2006; DiMaio and DiMaio 2006). From the extensive reviews in other chapters of this volume, the importance of catecholamine excess and autonomic imbalance or over-activity in the pathomechanism of SUDEP cases,
48 Sudden Death in Epilepsy: Forensic and Clinical Issues
it is not surprising that it may come into play when some epileptic individuals become delirious and agitated, perhaps in the postictal state, as illustrated in the previous cases. These types of cases, like all the remainder without epilepsy, are difficult to analyze and develop an unambiguous cause and mechanism of death. One can only collect as much information as one can about a given case, and somehow rank the factors that are present in coming to a causal judgment, if one can. Like Case B, sometimes forensic pathologists feel compelled to render a manner of death that might seem provocative, such as homicide. In such cases, one must remember that “homicide” is not necessarily murder but simply death at the hands of another. In this case, the pathologist somehow felt the preponderance of the evidence indicated that someone was responsible. His pronouncement was challenged, of course, in the legal proceedings that followed. In general, it is probably most rational unless very special circumstances are present to make use of the “undetermined” manner of death designation.
2.8â•…SUDEP in Criminal Cases In Chapter 24 of this book, Dr. Wanamaker recounts the case of an unfortunate woman who was assaulted by a home intruder and, as a result, suffered permanent and debilitating head injuries that caused her to become epileptic. Many years after the beating, she was found dead at home in her bathroom with no obvious anatomic cause of death. Her death was judged to be a SUDEP, which, according to the judgment of the U.S. attorney (the
Case D This 14-year-old girl was born with a large ventriculoseptal heart defect and tricuspid valve abnormality, for which surgery had been performed. Apparently, the surgery was a so-called Fontan procedure, which essentially diverted venous blood from the right atrium to the pulmonary trunk, bypassing the right ventricle (Kerendi et al. 2009). This is a treatment for tricuspid atresia, which she had. Within a few years of€ birth, she also developed a seizure disorder that was characterized as being of the€GTC variety, for which she was medicated with phenytoin with variable success. Not long after her heart surgery, it was necessary for her to be anticoagulated and to be treated with digitalis. About 2 months before she died for unknown reasons, her anticonvulsant medication was discontinued. A few weeks before her death, she was given a number of immunizations that caused her to become quite ill and necessitated her being conἀned to bed. A week before death, she commenced her menarche and had difficulties with maintaining her International Normalized Ratio (INR) in acceptable ranges. It appears she also experienced one or more seizures, with one of them causing a bite on her tongue that continued to bleed. She complained of headaches. She was found dead beside her bed in the morning after having been ill for about 2 weeks. An autopsy was performed that showed evidence of a head impact in the left temporal region, an acute subdural hemorrhage, an apparent basal skull fracture, a large
Forensic Considerations and Sudden Unexpected Death in Epilepsy
laceration with hemorrhage of the tongue with aspiration of blood, a number of focal hemorrhagic sites in the gut, mesentery bladder, spleen, and kidney, and some bruising on the legs. The autopsy pathologist concluded that the girl had been assaulted and classiἀed her death as being due to blunt force injuries with manner of death as undetermined. The local prosecutor was pursuing an indictment against the mother of the child for homicide. Independent examination of the autopsy tissues with microscopic examinations indicated that the subdural hematoma was relatively thin and was 1 to 2 weeks old by histological criteria. A skull fracture was present. It was reasonable to attribute the numerous areas of hemorrhage to dosage problems with her anticoagulant and not to having been assaulted. As to the mechanism(s) of death, the victim clearly had serious cardiovascular disease, which in and of itself could account for a sudden death, but there was evidence of recent seizure activity as exempliἀed by the hemorrhagic tongue bite and aspiration of blood and the position of the body beside the bed. It might be said that SUDEP was a reasonable possibility, but could not be proven. The case has languished for many years and it is unlikely to be adjudicated.
Case E A 10-year-old boy who had experienced a birth-related injury that left him with a spastic form of diplegia, intractable epilepsy, and mental retardation had been cared for in various institutions and by the parents in the child’s home over his lifetime. The child was capable of ambulating but with difficulty, could not speak intelligibly but apparently could understand spoken language, and was not apparently visually impaired. After a number of years of gastrostomy feedings, the child was capable of being fed manually and even managed to partially feed himself. The child had a ventriculoperitoneal shunt for hydrocephalus with several shunt revisions, but apparently the hydrocephalus had stabilized. The child’s abiding problem was one of seizures that were cyclical in severity and frequency. A number of anticonvulsant medications had been tried, but never fully controlled the child’s epilepsy which was of the GTC type. One morning, the child was found dead in bed by the parents. An autopsy was performed by a medical examiner facility and the child was found to have some contractures of the lower extremity and many bruises on them and on the upper extremities. Several bruises were found on the child’s face and head. A number of healing abrasions were found on the arms and legs. There were no fractures. No pneumonia or other infections were found. The child’s brain showed typical rostral cortical atrophy with some cyst formation in the white matter, hydrocephalus that was not severe, and bilateral subdural hematoma membranes with a minimal amount of recent hemorrhage. The viscera were within normal limits. The autopsy pathologist concluded that the child had died from blunt force injuries that were inflicted and the manner of death was deemed homicide. The parents were charged with homicide.
49
50 Sudden Death in Epilepsy: Forensic and Clinical Issues
An independent examination of the case and the autopsy materials revealed the obvious cerebral palsy pathology of the child and revealed the subdural hematoma to be likely many years old and essentially undatable with accuracy. The recent hemorrhage was minimal. The skin bruises were of different ages by visual inspection, as were the healing abrasions. Put in the context of how the child functioned (impaired mobility, frequent falls with and without seizures), the injuries were not inconsistent with the circumstances of the child. No acute signiἀcant impact site was found on the head. The subdural hematoma bleeding was found to be typical for any chronic subdural hematoma and could not speciἀcally be related to any known traumatic episode. Given the location of the body (in bed), the chronic problem of seizures, and no anatomic cause of death, the child’s death was concluded to be SUDEP. Eventually, charges were dropped against the parents.
assault occurred on a federal reservation), was directly caused by the assailant who became known to him and was charged. Such a case is distinctly unusual, not only because of the basic facts of the case, but also because of the time that had elapsed between the inflicted injury and the woman’s death and when her assailant was brought to justice. Most criminal cases that might involve a SUDEP scenario are much less complex or unusual but nonetheless can be challenging if not controversial. A not uncommon circumstance that may involve criminal prosecution is the death of a neurologically compromised child, usually at home but occasionally in some form of care facility. In many of these cases, the child suffered from congenital brain malformations or birth-related injury (cerebral palsy) associated with chronic seizures. Sometimes, the child may have been the victim of an acute life-threatening event (ALTE) with persistent neurological impairment that may have been due to inflicted injury (abuse), accident, or to a circumstance that is never explained. When such a child dies, commonly due to aspiration and pneumonia, urinary tract infection, shunt malfunction, or other issue related to chronic illness, these conditions can usually be identiἀed and put in their proper context with a competent autopsy. Occasionally, the child will not have an obvious anatomic cause of death and may ἀt into the SUDEP category. The forensic pathologist must be mindful of this latter form of death and not leap to the conclusion that, absent an obvious cause of death, someone must have caused it. Cases such as this one point out the many challenges of evaluating and interpreting infant and childhood deaths, which almost invariably have a cloud of abusive injury hovering over them, deserved or not.
2.9â•…SUDEP and Anticonvulsant Medication Whether anticonvulsant medication by some aberrant pharmacological reaction, noncompliance, under-dosage, or cessation of administration can lead to SUDEP remains a controversial subject and is dealt with in detail in several chapters in the volume. This
Forensic Considerations and Sudden Unexpected Death in Epilepsy
51
discussion will not be repeated here. Suffice it to say that this issue can have forensic and litigative consequences. Dr. Wanamaker has highlighted some case examples of this problem that largely center about physician-patient interactions, namely the responsibility of the doctor to warn an epileptic patient about the possibility of SUDEP when prescribing, switching drugs, tapering, or discontinuing anticonvulsant drugs. Such cases come, not infrequently, to civil litigation. The above case is similar to many that have reached litigation in the United States and elsewhere in recent years. In many cases, the doctor has no record of patient conversations or instructions, relying on memory or usual practice. Recently such conversations are recorded, videotaped, or immortalized in some fashion, sometimes along with a signed statement by the patient that they were informed of risks of medication and its discontinuance, including the facts about SUDEP. Informational packets have been prepared by some physicians to aid in this process. To the author’s knowledge, the majority of SUDEP-related
Case F This 28-year-old woman had been epileptic since childhood, suffering ἀrst from absence seizures that then gave way to GTC seizures as an adult. Other than her epilepsy, she had enjoyed good health and had recently gotten married. Her seizure frequency was very low, and it had been several years since she had had a seizure. Since her marriage, she had wanted to become pregnant and had indeed done so, visiting her neurologist once she was aware of her pregnancy to seek advice about her anticonvulsant medication and its potential effects on her unborn baby. The doctor, who immortalized his conversation with his patient in a very brief note in his office records, indicated that probably the risk to the baby was quite low, but that if the patient was concerned about her medication, in the face of no seizures for several years, it would be appropriate to taper the medication and discontinue it for the duration of the pregnancy. He pointed out that if a seizure were to occur, they would simply begin medication again and go on. A few months later, the woman was found dead in bed. Autopsy revealed the pregnancy, but no anatomic cause of death. The husband reported that he had never observed a seizure in his wife nor had she said anything about having had a seizure. A lawsuit stipulating neglectful treatment and wrongful death was brought against the neurologist. At trial, the doctor’s records were offered in evidence to support the fact that he had a treatment plan and had discussed it with his patient, but apparently did not feel bound to warn her about the risk of SUDEP. At trial, various experts offered testimony regarding what SUDEP was, how it was diagnosed, and, probably, what caused it. The issue of anticonvulsant medication in relation to the possible cause and prevention of SUDEP was explored. The defense expert presented the results of several of his own studies and those of others and indicated that, while many studies showed a statistical correlation of subtherapeutic or no anticonvulsant medication with SUDEP, others did not and it could not be inferred that stopping medication was causal or could predict SUDEP. The jury in the case acquitted the doctor in the action.
52 Sudden Death in Epilepsy: Forensic and Clinical Issues
litigations have been adjudicated in favor of the physicians. Suffice it to say that it is vital that physicians share information with their patients and document that this occurred and what was communicated and when.
References Armour, J. A., and J. L. Ardell, eds. 1984. Neurocardiology. New York, NY: Oxford University Press. Bell, G. S., and J. W. Sander. 2006. Sudden unexpected death in epilepsy. Risk factors, possible mechanisms and prevention: A reappraisal. Acta Neurol Taiwan 15 (2): 72–83. Bharati, S., and M. Lev. 1990. The Cardiac Conduction System in Sudden Unexplained Death. Mt. Kisco, NY: Futura. Chan, T. C., G. M. Vilke, T. Neuman, and J. L. Clausen. 1997. Restraint position and positional asphyxia. Ann Emerg Med 30 (5): 578–586. Chan, T. C., T. Neuman, J. Clausen, J. Eisele, and G. M. Vilke. 2004. Weight force during prone restraint and respiratory function. Am J Forensic Med Pathol 25 (3): 185–189. Davis, J. H., and R. K. Wright. 1980. The very sudden cardiac death syndrome—a conceptual model for pathologists. Hum Pathol 11 (2): 117–121. de la Grandmaison, G. L., and M. Durigon. 2002. Sudden adult death: A medico-legal series of 77 cases between 1995 and 2000. Med Sci Law 42 (3): 225–232. DiMaio, T. G., and V. J. M. DiMaio, eds. 2006. Excited Delirium Syndrome. Cause of Death and Prevention. Boca Raton, FL: CRC Press. DiMaio, V. J., and D. DiMaio. 2001. Forensic pathology. In Practical Aspects of Criminal and Forensic Investigations, ed. V. Geberth. Boca Raton, FL: CRC Press. Engel, J., Jr., and T. A. Pedley, eds. 2008. Epilepsy: A Comprehensive Textbook. 2nd ed. Philadelphia, PA: Wolters Kluwer/Lippincott Williams & Wilkins. Fineschi, V., G. Baroldi, and M. D. Silver. 2006. Pathology of the Heart and Sudden Death in Forensic Medicine. Boca Raton, FL: CRC Press. Gastaut, H. 1969. Classiἀcation of the epilepsies. Proposal for an international classiἀcation. Epilepsia 10 (Suppl): 14–21. Gastaut, H., and B. G. Zifkin. 1985. Classiἀcation of the epilepsies. J Clin Neurophysiol 2 (4): 313–326. George, J. R., and G. G. Davis. 1998. Comparison of anti-epileptic drug levels in different cases of sudden death. J Forensic Sci 43 (3): 598–603. Greenberg, H. M., and E. M. Dwyer Jr., eds. 1982. Sudden Coronary Death, Vol. 382, Annals of the New York Academy of Sciences. New York, NY: New York Academy of Sciences. Haerem, J. W. 1978. Sudden, unexpected coronary death. The occurrence of platelet aggregates in the epicardial and myocardial vessels of man. Acta Pathol Microbiol Scand Suppl (265): 1–47. Hitiris, N., S. Suratman, K. Kelly, L. J. Stephen, G. J. Sills, and M. J. Brodie. 2007. Sudden unexpected death in epilepsy: A search for risk factors. Epilepsy Behav 10 (1): 138–141. James, S. H., P. E. Kish, and T. P. Sutton. 2005. Principles of bloodstain pattern analysis. Theory and practice. In Practical Aspects of Criminal and Forensic Investigations, ed. V. Geberth. Boca Raton, FL: CRC Press. Johnson, R. H., D. G. Lambie, and J. M. K. Spalding, eds. 1984. Neurocardiology, Major Problems in Neurology, Vol. 13, ed. J. Walton. Philadelphia, PA: W. B. Saunders. Kerendi, F., Z. B. Kramer, W. T. Mahle, B. E. Kogon, K. R. Kanter, and P. M. Kirshbom. 2009. Perioperative risks and outcomes of atrioventricular valve surgery in conjunction with Fontan procedure. Ann Thorac Surg 87 (5): 1484–1488; discussion 1488–1489. Knight, B. 1996. Forensic Pathology. 2nd ed. London: Arnold. Kuller, L. 1966. Sudden and unexpected non-traumatic deaths in adults: A review of epidemiological and clinical studies. J Chronic Dis 19 (11): 1165–1192.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
53
Kuller, L., A. Lilienfeld, and R. Fisher. 1966. Epidemiological study of sudden and unexpected deaths due to arteriosclerotic heart disease. Circulation 34 (6): 1056–1068. Laidlaw, J., and A. Richens, eds. 1982. A Textbook of Epilepsy. Edinburgh: Churchill Livingstone. Langan, Y. 2000. Sudden unexpected death in epilepsy (SUDEP): Risk factors and case control studies. Seizure 9 (3): 179–183. Langan, Y., L. Nashef, and J. W. Sander. 2005. Case-control study of SUDEP. Neurology 64 (7): 1131–1133. LaPosata, E. A. 2006. Restraint stress. In Sudden Deaths in Custody, ed. D. L. Ross and T. C. Chan. Totowa, NJ: Humana Press. Lear-Kaul, K. C., L. Coughlin, and M. J. Dobersen. 2005. Sudden unexpected death in epilepsy: A retrospective study. Am J Forensic Med Pathol 26 (1): 11–17. Leestma, J. E. 1990a. Natural history of epilepsy. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder. New York, NY: Marcel Dekker. Leestma, J. E. 1990b. Sudden unexpected death associated with seizures: A pathological review. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder. New York, NY: Marcel Dekker. Leestma, J. E. 2009a. Forensic aspects of adult general neuropathology. In Forensic Neuropathology, ed. J. E. Leestma. Boca Raton, FL: CRC Press. Leestma, J. E. 2009b. Forensic aspects of complex neural function. In Forensic Neuropathology, ed. J.€E. Leestma. Boca Raton, FL: CRC Press. Leestma, J. E., and E. W. Sharp. 2009. Pathology and neuropathology in the forensic setting. In Forensic Neuropathology, ed. J. E. Leestma. Boca Raton, FL: CRC Press. Leestma, J. E., J. F. Annegers, M. J. Brodie, S. Brown, P. Schraeder, D. Siscovick, B. B. Wannamaker, P. S. Tennis, M. A. Cierpial, and N. L. Earl. 1997. Sudden unexplained death in epilepsy: Observations from a large clinical development program. Epilepsia 38 (1): 47–55. Leestma, J. E., J. R. Hughes, S. S. Teas, and M. B. Kalelkar. 1985. Sudden epilepsy deaths and the forensic pathologist. Am J Forensic Med Pathol 6 (3): 215–218. Leestma, J. E., T. Walczak, J. R. Hughes, M. B. Kalelkar, and S. S. Teas. 1989. A prospective study on sudden unexpected death in epilepsy. Ann Neurol 26 (2): 195–203. Lhatoo, S. D., and J. W. Sander. 2002. Sudden unexpected death in epilepsy. Hong Kong Med J 8 (5): 354–358. Luke, J. L., and M. Helpern. 1968. Sudden unexpected death from natural causes in young adults. A review of 275 consecutive autopsied cases. Arch Pathol 85 (1): 10–17. Lund, A., and H. Gormsen. 1985. The role of antiepileptics in sudden death in epilepsy. Acta Neurol Scand 72 (4): 444–446. McGugan, E. A. 1999. Sudden unexpected deaths in epileptics—A literature review. Scott Med J 44 (5): 137–139. McKee, J. R., and J. W. Bodἀsh. 2000. Sudden unexpected death in epilepsy in adults with mental retardation. Am J Ment Retard 105 (4): 229–235. Milroy, C. M. 1999. Forensic taphonomy: The postmortem fate of human remains. BMJ 319 (7207): 458. Modell, J. H., M. Bellefleur, and J. H. Davis. 1999. Drowning without aspiration: Is this an appropriate diagnosis? J Forensic Sci 44 (6): 1119–1123. Monte, C. P., J. B. Arends, I. Y. Tan, A. P. Aldenkamp, M. Limburg, and M. C. de Krom. 2007. Sudden unexpected death in epilepsy patients: Risk factors. A systematic review. Seizure 16 (1): 1–7. Morentin, B., and R. Alcaraz. 2002. Sudden unexpected death in epilepsy in children and adolescents. Rev Neurol 34 (5): 462–465. Moritz, A. R. 1954. Sudden and unexpected death due to disease. GP 10 (6): 35–42. Natelson, B. H., R. V. Suarez, C. F. Terrence, and R. Turizo. 1998. Patients with epilepsy who die suddenly have cardiac disease. Arch Neurol 55 (6): 857–860.
54 Sudden Death in Epilepsy: Forensic and Clinical Issues Nilsson, L., B. Y. Farahmand, P. G. Persson, I. Thiblin, and T. Tomson. 1999. Risk factors for sudden unexpected death in epilepsy: A case-control study. Lancet 353 (9156): 888–893. Nilsson, L., U. Bergman, V. Diwan, B. Y. Farahmand, P. G. Persson, and T. Tomson. 2001. Antiepileptic drug therapy and its management in sudden unexpected death in epilepsy: A case-control study. Epilepsia 42 (5): 667–673. Office of the Medical Examiner, Cook County, IL. 1979. Annual Report, 1977–1979. Chicago, IL: Office of the Medical Examiner. O’Halloran, R. L. 2004. Reenactment of circumstances in deaths related to restraint. Am J Forensic Med Pathol 25 (3): 190–193. O’Halloran, R. L., and J. G. Frank. 2000. Asphyxial death during prone restraint revisited: A report of 21 cases. Am J Forensic Med Pathol 21 (1): 39–52. O’Halloran, R. L., and L. V. Lewman. 1993. Restraint asphyxiation in excited delirium. Am J Forensic Med Pathol 14 (4): 289–295. Okada, R., and S. Kawai. 1983. Histopathology of the conduction system in sudden cardiac death. Jpn Circ J 47 (5): 573–580. Opeskin, K., A. S. Harvey, S. M. Cordner, and S. F. Berkovic. 2000. Sudden unexpected death in epilepsy in Victoria. J Clin Neurosci 7 (1): 34–37. Opeskin, K., M. P. Burke, S. M. Cordner, and S. F. Berkovic. 1999. Comparison of antiepileptic drug levels in sudden unexpected deaths in epilepsy with deaths from other causes. Epilepsia 40 (12): 1795–1798. Pachar, J. V., and J. M. Cameron. 1993. The diagnosis of drowning by quantitative and qualitative diatom analysis. Med Sci Law 33 (4): 291–299. Parkes, J. 2008. Sudden death during restraint: Do some positions affect lung function? Med Sci Law 48 (2): 137–141. Piette, M. H., and E. A. De Letter. 2006. Drowning: Still a difficult autopsy diagnosis. Forensic Sci Int 163 (1–2): 1–9. Pollanen, M. S., D. A. Chiasson, J. T. Cairns, and J. G. Young. 1998. Unexpected death related to restraint for excited delirium: A retrospective study of deaths in police custody and in the community. CMAJ 158 (12): 1603–1607. Reay, D. T., and J. W. Eisele. 1982. Death from law enforcement neck holds. Am J Forensic Med Pathol 3 (3): 253–258. Reay, D. T., and G. A. Holloway Jr. 1982. Changes in carotid blood flow produced by neck compression. Am J Forensic Med Pathol 3 (3): 199–202. Reay, D. T., C. L. Fligner, A. D. Stilwell, and J. Arnold. 1992. Positional asphyxia during law enforcement transport. Am J Forensic Med Pathol 13 (2): 90–97. Reay, D. T., J. D. Howard, C. L. Fligner, and R. J. Ward. 1988. Effects of positional restraint on oxygen saturation and heart rate following exercise. Am J Forensic Med Pathol 9 (1): 16–18. Ross, D. L., and T. C. Chan, eds. 2006. Sudden Deaths in Custody. Totowa, NJ: Humana Press. Rossi, L. 1982. Pathologic changes in the cardiac conduction and nervous system in sudden coronary death. Ann N Y Acad Sci 382: 50–68. Ruttenber, A. J., J. Lawler-Heavner, M. Yin, C. V. Wetli, W. L. Hearn, and D. C. Mash. 1997. Fatal excited delirium following cocaine use: Epidemiologic ἀndings provide new evidence for mechanisms of cocaine toxicity. J Forensic Sci 42 (1): 25–31. Ruttenber, A. J., H. B. McAnally, and C. V. Wetli. 1999. Cocaine-associated rhabdomyolysis and excited delirium: Different stages of the same syndrome. Am J Forensic Med Pathol 20 (2): 120–127. Schraeder, P. L., K. Delin, R. L. McClelland, and E. L. So. 2006. Coroner and medical examiner documentation of sudden unexplained deaths in epilepsy. Epilepsy Res 68 (2): 137–143. Schwartz, C. J., and R. G. Gerrity. 1975. Anatomical pathology of sudden unexpected cardiac death. Circulation 52 (6 Suppl): III18–III26. Schwartz, C. J., and W. J. Walsh. 1971. The pathologic basis of sudden death. Prog Cardiovasc Dis 13 (5): 465–481.
Forensic Considerations and Sudden Unexpected Death in Epilepsy
55
Schwender, L. A., and J. C. Troncoso. 1986. Evaluation of sudden death in epilepsy. Am J Forensic Med Pathol 7 (4): 283–287. Scorza, F. A., M. Albuquerque, R. M. Arida, and E. A. Cavalheiro. 2007. Cardiovascular alterations and sudden death in epilepsy. Arq Neuropsiquiatr 65 (2B): 461–466. Shields, L. B., D. M. Hunsaker, 3rd, J. C. Hunsaker, and J. C. Parker Jr. 2002. Sudden unexpected death in epilepsy: Neuropathologic ἀndings. Am J Forensic Med Pathol 23 (4): 307–314. Stratton, S. J., C. Rogers, and K. Green. 1995. Sudden death in individuals in hobble restraints during paramedic transport. Ann Emerg Med 25 (5): 710–712. Tennis, P., T. B. Cole, J. F. Annegers, J. E. Leestma, M. McNutt, and A. Rajput. 1995. Cohort study of incidence of sudden unexplained death in persons with seizure disorder treated with antiepileptic drugs in Saskatchewan, Canada. Epilepsia 36 (1): 29–36. Thom, M., B. Griffin, J. W. Sander, and F. Scaravilli. 1999. Amygdala sclerosis in sudden and unexpected death in epilepsy. Epilepsy Res 37 (1): 53–62. Timmings, P. L. 1993. Sudden unexpected death in epilepsy: A local audit. Seizure 2 (4): 287–290. Tomson, T., T. Walczak, M. Sillanpaa, and J. W. Sander. 2005. Sudden unexpected death in epilepsy: A review of incidence and risk factors. Epilepsia 46 (Suppl 11): 54–61. Ulrich, J., and H. Maxeiner. 2003. Tongue bite injuries—a diagnostic criterium for death in epileptic seizure? Arch Kriminol 212 (1–2): 19–29. Vilke, G. M. 2006. Neck holds. In Sudden Deaths in Custody, ed. D. L. Ross and T. C. Chan. Totowa, NJ: Humana Press. Vlooswijk, M. C., H. J. Majoie, M. C. De Krom, I. Y. Tan, and A. P. Aldenkamp. 2007. SUDEP in the Netherlands: A retrospective study in a tertiary referral center. Seizure 16 (2): 153–159. Walczak, T. 2003. Do antiepileptic drugs play a role in sudden unexpected death in epilepsy? Drug Saf 26 (10): 673–683. Walczak, T. S., I. E. Leppik, M. D’Amelio, J. Rarick, E. So, P. Ahman, K. Ruggles, G. D. Cascino, J. F. Annegers, and W. A. Hauser. 2001. Incidence and risk factors in sudden unexpected death in epilepsy: A prospective cohort study. Neurology 56 (4): 519–525.
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy Guardian of the Brain–€Heart Connection
3
Fulvio A. Scorza Esper A. Cavalheiro Ricardo M. Arida Vera C. Terra Carla A. Scorza Eliza Y. F. Sonoda Roberta M. Cysneiros
Contents 3.1 General Aspects of Sudden Unexpected Death in Epilepsy 3.2 Evidence for the Cardiovascular Beneἀts of Omega-3 3.3 The Potential Role of Omega-3 in the Management of Epilepsy 3.4 Final Considerations and Future Remarks Acknowledgment References
57 59 59 62 63 63
3.1â•…General Aspects of Sudden Unexpected Death in Epilepsy Epilepsy is the most common serious chronic neurological condition in the world. Approximately 50 million people worldwide have epilepsy (Annegers 1997; Sander 2003; Yuen and Sander 2004). Epidemiological studies suggest that, with proper treatment, between 70% and 80% of people developing epilepsy will go into remission, while the remaining patients continue to have seizures and are refractory to treatment with the currently available therapies (Sander 1993; Kwan and Sander 2004). The most common risk factors for epilepsy are cerebrovascular diseases, brain tumors, alcohol, traumatic head injuries, malformations of cortical development, genetic inheritance, and infections of the central nervous system (Halatchev 2000). In resource-poor countries, endemic infections, such as malaria and neurocysticercosis, seem to be major risk factors (Duncan et al. 2006). Temporal lobe epilepsy (TLE) is the most common form of partial epilepsy, affecting at least 20% of all patients with epilepsy (Babb 1999), and is the most common form of drugrefractory epilepsy (Engel 1993). Atrophy of mesial temporal structures is well known to be associated with TLE and hippocampal sclerosis, which is a very frequent histological abnormality in this form of epilepsy (Cendes et al. 1993). Sudden unexpected death in epilepsy (SUDEP) represents the leading cause of mortality€ in adults with refractory epilepsy (Tomson et al. 2005). SUDEP is deἀned as sudden, 57
58 Sudden Death in Epilepsy: Forensic and Clinical Issues
unexpected, witnessed or unwitnessed, nontraumatic, and nondrowning deaths in patients with epilepsy, with or without evidence of a seizure and excluding documented status epilepticus, in which postmortem examination does not reveal a toxicological or anatomical cause of death (Nashef 1997). Comparisons of incidence estimates for SUDEP are difficult since different deἀnitions of SUDEP are used, not all patients have a postmortem examination, and case ascertainment methods and source populations are varied (Tomson et al. 2005). The reported incidence of sudden unexpected deaths has been variably estimated as 3.5/1000 person-years* in a Lamotrigine clinical trial (Leestma et al. 1997), 0.5–1.4/1000 person-years in people with treated epilepsy (Tennis et al. 1995), 5.9/1000 person-years in outpatients with epilepsy at a tertiary referral center (Nashef et al. 1995), 9/1000 person-years in candidates for epilepsy surgery, and 0.35/1000 person-years in the general population (Ficker et al. 1988). Only one death attributable to SUDEP has been recorded in approximately 8000 personyears of follow-up in the National General Practice Study of Epilepsy in the United Kingdom, a community-based prospective observational study of incidence cases with epilepsy realized in a population of 792 patients with newly diagnosed epilepsy (Lhatoo et al. 1999). The results of the Medical Research Council Antiepileptic Drug Withdrawal Study showed that SUDEP among patients with epilepsy in remission is a rare event (Medical Research Council 1991). Information concerning risk factors for SUDEP is conflicting, but potential risk factors include age (Tennis et al. 1995), early onset of epilepsy (Nilsson et al. 1999), duration of epilepsy (Walczak et al. 2001), uncontrolled seizures, mainly TLE (Sperling et al. 1999; Langan et al. 2005), seizure frequency (Sperling et al. 1999; Walczak et al. 2001; Langan et al. 2005), seizure type (Kloster and Engelskjon 1999; Walczak et al. 2001; Langan et al. 2005), AED numbers (Nilsson et al. 1999; Walczak et al. 2001), and winter temperatures (Scorza et al. 2007). More recently, an elegant review article by Lathers and colleagues (2008) addressed other risk factors that could be operant in SUDEP and in cardiac disease, such as psychological factors (stress/anxiety/depression states and anger/frustration), patients’ lifestyle (e.g., cigarette smoking), and high prevalence of metabolic syndrome (obesity, dyslipidemia, glucose intolerance, and hypertension). Additionally, potential pathomechanisms for SUDEP are unknown, but a number of interictal, ictal, and postmortem cardiac abnormalities account for the possibility of seizure-induced cardiogenic SUDEP (Tomson et al. 2005; Scorza et al. 2007). Along these lines, early animal studies have also examined the role of the autonomic nervous system and cardiac arrhythmias, interictal and ictal epileptogenic activity, and SUDEP (Lathers and Schraeder 1982). Speciἀcally, Lathers and Schraeder demonstrated that intravenous pentylenetetrazol in anesthetized cats induced autonomic dysfunction associated with both interictal and ictal epileptogenic activity. The autonomic dysfunction was manifested by the fact that autonomic cardiac nerves did not always respond in a predictable manner to changes in blood pressure, the development of a marked increase in variability in mean autonomic cardiac nerve discharge, and the appearance of a very large increase in the variability of the discharge rate of parasympathetic nerves, ἀrst and then second, in sympathetic discharge. The authors concluded that altered autonomic cardiac nerve discharge was associated with interictal epileptogenic activity and arrhythmia, which may contribute to sudden unexplained death in patients with epilepsy (Lathers and Schraeder 1982).
* Person-years: the specific amount of time (years) members of the population experience over the risk period.
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy
59
3.2â•…Evidence for the Cardiovascular Benefits of Omega-3 The beneἀcial effects of omega-3 fatty acids in the cardiovascular system have been described since the 1970s. Dyerberg and Bang (1979) suggested the low prevalence of cardiac diseases in Eskimos might be due to high dietary ingestion of omega-3 fatty acids. In the same decade, a number of experimental studies showed an antiarrhythmic role of the omega-3 fatty acid (Gudbjarnason and Hallgrimsson 1976). McLennan et al. (1992) conducted several experiments to conἀrm the possible antiarrhythmic role of omega-3. Initially, it was demonstrated that a diet high in ἀsh oil (tuna) could prevent the ventricular ἀbrillation in rats induced by coronary artery occlusion following reperfusion (McLennan et al. 1992; McLennan 1993). Subsequent studies conἀrmed their previous data (McLennan et al. 1992; Yang et al. 1993; Jacobsen et al. 1997). Billman and colleagues (1997), using a sudden cardiac death model in dogs, observed a reduction of arrhythmias and sudden cardiac death following induction of ischemia after omega-3 administration (Billman et al. 1994, 1997). Moreover, several work studies demonstrated positive effects of omega-3 in arrhythmia reduction (Kang and Leaf 1994; Xiao et al. 1995; Kang and Leaf 1996; Xiao et al. 1997, 2000). The antiarrhythmic mechanism induced by omega-3 was modulated by Na+ and Ca2+ currents in cardiac cells (Leaf et al. 2003). In the same way, positive effects of omega-3 have also been observed in clinical studies. Accordingly, several studies in the 1990s demonstrated that ἀsh consumption one or two times per week was associated with a 50% reduction of sudden cardiac death (Albert et al. 1998; Siscovick et al. 2003). Furthermore, a clinical study for infarct prevention conducted by an Italian group (GISSIPrevenzione), using a dose of 850 mg/day of omega-3 in 11,324 subjects presenting a ἀrst myocardial infarction episode, observed a signiἀcant reduction of death caused by cardiovascular complications (30%) as well as in sudden death (45%) when compared to control subjects, suggesting an antiarrhythmic role of omega-3 (Marchioli 1999; Marchioli et al. 2002). In conclusion, human and animals studies have demonstrated a possible action of omega-3 in the prevention of cardiovascular abnormalities and the reduction of occurrence of sudden cardiac death.
3.3â•…The Potential Role of Omega-3 in the Management of Epilepsy As discussed above, SUDEP is the most important direct epilepsy-related situation of death (Tomson et al. 2005) and cardiovascular abnormalities during and between seizures is directly related to a high frequency of SUDEP (Stollberger and Finsterer 2004). In addition, substantial evidence from epidemiological and case-control studies indicates that omega-3 reduces the risk of cardiovascular mortality, with an especially potent effect on sudden cardiac death (Calder 2004). Thus, a possible relationship between omega-3, epilepsy, and SUDEP could be considered. Along these lines, some animal and clinical studies have shown that omega-3 could be useful in the prevention and treatment of epilepsy. In 1998, Voskuyl and colleagues, using the cortical stimulation seizure model in rats, demonstrated a modest anticonvulsant effect of long duration with the polyunsaturated fatty acids. Moreover, pharmacology studies show that polyunsaturated fatty acids applied extracellularly raise the stimulatory thresholds of CA1 neurons in hippocampal slices (Xiao and Li 1999). Recently, our group was the ἀrst to demonstrate that chronic treatment with omega-3 promotes neuroprotection
60 Sudden Death in Epilepsy: Forensic and Clinical Issues
and increases parvalbumin-positive neurons in the hippocampal formation of rats with epilepsy (Ferrari et al. 2008), suggesting that omega-3 leads to prominent positive plastic changes in the hippocampal formation of rats with epilepsy (Figure 3.1). From a clinical viewpoint, Schlanger et al. (2002) reported on an open clinical trial in which ἀve patients took omega-3 supplements. In this study, a special food spread containing 65% omega-3 fatty acids was added to the daily diet of ἀve patients with epilepsy. The patients consumed 5 g of this spread at every breakfast for 6 months and all of them showed a marked reduction in both frequency and severity of epileptic seizures, suggesting that a dietary supplement containing omega-3 may be beneἀcial in the suppression of some cases of epileptic seizures. Recently, in the ἀrst randomized, placebo-controlled, parallel group of omega-3 supplementation, seizure frequency was reduced over the ἀrst 6 weeks of treatment in the supplement group, but this effect was not sustained (Yuen and Sander 2004). The authors think the decrease in seizures following the initial 6 weeks is a result of omegaÂ�-3 preparations, doses, treatment duration, and sample sizes. Speciἀcally, the researchers used a total daily dose of approximately 1.7 g omega-3, approximately 1 g eicosapentaenoic acid (EPA)
CV
CW
CA1
EV
EW
HILUS CA3
CA1
CA3
Hilus
Figure 3.1╇ Photomicrographs of PV-stained coronal sections in the hippocampal formation (CA1, CA3 regions and hilus of the dentate gyrus) of animals treated daily with vehicle (cremophor 0.009%) (CV); animals treated daily with 85 mg/kg omega-3 (CW); animals with epilepsy treated with vehicle (EV) and animals with epilepsy treated with 85 mg/kg omega-3, on a daily basis (EW). PV-positive neurons are significantly higher in animals with epilepsy treated with omega-3 (EW) when compared with untreated animals with epilepsy (EV), and control animals (CV, CW). (Scale bar, 800 µm.)
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy
61
and 0.7 g docosahexaenoic acid (DHA), and suggested that additional doses and omega-3 preparations should be tested. Concerning treatment duration and sample sizes, a 12-week, double-blind, placebo-controlled, parallel group trial of omega-3 supplementation in 57 patients with refractory epilepsy was evaluated. Since a reduction in seizures within the ἀrst 6 weeks of starting supplementation with omega-3 was observed, the authors also purposed that studies using longer treatment durations with larger sample sizes should be undertaken. As omega-3 fatty acids, per se, have been shown to reduce cardiac arrhythmias and sudden cardiac deaths (Calder 2004), Yuen and Sander (2004) proposed the interesting hypothesis that omega-3 fatty acid supplementation in patients with refractory seizures may reduce seizures and seizure-associated cardiac arrhythmias and, hence, SUDEP. According to this reasoning, two experimental studies developed by our group could reinforce this hypothesis. First, we evaluated the heart rate, using in vivo (ECG) and isolated ex vivo preparations (Langendorf preparation) of rats with epilepsy (Colugnati et al. 2005). Our results showed signiἀcant differences in the mean heart rate in vivo between the groups. In contrast, we did not ἀnd differences during isolated ex vivo situations, suggesting a central nervous system modulation on the heart, which could explain a risk for SUDEP (Figure€3.2). Quite interestingly, Scorza and colleagues (unpublished data) evaluated the same set of experiments (heart rate in vivo and isolated ex vivo preparation) in rats
(a) 300 200 100 0
Heart rate in vitro (bpm)
200
Control
Rats with epilepsy Ventricular pressure (mm Hg) in vitro
Heart rate in vivo (bpm)
400
(b)
150 100 50 0
Control
Rats with epilepsy
80 70
(c)
60 50 40 30 20 10 0
Control
Rats with epilepsy
Figure 3.2╇ Results obtained by Colugnati, Gomes, and Arida (2005). (a) Heart rate in vivo; Heart rate of isolated ex vivo preparation (b); Ventricular pressure of isolated ex vivo situation (c) from control and rats with epilepsy. Note that heart rate in vivo is significantly higher in rats with epilepsy. *p < 0.05.
62 Sudden Death in Epilepsy: Forensic and Clinical Issues
with epilepsy before and after chronic omega-3 administration. The results showed differences in the mean heart rate in vivo but, surprisingly, no differences in heart rates could be observed in the isolated ex vivo condition. It has been suggested that the use of certain antiepileptic drugs, especially carbaÂ� mazepine (CBZ), may predispose patients to SUDEP (Stollberger and Finsterer 2004). Furthermore, carbamazepine has been shown to affect the autonomic nervous system and the conduction system of the heart, mainly when associated with elevated plasma levels above 40 µmol/l (Stollberger and Finsterer 2004). Following this reasoning, Yuen and coworkers (2008) reported very recently the fatty acids (FAs) proἀles in red blood cells and plasma obtained prior to and following omega-3 FA supplementation in 56 patients with epilepsy, providing an opportunity to examine potential effects of antiepileptic drugs on FA proἀles (Yuen et al. 2008). They showed that patients on CBZ exhibited a less favorable FAs proἀle, associated with a greater risk of coronary heart disease mortality. In summary, the authors concluded that, as arrhythmias are thought to be important mechanisms in coronary heart disease mortality and SUDEP, the effect of CBZ in reducing omega-3 FAs might potentially explain some cases of SUDEP among patients prescribed the antiepileptic drug. Taking all of the data together, the ἀrst randomized, placebo-controlled parallel group study of omega-3 supplementation in patients with chronic epilepsy showed only a transient effect on seizure frequency that was not conἀrmed by other research groups, but indicates that additional trials are required (DeGiorgio and Miller 2008; Scorza et al. 2008). These results did not totally conἀrm that omega-3 fatty acids reduce the frequency of epileptic seizures in patients with intractable epilepsy; however, they established the safety of omega-3 supplementation in people with epilepsy (DeGiorgio and Miller 2008). Quite interestingly, there is now great interest in n-3 fatty acids for the prevention of SUDEP (DeGiorgio and Miller 2008; Scorza et al. 2008) and we have to bear in mind that, as omega-3 fatty acids have been shown to reduce cardiac arrhythmias and sudden cardiac deaths, it could be suggested that omega-3 fatty acid supplementation in patients with refractory seizures may reduce seizures and seizure-associated cardiac arrhythmias and, hence, SUDEP. Nonetheless, it is very important to emphasize that nutritional therapy (e.g., omega-3 supplementation) is not a substitute for anticonvulsant medications.
3.4â•…Final Considerations and Future Remarks Polyunsaturated fatty acids are present at high levels in the brain (DeGiorgio and Miller 2008). The 04 polyunsaturated fatty acids are EPA and DHA, which are n-3 fatty acids (omega-3) and dihomogammalinolenic acid (DGLA) and arachidonic acid (AA), which are n-6 fatty acids (omega-6) (Calon and Cole 2007; Ohara 2007). Dietary consumption of the long-chain omega-3 fatty acids, commonly found in ἀsh and ἀsh oil, not only contribute to human central nervous system development, but also may modify the risk for certain adult nervous system diseases, including epilepsy (Voskuyl et al. 1998; Bourre 2004). Following this reasoning, eating ἀsh is certainly a good way to improve the development of the brain, ranging from the composition of cell membranes to cerebral function. All omega-3 fatty acids are important for treatment or prevention of cardiovascular and neurological diseases (Bourre and Paquotte 2008; Scorza et al. 2008). The only foods that provide large amounts of omega-3 are seafood such as certain types of ἀnἀsh and shellἀsh. The highest
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy
63
omega-3 concentrations with the lowest levels of mercury are anchovies, Atlantic herring, Atlantic mackerel, scallops, wild salmon, canned salmon, sardines, and trout (Smith and Sahyoun 2005; Bourre and Paquotte 2008). In sum, a number of different dietary modiἀcations, nutritional supplements, and hormones may help prevent seizures or improve other aspects of health in patients with epilepsy (Gaby 2007). Based on this, new diet-based supplementary therapeutic strategies should be developed with the aim of decreasing seizure frequency and severity in people with epilepsy. Concerning cardioprotective omega-3, it has long been believed that a daily intake of 3000 to 4000 mg of ἀsh oil supplements or two to three servings of fatty ἀsh per week are safe and effective for adults in general, including those with neurological, inflammatory, and neurodegenerative diseases, such as multiple sclerosis, Alzheimer’s disease, and Parkinson’s disease (Mazza et al. 2007). While it is very important to emphasize that nutritional therapy (including omega-3 supplementation) is not a substitute for anticonvulsant medications, experimental, epidemiological, and clinical studies should be evaluated to establish with precision the possible supplementary beneἀt of omega-3 in the treatment of epilepsy.
Acknowledgment The authors thank Danuza Ferrari for technical assistance, and FAPESP, CInAPCeFAPESP, and CNPq for supporting this study.
References Albert, C. M., C. H. Hennekens, C. J. O’Donnell, et al. 1998. Fish consumption and risk of sudden cardiac death. JAMA 279: 23–28. Annegers, J. F. 1997. Epidemiology of epilepsy. In The Treatment of Epilepsy: Principles and Practice, 2nd ed., ed. E. Wyllie, 165–172. Baltimore, MD: Williams & Wilkins. Babb, T. L. 1999. Synaptic reorganizations in human and rat hippocampal epilepsy. Adv Neurol 79: 763–779. Billman, G. E., H. Hallaq, and A. Leaf. 1994. Prevention of ischemia-induced ventricular ἀbrillation by omega 3 fatty acids. Proc Natl Acad Sci U S A (91): 4427–4430. Billman, G. E., J. X. Kang, and A. Leaf. 1997. Prevention of ischemia-induced cardiac sudden death by n-3 polyunsaturated fatty acids in dogs. Lipids 32: 1161–1168. Bourre, J. M. 2004. Roles of unsaturated fatty acids (especially omega-3 fatty acids) in the brain at various ages and during aging. J Nutr Health Aging 8: 163–174. Bourre, J. M., and P. Paquotte. 2008. Seafood (wild and farmed) for the elderly: Contribution to the dietary intakes of iodine, selenium, DHA and vitamins B12 and D. J Nutr Health Aging 12: 186–192. Calder, P. C. 2004. N-3 fatty acids and cardiovascular disease: Evidence explained and mechanisms explored. Clin Sci 107: 1–11. Calon, F., and G. Cole. 2007. Neuroprotective action of omega-3 polyunsaturated fatty acids against neurodegenerative diseases: Evidence from animal studies. Prostaglandins Leukot Essent Fatty Acids 77: 287–293. Cendes, F., F. Leproux, D. Melanson, et al. 1993. MRI of amygdala and hippocampus in temporal lobe epilepsy. J Comput Assist Tomogr 17: 206–210. Colugnati, D. B., P. A. Gomes, R. M. Arida, et al. 2005. Analysis of cardiac parameters in animals with epilepsy: Possible cause of sudden death? Arq Neuropsiquiatr 23: 1035–1041.
64 Sudden Death in Epilepsy: Forensic and Clinical Issues DeGiorgio, C. M., and P. Miller. 2008. N-3 fatty acids (eicosapentanoic and docosahexanoic acids) in epilepsy and for the prevention of sudden unexpected death in epilepsy. Epilepsy Behav 13: 712–713. Duncan, J. S., J. W. Sander, S. M. Sisodiya, and M. C. Walker. 2006. Adult epilepsy. Lancet 367: 1087–1100. Dyerberg, J., and H. O. Bang. 1979. Haemostatic function and platelet polyunsaturated fatty acids in Eskimos. Lancet 2: 433–435. Engel, Jr., J. 1993. Update on surgical treatment of the epilepsies. Summary of the Second International Palm Desert Conference on the Surgical Treatment of the Epilepsies. Neurology 43: 1612–1617. Ferrari, D., R. M. Cysneiros, C. A. Scorza, et al. 2008. Neuroprotective activity of omega-3 fatty acids against epilepsy-induced hippocampal damage: Quantiἀcation with immunohistochemical for calcium-binding proteins. Epilepsy Behav 13: 36–42. Ficker, D. M., E. L. So, W. K. Shen, et al. 1998. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 515: 1270–1274. Gaby, A. R. 2007. Natural approaches to epilepsy. Altern Med Rev 12: 9–24. Gudbjarnason, S., and J. Hallgrimsson. 1976. Prostaglandins and polyunsaturated fatty acids in heart muscle. Acta Biol Med Ger 35: 1069–1080. Halatchev, V. N. 2000. Epidemiology of epilepsy—recent achievements and future. Folia Med (Plovdiv) 42: 17–22. Jacobsen, A. N., X. J. Du, A. M. Dart, and E. A. Woodcock. 1997. Ins (1, 4, 5) P3 and arrhythmogenic responses during myocardial reperfusion: Evidence for receptor speciἀcity. Am J Physiol 273: H1119–H1125. Kang, J. X., and A. Leaf. 1994. Effects of long-chain polyunsaturated fatty acids on the contraction of neonatal rat cardiac myocytes. Proc Natl Acad Sci U S A 91: 9886–9890. Kang, J. X., and A. Leaf. 1996. Antiarrhythmic effects of polyunsaturated fatty acids. Recent studies. Circulation 94: 1774–1780. Kloster, R., and T. Engelskjon. 1999. Sudden unexpected death in epilepsy (SUDEP): A clinical perspective and a search for risk factors. J Neurol Neurosurg Psychiatry 67: 439–444. Kwan, P., and J. W. Sander. 2004. The natural history of epilepsy: An epidemiological view. J Neurol Neurosurg Psychiatry (75): 1376–1381. Langan, Y., L. Nashef, and J. W. Sander. 2005. Case-control study of SUDEP. Neurology 64: 1131–1133. Lathers, C. M., and P. L. Schraeder. 1982. Autonomic dysfunction in epilepsy: Characterization of autonomic cardiac neural discharge associated with pentylenetetrazol-induced epileptogenic activity. Epilepsia 23: 633–647. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008. The mystery of sudden death: Mechanisms for risks. Epilepsy Behav 12: 3–24. Leaf, A., J. X. Kang, Y. F. Xiao, and G. E. Billman. 2003. Clinical prevention of sudden cardiac death by n-3 polyunsaturated fatty acids and mechanism of prevention of arrhythmias by n-3 ἀsh oils. Circulation 107: 2646–2652. Leestma, J. E., J. F. Annegers, M. J. Brodie, et al. 1997. Sudden unexplained death in epilepsy: Observations from a large clinical development program. Epilepsia 38: 47–55. Lhatoo, S. D., Y. Langan, B. K. MacDonald, S. Zeidan, and J. W. Sander. 1999. Sudden unexpected death: A rare event in a large community based prospective cohort with newly diagnosed epilepsy and high remission rates. J Neurol Neurosurg Psychiatry 66: 692–693. Marchioli, R. 1999. Results of GISSI Prevenzione: Diet, drugs, and cardiovascular risk. Researchers of GISSI Prevenzione. Cardiologia 44: 745–746. Marchioli, R., F. Barzi, E. Bomba, et al. 2002. GISSI-Prevenzione Investigators. Early protection against sudden death by n-3 polyunsaturated fatty acids after myocardial infarction: Time-course analysis of the results of the Gruppo Italiano per lo Studio della Sopravvivenza nell’Infarto Miocardico (GISSI)-Prevenzione. Circulation 105: 1897–1903.
Omega-3 Fatty Acids in Sudden Unexpected Death in Epilepsy
65
Mazza, M., M. Pomponi, L. Janiri, P. Bria, and S. Mazza. 2007. Omega-3 fatty acids and antioxidants in neurological and psychiatric diseases: An overview. Prog Neuropsychopharmacol Biol Psychiatry 31: 12–26. McLennan, P. L. 1993. Relative effects of dietary saturated, monounsaturated, and polyunsaturated fatty acids on cardiac arrhythmias in rats. Am J Clin Nutr 57: 207–212. McLennan, P. S., T. M. Bridle, M. Y. Abeywardena, and J. S. Charnock. 1992. Dietary lipid modulation of ventricular ἀbrillation threshold in the marmoset monkey. Am Heart J 123: 1555–1561. Medical Research Council. 1991. Antiepileptic Drug Withdrawal Study Group. Randomised study of antiepileptic drug withdrawal in patients in remission. Lancet 337: 1175–1180. Nashef, L. 1997. Sudden unexpected death in epilepsy: Terminology and deἀnitions. Epilepsia 38: S6–S8. Nashef, L., D. R. Fish, J. W. Sander, and S. D. Shorvon. 1995. Incidence of sudden unexpected death in an adult outpatient cohort with epilepsy at a tertiary referral centre. J Neurol Neurosurg Psychiatry 58: 462–464. Nilsson, L., B. Y. Farahmand, P. G. Persson, I. Thiblin, and T. Tomson. 1999. Risk factors for sudden unexpected death in epilepsy: A case-control study. Lancet 353: 888–893. Ohara, K. 2007. The n-3 polyunsaturated fatty acid/dopamine hypothesis of schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 31: 469–474. Sander, J. W. 1993. Some aspects of prognosis in the epilepsies: A review. Epilepsia 34: 1007–1016. Sander, J. W. 2003. The epidemiology of epilepsy revisited. Curr Opin Neurol 16: 165–170. Schlanger, S., M. Shinitzky, and D. Yam. 2002. Diet enriched with omega-3 fatty acids alleviates convulsion symptoms in epilepsy patients. Epilepsia 43: 103–104. Scorza, F. A., M. Albuquerque, R. M. Arida, and E. A. Cavalheiro. 2007. Sudden unexpected death in epilepsy: Are winter temperatures a new potential risk factor? Epilepsy Behav 10: 509–510. Scorza, F. A., R. M. Cysneiros, R. M. Arida, V. C. Terra-Bustamante, M. de Albuquerque, and E. A. Cavalheiro. 2008. The other side of the coin: Beneἀciary effect of omega-3 fatty acids in sudden unexpected death in epilepsy. Epilepsy Behav 13: 279–283. Siscovick, D. S., R. N. Lemaitre, and D. Mozaffarian. 2003. The ἀsh story: A diet-heart hypothesis with clinical implications: n-3 polyunsaturated fatty acids, myocardial vulnerability, and sudden death. Circulation 107: 2632–2634. Smith, K. M., and N. R. Sahyoun. 2005. Fish consumption: Recommendations versus advisories, can they be reconciled? Nutr Rev 63: 39–46. Sperling, M. R., H. Feldman, J. Kinman, J. D. Liporace, and M. J. O’Connor. 1999. Seizure control and mortality in epilepsy. Ann Neurol 46: 45–50. Stollberger, C., and J. Finsterer. 2004. Cardiorespiratory ἀndings in sudden unexplained/unexpected death in epilepsy (SUDEP). Epilepsy Res 59: 51–60. Tennis, P., T. B. Cole, J. F. Annegers, J. E. Leestma, M. McNutt, and A. Rajput. 1995. Cohort study of incidence of sudden unexplained death in persons with seizure disorder treated with antiepileptic drugs in Saskatchewan, Canada. Epilepsia 36: 29–36. Tomson, T., T. Walczak, M. Sillanpaa, and J. W. Sander. 2005. Sudden unexpected death in epilepsy: A review of incidence and risk factors. Epilepsia 46: 54–61. Voskuyl, R. A., M. Vreugdenhil, J. X. Kang, and A. Leaf. 1998. Anticonvulsant effect of polyunsaturated fatty acids in rats, using the cortical stimulation model. Eur J Pharmacol 341 (2–3): 145–52. Walczak, T. S., I. E. Leppik, M. D’Amelio, et al. 2001. Incidence and risk factors in sudden unexpected death in epilepsy: A prospective cohort study. Neurology 56: 519–525. Xiao, Y., and X. Li. 1999. Polyunsaturated fatty acids modify mouse hippocampal neuronal excitability during excitotoxic or convulsant stimulation. Brain Res 846: 112–121. Xiao, Y. F., A. M. Gomez, J. P. Morgan, W. J. Lederer, and A. Leaf. 1997. Suppression of voltage-gated L-type Ca2+ currents by polyunsaturated fatty acids in adult and neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A 94: 4182–4187. Xiao, Y. F., J. X. Kang, J. P. Morgan, and A. Leaf. 1995. Blocking effects of polyunsaturated fatty acids on Na+ channels of neonatal rat ventricular myocytes. Proc Natl Acad Sci U S A 92: 11000–11004.
66 Sudden Death in Epilepsy: Forensic and Clinical Issues Xiao, Y. F., S. N. Wright, G. K. Wang, J. P. Morgan, and A. Leaf. 2000. Coexpression with beta(1)subunit modiἀes the kinetics and fatty acid block of hH1(alpha) Na(+) channels. Am J Physiol Heart Circ Physiol 279: H35–H46. Yang, B. C., T. G. Saldeen, J. L. Bryant, W. W. Nichols, and J. L. Mehta. 1993. Long-term dietary ἀsh oil supplementation protects against ischemia–reperfusion-induced myocardial dysfunction in isolated rat hearts. Am Heart J 126: 1287–1292. Yuen, A. W., and J. W. Sander. 2004. Is omega-3 fatty acid deἀciency a factor contributing to refractory seizures and SUDEP? A hypothesis. Seizure 13: 104–107. Yuen, A. W., J. W. Sander, D. Flugel, et al. 2008. Erythrocyte and plasma fatty acid proἀles in patients with epilepsy: Does carbamazepine affect omega-3 fatty acid concentrations? Epilepsy Behav 12: 317–323.
Unanswered Questions SUDEP Studies Needed Claire M. Lathers Paul L. Schraeder Michael W. Bungo
4
Contents 4.1 Omega-3 Fatty Acid Nutritional Deἀciency 4.2 Low Temperatures as a Risk Factor for Cardiovascular Abnormalities and Sudden Death 4.3 Mechanisms of SUDEP: Possible Role of Autonomic Effects Such as Cardiorespiratory Disturbances 4.3.1 Beneἀcial Effects of Physical Activity Related to Reductions in Sympathetic Activity 4.3.2 Autonomic Cardiorespiratory Disturbances as Factors for SUD or SUDEP 4.3.3 Langendorf Isolated Heart Preparation References
67 68 69 69 69 71 72
Our recent review article entitled “Mystery of Sudden Death: Mechanisms for Risks” (Lathers et al. 2008a) examined the overlapping mechanisms that apply to the risk of sudden unexpected death occurring in epilepsy (SUDEP) and in cardiac disease. The information in this article has been updated in Chapter 1 of this book (Lathers et al. 2010). The role of central and peripheral autonomic nervous systems and the cardiopulmonary systems and the interaction between them was explored. The potential interactive role of genetically determined subtle cardiac risk factors for arrhythmias with a predisposition for seizure-Â�related cardiac arrhythmias and the possible mechanisms that are operant in producing both epileptogenic and cardiogenic arrhythmias were addressed. Potential preventive measures to minimize risk of both SUDEP and sudden cardiac death were presented. This information has been updated in several chapters in this book (Lathers 2010, animal models; Lathers and Schraeder 2010b, AED; Lathers and Schraeder 2010c, SUDEP animal model). Scorza et al. (2008, 2010, Chapter 3), raised important issues above and beyond standard medical intervention for the prevention of sudden death in cardiac patients, or in patients with epilepsy at risk for sudden death, by focusing on the importance of lifestyle issues. We discuss these lifestyle issues and comment on several points of clariἀcation of the information presented by Scorza et al. (2008, 2010, Chapter 3).
4.1â•…Omega-3 Fatty Acid Nutritional Deficiency The beneἀcial effect of nutritional aspects of omega-3 fatty acids may decrease cardiac arrhythmias and sudden death (SUD) in patients with cardiac disease. Some questions must be raised for future studies; for example: 67
68 Sudden Death in Epilepsy: Forensic and Clinical Issues
1. Does a nutritional deἀciency in omega-3 fatty acids become a risk factor for SUDEP? Today, there is no answer. Whether Omega-3 fatty acids deἀciency is a risk factor for the relatively young population prone to SUDEP, mean age 32.5–43.5 years (Leestma 1990), is unknown. Studies designed to address this question are needed. Unless someone has familial hypercholesterolemia with very high levels of cholesterol at a young age, we do not see that cholesterol is a clinically signiἀcant risk or predisposition to cardiac disease for the young population at risk for SUDEP. The beneἀcial cardiovascular effect of omega-3 fatty acids to decrease sudden death in cardiac patients may be due to actions on cholesterol levels. 2. Will this cardioprotective effect, independent of the effect on cholesterol levels, be of beneἀt to patients with epilepsy? The answer does not exist at this time, but there is nothing bad to be said for including omega-3 fatty acids in your diet to gain long term nutritional beneἀts, since eating ἀsh containing omega-3 fatty acids may decrease the risk of sudden cardiac death. We do not see a downside to consuming omega-3 fatty acids to decrease the risk of SUDEP, even though at this time there is no proven possibility that omega-3 fatty acids may also have a speciἀc beneἀcial effect on SUDEP. While nutritional therapy that includes omega-3 fatty acids supplementation is not a substitute for anticonvulsant medications, there may be a role for these fatty acids as a supplement to antiepileptic drugs (Scorza et al. 2008).
4.2â•…Low Temperatures as a Risk Factor for Cardiovascular Abnormalities and Sudden Death Scorza et al. (2008) discussed low ambient temperatures as a potential risk factor for cardiovascular abnormalities and, possibly, sudden death. When considering the possible role of low temperatures as a risk factor, several questions must be raised: 1. Exactly how does one deἀne low temperatures? 2. What is the degree range used to deἀne low temperatures and the duration necessary in this low degree range? 3. Is there a dose response with an increased risk of sudden death related to the lower temperatures? 4. If low temperatures are a risk factor for sudden death, how does one counsel patients to avoid cold? Should patients be advised to not ski, snow shoe, ice skate, or walk in the cold and be advised to dress warmly, avoid hypothermia, and move to Houston, Florida, or Southern Spain? During the winter, increases in hemoconcentration (erythrocyte count, plasma cholesterol, and plasma ἀbrinogen levels) occur and may contribute to arterial thrombosis (Neild et al. 1994). It is important to differentiate between the pathological and normal response of the body for protection versus the response to hypothermia. If these physiological changes are normal defense mechanisms, they may be difficult to modify except for a physical move to a temperate climate. One would also not expect patients living in a colder climate to stop participation in outdoor winter activities. Additional studies are needed to
Unanswered Questions: SUDEP Studies Needed
69
conἀrm the basis of this cold theory since it has been challenged by several epidemiological studies, including the study of Kloner et al. (1999).
4.3â•…Mechanisms of SUDEP: Possible Role of Autonomic Effects Such as Cardiorespiratory Disturbances 4.3.1â•…Beneficial Effects of Physical Activity Related to Reductions in Sympathetic Activity Morbidity and mortality in cardiovascular disease are often associated with elevations in sympathetic nervous system activity (Scorza et al. 2008). Increased physical activity does have a beneἀcial cardiovascular interaction. This raises the question: “Will increased physical activity be of beneἀcial input if one assumes cardiovascular sympathetic dysfunction or insufficiency in persons with epilepsy?” In general, exercise does not have a downside, if the patient is sufficiently cardiovascularly ἀt to perform the exercise regimen selected. If exercise is beneἀcial in preventing SUDEP, it will be a great ἀnding. However, even if there is no protective or preventive effect for sudden death resulting from exercise, there is certainly no reason for a patient with epilepsy not to exercise. 4.3.2â•…Autonomic Cardiorespiratory Disturbances as Factors for SUD or SUDEP Autonomic involvement in SUDEP is associated with even minimal epileptogenic activity and may cause altered autonomic activity and balance (Scorza et al. 2008). This may be characterized by alterations in cardiorespiratory parameters including ECG changes, blood pressure, respiration, and vasomotor tone (Hirsh and Martin 1971; Lathers and Schraeder 1982; Schraeder and Lathers 1983; Wannamaker 1985). ECG changes observed in experimental epilepsy include heart rate changes, arrhythmias, conduction blocks, altered ECG morphology, and QT interval changes (Lathers and Schraeder 1982, 1987; Schraeder and Lathers 1983; Lathers et al. 1987; Mameli et al. 1988). Paroxysmal autonomic dysfunction associated with epileptogenic discharges may be a factor in sudden death as they cause a disruption of cardiac and/or respiratory function (Schraeder and Lathers 1990; Lathers and Schraeder 2010c, Chapter 28). Stress itself must also be considered in sudden death, since the occurrence of a seizure may cause the release of catecholamines from the adrenal glands (Doba et al. 1975) and may predispose the heart to development of arrhythmias when confronted with a sudden sympathetic neural barrage induced by epileptogenic discharges (Lathers et al. 2008a, 2008b; Schraeder and Lathers 1990; Pickworth et al. 1990; Lathers and Schraeder 2006, 2010a, 2010b, 2010c). The central nervous system modiἀes the heart in response to environmental stress (Lathers and Schraeder 2006, 2010a). Adverse emotional states impact the autonomic control of cardiac rhythm and are known factors leading to cardiac dysrhythmias in humans. Interactions between emotional factors and the arrythmogenic potential of epileptiform discharges, as well as the possible beneἀt from stress management intervention have yet to be investigated (Lathers and Schraeder 2006). Central nervous system modulation of peripheral autonomic neural discharges to the heart is a risk factor for sudden death in patients with cardiac disease (Lathers et al.
70 Sudden Death in Epilepsy: Forensic and Clinical Issues
1977, 1978; Evans and Gillis 1978) and is also a risk factor for sudden death in persons with epilepsy. Lathers and Schraeder (1982) and Schraeder and Lathers (1983) developed a cat model with an intact central nervous system to explore epilepsy/autonomic neural/ cardiopulmonary system relationships as possible mechanisms of SUDEP. They reported cardiac sympathetic neural nonuniform discharges in association with seizure discharges congruent with increased temporal dispersion of the recovery of ventricular excitability, leading to an underlying electrical instability that predisposes the ventricular myocardium to arrhythmia (Han and Moe 1964). Druschky et al. (2001) reported sympathetic dysfunction in the form of altered postganglionic cardiac sympathetic innervation in patients with chronic temporal lobe epilepsy and suggested altered postganglionic cardiac sympathetic innervation may increase risk of cardiac abnormalities and/or SUDEP. Studies are needed to explore both the developmental and regulatory mechanisms responsible for determining the density and pattern of cardiac sympathetic innervation and the exact role of disturbances associated with the exact location of the innervation in arrhythmogenesis (see discussion by Lathers and Levin 2010, Chapter 33). When evaluating mechanisms of SUDEP, one must also consider that there may be an underlying, undeἀned genetic predisposition to arrhythmias. Thus, it is very likely that the mechanism of sudden death varies from patient to patient, depending on a predisposition to neurogenically induced autonomic dysfunction, be it sympathetic or parasympathetic, and on the status of symptoms and disease present at the time of death. Animal data (Lathers et al. 1987; Stauffer et al. 1989; Lathers et al. 1990) demonstrated the lockstep phenomenon (LSP), postganglionic cardiac sympathetic and vagal discharges that were time-locked to ictal and interictal cortical epileptiform activity. It was suggested that the LSP may explain propagation of electrical impulses to autonomic nervous system regulatory centers, thus initiating arrhythmogenic potentials and premature ventricular contractions, ST/T changes, and conduction blocks occurring concurrently with the cerebral discharges (see Chapter 28, Lathers and Schraeder 2010c, LSP). Numerous experimental preparations could be devised to study in vivo and in vitro methods to modify function of the central nervous system and peripheral autonomic neural activity—reserpine, 6-OH dopamine or bretylium denervation, surgical denervation, adrenalectomy, and various combinations (Lathers et al. 1981, 1982; Lathers 2010, animal models). Epileptogenic activity is associated with cardiac rate and rhythm changes (Howell and Blumhardt 1990). Quint et al. (1990) discussed power spectral analysis of the heart rate as a technique to assess autonomic activity related to risk factors for SUDEP. Goodman et al. (1990; 2010, Chapter 40) found a typical cardiovascular response during a generalized kindled seizure in rats consisted of a large increase in blood pressure accompanied by a profound bradycardia during the ἀrst 20–30 seconds of the seizure. Lathers and Schraeder (1982) reported bradycardia associated with interictal subconvulsant epileptogenic in cats that died in asystole; an increase in heart rate occurred in animals dying in ventricular ἀbrillation. GABA neurotransmission regulates, in part, the central control of cardiovascular function (Schwartz and Lathers 1990). Inhibition of central GABAergic tone using picrotoxin or bicuculline results in enhanced sympathetic outflow to the heart and increased coronary resistance and arrhythmias (Segal et al. 1984). GABAA, introduced into the cerebroventricles prior to the agonist muscimol, prevents these cardiac changes. It may be clearly seen that neuronal excitability/inhibitory state in the central nervous system is important for development of seizures and cardiovascular abnormalities, including arrhythmias. When patients with generalized tonic–clonic seizures on no medications were compared with normal controls, the patients exhibited higher standard deviation of all R–R
Unanswered Questions: SUDEP Studies Needed
71
intervals, standard deviation of mean R–R intervals in 5-min recordings, and heart rate variability compared to normal controls. Heart rate variability exhibited a reduction in high-frequency parasympathetic activity and an increase in low-frequency sympathetic values (Everengul et al. 2005). Heart rate variability in epilepsy patients is lower at night than during the daytime, indicating subtle autonomic dysfunction at night, when risk of SUDEP is greatest (Woodley et al. 1977). Control of the heart rate is perturbed by alterations in neuroautonomic function in clinical syndromes of sudden cardiac death, congestive failure, space sickness, and physiologic aging. Fractal mechanisms in cardiac electrophysiology suggest that loss of normal fractal complexity in the interbeat interval dynamics may not be detected using conventional statistics but are quantiἀed using methods derived from the “chaos theory” (Goldberger 1991). There is a loss of complex physiological variability in pathological conditions, including heart rate dynamics, before sudden death. Cardiac chaos is prevalent in healthy hearts and a decrease of cardiac chaos occurs in congestive heart failure (Poon and Merrill 1997). Use of detrended fluctuation analysis of heart beat time series may distinguish healthy from pathologic data sets (Peng et al. 1995). Studies on patients need to be done to determine how to identify which persons with epilepsy are at risk for SUDEP. Arrhythmogenesis and acute hypoxia have been shown to interact in a negative manner and the combination becomes a risk factor for SUDEP. Acute pulmonary edema may develop during a clinical seizure and lung weights are known to be increased in animal studies (Lathers and Schraeder 1982; Carnel et al. 1985) and in victims of SUDEP (Koehler et al. 2010, Chapter 9). Simon et al. (1982) and Johnston et al. (1995, 1997) demonstrated that seizure induction in a sheep model produced acute pulmonary edema and a neurogenically induced increase in pulmonary microvascular pressure with an accompanying prolonged change in endothelial conductance to protein. In some animals, the neurogenic pulmonary edema was linked to seizures associated with central nervous system–induced apnea. Thus, when an increased risk for arrhythmias is combined with acute hypoxemia associated with the occurrence of neurogenic pulmonary edema and/or associated central apnea, sudden death may be the outcome. For additional information about the role of arrhythmogenesis and acute hypoxia as risk factors for SUDEP, the reader is referred to Lathers et al. (2008), Mameli and Alessandro (2010, Chapter 37), and Lathers et al. (2010, Chapter 1). 4.3.3â•…Langendorf Isolated Heart Preparation Cardiac arrhythmias may trigger sudden death in cardiac patients, originating from three sources: directly from the heart; from the peripheral autonomic nervous system; from the central nervous system; or from combinations of some or all of these factors (Lathers et al. 1977, 1978). Central and peripheral autonomic neural input is not present in the Langendorf isolated beating heart preparation. This preparation is used to examine drug actions on the heart, independent of autonomic neural input and independent of circulating substances such as catecholamines (Lathers et al. 1981, 1982). In vivo animal data may be compared with data obtained in the Langendorf preparation to study the contributory role of the autonomic nervous system to cardiac arrhythmias and/or death. Langendorf hearts may be obtained from animals denervated chemically by pretreatment with reserpine, bretylium or 6-hydroxydopamine, or from rats whose hearts were surgically denervated. Comparison of data from these various animal models reveals data about the role
72 Sudden Death in Epilepsy: Forensic and Clinical Issues
of the actual heart rate in initiation of cardiac arrhythmias and/or sudden death. Thus, the various experimental designs allow clariἀcation of the role of autonomic innervation and influences of the central and peripheral nervous system in relation to epileptogenic activity, heart rate, arrhythmias, and sudden death. Comparison of mean heart rates in vivo and in isolated ex vivo preparation (Langendorf preparation) in rats with epilepsy has been done (Colugnati et al. 2005). Data showed differences in mean heart rates in vivo, but no differences in heart rate in ex vivo, suggesting a central nervous system modulation of the heart may lead to SUDEP. This conclusion seems logical since the Langendorf preparation is an isolated heart preparation devoid of input from the central nervous system. The Langendorf preparation has been used to study the ability of digitalis glycosides to induce arrhythmias and seizures (Lathers, 1990). In conclusion, mechanisms of SUDEP include risk categories of arrhythmogenic factors, respiratory factors and hypoxia, and psychological factors (Lathers et al. 2008a, 2008b). Clariἀcation of risk factors and establishment of the mechanisms of SUDEP will help to develop preventative measures for SUDEP. It appears to be most important to attempt full seizure control. Scorza et al. (2008) encourage patients with epilepsy to receive nonmedical, lifestyle-modifying interventions that have accepted public health beneἀts, even though there is as yet no consensus that they may or may not prevent sudden death. Both animal studies and clinical studies are needed to deἀnitely address the risk factors of omega-3 fatty acids, cold temperatures, exercise, and heart rate for development of cardiac arrhythmias and/or SUDEP. Prospective studies of persons with epilepsy are needed to determine how to identify which persons with epilepsy are at risk for SUDEP (Lathers et€al. 2008a, 2008b).
References Carnel, S. B., P. L. Schraeder, and C. M. Lathers. 1985. The effect of phenobarbital pretreatment on cardiac neural discharge and pentylenetetrazol-induced epileptogenic activity. Pharmacology 20: 225–240. Colugnati, D. B., P. A. Gomes, R. M. Arida et al. 2005. Analysis of cardiac parameters in animals with epilepsy: Possible cause of sudden death? Arq Neuropsiquiatr 46: 54–61. Doba, N., H. R. Beresford, and D. J. Reis. 1975. Changes in regional blood flow and cardiodynamics associated with electrically and chemically induced epilepsy in the cat. Brain Res 47: 487–491. Druschky, A., M. J. Hiltz, P. Hopp et al. 2001. Interictal cardiac autonomic dysfunction in temporal lobe epilepsy demonstrated by 123I meta-iodobenzylguanidine-SPECT. Brain 124: 372–382. Evans, D. E., and R. A. Gillis. 1978. Reflex mechanisms involved in cardiac arrhythmias induced by hypothalamic stimulation. Am J Physiol 234: H199–H209. Everengul, H., H. Tanriverdi, D. Dursunoglu et al. 2005. Time frequency domain analyses of heart rate variability in patients with epilepsy. Epilepsy Res 63: 131–139. Fowler, R. S., L. Rathl, and J. D. Keith. 1964. Accidental digitalis intoxication in children. J Pediatr 64: 188–199. Goldberger, A. L. 1992. Fractal mechanisms in the electrophysiology of the heart. IEEE Eng Med Biol Mag 11: 47–52. Goldberger, A. L. 1991. Is the normal heartbeat chaotic or homeostatic? New Physiol Sci 6: 87–91. Goodman, J., R. W. Homan, and I. L. Crawford. 2010. Cardiovascular responses during kindled seizures. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 40. Boca Raton, FL: CRC Press.
Unanswered Questions: SUDEP Studies Needed
73
Goodman, J. H., R. W. Homan, and I. L. Crawford. 1990. Acute cardiovascular response during kindled seizures. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter€11, 169–186. New York, NY: Marcel Dekker. Han, J., and G. K. Moe. 1964. Nonuniform recovery of excitability in ventricular muscle. Circ Res 14: 44–60. Hirsh, C. S., and L. M. Martin. 1971. Unexpected death in young epileptics. Neurology 21: 682–690. Howell, S. J., and L. D. Blumhardt. 1990. The role of EEG monitoring in the diagnosis of epilepsyrelated cardiac arrhythmias and of cardiac arrhythmias mimicking epilepsy. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 7, 101–119. New York, NY: Marcel Dekker. Johnston, S. C., J. K. Horn, U. Valente, and R. P. Simon. 1995. The role of hypoventilation in a sheep model of epileptic sudden death. Ann Neurol 37: 531–537. Johnston, S. C., R. Siedenberg, J. K. Min, E. H. Jerome, and K. D. Laxer. 1997. Central apnea and acute cardiac ischemia in a sheep model of epileptic sudden death. Ann Neurol 42: 588–594. Kloner, R. A., W. K. Poole, and R. L. Perritt. 1999. When throughout the year is coronary death most likely to occur?: A 12-year population-based analysis of more than 200,000 cases. Circulation 100: 1630–1634. Koehler, S. A., P. L. Schraeder, C. M. Lathers, and C. Wecht. 2010. Forensic postmortem results of sudden epilepsy death. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 9. Boca Raton, FL: CRC Press. Lathers, C. M. 2010. Sudden death animal models to study nervous system sites of action for disease and pharmacological intervention. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 25. Boca Raton, FL: CRC Press. Lathers, C. M. 1990. Glycoside-induced arrhythmias and seizures. 1990. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 20, 375–391. New York, NY: Marcel Dekker. Lathers, C. M., J. L. Gerard-Ciminera, S. I. Baskin, J. C. Krusz, G. J. Kelliher, and J. Roberts. 1981. The action of reserpine, 6-hydroxydopamine, and bretylium on digitalis-induced cardiotoxicity. Eur J Pharmacol 76: 371–379. Lathers, C. M., J. L. Gerard-Ciminera, S. I. Baskin et al. 1982. Role of the adrenergic nerve terminal in digitalis-induced cardiac toxicity: A study of the effects of pharmacological and surgical denervation. J Cardiovasc Pharmacol 4: 91–98. Lathers, C.M., K. F. Jim, W. H. Spivey, C. Kahn, K. Dolce, and W. D. Matthews. 1990. Antiepileptic activity of beta-blocking agents. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 24, 485–505. New York, NY: Marcel Dekker. Lathers, C. M., G. J. Kelliher, J. Roberts, and A. B. Beasley. 1978. Nonuniform cardiac sympathetic nerve discharge: Mechanism for coronary occlusion and digitalis-induced arrhythmia. Circulation 57: 1058–1065. Lathers, C. M., and R. M. Levin. 2010. Animal model for sudden cardiac death: Sympathetic innervation and myocardial beta-receptor densities. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 33. Boca Raton, FL: CRC Press. Lathers, C. M., J. Roberts, and G. J. Kelliher. 1977. Correlation of ouabain-induced arrhythmia and nonuniformity in the histamine-evoked discharge of cardiac sympathetic nerves. J Pharmacol Exp Ther 203: 467–479. Lathers, C. M., and P. L. Schraeder. 1982. Autonomic dysfunction in epilepsy: Characterization of autonomic cardiac neural discharge associated with pentylenetetrazol-induced epileptogenic activity. Epilepsia 23: 633–647. Lathers, C. M., and P. L. Schraeder. 1987. Review of autonomic dysfunction, cardiac arrhythmias and epileptogenic activity. J Clin Pharmacol 27: 346–356.
74 Sudden Death in Epilepsy: Forensic and Clinical Issues Lathers, C. M., and P. L. Schraeder. 2006. Stress and sudden death. Epilepsy Behav 9: 236–242. Lathers, C. M., and P. L. Schraeder. 2010a. Stress and sudden death in persons with epilepsy (SUDEP). In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M.€W. Bungo, and J. E. Leestma, Chapter 17. Boca Raton, FL: CRC Press. Lathers, C. M., and P. L. Schraeder. 2010b. Antiepileptic drugs. Beneἀt/risk clinical pharmacology. Possible role in cause or prevention of SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 47. Boca Raton, FL: CRC Press. Lathers, C. M., and P. L. Schraeder. 2010c. Animal model for sudden unexpected death in persons with epilepsy (SUDEP). In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 28. Boca Raton, FL: CRC Press. Lathers, C. M., P. L. Schraeder, and M. Bungo. 2008a. Mystery of sudden death: Mechanisms for risks. Epilepsy Behav 12: 3–24. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008b. Reply. Epilepsy Behav 13: 265–269. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2010. Risk factors for sudden death. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 1. Boca Raton, FL: CRC Press. Lathers, C. M., P. L. Schraeder, and F. L. Winer. 1987. Synchronization of cardiac autonomic neural discharge with epileptogenic activity. The lockstep phenomenon. Electroencephalogr Clin Neurophysiol 67: 247–259. Leestma, J. E. 1990. Natural history of epilepsy. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 1, 11–26. New York, NY: Marcel Dekker. Mameli, O., and C. M. Alessandro. 2010. Sudden epileptic death in experimental animal models. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 37. Boca Raton, FL: CRC Press. Mameli, P., O. Mameli, E. Tolu et al. 1988. Neurogenic myocardial arrhythmias in experimental focal epilepsy. Epilepsia 29: 74–82. Neild, P. J., D. Syndercombe-Court, W. R. Keatinge, G. C. Donaldson, M. Mattock, and M. Caunce. 1994. Cold-induced increases in erythrocyte count, plasma cholesterol and plasma ἀbrinogen of elderly people without a comparable rise in protein C or factor X. Clin Sci 86: 43–48. Peng, C. K., S. Havlin, H. E. Stanley, and A. L. Goldberger. 1995. Quantiἀcation of scaling exponents and crossover phenomena in nonstationary heartbeat time series. Chaos 5: 82–87. Pickworth, W. B., J. Gerard-Ciminera, and C. M. Lathers. 1990. Stress, arrhythmias, and seizures. In Epilepsy and Sudden Death, ed C. M. Lathers and P. L. Schraeder, Chapter 22, 417–446. New York, NY: Marcel Dekker. Poon, C. S., and C. K. Merrill. 1997. Decrease of cardiac chaos in congestive heart failure. Nature 389: 492–495. Quint, S. R., J. A. Messenheimer, and M. B. Tennison. 1990. Power spectral analysis as a procedure for assessing autonomic activity related to risk factors for sudden and unexplained death in epilepsy. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 16, 261–291. New York, NY: Marcel Dekker. Schraeder, P. L., and C. M. Lathers. 1983. Cardiac neural discharge and epileptogenic activity in the cat: An animal model for unexplained death. Life Sci. 32: 1371–1382. Schraeder, P. L., and C. M. Lathers. 1990. Paroxysmal autonomic dysfunction. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, Chapter 8, 121–133. New York, NY: Marcel Dekker. Schwartz, R. D., and C. M. Lathers. 1990. CM GAMA transmission, epileptogenic activity, and cardiac arrhythmias. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder. Chapter€17, 293–308. New York, NY: Marcel Dekker. Scorza, F. A., R. M. Arida, and E. A. Cavalheiro. 2008. Preventive measures for sudden cardiac death in epilepsy beyond therapies. Epilepsy Behav 13: 263–244.
Unanswered Questions: SUDEP Studies Needed
75
Scorza, F. A., A. Esper, A. Cavalheiro et al. 2010. Omega-3 fatty acids in SUDEP: Guardian of the brain-heart connection. In Sudden Death in Epilepsy: Forensic and Clinical Issues, ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma, Chapter 3. Boca Raton, FL: CRC Press. Segal, S. A., T. Jacob, and R. A. Gillis. 1984. Blockade of central nervous system GABAergic tone causes sympathetic-mediated increases in coronary vascular resistance in cats. Circ Res 55: 404–414. Simon, R. P., L. L. Bayne, R. F. Tranbaugh, and F. R. Lewis. 1982. Elevated pulmonary flow and protein content during status epilepticus in sheep. J Appl Physiol 52: 91–95. Stauffer, A. Z., J. Dodd-O, and C. M. Lathers. 1989. The relationship of the lock step phenomenon and precipitous changes in mean arterial blood pressure. Electroencephalogr Clin Neurophysiol 72: 340–345. Wannamaker, B. B. 1985. Autonomic nervous system and epilepsy. Epilepsia 26 (S1): 31–39. Woodley, D., W. Chambers, H. Starke, B. Dzindzio, and A. D. Forker. 1977. Intermittent complete atrioventricular block masquerading as epilepsy in the mitral valve prolapse syndrome. Chest 72: 369–372.
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome Implications in SUDEP
5
David S. Paterson
Contents 5.1 5.2 5.3 5.4
Sudden Infant Death Syndrome Serotonin and the Medullary 5-HT System Abnormalities in the Medullary 5-HT System in SIDS Medullary 5-HT Abnormalities and SIDS Risk Factors 5.4.1 Sleep Environment and Infection 5.4.2 Male Gender 5.4.3 Maternal Smoking 5.4.4 Maternal Drinking 5.5 5-HT Gene Polymorphisms and SIDS 5.6 SIDS as a Developmental Disorder That Originates in Utero 5.7 SIDS Results from a Combination of€Environmental and Genetic Factors 5.8 Brain Stem 5-HT Dysfunction and SUDEP 5.9 Conclusions References
77 78 79 80 81 81 83 84 84 85 85 86 87 87
5.1â•…Sudden Infant Death Syndrome The sudden infant death syndrome (SIDS) is deἀned as the sudden death of an infant less than 1 year of age, with the onset of the fatal episode occurring during sleep, that remains unexplained after a thorough investigation, including performance of a complete autopsy and review of the circumstances of death and the clinical history (Krous et al. 2004). Despite signiἀcant reductions in SIDS rates in recent years due to successful risk-reduction campaigns, SIDS remains the leading type of death of infants between 1 month and 1 year of age in developed countries (Moon et al. 2007). The majority (90%) of SIDS deaths occur within the ἀrst 6 postnatal months, with the peak incidence observed at 2–4 months of age (Task Force on Sudden Infant Death Syndrome 2005). Multiple studies have identiἀed robust associations between SIDS and environmental risk factors, including prone or face-down sleeping, bed sharing, and overbundling (Task Force on Sudden Infant Death Syndrome 2005). Several risk factors for SIDS relate to the mother and pregnancy, including prematurity, low birth weight, maternal cigarette smoking, and alcohol, cocaine, and heroin use during pregnancy (Kinney and Paterson 2004; Task Force on Sudden Infant Death Syndrome 2005). Evidence of recent infection is a common ἀnding in SIDS cases 77
78 Sudden Death in Epilepsy: Forensic and Clinical Issues Critical period
2–4 Postnatal months
Underlying abnormality
e.g., 5-HT defect
Vulnerable infant
SIDS
Prone sleeping, overbundling, infection
Stressor
Figure 5.1╇ The Triple Risk Model of SIDS. SIDS occurs when three factors impinge on the
infant simultaneously—an underlying vulnerability in the infant, a critical period in developÂ� ment, and a homeostatic stressor at the time of infant death. (From Filiano, J. J., and H. C. Kinney, Biol Neonate, 65 (3–4), 194–197, 1994. With permission.)
at autopsy (Task Force on Sudden Infant Death Syndrome 2005). There is also a male bias in SIDS with twice as many boys dying of SIDS than girls (Moon et al. 2007). The triple risk hypothesis of SIDS has proven useful in thinking about SIDS causation (see Figure 5.1) (Filiano and Kinney 1994). It posits that SIDS occurs when three factors impinge on the infant simultaneously—an underlying vulnerability in the infant, a critical period in development (the ἀrst 6 postnatal months when 90% of SIDS occurs), and a homeostatic stressor at the time of infant death (e.g., hypercapnia from rebreathing exhaled air as a result of sleeping prone in the face-down position). Increasing evidence, including studies from our laboratory, suggests that the underlying vulnerability involves a developmental defect in brain stem serotonergic (5-HT) systems that results in the failure of protective cardiorespiratory responses to potentially life-threatening but normally occurring events (e.g., hypoxia, hypercapnia), in the infant during sleep. In this chapter, I review the evidence to support a role of medullary 5-HT abnormalities in the pathogenesis of SIDS, the putative in utero origin of these abnormalities, and how environmental and genetic factors interact to ultimately result in sudden death of the infant. I begin by describing the medullary 5-HT system and its role in maintenance of homeostasis.
5.2â•…Serotonin and the Medullary 5-HT System Serotonin (5-HT) is a monoamine neurotransmitter, the synthesis of which involves the rate-limiting enzyme tryptophan hydroxylase (TPH), which is in turn the marker of the 5-HT cell phenotype. Neurons synthesizing 5-HT (and expressing TPH) are exclusive to the brain stem in distinct cell groups classically deἀned as B1–B9 that differentially project to virtually all regions of the neuraxis (Hornung 2003; Tork and Hornung 1990). These cell groups are divided into a rostral domain consisting of groups B4–B9, and a caudal domain consisting of groups B1–B3. The two domains of the brain stem 5-HT neurons are distinct
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome Caudal
Mid
GC
HG
Arc
Rostral
NTS
NTS
PIO
79
GC
Rob
PGCL
IRZ
Rob
PGCL
PIO
PIO Arc
Arc
Figure 5.2╇ The medullary 5-HT system consists of 5-HT neurons (areas in red) in the midline
raphe [raphe obscurus (Rob)], extra-raphe [gigantocellularis (GC), paragigantocellularis lateralis (PGCL), and intermediate reticular nucleus (IRZ)], and the ventral medullary surface [arcuate nucleus (Arc)] and the sites that they project to (blue areas) that do not contain 5-HT neurons, but mediate homeostatic functions [e.g., the hypoglossal nucleus (HG) and the nucleus of the solitary tract (NTS)]. This figure shows coronal sections at the level of the caudal, mid, and rostral medulla. (From Kinney, H. C. et al., Auton Neurosci, 132 (1–2), 81–102, 2007. With permission.)
in their developmental origins, functions, and connectivity (Hornung 2003; Tork and Hornung 1990). The rostral domain, located in the upper brain stem, projects “rostrally” and diffusely to the cerebral cortex, thalamus, hypothalamus, basal ganglia, hippocampus, and amygdala. It participates in the mediation of arousal, cognition, mood, motor activity, and cerebral blood flow. The caudal domain in the lower brain stem or medulla projects “caudally” and diffusely to other brain stem sites and to the cerebellum and spinal cord (Hornung 2003; Tork and Hornung 1990). Extensive animal data indicates that 5-HT neurons in the caudal medullary domain influence multiple homeostatic functions mediated by the medulla, including chemosensitivity (Bernard et al. 1996; Dreshaj et al. 1998; Messier et al. 2004; Richerson 1995, 1997, 2004; Wang et al. 1998), respiratory rhythm generation (Pena and Ramirez 2002; Tryba et al. 2006), drive (Bou-Flores et al. 2000), plasticity (Baker-Herman et al. 2004; Ling et al. 2001), blood pressure regulation (Henderson et al. 2000), thermoregulation (Berner et al. 1999), upper airway reflexes (Hilaire et al. 1993; Holtman et al. 1987; Kubin et al. 1992), and arousal (Bartlett et al. 1990; Darnall et al. 2005; Krammer et al. 1979). The medullary 5-HT system, as deἀned by us, consists of the 5-HT neuronal cell bodies located in the midline raphe, lateral extra-raphe, and ventral surface of the medulla in the caudal 5-HT domain (see Figure 5.2) (Kinney and Paterson 2004). We view the medullary 5-HT system as the “central integrator” for the coordination of synchronous homeostatic function via projections to and modulation of effector neurons, or mediating circuits that produce speciἀc homeostatic responses (Kinney et al. 2007).
5.3â•…Abnormalities in the Medullary 5-HT System in SIDS Abnormalities in markers of 5-HT function have been observed in the medullary 5-HT system (i.e., raphe obscurus, gigantocellularis, paragigantocellularis lateralis, intermediate reticular zone, arcuate nucleus, and hypoglossal nucleus) in SIDS infants, including an increased number of 5-HT neurons, many of which are immature (Paterson et al. 2006),
80 Sudden Death in Epilepsy: Forensic and Clinical Issues 3
H-8-OH-DPAT
Control
5-HT1A Receptor Binding Medullary 5-HT Source Nuclei
3
SIDS
Rob
H-8-OH-DPAT Binding Density (fmol/mg)
70 60 50 40 30 20 10 0 (a)
(b)
Rob
GC
PGCL
IRN
ARC
Figure 5.3╇ 5-HT1A receptor binding density in SIDS and control cases. (a) Illustrative autoradiograms displaying 3H-8-OH-DPAT binding (fmol/mg ± SEM) to 5-HT1A receptors in a tissue section from a control and a SIDS case at the mid-medulla level. The density of 5-HT1A receptor binding sites, including in the raphe obscurus (Rob), is visually lower in the SIDS case compared to the control case. (b) Graph comparing the density of 3H-8-OH-DPAT binding to 5-HT1A receptors in medullary nuclei containing 5-HT cells in SIDS and control cases. 5-HT1A receptor binding density is significantly lower in SIDS cases compared to controls. (***p€< 0.001, **p€< 0.01, *p < 0.05, ANCOVA.) RO, raphe obscurus; GC, gigantocellularis nucleus; PGCL, paragigantocellularis lateralis nucleus; IRN, intermediate reticular nucleus; ARC, arcuate nucleus. (From Paterson, D. S. et al., JAMA, 296 (17), 2124–2132, 2006. With permission.)
reduced 5-HT1A (see Figure 5.3), and 5-HT2A receptor expression (Kinney et al. 2003; Ozawa and Okado 2002; Ozawa and Takashima 2002; Panigrahy et al. 2000; Paterson et al. 2006), reduced 5-HTT binding (Paterson et al. 2006), abnormal TPH expression (Machaalani et al. 2009; Sawaguchi et al. 2003), reduced brain 5-HT levels (Sparks and Hunsaker 1991), altered 5-HT turnover (Cann-Moisan et al. 1999), and altered 5-HT breakdown (Sparks and Hunsaker 1991). These observations inform the idea that multiple elements of respiratory and autonomic regulation, mediated by the 5-HT system, are defective in SIDS, including but not restricted to respiratory rhythmogenesis and respiratory responses to hypercapnic and/or hypoxic challenge. This idea is supported by a SIDS infant who was observed to have subtle respiratory and cardiac dysfunction at birth and 5-HT receptor binding abnormalities at autopsy 2 weeks later (Kinney et al. 2005). Taken together, the above observations provide evidence to support the idea that medullary 5-HT abnormalities cause homeostatic dysfunction that potentially contributes to the death of the infant in SIDS, i.e., in terms of the Triple Risk Model of SIDS, the medullary 5-HT defect is, or is part of, the underlying abnormality that predisposes the infant to sleep-related death, particularly when combined with an environmental stressor, such as prone sleeping, during the critical developmental period.
5.4â•…Medullary 5-HT Abnormalities and SIDS Risk Factors Multiple studies have identiἀed robust correlations between environmental factors such as sleep position, infection, and prenatal exposure to cigarette smoke and alcohol, and
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome
81
increased risk of SIDS. The mechanisms by which these risk factors adversely affect and predispose an infant to SIDS, however, are unknown and their elucidation is a major goal of SIDS research. In our SIDS studies, we have explored the potential effects of recognized SIDS risk factors on markers of 5-HT function to determine their potential role in the pathogenesis of SIDS. We categorize SIDS risk factors as either vulnerability factors or stressors based on the nature of their contribution to the Triple Risk Model of SIDS. Vulnerability factors are related to the development of the underlying abnormality (i.e., medullary 5-HT abnormality) that predisposes infants to increased SIDS risk and include male gender, race, and prematurity. Stressors are exogenous environmental factors that impact upon the infant at the time of death including prone sleep position, face-down sleeping, bed sharing, and infection. Prenatal and neonatal exposure to alcohol and cigarette smoke can be considered as both vulnerability factors and stressors because they may contribute to the development of the underlying abnormality as well as have a direct adverse effect on the protective physiological responses to homeostatic challenges in the infant at the time of death. The relationship between SIDS risk factors and medullary 5-HT abnormalities in SIDS is discussed below. 5.4.1â•…Sleep Environment and Infection In our most recent study of SIDS (Paterson et al. 2006), despite public health campaigns promoting safe sleep practices for infants, we found that 77% (24/31) of SIDS deaths were associated with an unsafe sleep environment (i.e., prone/side sleeping, or bed-sharing), with 48% (15/31) found in the prone sleep position. Similarly, we found that 42% (13/31) of SIDS cases had a history of illness in the days prior to death. Unsafe sleep environment, prematurity, and infection remain, therefore, major risk factors for SIDS. However, we did not observe a signiἀcant association between any of these risk factors and markers of 5-HT function in SIDS. These observations are based on a relatively small sample size and, thus, need to be repeated in a larger dataset to conἀrm their validity. However, these observations support the idea that environmental stressors expose an underlying vulnerability (i.e., medullary 5-HT abnormalities) in SIDS infants that renders them unable to adequately respond to changing physiological conditions, ultimately leading to the death of the infant. 5.4.2â•…Male Gender Twice as many male infants die of SIDS as female infants (Task Force on Sudden Infant Death Syndrome 2005). The reason for this is unknown, but the identiἀcation of a signiἀcantly lower density of 5-HT1A receptor binding in male compared to female SIDS infants (see Figure 5.4) (Paterson et al. 2006) suggests that sexual dimorphism in 5-HT function may play a role in predisposing male infants to SIDS. Indeed, signiἀcant differences in TPH, 5-HT, 5-HT metabolites, and 5-HT receptor expression normally exist between males and females in several brain regions including a lower level of 5-HT1A receptors (Arango et al. 1995; Dillon et al. 1991; Ferrari et al. 1999; Parsey et al. 2002). Evidence from studies in animals with 5-HT lesions have reported male gender-speciἀc abnormalities in respiration, chemosensitivity, and thermoregulation (Hodges et al. 2008; Li and Nattie 2008; Penatti et al. 2006) and responses that are modulated in part by 5-HT1A receptors in the medullary raphe and extra-raphe (Brown et al. 2008; Darnall et al. 2005; Hoffman et al.
82 Sudden Death in Epilepsy: Forensic and Clinical Issues 70 5-HT1A binding (fmol/mg)
60 50
Controls n = 6 Female SIDS n = 6 Male SIDS n = 6
40 30 20 10 0
Figure 5.4╇ 5-HT1A receptor binding in the raphe obscurus by sex. 5-HT1A receptor binding is
lower in male SIDS cases. Graph comparing 5-HT1A receptor binding density measured with 3H 8-OH DPAT autoradiography in the raphe obscurus in male and female SIDS cases, compared to controls infants. 5-HT1A receptor binding density in male SIDS infants is significantly lower compared to female SIDS infants (*p = 0.04). 5-HT1A receptor binding in both male (p = 0.02) and female (p = 0.05) SIDS infants is significantly lower compared to controls. (From Paterson, D.S. et al., JAMA, 296 (17), 2124–2132, 2006. With permission.)
2007; Messier et al. 2004). These observations raise the possibility that male human infants may similarly have reduced sensitivity to CO2 and temperature and that loss of medullary 5-HT1A receptors, as observed in SIDS, may attenuate protective homeostatic responses to a greater extent in male compared to female infants, thus placing them at greater risk for SIDS. Evidence from animal studies also suggests reduced plasticity in 5-HT neuron function in males compared to females. Deἀcits in postnatal brain levels of 5-HT1A receptor expression following prenatal cocaine and cigarette smoke exposure persist for a greater length of time in male compared to female rats (Johns et al. 2002; Slotkin et al. 2007a, 2007b), suggesting that the neonatal male infant brain is less resilient to exposure to at least some pharmacologically active toxins affecting 5-HT function in the maternal circulation than the neonatal female brain. The reason for these differences is unclear, but may in part be due to intrinsic differences in the level of sex steroids in males and females as both testosterone and estrogen influence the 5-HT system and its control of respiration (Bayliss et al. 1990; Bayliss and Millhorn 1992; Emery et al. 1994; Fogel et al. 2001; Liu et al. 2003; Matsumoto et al. 1985; Pickett et al. 1989; Regensteiner et al. 1990; Zhou et al. 2003). Moreover, SIDS infants have elevated levels of serum testosterone compared to controls (Emery et al. 2005); preterm infants—a high risk population—have signiἀcantly higher adrenal-derived androgens in the ἀrst year of life compared to term infants (Tapanainen et al. 1981); and the peak SIDS incidence between 2 and 4 months of age coincides with the peak postnatal increase in gonadal steroids (Forest et al. 1980; Peterson and Kennedy 1979; Winter et al. 1976). Thus, the normal higher levels of testosterone in male infants compared to female infants may be responsible for blunted respiratory responses to homeostatic challenges such as hypercapnia, thereby contributing to their greater SIDS risk. Taking these observations together, intrinsic differences in baseline brain 5-HT function, 5-HT neuronal plasticity, and CO2 sensitivity between males and females provide evidence that may explain, at least in part, the greater risk of SIDS in male infants.
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome
83
5.4.3â•…Maternal Smoking The Aberdeen Indian Health Service Infant Mortality Study (Randall et al. 2001) involved analysis of factors contributing to infant death in a high-risk population for SIDS, the American Indians in the Northern Plains (Kinney et al. 2003). At the time of the study (1992–1996), the SIDS rate in this population was 3.46/1000 live births, compared to an overall SIDS rate in the United States of 0.76/1000 live births, and the overall rate in the Indian Health Service of 1.6/1000 (Iyasu et al. 2002). As part of this study, we explored the effect of prenatal exposure to cigarette smoke on medullary 5-HT binding in a dataset of SIDS cases and controls. Multivariate analyses revealed that 5-HT receptor binding was signiἀcantly lower in infants whose mothers smoked during pregnancy (irrespective of the cause of infant death) (see Figure 5.5), and suggest that prenatal smoking exposures adversely affect postnatal 5-HT receptor binding in the medullary 5-HT system. Evidence from studies in experimental animals supports the idea that prenatal exposure to nicotine and cigarette smoke alters 5-HT development and function, including altered 5-HT neuron ἀring, 5-HT receptor expression (Kenny et al. 2001; Slotkin et al. 2006a, 2006b; Slotkin and Ryde 2007; Slotkin and Seidler 2006), 5-HTT expression (Muneoka et al. 2001) Slotkin et al. 2007a, 2007b; Slotkin and Ryde 2007; Xu et al. 2001), 5-HT turnover, and depletion of the brain 5-HT in the postnatal period (King et al. 1991; Muneoka et al. 1997). These adverse effects appear to result from the binding of nicotine to nicotinic and/or 5-HT receptors on 5-HT neurons (Aznar et al. 2005; Bitner and Nikkel 2002; Cucchiaro and Commons 2003). In the developing human medulla, we found that nicotinic receptors are expressed by 5-HT neurons throughout the medullary 5-HT system, including in the raphe obscurus and arcuate nucleus (Duncan et al. 2008a). These observations suggest, therefore, that the increased risk of SIDS associated with maternal smoking during pregnancy involves, at least in part, mechanisms that alter the development and function of the medullary 5-HT system in the infant.
15
No Yes
10
*
5
0
Maternal smoking
Maternal drinking
Figure 5.5╇ Effect of maternal smoking and drinking on infant 5-HT receptor binding. 5-HT
receptor binding is significantly lower in the arcuate nucleus of infants exposed to cigarette smoke prenatally. Graphs comparing the effects of prenatal smoking and prenatal drinking on the effects of 5-HT receptor binding measured with 3H LSD autoradiography in the infant postnatally. Maternal smoking during pregnancy is associated with a 40% reduction (*p = 0.011) and maternal drinking during pregnancy is associated with a 32% reduction (p = 0.075) in 5-HT receptor binding postnatally in the infant. (From Kinney, H. C. et al., J€Neuropathol Exp Neurol, 62 (11), 1178–1191, 2003. With permission.)
84 Sudden Death in Epilepsy: Forensic and Clinical Issues
5.4.4â•…Maternal Drinking In the Aberdeen Area Infant Mortality Study (AAIMS), we also explored the effect of prenatal exposure to alcohol on medullary 5-HT binding. A trend for reduced 5-HT receptor binding was observed in the arcuate nucleus of infants of mothers who drank alcohol compared to nondrinking mothers (see Figure 5.5) (Kinney et al. 2003). In animal models of prenatal alcohol exposure, various abnormalities of the 5-HT system have been observed, including reduced cortical 5-HT levels and 5-HT receptors (Druse and Paul 1988), retarded process outgrowth and migration of 5-HT neurons, reduced density of 5-HT ἀbers in the medial forebrain bundle, and reduced 5-HT neurons in the median and dorsal raphe (Sari et al. 2001; Zhou et al. 2002) and lower brain stem (Druse et al. 2004). Prenatal alcohol also adversely affects signaling molecules and transcription factors necessary for 5-HT development, e.g., sonic hedgehog, which is involved in the early speciἀcation of 5-HT precursors (Ahlgren and Bronner-Fraser 1999; Ahlgren et al. 2002). The delivery of the 5-HT1A agonist buspirone or ipsapirone in maternal rats prevents the alcohol-induced loss of brain stem 5-HT neurons in the pups, underscoring the potential value of targeting 5-HT receptors clinically as a successful therapeutic strategy (Druse et al. 2004; Kim and Druse 1996). Therefore, prenatal exposure to alcohol, particularly in combination with exposure to cigarette smoke, may adversely affect the development and function of the medullary 5-HT system, thereby potentially increasing the risk of the exposed infant to SIDS.
5.5â•…5 -HT Gene Polymorphisms and SIDS Several studies have identiἀed signiἀcant associations between SIDS and gene polymorphisms resulting in alterations in 5-HT neuronal function and development. These include two polymorphisms in the 5-HTT gene that result in differential gene expression. The ἀrst of these is an insertion/deletion polymorphism in the gene promoter region (5-HTTLPR), producing a short “S” and a long “L” allele that consist of 14 copies and 16 copies of the insertion, respectively (Heils et al. 1997; Lesch and Mossner 1998). The L allele and LL genotype are associated with increased gene expression and have been observed more frequently in SIDS cases compared to controls (Narita et al. 2001; Nonnis Marzano et al. 2008; Opdal et al. 2008; Weese-Mayer et al. 2003). The second polymorphism is a variable number tandem repeat (VNTR) polymorphism in the second intron of the 5-HTT gene (Intron 2) that consists of 9, 10, or 12 copies of the repeat element (Ogilvie et al. 1996). Similarly, the 12/12 genotype is associated with increased gene expression and is observed more frequently in SIDS populations (Fiskerstrand et al. 1999; MacKenzie and Quinn 1999; Weese-Mayer et al. 2003). Reuptake activity is thought to be higher in the brains of individuals with the L and/or 12 alleles because there is increased gene expression and efficiency of 5-HT uptake in vitro (Greenberg et al. 1999; Heils et al. 1997; Lesch and Mossner 1998; van Dyck 2004). Thus, 5-HT concentrations at the synapse are likely lower in SIDS infants with the LL and/or the 12/12 genotype, which may exacerbate an existing 5-HT defect. Another study identiἀed an increased frequency of a VNTR polymorphism in the promoter region of the monoamine oxidase A (MAOA) gene in SIDS cases, compared to controls (Nonnis Marzano et al. 2008). MAOA is the major catabolic enzyme for 5-HT degradation and, therefore, plays an important role in the regulation of brain 5-HT levels. The polymorphism consists of a 30-bp repeat sequence present in 3, 3.5, 4, or 5 copies that
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome
85
affect gene transcriptional activity, with 3.5 or 4 copies of the repeat sequence associated with increased transcription (Deckert et al. 1999; Sabol et al. 1998). Filonzi et al. (2009) identiἀed an increased frequency of the 4/4 genotype in SIDS cases compared to controls, suggesting increased expression of MAOA and, by extrapolation, reduced levels of 5-HT in SIDS cases, compared to controls. Thus, each of the three polymorphisms described above putatively results in reduced availability of 5-HT in SIDS. A rare mutation (IVS2 191_190insA) upstream of the third exon of the human ἀfth Ewing variant (FEV) gene has also been associated with SIDS (Rand et al. 2007). FEV is the human homologue of the ETS domain transcription factor Pet-1 that is necessary for differentiation and development of 5-HT neurons (Hendricks et al. 1999), including regulation of TPH, 5-HTT, and 5-HT1A receptor gene expression (Hendricks et al. 1999, 2003; Iyo et al. 2005; Maurer et al. 2004; Pfaar et al. 2002). Loss of the Pet-1 gene in mice results in failure of approximately 70% of 5-HT neurons to differentiate (Hendricks et al. 1999) and deἀcient expression of genes required for 5-HT synthesis, uptake, and vesicular storage in the remaining 5-HT neurons (Hendricks et al. 2003). The FEV gene mutation may, therefore, result in or predispose an infant to medullary 5-HT dysfunction and, thus, SIDS.
5.6â•…SIDS as a Developmental Disorder That Originates in Utero Several observations indicate that SIDS is a developmental disorder that originates during fetal life. The incidence of SIDS is greater in preterm and growth-restricted infants; the peak incidence of SIDS is related to a critical and ἀnite early developmental period (2–4 postnatal months), and prenatal exposure to environmental toxins including cigarette smoke (Anderson et al. 2005; Blair et al. 1996; Fleming et al. 1996; Haglund 1993; MacDorman et al. 1997; Mitchell and Milerad 2006; Schoendorf and Kiely 1992; Wisborg et al. 2000) and alcohol (Alm et al. 1999; Duncan et al. 2008b; Filonzi et al. 2009; Iyasu et al. 2002; Kinney et al. 2003; Klug et al. 2003; Scragg et al. 1993) are major risk factors for SIDS. Evidence from postmortem human studies suggests that the development of the medullary 5-HT system is abnormal in SIDS, including an increased number of 5-HT neurons with immature morphology (Paterson et al. 2006), abnormal/immature synapse formation (Paterson et al. 2006), and differential age-related changes in 5-HT receptor binding (i.e., binding decreases signiἀcantly with postnatal age in SIDS cases but not in controls) in the medulla of SIDS cases compared to controls (Kinney et al. 2003; Panigrahy et al. 2000). These observations offer a possible explanation for the low incidence of SIDS during the ἀrst postnatal month, followed by the period of peak incidence at 2–4 months: At birth, 5-HT function is relatively normal, but becomes progressively defective during the ἀrst postnatal month as 5-HT receptor binding decreases; by 2–4 months, 5-HT dysfunction reaches the threshold, whereby the infant is unable to respond appropriately to an environmental stressor (e.g., hypoxia), ultimately leading to the sudden death of the infant.
5.7╅SIDS Results from a Combination of€Environmental and Genetic Factors Fetal programming refers to the concept that prenatal exposure to drugs or other toxic agents can permanently reorganize or reprogram neural circuitry, altering physiological
86 Sudden Death in Epilepsy: Forensic and Clinical Issues
and behavioral systems, and thereby increasing vulnerability to illness or disorders in later life (de Moura et al. 2008; Rinaudo and Lamb 2008; Tremblay and Hamet 2008). Despite the adverse effects of prenatal alcohol and cigarette smoke exposure on fetal medullary 5-HT function and development, it is unlikely that exposure to environmental toxins alone is sufficient to cause SIDS, as only some infants exposed to alcohol and cigarette smoke die while others do not. Similarly, not all infants who sleep prone die of SIDS. Thus, some infants must be inherently more susceptible to SIDS than others, e.g., those with 5-HT gene mutations that render the fetus less resilient to toxic exposures and homeostatic stressors. We propose, therefore, that SIDS is a multifactorial disease that results from the superimposition of environmental toxins upon a predisposing genetic background.
5.8â•…Brain Stem 5-HT Dysfunction and SUDEP Sudden unexplained death in epilepsy (SUDEP) is the sudden unexpected death of an individual with epilepsy, who was otherwise well, and in whom no other cause for death can be found, despite thorough postmortem examination and blood tests (Langan et al. 2005; Nei et al. 2004; Tomson et al. 2005). SUDEP is frequently associated with sleep and, while the cause is unknown, it is proposed to result from mechanisms involving cardiorespiratory and autonomic dysfunction (So et al. 2009). Indeed, patients with epilepsy commonly display acidosis, hypoxia (Swallow et al. 2002), apnea (Blum et al. 2000), bradycardia, asystole (Rugg-Gunn et al. 2004), and arrhythmias (Nei et al. 2004; Zijlmans et al. 2002) after seizure. SUDEP, therefore, shares a number of deἀning characteristics with SIDS, raising the possibility that the diseases share a common pathogenesis, i.e., SUDEP results from an underlying medullary 5-HT abnormality that results in failure of cardiorespiratory function, leading to the death of the individual following seizure. Indeed, 5-HT dysfunction is associated with epilepsy and seizure generation: Plasma levels and the brain uptake rate of the 5-HT precursor tryptophan are lower in epileptics compared to nonepileptics (Albano et al. 2006). Similarly, seizure activity in mice is increased by depletion of 5-HT following the ablation of midbrain 5-HT neurons (Merrill et al. 2007) and by administration of 5-HT receptor antagonists (Tupal and Faingold 2006). In contrast, agents that elevate the levels of available 5-HT, including administration of the 5-HT precursor 5-hydroxy tryptophan (Truscott 1975) and SSRIs such as fluoxetine, have consistently been observed to act as anticonvulsants in both rodents (Leander 1992; Pasini et al. 1992; Prendiville and Gale 1993; Wada et al. 1995) and humans (Albano et al. 2006). Recent observations indicate that 5-HT mechanisms may also play a role in the cardiorespiratory dysfunction proposed to underlie SUDEP. In a recent study, administration of fluoxetine 25 min before seizure stimulus, at a dose that did not reduce seizure severity, signiἀcantly reduced postseizure respiratory arrest in audiogenic seizing mice (Tupal and Faingold 2006). This observation supports the idea that a subtle abnormality in the medullary 5-HT system (as in SIDS) may predispose an individual to respiratory arrest and, thus, potentially SUDEP following seizure, regardless of the seizure-generating mechanism. This idea is also supported by the observation that in tilt stress tests, patients with epilepsy display abnormal heart rate variability (Ansakorpi et al. 2000) similar to that observed in an infant that subsequently died of SIDS and that was observed to have reduced medullary 5-HT receptor binding density at autopsy (Kinney et al. 2005). Taken together, these observations provide potential new avenues of research in SUDEP, including analysis of predisposing risk factors such as
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome
87
prenatal exposures, and postmortem analysis of the brain stem to determine the presence of medullary 5-HT abnormalities.
5.9â•…Conclusions The observations discussed in the preceding sections support the idea that multiple abnormalities in the medullary 5-HT system, resulting in failure of homeostatic responses to normal challenges during sleep, play a role in the pathogenesis of SIDS. In addition, evidence suggests that the medullary 5-HT abnormality in SIDS is a progressive developmental disorder that originates in utero and involves exposure of the fetus to environmental toxins in combination with a predisposing genetic background. However, the speciἀc nature of the 5-HT dysfunction in SIDS is still unclear. Is there an excess or a deἀcit of available 5-HT in SIDS? The abnormalities in markers of 5-HT function described above may be interpreted as evidence that either an increased number of 5-HT neurons may lead to an excess of extracellular 5-HT and a compensatory downregulation of 5-HT receptors or, alternatively, 5-HT synthesis and/or release may be dysfunctional in the 5-HT neurons (which are overabundant in compensation), resulting in a deἀciency of extracellular 5-HT. Indeed, both an excess and a deἀcit in 5-HT levels during development and in the postnatal period produce respiratory dysfunction in animal models. Determination of the level of available 5-HT in SIDS medulla is, therefore, critical in determining the speciἀc nature and pathogenesis of 5-HT dysfunction in SIDS. Such studies are currently underway in our laboratory. Given the similarities in the deἀning characteristics of SIDS and SUDEP and the evidence implicating 5-HT dysfunction in seizure genesis and cardiorespiratory failure following seizure, it is reasonable to hypothesize that medullary 5-HT dysfunction also underlies the pathogenesis of SUDEP. The brain stem and other studies described above for SIDS, therefore, suggest a possible direction for SUDEP research and may provide novel insight into the pathogenesis of this disease.
References Ahlgren, S. C., and M. Bronner-Fraser. 1999. Inhibition of sonic hedgehog signaling in vivo results in craniofacial neural crest cell death. Curr Biol 9 (22): 1304–1314. Ahlgren, S. C., V. Thakur, and M. Bronner-Fraser. 2002. Sonic hedgehog rescues cranial neural crest from cell death induced by ethanol exposure. Proc Natl Acad Sci U S A 99 (16): 10476–10481. Albano, C., A. Cupello, P. Mainardi, S. Scarrone, and E. Favale. 2006. Successful treatment of epilepsy with serotonin reuptake inhibitors: Proposed mechanism. Neurochem Res 31 (4): 509–514. Alm, B., G. Wennergren, G. Norvenius, R. Skjaerven, N. Oyen, K. Helweg-Larsen, H. Lagercrantz, and L. M. Irgens. 1999. Caffeine and alcohol as risk factors for sudden infant death syndrome. Nordic Epidemiological SIDS Study. Arch Dis Child 81 (2): 107–111. Anderson, M. E., D. C. Johnson, and H. A. Batal. 2005. Sudden infant death syndrome and prenatal maternal smoking: Rising attributed risk in the back to sleep era. BMC Med 3: 4. Ansakorpi, H., J. T. Korpelainen, K. Suominen, U. Tolonen, V. V. Myllyla, and J. I. Isojarvi. 2000. Interictal cardiovascular autonomic responses in patients with temporal lobe epilepsy. Epilepsia 41 (1): 42–47. Arango, V., M. D. Underwood, A. V. Gubbi, and J. J. Mann. 1995. Localized alterations in pre- and postsynaptic serotonin binding sites in the ventrolateral prefrontal cortex of suicide victims. Brain Res 688 (1–2): 121–133.
88 Sudden Death in Epilepsy: Forensic and Clinical Issues Aznar, S, V. Kostova, S. H. Christiansen, and G. M. Knudsen. 2005. Alpha 7 nicotinic receptor subunit is present on serotonin neurons projecting to hippocampus and septum. Synapse 55 (3): 196–200. Baker-Herman, T. L., D. D. Fuller, R. W. Bavis, A. G. Zabka, F. J. Golder, N. J. Doperalski, R. A. Johnson, J. J. Watters, and G. S. Mitchell. 2004. BDNF is necessary and sufficient for spinal respiratory plasticity following intermittent hypoxia. Nat Neurosci 7 (1): 48–55. Bartlett, D., Jr., J. C. Leiter, and S. L. Knuth. 1990. Control and actions of the genioglossus muscle. Prog Clin Biol Res 345: 99–107; discussion 108. Bayliss, D. A., and D. E. Millhorn. 1992. Central neural mechanisms of progesterone action: Application to the respiratory system. J Appl Physiol 73 (2): 393–404. Bayliss, D. A., J. A. Cidlowski, and D. E. Millhorn. 1990. The stimulation of respiration by progesterone in ovariectomized cat is mediated by an estrogen-dependent hypothalamic mechanism requiring gene expression. Endocrinology 126 (1): 519–527. Bernard, D. G., A. Li, and E. E. Nattie. 1996. Evidence for central chemoreception in the midline raphe. J Appl Physiol 80 (1): 108–115. Berner, N. J., D. A. Grahn, and H. C. Heller. 1999. 8-OH-DPAT-sensitive neurons in the nucleus raphe magnus modulate thermoregulatory output in rats. Brain Res 831 (1–2): 155–164. Bitner, R. S., and A. L. Nikkel. 2002. Alpha-7 nicotinic receptor expression by two distinct cell types in the dorsal raphe nucleus and locus coeruleus of rat. Brain Res 938 (1–2): 45–54. Blair, P. S., P. J. Fleming, D. Bensley, I. Smith, C. Bacon, E. Taylor, J. Berry, J. Golding, and J. Tripp. 1996. Smoking and the sudden infant death syndrome: Results from 1993–5 case-control study for conἀdential inquiry into stillbirths and deaths in infancy. Conἀdential Enquiry into Stillbirths and Deaths Regional Coordinators and Researchers. BMJ 313 (7051): 195–198. Blum, A. S., J. R. Ives, A. L. Goldberger, I. C. Al-Aweel, K. B. Krishnamurthy, F. W. Drislane, and D.€L. Schomer. 2000. Oxygen desaturations triggered by partial seizures: Implications for cardiopulmonary instability in epilepsy. Epilepsia 41 (5): 536–541. Bou-Flores, C., A. M. Lajard, R. Monteau, E. De Maeyer, I. Seif, J. Lanoir, and G. Hilaire. 2000. Abnormal phrenic motoneuron activity and morphology in neonatal monoamine oxidase A–deἀcient transgenic mice: Possible role of a serotonin excess. J Neurosci 20 (12): 4646–4656. Brown, J. W., E. A. Sirlin, A. M. Benoit, J. M. Hoffman, and R. A. Darnall. 2008. Activation of 5-HT1A receptors in medullary raphe disrupts sleep and decreases shivering during cooling in the conscious piglet. Am J Physiol Regul Integr Comp Physiol 294 (3): R884–R894. Cann-Moisan, C., E. Girin, J. D. Giroux, P. Le Bras, and J. Caroff. 1999. Changes in cerebrospinal fluid monoamine metabolites, tryptophan, and gamma-aminobutyric acid during the 1st year of life in normal infants: Comparison with victims of sudden infant death syndrome. Biol Neonate 75 (3): 152–159. Cucchiaro, G., and K. G. Commons. 2003. Alpha 4 nicotinic acetylcholine receptor subunit links cholinergic to brainstem monoaminergic neurotransmission. Synapse 49 (3): 195–205. Darnall, R. A., M. B. Harris, W. H. Gill, J. M. Hoffman, J. W. Brown, and M. M. Niblock. 2005. Inhibition of serotonergic neurons in the nucleus paragigantocellularis lateralis fragments sleep and decreases rapid eye movement sleep in the piglet: Implications for sudden infant death syndrome. J Neurosci 25 (36): 8322–8332. de Moura, E. G., P. C. Lisboa, and M. C. Passos. 2008. Neonatal programming of neuroimmunomodulation—Role of adipocytokines and neuropeptides. Neuroimmunomodulation 15 (3): 176–188. Deckert, J., M. Catalano, Y. V. Syagailo, M. Bosi, O. Okladnova, D. Di Bella, M. M. Nothen et al. 1999. Excess of high activity monoamine oxidase A gene promoter alleles in female patients with panic disorder. Hum Mol Genet 8 (4): 621–624. Dillon, K. A., R. Gross-Isseroff, M. Israeli, and A. Biegon. 1991. Autoradiographic analysis of serotonin 5-HT1A receptor binding in the human brain postmortem: Effects of age and alcohol. Brain Res 554 (1–2): 56–64. Dreshaj, I. A., M. A. Haxhiu, and R. J. Martin. 1998. Role of the medullary raphe nuclei in the respiratory response to CO2. Respir Physiol 111 (1): 15–23.
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome
89
Druse, M. J., and L. H. Paul. 1988. Effects of in utero ethanol exposure on serotonin uptake in cortical regions. Alcohol 5 (6): 455–459. Druse, M. J., N. F. Tajuddin, R. A. Gillespie, E. Dickson, M. Atieh, C. A. Pietrzak, and P. T. Le. 2004. The serotonin-1A agonist ipsapirone prevents ethanol-associated death of total rhombenceÂ� phalic neurons and prevents the reduction of fetal serotonin neurons. Brain Res Dev Brain Res 150 (2): 79–88. Duncan, J. R., D. S. Paterson, and H. C. Kinney. 2008a. The development of nicotinic receptors in the human medulla oblongata: Inter-relationship with the serotonergic system. Auton Neurosci 144 (1–2): 61–75. Duncan, J. R., L. L. Randall, R. A. Belliveau, F. L. Trachtenberg, B. Randall, D. Habbe, F. Mandell, T. K. Welty, S. Iyasu, and H. C. Kinney. 2008b. The effect of maternal smoking and drinking during pregnancy upon (3)H-nicotine receptor brainstem binding in infants dying of the sudden infant death syndrome: Initial observations in a high risk population. Brain Pathol 18 (1): 21–31. Emery, M. J., M. P. Hlastala, and A. M. Matsumoto. 1994. Depression of hypercapnic ventilatory drive by testosterone in the sleeping infant primate. J Appl Physiol 76 (4): 1786–1793. Emery, M. J., H. F. Krous, J. M. Nadeau-Manning, B. T. Marck, and A. M. Matsumoto. 2005. Serum testosterone and estradiol in sudden infant death. J Pediatr 147: 586–591. Ferrari, P. F., S. Lowther, H. Tidbury, P. Greengrass, C. A. Wilson, and R. W. Horton. 1999. The influence of gender and age on neonatal rat hypothalamic 5-HT1A and 5-HT2A receptors. Cell Mol Neurobiol 19 (6): 775–784. Filiano, J. J., and H. C. Kinney. 1994. A perspective on neuropathologic ἀndings in victims of the sudden infant death syndrome: The triple-risk model. Biol Neonate 65 (3–4): 194–197. Filonzi, L., C. Magnani, A. M. Lavezzi, G. Rindi, S. Parmigiani, G. Bevilacqua, L. Matturri, and F. N. Marzano. 2009. Association of dopamine transporter and monoamine oxidase molecular polymorphisms with sudden infant death syndrome and stillbirth: New insights into the serotonin hypothesis. Neurogenetics 10 (1): 65–72. Fiskerstrand, C. E., E. A. Lovejoy, and J. P. Quinn. 1999. An intronic polymorphic domain often associated with susceptibility to affective disorders has allele dependent differential enhancer activity in embryonic stem cells. FEBS Lett 458 (2): 171–174. Fleming, P. J., P. S. Blair, C. Bacon, D. Bensley, I. Smith, E. Taylor, J. Berry, J. Golding, and J. Tripp. 1996. Environment of infants during sleep and risk of the sudden infant death syndrome: Results of 1993–5 case-control study for conἀdential inquiry into stillbirths and deaths in infancy. Conἀdential Enquiry into Stillbirths and Deaths Regional Coordina. BMJ 313 (7051): 191–195. Fogel, R. B., A. Malhotra, G. Pillar, J. K. Edwards, J. Beauregard, S. A. Shea, and D. P. White. 2001. Genioglossal activation in patients with obstructive sleep apnea versus control subjects. Mechanisms of muscle control. Am J Respir Crit Care Med 164 (11): 2025–2030. Forest, M. G., E. de Peretti, and J. Bertrand. 1980. Testicular and adrenal androgens and their binding to plasma proteins in the perinatal period: Developmental patterns of plasma testosterone, 4-androstenedione, dehydroepiandrosterone and its sulfate in premature and small for date infants as compare. J Steroid Biochem 12: 25–36. Greenberg, B. D., T. J. Tolliver, S. J. Huang, Q. Li, D. Bengel, and D. L. Murphy. 1999. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 88 (1): 83–87. Haglund, B. 1993. Cigarette smoking and sudden infant death syndrome: Some salient points in the debate. Acta Paediatr Suppl 82 (Suppl 389): 37–39. Heils, A., R. Mossner, and K. P. Lesch. 1997. The human serotonin transporter gene polymorphism— Basic research and clinical implications. J Neural Transm 104 (10): 1005–1014. Henderson, L. A., K. A. Keay, and R. Bandler. 2000. Caudal midline medulla mediates behaviourallycoupled but not baroreceptor-mediated vasodepression. Neuroscience 98 (4): 779–792. Hendricks, T., N. Francis, D. Fyodorov, and E. S. Deneris. 1999. The ETS domain factor Pet-1 is an early and precise marker of central serotonin neurons and interacts with a conserved element in serotonergic genes. J Neurosci 19 (23): 10348–10356.
90 Sudden Death in Epilepsy: Forensic and Clinical Issues Hendricks, T. J., D. V. Fyodorov, L. J. Wegman, N. B. Lelutiu, E. A. Pehek, B. Yamamoto, J. Silver, E. J. Weeber, J. D. Sweatt, and E. S. Deneris. 2003. Pet-1 ETS gene plays a critical role in 5-HT neuron development and is required for normal anxiety-like and aggressive behavior. Neuron 37 (2): 233–247. Hilaire, G., D. Morin, A. M. Lajard, and R. Monteau. 1993. Changes in serotonin metabolism may elicit obstructive apnoea in the newborn rat. J Physiol 466: 367–381. Hodges, M. R., G. J. Tattersall, M. B. Harris, S. D. McEvoy, D. N. Richerson, E. S. Deneris, R. L. Johnson, Z. F. Chen, and G. B. Richerson. 2008. Defects in breathing and thermoregulation in mice with near-complete absence of central serotonin neurons. J Neurosci 28 (10): 2495–2505. Hoffman, J. M., J. W. Brown, E. A. Sirlin, A. M. Benoit, W. H. Gill, M. B. Harris, and R. A. Darnall. 2007. Activation of 5-HT1A receptors in the paragigantocellularis lateralis decreases shivering during cooling in the conscious piglet. Am J Physiol Regul Integr Comp Physiol 293 (1): R518–R527. Holtman, J. R., Jr., T. E. Dick, and A. J. Berger. 1987. Serotonin-mediated excitation of recurrent laryngeal and phrenic motoneurons evoked by stimulation of the raphe obscurus. Brain Res 417 (1): 12–20. Hornung, J. P. 2003. The human raphe nuclei and the serotonergic system. J Chem Neuroanat 26 (4): 331–343. Iyasu, S., L. L. Randall, T. K. Welty, J. Hsia, H. C. Kinney, F. Mandell, M. McClain, B. Randall, D. Habbe, H. Wilson, and M. Willinger. 2002. Risk factors for sudden infant death syndrome among northern plains Indians. JAMA 288 (21): 2717–2723. Iyo, A. H., B. Porter, E. S. Deneris, and M. C. Austin. 2005. Regional distribution and cellular localization of the ETS-domain transcription factor, FEV, mRNA in the human postmortem brain. Synapse 57 (4): 223–228. Johns, J. M., D. A. Lubin, J. A. Lieberman, and J. M. Lauder. 2002. Developmental effects of prenatal cocaine exposure on 5-HT1A receptors in male and female rat offspring. Dev Neurosci 24 (6): 522–530. Kenny, P. J., S. E. File, and M. Rattray. 2001. Nicotine regulates 5-HT(1A) receptor gene expression in the cerebral cortex and dorsal hippocampus. Eur J Neurosci 13 (6): 1267–1271. Kim, J. A., and M. J. Druse. 1996. Protective effects of maternal buspirone treatment on serotonin reuptake sites in ethanol-exposed offspring. Brain Res Dev Brain Res 92 (2): 190–198. King, J. A., M. Davila-Garcia, E. C. Azmitia, and F. L. Strand. 1991. Differential effects of prenatal and postnatal ACTH or nicotine exposure on 5-HT high affinity uptake in the neonatal rat brain. Int J Dev Neurosci 9 (3): 281–286. Kinney, H. C., L. L. Randall, L. A. Sleeper, M. Willinger, R. A. Belliveau, N. Zec, L. A. Rava et al. 2003. Serotonergic brainstem abnormalities in Northern Plains Indians with the sudden infant death syndrome. J Neuropathol Exp Neurol 62 (11): 1178–1191. Kinney, H. C., M. M. Myers, R. A. Belliveau, L. L. Randall, F. L. Trachtenberg, S. T. Fingers, M. Youngman, D. Habbe, and W. P. Fifer. 2005. Subtle autonomic and respiratory dysfunction in sudden infant death syndrome associated with serotonergic brainstem abnormalities: A case report. J Neuropathol Exp Neurol 64 (8): 689–694. Kinney, H. C., R. A. Belliveau, F. L. Trachtenberg, L. A. Rava, and D. S. Paterson. 2007. The development of the medullary serotonergic system in early human life. Auton Neurosci 132 (1–2): 81–102. Kinney, H. C., and D. S. Paterson. 2004. Sudden infant death syndrome. In Pathololgy and Genetics: Developmental Neuropathology, ed. J. Golden and B. Harding. Basel: Neuropath Press. Klug, M. G., L. Burd, J. Kerbeshian, B. Benz, and J. T. Martsolf. 2003. A comparison of the effects of parental risk markers on pre- and perinatal variables in multiple patient cohorts with fetal alcohol syndrome, autism, Tourette syndrome, and sudden infant death syndrome: An enviromic analysis. Neurotoxicol Teratol 25 (6): 707–717. Krammer, E. B., T. Rath, and M. F. Lischka. 1979. Somatotopic organization of the hypoglossal nucleus: A HRP study in the rat. Brain Res 170 (3): 533–537.
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome
91
Krous, H. F., J. B. Beckwith, R. W. Byard, T. O. Rognum, T. Bajanowski, T. Corey, E. Cutz, R. Hanzlick, T. G. Keens, and E. A. Mitchell. 2004. Sudden infant death syndrome and unclassiἀed sudden infant deaths: A deἀnitional and diagnostic approach. Pediatrics 114 (1): 234–238. Kubin, L., H. Tojima, R. O. Davies, and A. I. Pack. 1992. Serotonergic excitatory drive to hypoglossal motoneurons in the decerebrate cat. Neurosci Lett 139 (2): 243–248. Langan, Y., L. Nashef, and J. W. Sander. 2005. Case-control study of SUDEP. Neurology 64 (7): 1131–1133. Leander, J. D. 1992. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and ameltolide (LY201116). Epilepsia 33 (3): 573–576. Lesch, K. P., and R. Mossner. 1998. Genetically driven variation in serotonin uptake: Is there a link to affective spectrum, neurodevelopmental, and neurodegenerative disorders? Biol Psychiatry 44 (3): 179–192. Li, A., and E. Nattie. 2008. Serotonin transporter knockout mice have a reduced ventilatory response to hypercapnia (predominantly in males) but not to hypoxia. J Physiol 586 (9): 2321–2329. Ling, L., D. D. Fuller, K. B. Bach, R. Kinkead, E. B. Olson Jr., and G. S. Mitchell. 2001. Chronic intermittent hypoxia elicits serotonin-dependent plasticity in the central neural control of breathing. J Neurosci 21 (14): 5381–5388. Liu, P. Y., B. Yee, S. M. Wishart, M. Jimenez, D. G. Jung, R. R. Grunstein, and D. J. Handelsman. 2003. The short-term effects of high-dose testosterone on sleep, breathing, and function in older men. J Clin Endocrinol Metab 88 (8): 3605–3613. MacDorman, M. F., S. Cnattingius, H. J. Hoffman, M. S. Kramer, and B. Haglund. 1997. Sudden infant death syndrome and smoking in the United States and Sweden. Am J Epidemiol 146 (3): 249–257. Machaalani, R., M. Say, and K. A. Waters. 2009. Serotoninergic receptor 1A in the sudden infant death syndrome brainstem medulla and associations with clinical risk factors. Acta Neuropathol 117 (3): 257–265. MacKenzie, A., and J. Quinn. 1999. A serotonin transporter gene intron 2 polymorphic region, correlated with affective disorders, has allele-dependent differential enhancer-like properties in the mouse embryo. Proc Natl Acad Sci U S A 96 (26): 15251–15255. Matsumoto, A. M., R. E. Sandblom, R. B. Schoene, K. A. Lee, E. C. Giblin, D. J. Pierson, and W. J. Bremner. 1985. Testosterone replacement in hypogonadal men: Effects on obstructive sleep apnoea, respiratory drives, and sleep. Clin Endocrinol (Oxf) 22 (6): 713–721. Maurer, P., S. Rorive, d’Exaerde A. de Kerchove, S. N. Schiffmann, I. Salmon, and Y. de Launoit. 2004. The Ets transcription factor Fev is speciἀcally expressed in the human central serotonergic neurons. Neurosci Lett 357 (3): 215–218. Merrill, M. A., R. W. Clough, J. W. Dailey, P. C. Jobe, and R. A. Browning. 2007. Localization of the serotonergic terminal ἀelds modulating seizures in the genetically epilepsy-prone rat. Epilepsy Res 76 (2–3): 93–102. Messier, M. L., A. Li, and E. E. Nattie. 2004. Inhibition of medullary raphe serotonergic neurons has age-dependent effects on the CO2 response in newborn piglets. J Appl Physiol 96 (5): 1909–1919. Mitchell, E. A., and J. Milerad. 2006. Smoking and the sudden infant death syndrome. Rev Environ Health 21 (2): 81–103. Moon, R. Y., R. S. Horne, and F. R. Hauck. 2007. Sudden infant death syndrome. Lancet 370 (9598): 1578–1587. Muneoka, K., T. Ogawa, K. Kamei, S. Muraoka, R. Tomiyoshi, Y. Mimura, H. Kato, M. R. Suzuki, and M. Takigawa. 1997. Prenatal nicotine exposure affects the development of the central serotoÂ� nergic system as well as the dopaminergic system in rat offspring: Involvement of route of drug administrations. Brain Res Dev Brain Res 102 (1): 117–126. Muneoka, K., T. Ogawa, K. Kamei, Y. Mimura, H. Kato, and M. Takigawa. 2001. Nicotine exposure during pregnancy is a factor which influences serotonin transporter density in the rat brain. Eur J Pharmacol 411 (3): 279–282.
92 Sudden Death in Epilepsy: Forensic and Clinical Issues Narita, N., M. Narita, S. Takashima, M. Nakayama, T. Nagai, and N. Okado. 2001. Serotonin transporter gene variation is a risk factor for sudden infant death syndrome in the Japanese population. Pediatrics 107 (4): 690–692. Nei, M., R. T. Ho, B. W. Abou-Khalil, F. W. Drislane, J. Liporace, A. Romeo, and M. R. Sperling. 2004. EEG and ECG in sudden unexplained death in epilepsy. Epilepsia 45 (4): 338–345. Nonnis Marzano, F., M. Maldini, L. Filonzi, A. M. Lavezzi, S. Parmigiani, C. Magnani, G. Bevilacqua, and L. Matturri. 2008. Genes regulating the serotonin metabolic pathway in the brain stem and their role in the etiopathogenesis of the sudden infant death syndrome. Genomics 91 (6): 485–491. Ogilvie, A. D., S. Battersby, V. J. Bubb, G. Fink, A. J. Harmar, G. M. Goodwim, and C. A. Smith. 1996. Polymorphism in serotonin transporter gene associated with susceptibility to major depression. Lancet 347 (9003): 731–733. Opdal, S. H., A. Vege, and T. O. Rognum. 2008. Serotonin transporter gene variation in sudden infant death syndrome. Acta Paediatr 97 (7): 861–865. Ozawa, Y., and N. Okado. 2002. Alteration of serotonergic receptors in the brain stems of human patients with respiratory disorders. Neuropediatrics 33 (3): 142–149. Ozawa, Y., and S. Takashima. 2002. Developmental neurotransmitter pathology in the brainstem of sudden infant death syndrome: A review and sleep position. Forensic Sci Int 130 (Suppl): S53–S59. Panigrahy, A., J. Filiano, L. A. Sleeper, F. Mandell, M. Valdes-Dapena, H. F. Krous, L. A. Rava, E. Foley, W. F. White, and H. C. Kinney. 2000. Decreased serotonergic receptor binding in rhombic lipderived regions of the medulla oblongata in the sudden infant death syndrome. J Neuropathol Exp Neurol 59 (5): 377–384. Parsey, R. V., M. A. Oquendo, N. R. Simpson, R. T. Ogden, R. Van Heertum, V. Arango, and J. J. Mann. 2002. Effects of sex, age, and aggressive traits in man on brain serotonin 5-HT1A receptor binding potential measured by PET using [C-11]WAY-100635. Brain Res 954 (2): 173–182. Pasini, A., A. Tortorella, and K. Gale. 1992. Anticonvulsant effect of intranigral fluoxetine. Brain Res 593 (2): 287–290. Paterson, D. S., F. L. Trachtenberg, E. G. Thompson, R. A. Belliveau, A. H. Beggs, R. Darnall, A. E. Chadwick, H. F. Krous, and H. C. Kinney. 2006. Multiple serotonergic brainstem abnormalities in sudden infant death syndrome. JAMA 296 (17): 2124–2132. Pena, F., and J. M. Ramirez. 2002. Endogenous activation of serotonin-2A receptors is required for respiratory rhythm generation in vitro. J Neurosci 22 (24): 11055–11064. Penatti, E. M., A. V. Berniker, B. Kereshi, C. Cafaro, M. L. Kelly, M. M. Niblock, H. G. Gao, H. C. Kinney, A. Li, and E. E. Nattie. 2006. Ventilatory response to hypercapnia and hypoxia after extensive lesion of medullary serotonergic neurons in newborn conscious piglets. J Appl Physiol 101 (4): 1177–1188. Peterson, B. A., and B. J. Kennedy. 1979. Aging and cancer management: Part I. Clinical observations. CA Cancer J Clin 29 (6): 322–332. Pfaar, H., A. von Holst, D. M. Vogt Weisenhorn, C. Brodski, J. Guimera, and W. Wurst. 2002. mPet-1, a mouse ETS-domain transcription factor, is expressed in central serotonergic neurons. Dev Genes Evol 212 (1): 43–46. Pickett, C. K., J. G. Regensteiner, W. D. Woodard, D. D. Hagerman, J. V. Weil, and L. G. Moore. 1989. Progestin and estrogen reduce sleep-disordered breathing in postmenopausal women. J Appl Physiol 66 (4): 1656–1661. Prendiville, S., and K. Gale. 1993. Anticonvulsant effect of fluoxetine on focally evoked limbic motor seizures in rats. Epilepsia 34 (2): 381–384. Rand, C. M., E. M. Berry-Kravis, L. Zhou, W. Fan, and D. E. Weese-Mayer. 2007. Sudden infant death syndrome: Rare mutation in the serotonin system FEV gene. Pediatr Res 62 (2): 180–182. Randall, L. L., C. Krogh, T. K. Welty, M. Willinger, and S. Iyasu. 2001. The Aberdeen Indian Health Service Infant Mortality Study: Design, methodology, and implementation. Am Ind Alaska Native Ment Hlth Res: J Natl Cent 10: 1–20.
Medullary Serotonergic Abnormalities in Sudden Infant Death Syndrome
93
Regensteiner, J. G., R. G. McCullough, R. E. McCullough, C. K. Pickett, and L. G. Moore. 1990. Combined effects of female hormones and exercise on hypoxic ventilatory response. Respir Physiol 82 (1): 107–114. Richerson, G. B. 1995. Response to CO2 of neurons in the rostral ventral medulla in vitro. J Neurophysiol 73 (3): 933–944. Richerson, G. B. 1997. Sudden infant death syndrome: The role of central chemosensitivity. Neuroscientist 3: 3–7. Richerson, G. B. 2004. Serotonergic neurons as carbon dioxide sensors that maintain pH homeostasis. Nat Rev Neurosci 5 (6): 449–461. Rinaudo, P. F., and J. Lamb. 2008. Fetal origins of perinatal morbidity and/or adult disease. Semin Reprod Med 26 (5): 436–445. Rugg-Gunn, F. J., R. J. Simister, M. Squirrell, D. R. Holdright, and J. S. Duncan. 2004. Cardiac arrhythmias in focal epilepsy: A prospective long-term study. Lancet 364 (9452): 2212–2219. Sabol, S. Z., S. Hu, and D. Hamer. 1998. A functional polymorphism in the monoamine oxidase A gene promoter. Hum Genet 103 (3): 273–279. Sari, Y., T. Powrozek, and F. C. Zhou. 2001. Alcohol deters the outgrowth of serotonergic neurons at midgestation. J Biomed Sci 8 (1): 119–125. Sawaguchi, T., F. Patricia, H. Kadhim, J. Groswasser, M. Sottiaux, H. Nishida, and A. Kahn. 2003. The correlation between serotonergic neurons in the brainstem and sleep apnea in SIDS victims. Early Hum Dev 75 (Suppl): S31–S40. Schoendorf, K. C., and J. L. Kiely. 1992. Relationship of sudden infant death syndrome to maternal smoking during and after pregnancy. Pediatrics 90 (6): 905–908. Scragg, R., E. A. Mitchell, B. J. Taylor, A. W. Stewart, R. P. Ford, J. M. Thompson, E. M. Allen, and D. M. Becroft. 1993. Bed sharing, smoking, and alcohol in the sudden infant death syndrome. New Zealand Cot Death Study Group. BMJ 307 (6915): 1312–1318. Slotkin, T. A., K. E. Pinkerton, and F. J. Seidler. 2006a. Perinatal environmental tobacco smoke exposure in rhesus monkeys: Critical periods and regional selectivity for effects on brain cell development and lipid peroxidation. Environ Health Perspect 114 (1): 34–39. Slotkin, T. A., C. A. Tate, M. M. Cousins, and F. J. Seidler. 2006b. Prenatal nicotine exposure alters the responses to subsequent nicotine administration and withdrawal in adolescence: Serotonin receptors and cell signaling. Neuropsychopharmacology 31 (11): 2462–2475. Slotkin, T. A., E. A. MacKillop, C. L. Rudder, I. T. Ryde, C. A. Tate, and F. J. Seidler. 2007a. Permanent,€ sex-selective effects of prenatal or adolescent nicotine exposure, separately or sequentially, in rat€brain regions: Indices of cholinergic and serotonergic synaptic function, cell signaling, and neural cell number and size at 6 months of. Neuropsychopharmacology 32 (5): 1082–1097. Slotkin, T. A., I. T. Ryde, C. A. Tate, and F. J. Seidler. 2007b. Lasting effects of nicotine treatment and withdrawal on serotonergic systems and cell signaling in rat brain regions: Separate or sequential exposure during fetal development and adulthood. Brain Res Bull 73 (4–6): 259–272. Slotkin, T. A., and F. J. Seidler. 2006. Cholinergic receptor subtypes in the olfactory bulbectomy model of depression. Brain Res Bull 68 (5): 341–345. So, E. L., J. Bainbridge, J. R. Buchhalter, J. Donalty, E. J. Donner, A. Finucane, N. M. Graves et al. 2009. Report of the American Epilepsy Society and the Epilepsy Foundation joint task force on sudden unexplained death in epilepsy. Epilepsia 50 (4): 917–922. Sparks, D. L., and J. C. Hunsaker 3rd. 1991. Sudden infant death syndrome: Altered aminergic– cholinergic synaptic markers in hypothalamus. J Child Neurol 6 (4): 335–339. Swallow, R. A., C. E. Hillier, and P. E. Smith. 2002. Sudden unexplained death in epilepsy (SUDEP) following previous seizure-related pulmonary oedema: Case report and review of possible preventative treatment. Seizure 11 (7): 446–448. Task Force on Sudden Infant Death Syndrome. 2005. The changing concept of sudden infant death syndrome: Diagnostic coding shifts, controversies regarding the sleeping environment, and new variables to consider in reducing risk. Pediatrics 116 (5): 1245–1255.
94 Sudden Death in Epilepsy: Forensic and Clinical Issues Tapanainen, J., P. Kellokumpu-Lehtinen, L. Pelliniemi, and I. Huhtaniemi. 1981. Age-related changes in endogenous steroids of human fetal testis during early and midpregnancy. J Clin Endocrinol Metab 52 (1): 98–102. Tomson, T., T. Walczak, M. Sillanpaa, and J. W. Sander. 2005. Sudden unexpected death in epilepsy: A review of incidence and risk factors. Epilepsia 46 (Suppl 11): 54–61. Tork, I, and J. P. Hornung. 1990. Raphe nuclei and the serotonergic system. In The Human Nervous System, ed. G. Paxinos. San Diego, CA: Academic Press. Tremblay, J., and P. Hamet. 2008. Impact of genetic and epigenetic factors from early life to later disease. Metabolism 57 (Suppl 2): S27–S31. Truscott, T. C. 1975. Effects of phenylalanine and 5-hydroxytryptophan on seizure severity in mice. Pharmacol Biochem Behav 3 (5): 939–941. Tryba, A. K., F. Pena, and J. M. Ramirez. 2006. Gasping activity in vitro: A rhythm dependent on 5-HT2A receptors. J Neurosci 26 (10): 2623–2634. Tupal, S., and C. L. Faingold. 2006. Evidence supporting a role of serotonin in modulation of sudden death induced by seizures in DBA/2 mice. Epilepsia 47 (1): 21–26. van Dyck, C. H. 2004. Understanding the latest advances in pharmacologic interventions for Alzheimer’s disease. CNS Spectr 9 (7 Suppl 5): 24–28. Wada, Y., J. Shiraishi, M. Nakamura, and H. Hasegawa. 1995. Prolonged but not acute fluoxetine adÂ�ministration produces its inhibitory effect on hippocampal seizures in rats. PsychopharmaÂ� cology (Berl) 118 (3): 305–309. Wang, W., J. H. Pizzonia, and G. B. Richerson. 1998. Chemosensitivity of rat medullary raphe neurones in primary tissue culture. J Physiol 511 (Pt 2): 433–450. Weese-Mayer, D. E., L. Zhou, E. M. Berry-Kravis, B. S. Maher, J. M. Silvestri, and M. L. Marazita. 2003. Association of the serotonin transporter gene with sudden infant death syndrome: A haplotype analysis. Am J Med Genet A 122A (3): 238–245. Winter, J. S., I. A. Hughes, F. I. Reyes, and C. Faiman. 1976. Pituitary–gonadal relations in infancy: 2.€Patterns of serum gonadal steroid concentrations in man from birth to two years of age. J Clin Endocrinol Metab 42 (4): 679–686. Wisborg, K., U. Kesmodel, T. B. Henriksen, S. F. Olsen, and N. J. Secher. 2000. A prospective study of smoking during pregnancy and SIDS. Arch Dis Child 83 (3): 203–206. Xu, Z., F. J. Seidler, S. F. Ali, W. Slikker Jr., and T. A. Slotkin. 2001. Fetal and adolescent nicotine administration: Effects on CNS serotonergic systems. Brain Res 914 (1–2): 166–178. Zhou, F. C., Y. Sari, T. K. Li, C. Goodlett, and E. C. Azmitia. 2002. Deviations in brain early serotoÂ� nergic development as a result of fetal alcohol exposure. Neurotox Res 4 (4): 337–342. Zhou, X. S., J. A. Rowley, F. Demirovic, M. P. Diamond, and M. S. Badr. 2003. Effect of testosterone on the apneic threshold in women during NREM sleep. J Appl Physiol 94 (1): 101–107. Zijlmans, M., D. Flanagan, and J. Gotman. 2002. Heart rate changes and ECG abnormalities during epileptic seizures: Prevalence and deἀnition of an objective clinical sign. Epilepsia 43 (8): 847–854.
Forensic Case Identification Paul L. Schraeder Elson L. So Claire M. Lathers
6
Contents 6.1 Postmortem Diagnosis in SUDEP 6.1.2 Strengths of Verbal Autopsy 6.1.3 Weaknesses of Verbal Autopsy References
95 103 103 105
6.1â•…Postmortem Diagnosis in SUDEP Sudden unexpected/unexplained death in epilepsy (SUDEP) is the death of a person with epilepsy that is sudden and unexpected, with no obvious circumstances other than a history of a seizure disorder, without the premorbid occurrence of status epilepticus, and with no cause of death being found on postmortem structural and toxicological examination (Nashef 1997; Leestma et al. 1997). Until recent years, the existence of SUDEP as a risk of having epilepsy and as a diagnosis of cause of death in persons with epilepsy has been a topic avoided at several levels, including neurologists, forensic pathologists, and lay support groups. What makes SUDEP a particularly egregious and tragic entity is that the average victim is a young adult in the prime of life, with a mean age in the early 30s. There is resistance by medical professionals to having it as a topic in information for patients and families. Several years ago, one of the authors (PLS) proposed having an informational session for a lay organization that would address the issue of SUDEP, only to be told by another epilepsy specialist that the topic was too controversial and potentially stressful for the patients and their families. It took several years before requests from families and patients resulted in impetus for this topic to be broached at an educational forum for the public. Since the sky did not fall consequent to open discussion of this important risk associated with having epilepsy, and since lay audience are receptive and even appreciative, there has been, in general, an increasing willingness to discuss this topic. At the other end of the spectrum, SUDEP as a ἀnal diagnosis of cause of death is usually not used on death certiἀcates in the circumstance of persons with epilepsy who die with no cause being found, other than having the diagnosis of a seizure disorder (Schraeder et al. 2006). Most epidemiological studies conἀrm that the overall mortality rate of persons with epilepsy is in general two to three times higher than that of the general population (Morgan and Kerr 2002), and the general spectrum of causes of deaths in this population is not much different from that of the general population. These causes include such entities as congenital neurological disorders, alcohol-related deaths, malignancies, cardiovascular disease, and cerebrovascular disorders. However, when the issue of nonaccidental 95
96 Sudden Death in Epilepsy: Forensic and Clinical Issues
unexpected death is examined, persons with epilepsy have up to a 24-fold greater risk of occurrence compared to the general population (Ficker et al. 1998). The issue of accuracy of the national data on deaths in persons with epilepsy seems to be a relatively widespread problem. For example, Tsai (2005) found in Taiwan that data derived from national vital statistics are inadequate to evaluate mortality in persons with epilepsy. This study compared the mortality ratio for epilepsy based on the national vital statistics for 1 year with the total population of Taiwan as the denominator. In Taiwan, almost every death is documented by a death certiἀcate. Using the official statistics, a crude death rate of 561 per 100,000 persons was found for the general population and 756 per 100,000 for the population with epilepsy. However, when the author applied the predicted death rate established for epilepsy from the Warsaw population study (Zielinski 1974), he speculated that persons with epilepsy were likely to have a 10-fold higher risk if the history of having epilepsy had been routinely reported on the death certiἀcates. The mortality data in a cohort of epilepsy cases from a university outpatient clinic was determined for 1224 persons with epilepsy who were followed for a total of 5704 patient years; 54 deaths occurred with a mortality rate of 0.9%. The diagnosis of SUDEP was listed as a cause of death in 2% of the vital statistics group and in 11% of the university clinic population. While this study seems to provide support for the idea that vital statistics data are inadequate to use in assessing the causes of mortality in persons with epilepsy, including SUDEP, the study population in a university epilepsy clinic is by nature biased in favor of patients with more severe epilepsy, and may be over-representative of a group at higher risk of dying. A review of studies conducted in developed countries (Forsgren et al. 2005) shows that the mortality rates for persons with epilepsy vary from country to country. There are only a few population-based studies of mortality in epilepsy. Standard mortality ratios range from 1.8 in Poland to 4.1 in France, with the United States, United Kingdom, Iceland, and Sweden in between. However, the standard mortality ratios vary within each study when comparing patients with different categories of etiology for their epilepsy. In all studies cited, persons with a severe neurological deἀcit had the highest standard mortality ratios (range, 7–50), whereas those with idiopathic epilepsy had the lowest standard mortality ratios (range, 1.1–1.8). Persons with remote symptomatic epilepsy had standard mortality ratios that were intermediate (range, 2.1–6.5). The selection of the population studied is a factor in explaining the standard mortality ratios’ variability. For example, selected epilepsy populations such as university epilepsy centers or epilepsy residential care facilities will have a higher standard mortality ratio than that of the general epilepsy population. The deaths in persons with epilepsy can be due to causes unrelated to epilepsy (e.g., infections, non-central-nervous-system neoplasm, stroke, or progressive degenerative disorders), related to the underlying cause of the epilepsy (e.g., brain tumor, cerebral vascular malformation), or related to a seizure episode (e.g., status epilepticus, drowning or other accidents caused by a seizure, and SUDEP). The rates of occurrence of SUDEP also differ based on the population studied, varying from 0.35 per 1000 person years in an unselectedÂ�population-based study, to 1.5–6 per 1000 person years in a less unselected population, to 1 per 100 person years in those referred for epilepsy surgery or in those with continued postsurgical seizures. Overall, the rate of SUDEP was 24 times greater than sudden death in the general population, making it the most common seizure-related cause of death in adolescents and young adults (Ficker et al. 1998). Data showing a marked increase in the occurrence of SUDEP so far are based on studies of localized populations (Leestma 1990; Earnest et al. 1992). Since SUDEP is
Forensic Case Identification
97
relatively infrequent compared to the more common causes of death, and since there is an acknowledged reluctance by coroners and medical examiners to utilize the term SUDEP on the death certiἀcate diagnosis in appropriate cases (Schraeder et al. 2006), the limited population-Â�based studies can give only an approximation of the extent of occurrence in persons with epilepsy. The use of death certiἀcate data to determine incidence or prevalence data on cause of death related to epilepsy is fraught with inaccuracy, since causes of such deaths are unreliable because both false positive and false negative information are common errors. Any national prevalence data based on death certiἀcate diagnoses, in all likelihood, are not reflective of the actual number of cases of SUDEP, even if adequately autopsied by coroners and medical examiners. Thus, if there is underutilization of the ἀnal diagnosis of SUDEP in thoroughly autopsied cases, one can only speculate about what the actual overall national prevalence of SUDEP is in cases of deaths in persons with epilepsy. Complicating the ability to determine even a reasonable approximation of the national prevalence of SUDEP is the fact that a diagnosis of deἀnite SUDEP can be made only in those victims who undergo a thorough autopsy and in which there was no other cause of death found, whereas a diagnosis of probable SUDEP is used in those that did not have an autopsy, but in which no other cause is extant from the evidence available. By deἀnition, then, a diagnosis of deἀnite SUDEP can only be made on the basis of an autopsy, and when an autopsy is not performed in the case of a sudden death of a person with epilepsy, in whom no other cause of death is evident (e.g., drowning, trauma, history of other underlying disorders such as cardiac disease, drug overdose, etc.), the diagnosis of probable SUDEP is appropriate. Ideally, the nonautopsy data should include a thorough gathering of information consisting of a description of the circumstances at time of death, review of the medical records, and interviews with family members in order to be conἀdent that a diagnosis of probable SUDEP is correct. Unless the coroners and medical examiners have sufficient resources to gather such premorbid information, conἀdence in a diagnosis of probable SUDEP is not adequate, leaving the diagnosis of possible SUDEP to be used in those cases without autopsy in which there may be another possible cause of death and in which historical information is incomplete (Leestma et al. 1997). Several methodological issues are inherent in the study of mortality in epilepsy (Logroscino and Hesdorffer 2005). Included in these issues is retrospective versus prospective design. The cohort can be undertaken either way with mortality ratios and case fatality rates as measures, along with standardized mortality ratios. Case control design can determine a proportionate mortality ratio. However, in any of these study designs, one must always be aware of the difference between incidence rate and prevalence rate. The former is the number of new cases of a disease in a population over a speciἀed period divided by the number of persons at risk for the disease during that period. The latter is the number of existing cases of the disease in a total population divided by the number of persons in that population. In entities with varying degrees of symptomatic expression and long survival, as in a chronic disorder such as epilepsy, prevalent cases would be predominantly survivors with the disorder. The differentiation between incidence and prevalence studies are important because they tend to measure different components of the same populations. For example, a prevalence cohort overestimate of mortality may occur if it includes persons with epilepsy who have not experienced recent seizures and are not included in the incidence cohort or may be due to unaccounted prevalent and incident cases. In any event, no study design is without flaws and in part explains the wide variability in results
98 Sudden Death in Epilepsy: Forensic and Clinical Issues
among studies of similar populations. Variables can only be minimized when studies are undertaken of population-based cohorts of incident cases that will allow complete collection of data and the observation of the disease, in this case epilepsy, from initial diagnosis to the time of death. Prevalence data for SUDEP are especially inaccurate because of its underutilization as a ἀnal diagnosis on death certiἀcates in appropriate cases. A better understanding of the prevalence, risk factors, and pathogenesis depends on the availability of complete and accurate postmortem data of persons with SUDEP. The lack of awareness of SUDEP as a common cause of death in persons with epilepsy is acknowledged in data from the United Kingdom (Lip and Brodie 1992; Coyle et al. 1994). In addition to being a problem in the United Kingdom, accurate determination of the national prevalence of SUDEP in the United States is hampered by the lack of mandatory requirements for postmortems, inaccurate death certiἀcate data, and the underuse of SUDEP as a ἀnal diagnosis, even in appropriate cases. Since prevalence data for SUDEP are hampered by the inaccuracy of death certiἀcate diagnoses, the questions of how and why these data are inaccurate need to be addressed. Why is there a bias toward underutilization of SUDEP as a death certiἀcate diagnosis in cases in which no other diagnosis is reasonable? A national survey on how coroners and medical examiners in the United States documented the deaths of persons with a history of epilepsy, and especially how they dealt with the question of SUDEP, found some surprising results (Schraeder et al. 2006). The professional background, demographics, numbers of cases with epilepsy seen annually, details of the seizure histories, percentage of postmortem examinations conducted, and causes of death, including use of SUDEP, were evaluated. Of the coroners and medical examiners who were trained as pathologists, the vast majority (83.5%) accepted SUDEP as a valid postmortem diagnosis, as opposed to 63% of physicians who were not trained as pathologists, and 58% of those who were not medical professionals. Other factors that influenced acceptance of SUDEP as a valid diagnosis included an urban setting, higher numbers of epilepsy-related deaths, and higher autopsy rates. Despite the relatively high level of acceptance of the validity of the diagnosis, the rate of use of SUDEP as an actual ἀnal diagnosis was low, regardless of the educational background of the coroners and medical examiners. For example, its use as a death certiἀcate diagnosis by pathologists as an actual ἀnal diagnosis in autopsied cases of persons with a history of epilepsy that had no other cause found was only 22.9%. The nature of the jurisdiction, i.e., urban versus nonurban, the number of annual cases with history of epilepsy, and the autopsy rate were not factors associated with the rate of utilization of SUDEP on the death certiἀcate in appropriate cases. The coroners and medical examiners more often used diagnoses such as status epilepticus, respiratory failure, fatal seizure, or cardiac arrhythmia in cases that should have been considered as SUDEP. The low utilization rate of this diagnosis, despite the acknowledgment of its being a valid diagnosis, underscores an unexplained paradox that supports two premises, namely, that public records underestimate the prevalence of SUDEP in the United States, and that having more accurate forensic data about the prevalence and cause of SUDEP is an important, but as of yet unachieved, need. The obvious dilemmas involved in establishing any semblance of an accurate rate of occurrence of SUDEP are related to the prevalent paucity of prospective cohort studies, the need for a higher rate of autopsy performance in cases of deaths in persons with a history of epilepsy, and overcoming the reluctance of coroners and medical examiners to recognize this diagnosis as a common cause of death in epilepsy in cases where no other explanation is
Forensic Case Identification
99
extant. The ἀrst dilemma can only be overcome by a well-funded, multiregional longitudinal study. The second can be overcome with a more zealous use of autopsies in persons with a history of epilepsy. The third dilemma requires an ongoing educational effort about the existence of SUDEP and its known risk factors directed to coroners and medical examiners. Any such educational program needs to be directed at reducing the reluctance of coroners and medical examiners, from all educational and professional backgrounds, to use SUDEP as a death certiἀcate diagnosis when appropriate, more than at educating them about its existence since, at least on an intellectual level, most seem to regard it as an entity. The diagnosis of SUDEP is fraught with a sense of uncertainty and is underutilized as a death certiἀcate diagnosis, even in cases where no other cause of death could be documented on autopsy. The reason for this resistance to use SUDEP as a ἀnal diagnosis by coroners and medical examiners is unknown. One could speculate that perhaps the detail of the postmortem examinations may be insufficient. The extent and quality of postmortem data collection in persons with a history of epilepsy was addressed in the United Kingdom (England, Scotland, Wales, and Northern Ireland) as part of a study of the quality of care for persons with epilepsy and published in the National Sentinel Clinical Audit of EpilepsyRelated Deaths Report (Hanna et al. 2002). During the 1-year study period of the audit, 2412 deaths with a history of epilepsy were examined, with 1023 having autopsies. The audit reviewed 439 (43%) of the autopsied cases and 156 (11%) of 1389 deaths that were certiἀed without autopsies. This national audit utilized investigation of 439 deaths with postmortem records and 156 doctor-certiἀed deaths without postmortems. The majority (87%) of deaths with postmortem examinations had an inadequate examination with a lack of or nonstandardized toxicological, histological, or neuropathology tests. Overall, 117 (27%) of the external exams and 29 (7%) of the internal examinations were unsatisfactory. The audit also found that information about epilepsy and the circumstances of death were variable, with pathologists having inconsistent access to such information. The documented inadequacies of the quality of postmortem performance in the United Kingdom were disappointing, especially in the context of there being detailed guidelines on autopsy practice for evaluation of deaths associated with epilepsy in existence (RCPath 1993). Certiἀcation of cause of death, with or without postmortem, was inconsistent and often inappropriate. Of the certiἀcations of death without postmortem as due to epilepsy, 38% were found to be sudden and/or unwitnessed and should have had autopsies. Of deaths having had a postmortem, certiἀcation was inadequate in 41%. This latter observation was the result of several behaviors: phrasing of cause of death was very variable, with the term SUDEP being used in only 10% of audited cases; causes such as asphyxia, aspiration, or status epilepticus were utilized despite a lack of pathological evidence; and, in some cases, every medical condition the person had was listed on the death certiἀcate, even though they were noncontributory to the death. If the deaths are not adequately investigated and categorized, the difficulty in establishing the true number of epilepsy-related deaths is self evident. Only 10% of deaths with no pathological evidence on autopsy and a history of epilepsy were categorized as SUDEP. One brief paragraph in this audit succinctly summarizes the problem: “Accurate death investigation and certiἀcation of epilepsy-related deaths is necessary if this is to be a reliable source of data for public health surveillance, research, and for effective policy-making in relation to the prevention of epilepsy-related deaths.” In what may be an indirect plea for supplementary verbal autopsy type of data, the audit panel also noted that it is important for the pathologists to have access to standardized information collected from all relevant sources, including family members, on the
100 Sudden Death in Epilepsy: Forensic and Clinical Issues
history of the deceased and the circumstances of death. As a result of the epilepsy audit, the Royal College of Pathology Working Party on the Autopsy (2005) developed guidelines on autopsy practice for deaths associated with epilepsy. The guidelines include the following categories: the role of the autopsy to establish that the epilepsy caused or contributed to the death; pathology encountered at autopsy, speciἀc health and safety aspects; clinical information relevant to the autopsy; the autopsy procedure; speciἀc signiἀcant organ systems (brain, heart, lung, bladder); organ retention and brain histopathology; recommended other blocks (organs) for histological examination; other samples required (including toxicology and frozen brain samples for future evaluation); clinicopathological summary; and cause of death opinions/statements. The leading subcategory of the last section deals with the deἀnition of SUDEP. The Royal College of Pathologists clearly is committed to expecting a high standard of evaluation of cause of death in persons with a history of epilepsy. Concern about the accuracy of prevalence data for the occurrence of SUDEP occurs on both sides of the Atlantic Ocean. In the United States, few data exist about how coroners and medical examiners utilized the diagnosis of SUDEP. The accurate and consistent identiἀcation of cases of SUDEP is, and for the foreseeable future will continue to be, problematic. While it is generally accepted that autopsy conἀrmation is the sine qua non for making a diagnosis of deἀnite SUDEP, the acknowledged lack of autopsies of persons with a history of epilepsy means that the diagnosis of probable SUDEP is, for practical purposes, as close as we can come to this standard. This unfortunate reality should provide impetus for the development of a system, a verbal autopsy if you will, that contains a sufficient spectrum and amount of information about the victim, providing the highest possible level of conἀdence in the accuracy of diagnosis of SUDEP, short of autopsy conἀrmation. In order to determine how to accumulate the most accurate non-autopsy-based diagnostic information, we suggest that a multicenter study should be designed that would fund autopsies for all persons who die with a history of epilepsy within each center’s jurisdiction. In parallel with this postmortem examination study, a well-designed set of investigative questions could be used to acquire all available relevant date about the victim. The goal of this comparative study would be to optimize the non-autopsy-based data with the expectation that it would approximate as close as possible the accuracy of the postmortem diagnoses. If it were to be determined that the so-called verbal autopsy data do not come close to approximating the autopsy-based data, the implication would be that the only feasible approach to improving the accuracy of diagnosis of SUDEP would be to create an ongoing educational effort for coroners and medical examiners, emphasizing the need to maximize the performance of autopsies in cases of epilepsy where the cause of death is unclear and in being comfortable with the diagnosis of SUDEP on death certiἀcates. When coroners and medical examiners in the United States were surveyed about the extent of autopsy examinations they actually performed on persons with epilepsy (Schraeder et al. 2009), it was determined that, regardless of the educational background of the officials, 82.2% stated that a forensic pathologist was engaged to perform the autopsy, and the rest used a general pathologist. The brain was more likely to be removed for examination when the coroner or medical examiner was a pathologist and was in an urban compared to a nonurban jurisdiction. Urban jurisdictions were more likely to collect postmortem blood samples for antiepileptic drug levels. Nonperformance of an autopsy was due to cost, lack of consent, lack of personnel, or lack of time. However, cost of autopsy was more of an issue in nonurban jurisdictions. It is clear from these data that there is a need for more routine brain removal and histopathology in jurisdictions not run by pathologists, and a need for
Forensic Case Identification
101
more diligent use of postmortem antiepileptic drug level determination. The overall quality of autopsy performance in the United States is adequate for the purpose of ἀnding a cause of death. The limitations in the cases of SUDEP are related to not doing autopsies in many of the appropriate cases, and a reluctance to use the diagnosis of SUDEP, even in autopsied cases where the diagnosis is indicated. To ἀnd solutions to a clinical problem, one must ἀrst understand how it is deἀned. To prevent SUDEP, one must understand the risk factors and mechanisms (Lathers et al. 2008). One obvious problem in deἀning the occurrence of SUDEP, as noted earlier, is that the diagnosis of SUDEP in the United States is underutilized as the actual diagnosis on death certiἀcates (Schraeder et al. 2006, 2008). Thus, the incidence of SUDEP, most likely, is not accurately reflected in any data utilizing death certiἀcate diagnoses and is, in reality, likely to be more prevalent than assumed. As early as 1994, Coyle et al. commented that the incidence of SUDEP might be difficult to ascertain due to variations in reporting the cause of death investigated by coroners. They examined this problem using information from the United Kingdom news press during the year 1992 to identify all likely cases of SUDEP. As required by law in the United Kingdom, these unexplained deaths were investigated by pathologists and coroners. All relevant information, including postmortem reports and witness statements, was considered in the 40 SUDEP cases. Coyle et al. (1994) noted inconsistencies in the investigations performed and the observations documented at the time of death, with widely differing degrees of detail concerning the type and history of epilepsy being found. In 70% of these cases, the type of epilepsy was not documented. Inconsistencies were also found concerning details of antiepileptic drug use, the position of the body, toxicology reporting, and the detailed exams of organs, including the brain. The causes of death attributed to the cases varied greatly, with epilepsy noted as a primary cause of death in fewer than half of the cases. Coroner verdicts varied, with no distinct pattern emerging in relation to attributed cause of death. Wide variation in practice of individual corners and pathologists in the investigation and registering of sudden deaths reflected inconsistent quality of performance. Since most deaths were unwitnessed, investigation by and statements from officials in the process of registering deaths are essential to providing accurate information. Finally, in order to obtain an accurate proἀle of individuals at risk for SUDEP, epilepsy, and especially SUDEP, must be written on the death certiἀcate. Until this happens, many more, if not the majority of these deaths, will continue to go unrecorded. Likewise, the data for third world countries, which is even more limited than that in Europe and North America, and that does not depend on the use of autopsies, indicates that SUDEP is an underreported cause of death in persons with epilepsy. In general, developing countries do not have a complete civil registration system in place to collect and provide data regarding public health issues (Hill et al. 2007). Collection of data regarding births, deaths and causes of death, population censuses, sample vital registry systems, descriptive epidemiology of the population, demographic surveillance sites, and internationally coordinated sample survey programs, combined with enhanced methods of assessment and analysis are not in place. For example, a SUDEP underreporting problem has been described in Nigeria where most deaths in individuals with epilepsy occur at home (Sanyo 2005), with autopsies usually not conducted to determine the cause of death, and thus are never reported. Several authors have discussed the burden of epilepsy in developing countries (Jallon 2002; Diop et al. 2005). Nearly 75% of 50 million patients with epilepsy live in countries where diagnostic and therapeutic options are either not affordable, inadequate, or
102 Sudden Death in Epilepsy: Forensic and Clinical Issues
nonexistent. Many patients with epilepsy do not receive treatment because drugs are not available or, even if available, may not be taken for cultural and/or socioeconomic reasons. Although one would not predict that the prevalence of epilepsy should differ in underdeveloped countries versus developed countries, epidemiological studies from developed countries do suggest differences, with a much higher occurrence in developed countries. The reason for this discrepancy is unknown, but stigmatization associated with having epilepsy, limited access to health care personnel and diagnostic and treatment options are likely factors. In underdeveloped countries in Africa, the incidence of epilepsy varies between 10 and 55 per 1000, with an estimated mean prevalence of 15 per 1000. This ἀgure has also been reported for Latin America. Higher rates are found in lower socioeconomic groups and in rural areas. Methodological limitations raise questions about the accuracy of the reported results from developing countries, and include case deἀnition, case diagnosis, classiἀcation, and selection bias. Jallon (2002) suggests that the World Health Organization questionnaire used in such studies does not provide adequate data on seizure type nor syndromic classiἀcation. Sanyo (2005) recommends, as one obvious approach to the problem of underreporting epilepsy as a cause of death, emphasizing the problem to clinicians through articles in the published literature, with a focus on case deἀnition and criteria for diagnosis, risk factors, pathophysiology discussion, and a discussion of treatment options. Since the incidence of SUDEP increases with seizure severity, early onset epilepsy, poor seizure control, generalized tonic–clonic seizures, use of multiple antiepileptic medications, and frequent adjustment of antiepileptic drugs, it is important to understand the interplay of these factors. The possibility of altered cardiorespiratory reflexes causing central apnea, hypoxia, and edema along with cardiac arrhythmia must be understood by all caregivers and family members. Patients, relatives, and caregivers should be educated about the clinical problem of SUDEP and the need to reduce the incidence of SUDEP. Optimal seizure management with effective monotherapy is a common target for the physician managing patients with epilepsy. If intractable epilepsy exists, vagal nerve stimulation and neurosurgery are options to be considered as early on in the treatment regimen as possible to prevent SUDEP. As deἀned earlier, SUDEP refers to the sudden death of an individual with a clinical history of epilepsy, in whom a postmortem examination fails to uncover a gross anatomic, toxicological, or environmental cause of death. Evidence of terminal seizure activity may not be present. In 2002, Shields et al. reported that 1–2% of natural deaths certiἀed by the medical legal death investigators in the United States are attributed to epilepsy and that increased microscopic examination of the brain postmortem has allowed identiἀcation of structural changes that are not grossly evident, but are, nonetheless, representative of the underlying substrates of epileptogenic foci. Over all, Shields et al. (2002) examined 70 death cases, all with known clinical history of seizures, and classiἀed them as:
1. Individuals who lacked a gross brain lesion 2. Individuals with a brain lesion demonstrable at autopsy 3. Individuals who lacked neuropathological evaluation because of decomposition 4. Individuals for whom only an external examination was done
One potential method to correct the problem of underreporting the occurrence of SUDEP is to use a version of verbal autopsies. To date, this technique that has been used primarily in underdeveloped countries. The methodology emphasizes the importance of
Forensic Case Identification
103
talking with members of the family and/or close friends of the patient who has died unexpectedly. Discussions must include determination of facts about the longitudinal history of epilepsy in the deceased, especially including information about the clinical events at the time of a witnessed death. Verbal autopsies are used to determine a likely cause of death for individuals with no direct clinical observation regarding the terminal event (Snow et al. 1993; Lathers and Schraeder 2009). In such situations, the interview conducted during the verbal autopsy seeks key symptoms and signs cited by the relatives and friends of the deceased. The ἀnal diagnosis of cause of death is assigned according to the symptom complexes. Hill et al. (2007) emphasize that these alternate methods do not replace the need for accurate cause of death registration and rather should be used as part of a full, comprehensive health information system. International organizations, national governments, and academics need to work on improving the collection of data and ensuring that methods to do so are continually updated. In many areas of Africa, with limited health personnel and facilities, data indicate 80–85% of those with epilepsy have not been diagnosed or treated, which is deἀned as the treatment gap (Diop et al. 2005). While worldwide data suggest that the mortality of those with epilepsy is two to three times greater than the general population, such information does not exist for Africa. Diop et al. (2005) also suggested that verbal autopsy studies are needed since they do not rely on mostly nonexistent physical autopsies and death certiἀcates. They examined existing studies and noted that one reported a 6-fold increase in mortality in Africa for those with epilepsy, a rate that is considerably higher than the 2- or 3-fold increase generally reported for developing countries. While the high prevalence of this problem means that the public health impact of epilepsy mortality is likely to be enormous, no mention is made of how many of these deaths in persons with epilepsy were SUDEP. As a consequence of the problems listed above, the use of verbal autopsy is increasing in low-income countries to ascertain the likely cause of death (Aspray 2005). Information is obtained on cause of death via interviews with relatives or other associates of the deceased. While it may be used in situations with inherently poor data on adult or pediatric mortality, one must be aware of the strengths and weaknesses of verbal autopsies. 6.1.2â•…Strengths of Verbal Autopsy
1. Verbal autopsy does not depend on access to clinic services. 2. Clinical experts are used for classiἀcation process. 3. Algorithms may be developed for automatic coding of the cause of death. 4. It offers insight into the cause of death in sudden, unexpected deaths in both developing and developed countries. 5. Alternatives such as death certiἀcates do not always provide complete information and may also be imprecise. 6.1.3â•…Weaknesses of Verbal Autopsy
1. Methodological issues of robustness when examining less-frequent causes of death 2. Inability to ascertain a deἀnite SUDEP mortality classiἀcation 3. Possible selection bias in assessing cause of death, e.g., social taboos 4. Reliability of the information provider
104 Sudden Death in Epilepsy: Forensic and Clinical Issues
Verbal autopsies are used as a means of determining probable causes of death for individuals with no reliable clinical information regarding the terminal illness (Snow et al. 1993). Chandramohan et al. (1998) examined maternal deaths using data obtained in a rural district hospital in Tanzania, a rural teaching hospital in Ethiopia, and a rural district hospital in Ghana. They found reasonable agreement between physician diagnoses and algorithms but reported individual misclassiἀcations of causes of death were higher in algorithm-based verbal autopsies. These authors also reported verbal autopsies by a panel of physicians performed better than those based on an algorithm. Validity of the verbal autopsy diagnosis was highest for acute febrile illnesses, TB/AIDS, tetanus, rabies, and injuries. In 1997, Reeves and Quigley reviewed data-derived methods for assigning causes of death from verbal autopsy data, citing three primary methods of empirical classiἀcation rules: linear and other discriminate techniques, probability density estimation and decision trees, and rule-based methods. They also discussed the factors that need to be taken into account when selecting a classiἀcation method to be used for assigning cause of death from verbal autopsy data. To compare the performance of classiἀers derived using different methods requires a large verbal autopsy data set. Quigley et al. (1999) compared diagnostic accuracy of physician review, expert algorithms, and data-derived algorithms in adult verbal autopsies conducted in hospitals in Tanzania, Ethiopia, and Ghana. They concluded that in settings where physician review is not feasible, expert and data-derived algorithms do provide a reasonable alternative approach for assigning many causes of death. Chandramohan et al. (2001) also discussed the fact that verbal autopsy is an indirect method of ascertaining cause of death from symptoms and signs obtained from bereaved relatives and friends and, thus, the mortality estimates are susceptible to bias due to misclassiἀcation of causes of death. These authors explored application of sensitivity and speciἀcity of verbal autopsy data obtained from a hospital-based validation study to adjust the effect of misclassiἀcation errors in data obtained during verbal autopsies from a demographic surveillance system. They concluded that it is not possible to use sensitivity and speciἀcity estimates derived from a location-speciἀc validation study to adjust for misclassiἀcation in verbal autopsy data from populations with substantially different patterns of cause-speciἀc mortality. Boulle et al. (2001) examined artiἀcial neural networks as a method of classifying the cause of death from verbal autopsy in a wide range of disciplines. Artiἀcial neural networks were applied to data from a verbal autopsy study as a means to classify cause of death. Large data sets are needed to improve performance of data-derived algorithms, especially in artiἀcial neural network models. Freeman et al. (2005) compared agreement between causes of death obtained from the verbal autopsy by physician review versus computer-based algorithms and recommended the analysis technique combine both methods. They concluded that further validation studies were needed to improve performance of the verbal autopsy for assigning causes of neonatal death. Verbal autopsy procedures, for use in sample vital registration, are important methods for deriving causespeciἀc mortality estimates where disease burdens are greatest and routine cause-speciἀc mortality data do not exist (Setel et al. 2006). Lee et al. (2008) used verbal autopsy methods to ascertain birth asphyxia deaths in a community-based setting in southern Nepal. The authors note that use of various verbal autopsy deἀnitions and hierarchical approaches to assign cause of death may substantially affect estimates of birth asphyxia–speciἀc mortality and analyses of risk factors. Verbal autopsy methods need to be standardized and validated to generate accurate global estimates to determine policy and resource allocation in developing countries.
Forensic Case Identification
105
To glean information about the circumstances of death in sudden death in epilepsy, Nashef et al. (1998) conducted interviews with referred bereaved relatives of patients with epilepsy who had died suddenly. These data were combined with information derived from coroners’ reports, postmortem reports, previous medical records, and EEG data. Thus, the verbal data obtained in this study was a useful supplement to the other data available and was helpful in addressing the question of the need of relatives of SUDEP victims to have had antemortem knowledge of the possible risk of SUDEP. Most of the relatives stated they would have preferred to have been told that epilepsy could be fatal. The interviews emphasized the needs of the bereaved relatives and their sense of isolation in the face of an unexpected death. Thus, in contrast to developing countries where verbal autopsy may be the only means of establishing a possible or probable cause of death, this technique may have a different use in more affluent countries, namely of helping to clarify questions not answered by the standard methods of coroner’s and postmortem reports and available medical records. In summary, the purpose of verbal autopsy can be multifaceted. When used in conjunction with postmortem autopsy data from persons with SUDEP, it can help in focusing on retrospective data that provide additional help in identifying more accurately the cause of death, and in conducting retrospective analyses of these postmortem examinations. The value of all of this cumulative information from all sources is that it provides information for future preventative policy. In circumstances where postmortem information was not or could not be collected, verbal autopsies do offer an alternative method to ἀnding information regarding the mechanism of death, whether conducted in developing countries or in developed countries. In either case, regardless of how it is acquired, the worldwide database on persons with epilepsy who die suddenly and unexpectedly will gain important information that will help in determining the prevalence of SUDEP and contribute to the quest for identiἀcation of preventive interventions. The technique of verbal autopsy makes the assumption that individual disease entities have discrete symptom complexes that can be easily and accurately recognized and remembered (Reeves and Quigley 1997). The accuracy of the verbal autopsy technique in cases of SUDEP needs to be established. One possible way of accomplishing this goal would be to compare the accuracy of this method of detailed information gathering in predicting a diagnosis of deἀnite SUDEP in the cases that end up with a postmortem examination and ἀnal autopsy diagnosis of SUDEP. If it were found that an adequate, standardized verbal autopsy compared favorably, in accuracy of diagnosis, with the ἀnal physical autopsy diagnosis, then in cases of epilepsy-related deaths in which, for whatever reason, an autopsy is not performed, the verbal autopsy could reasonably be used as a substitute. However, until such a study is forthcoming, the physical autopsy will continue to be essential to determine the diagnosis of deἀnite SUDEP.
References Aspray, T. J. 2005. The use of verbal autopsy in attributing cause of death from epilepsy. Epilepsia 46 (Suppl 11): 15–17. Boulle, A., D. Chandramohan, and P. Weller. 2001. A case study of using artiἀcial neural networks for classifying cause of death from verbal autopsy. Int J Epidemiol 30: 515–520. Chandramohan, D., G. H. Maude, L. C., and Rodriques, R. J. 1998a. Verbal autopsies for adult deaths: Their development and validation in a multicentre study. Trop Med Int Health 3: 436–446. Chandramohan, D., L. C. Rodriques, G. H. Maude, and R. J. Hayes. 1998b. The validity of verbal autopsies for assessing the causes of institutional maternal death. Stud Fam Plann 29: 414–422.
106 Sudden Death in Epilepsy: Forensic and Clinical Issues Chandramohan, D., P. Setel, and M. Quigley. 2001. Effect of misclassiἀcation of causes of death in verbal autopsy: Can it be adjusted? Int J Epidemiol 30: 509–514. Coyle, H. P., N. Baker-Brian, and S. W. Brown. 1994. Coroners’ autopsy reporting of sudden unexplained death in epilepsy (SUDEP) in the UK. Seizure 3: 247–254. Diop, A. G., D. C. Hesdorffer, G. Logroscino, and W. A. Hauser. 2005. Epilepsy and mortality in Africa: A review of the literature. Epilepsia 46: (Suppl 11): 33–35. Earnest, M. P., et al. 1992. The sudden unexplained death syndrome in epilepsy demographic, cÂ�linical, and postmortem features. Epilepsia 33: 310–316. Ficker, D. M., E. L. So, W. K. Shen et al. 1998. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 51: 1270–1274. Forsgren, L., W. A. Hauser, E. Olafsson et al. 2005. Mortality of epilepsy in developed countries: A review. Epilepsia 46 (S11): 18–27. Freeman, J. V., P. Christian, S. K. Khatry et al. 2005. Evaluation of neonatal verbal autopsy using physician review versus algorithm-based cause-of-death assignment in rural Nepal. Pediatr Perinat Epidemiol 19: 323–331. Hanna, N. J., M. Black, J. W. S. Sander et al. 2002. The National Sentinel Clinical Audit of EpilepsyRelated Death; The Stationery Office. Hill, K., A. D. Lopez, K. Shibuya, and P. Jha. 2007. On behalf of the monitoring of vital events (MoVE) writing group. Interim measures for meeting needs for health sector data: Births, deaths, and causes of death. Lancet 368. Jallon, P. 2002. Epilepsy and epileptic disorders, an epidemiological marker? Contribution of descriptive epidemiology. Epileptic Disorders 4: 1–13. Lathers, C. M., and P. L. Schraeder. 2009. Verbal autopsies and SUDEP. Epilepsy Behav 14: 573–576. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008. The mystery of sudden death: Mechanisms for risks. Epilepsy Behav 12: 3–24. Lee, A. C., L. C. Mullany, J. M. Tielsch et al. 2008. Verbal autopsy methods to ascertain birth asphyxia deaths in a community-based setting in southern Nepal. Pediatrics 121: E1372–E1380. Leestma, J. 1990. Sudden death associated with seizures: A pathological review. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder, 61–89. New York, NY: Marcel Dekker. Leestma, J. E., J. F. Annegers, M. J. Brodie et al. 1997. Sudden unexplained death in epilepsy: Observations from a large clinical development program. Epilepsia 38: 47–55. Lipp, G. Y., and M. J. Brodie. 1992. Sudden death in epilepsy: An avoidable outcome? J R Soc Med 85: 665–676. Logroscino, G., and D. C. Hesdorffer. 2005. Methodological issues in studies of mortality following epilepsy: Measures, types of studies, sources of cases, cohort effects, and competing risks. Epilepsia 46 (Suppl 11): 3–7. Morgan, C. L., and M. P. Kerr. 2002. Epilepsy and mortality: A record linkage study in a UK population. Epilepsia 43: 1251–1255. Nashef, L. 1997. Sudden unexpected death in epilepsy: Terminology and deἀnitions. Epilepsia 38 (sl11): S6–S8. Nashef, L., S. Garner, J. W. Sander, D. R. Fish, and S. D. Shorvon. 1998. Circumstances of death in sudden death in epilepsy: Interviews of bereaved relatives. J Neurol Neurosurg Psychiatry 64: 349–352. Quigley, M. A., D. Chandramohan, and L. C. Rodriques. 1999. Diagnostic accuracy of physician review, expert algorithms and data-derived algorithms in adult verbal autopsies. Int J Epidemiol 28: 1081–1087. RCPath. 1993. Guidelines for Post-Mortem Reports. Royal College of Pathologists, London. RCPath Working Party on Autopsy. 2005. Guidelines on Autopsy Practice. Scenario 6: Deaths Associated with Epilepsy. January 2005. Reeves, B. C., and M. Quigley. 1997. A review of data-derived methods for assigning causes of death from verbal autopsy data. Int J Epidemiol 26: 1080–1089.
Forensic Case Identification
107
Sanyo, E. O. 2005. Increasing awareness about sudden unexplained death in epilepsy—A review. Afr J Med Med Sci 34: 323–327. Schraeder, P. L., K. Delin, R. L. McClelland, and E. L. So. 2006. Coroner and medical examiner documentation of sudden unexplained deaths in epilepsy. Epilepsy Res 68: 137–143. Schraeder, P. L., K. Delin, R. L. McClelland, and E. L. So. 2009. A nationwide survey of the extent of autopsy examinations in sudden unexplained death in epilepsy. Am J Forensic Medicine Pathol 30(2): 123–126. Setel, P. W., D. R. Whiting, Y. Hemed et al. 2006. Validity of verbal autopsy procedures for determining cause of death in Tanzania. Trop Med Int Health 11: 681–696. Shields, L. B., D. M. Hunsaker, J. C. Hunsaker 3rd, and J. C. Parker Jr. 2002. Sudden unexpected death in epilepsy: Neuropathological ἀndings. Am J Forensic Med Pathol 23: 307–314. Snow, R. W., I. Basto de Azevedo, D. Forster et al. 1993. Maternal recall of symptoms associated with childhood deaths in rural east Africa. Int J Epidemiol 22: 677–683. Tsai, J. J. Mortality of epilepsy from national vital statistics and university epilepsy clinic in Taiwan. Epilepsia 46 (S11): 8–10. Zielinski, J. J. 1974. Epilepsy and mortality rate and cause of death. Epilepsia 15: 191–201.
Sudden Unexpected Death in Epilepsy Future Research Directions
7
Simona Parvulescu-Codrea
Contents 7.1 7.2 7.3 7.4
Introduction Why Should We Focus on SUDEP? Epidemiologic Data Supportive of a Cardiac Mechanism of SUDEP Clinical Evidence in Support of a Cardiac Mechanism: The Importance of Increased Heart Rate Associated with Epileptic Seizures 7.5 In Vivo Evidence for an Arrhythmogenic Substrate in the Hearts of Epilepsy Patients at Risk for SUDEP 7.6 Evidence of Sinus Tachycardia Associated with Epileptic Seizures 7.7 Bradycardia and Asystole 7.8 Ictal Cardiac SPECT Imaging Supportive of a Cardiac Mechanism of SUDEP 7.9 Future Research Avenues for an Underlying Cardiac Mechanism of SUDEP: Epilepsy, Depression, and Cardiac Disease 7.10 Evidence of Cardiac Arrhythmogenic Substrate for SUDEP: The Influence of Antiepileptic Drugs on the Heart 7.11 Summary and Clinical Perspectives Acknowledgment References
109 110 110 111 112 115 119 119 121 123 123 124 124
7.1â•…Introduction The systems in which our healthcare workers function are fragmented, complex, and narrowly specialized, creating gaps in communication, numerous hands-off circumstances, and more discipline-centered rather than patient-centered care (Begun et al. 2006). Consequently, as emphasized by Lathers et al. (2008) in the article “The Mystery of Sudden Death—Mechanisms for Risks,” sudden unexpected death in epilepsy (SUDEP) is an excellent example of a medical enigma, which in order to be solved, challenges scientists to break the current work paradigm and mount their efforts in a multidisciplinary team collaboration.
109
110 Sudden Death in Epilepsy: Forensic and Clinical Issues
7.2â•…Why Should We Focus on SUDEP? At least 50 million people in the world have epilepsy (WHO 2009). The estimated portion of the general population with active epilepsy, i.e., continuing to have seizures or need for treatment, at any given time is from 4 to 10 per 1000. Spratling (1902) was one of the ἀrst neurologists to recognize epilepsy as a disease that can destroy life suddenly and without warning during a single brief attack. Subsequently, many epidemiologic studies conἀrmed that epilepsy increases the risk of premature death by at least twofold to threefold, compared to the general population (WHO 2009). SUDEP is considered to be the most important culprit for seizure-related deaths. Nevertheless, despite the fact that epilepsy is so common and that we have been aware of the associated risk with SUDEP, investigation into the mechanisms and risk factors has so far been frustratingly unproductive. As one bereaved mother of a victim of SUDEP wrote, “Nobody knows how my son died because, although epilepsy is the most common neurological brain disorder in the world, it is also the most neglected.” (Hanna 2007). Accordingly, it is of vital importance that this area receives the deserved attention (Willams and Richens 1998).
7.3â•…Epidemiologic Data Supportive of a Cardiac Mechanism of SUDEP The mechanism of SUDEP is the subject of an ongoing scientiἀc debate. Literature over the past decade provides mounting epidemiologic evidence for increased frequency of cardiac abnormalities in patients experiencing epileptic seizures. This association proves to be more frequent than previously thought, especially in relation to SUDEP (Tinuper et al. 2001; Tigaran et al. 2003; Nei et al. 2000a; Chin et al. 2004; Ho et al. 2006; So and Sperling 2007; DeGiorgio et al. 2008; Scorza et al. 2008; Strzelczyk et al. 2008). Consequently, when the high incidence of SUDEP is taken into account (Pedley and Hauser 2002), there is a need for prompt and correct diagnosis of epilepsy and early recognition of possible risk factors that may be important in the prevention of SUDEP. Furthermore, it should be of special interdisciplinary interest to diagnose cases of epileptic seizures where the only ictal manifestation is autonomic dysfunction that may produce changes in the heart rhythm and rate (Zijlmans et al. 2002). Postmortem abnormalities such as subendocardial scarring in the myocardium, along with pathologic changes consisting of perivascular and interstitial ἀbrosis, contraction band necrosis, and the myocyte vacuolization found in autopsied SUDEP victims are supportive of a cardiac mechanism for SUDEP (Manno et al. 2005; P-Codrea Tigaran et al. 2005; Natelson et al. 1998; Falconer and Rajs 1976). Because of the discrete microscopic nature of the myocardial ἀbrosis, we may not be able to detect these abnormalities in vivo (Tigaran et al. 2002). However, cardiac ischemia, leading to the discrete areas of ἀbrosis in the myocardium, can create the pathophysiological substrate for fatal re-entrant arrhythmias, which may result in sudden unexpected death. Because the patients can ultimately die due to fatal arrhythmias, there is no postmortem evidence of the proposed cardiac mechanisms, because arrhythmias do not give any pathologic residua in the myocardium. Thus, we face a postmortem pathologic puzzle. Accordingly, awareness of the fact that pathological cardiac changes such as myocardial ἀbrosis triggered by repetitive epileptic seizures (P-Codrea Tigaran et al. 2005) potentially can lead to SUDEP, may be increasingly important in understanding neurocardiac mechanisms for SUDEP (Beran 2006).
Sudden Unexpected Death in Epilepsy
111
7.4â•…Clinical Evidence in Support of a Cardiac Mechanism: The Importance of Increased Heart Rate Associated with Epileptic Seizures The subendocardium has long been considered the region most vulnerable to ischemia, which occurs whenever there is an imbalance between myocardial oxygen supply and oxygen demand (Hoffman and Buckberg 1975). In the experimental situation, the pressure overload consequent to aortic stenosis disrupts the adequacy of subendocardial perfusion, induces evidence of ischemia, such as lactate accumulation, in response to a heart rate increase from 120 to 180 beats/min or in response to an increase in the severity of aortic stenosis (Brazier and Buckberg 1975). Subendocardial ischemia and infarction occur in association with aortic stenosis despite the absence of anatomic obstruction to coronary blood flow. This ischemia occurs when myocardial oxygen demands are increased as a result of the tachycardia of exercise or catecholamine infusion in patients with aortic stenosis. Similar increments in heart rate or stress do not cause EKG abnormalities in patients without left ventricular outflow obstruction or coronary artery disease. These observations suggest that the ischemia occurs because subendocardial oxygen delivery does not rise sufficiently to meet myocardial oxygen demands. Tachycardia shortens diastole more than systole and would tend to jeopardize blood flow to the subendocardium, since this region receives its blood supply during this phase of the cardiac cycle. Normally, coronary flow is augmented by vasodilation during tachycardia to supply added oxygen to meet the rate-induced rise in metabolic needs. In aortic stenosis, the coronary arteries may be nearly maximally dilated under resting conditions so that coronary flow can meet the increased oxygen requirements. Increasing heart rate in aortic stenosis may therefore limit available subendocardial blood supply and cause ischemia. In these studies, the relationship between myocardial oxygen supply and demand was deἀned by the diastolic and sytolic tension time index. It was demonstrated that changes in these indices induced by tachycardia were related to redistribution of blood flow away from the subendocardium and a reduced subendocardial oxygen delivery per unit of demand (Brazier and Buckberg 1975). The use of these indices has been expanded to include situations where aortic stenosis is not present. Foster et al. (1981) demonstrated that humans showed slightly compromised left ventricle contractile function when subjected to sudden strenuous exercise, but normal responses when exposed to graded exercise. They then suggested that this mechanism might be applicable to a group reported to have ischemic changes with sudden strenÂ� uous exercise (Foster et al. 1981, 1982). Their hypothesis, that subendocardial ischemia could occur in response to sudden strenuous exercise due to supply and demand imbalÂ� ances, relies on these indices. This concept is further supported by data demonstrating that sudden strenuous exercise performed without warm-up (Duncan et al. 1987) results in a transitory decrease in coronary blood flow at the onset of exercise, at a time when myocardial oxygen requirements are rapidly increasing. This may be due to abrupt increases in alpha adrenergic tone that are known to occur with sudden exertion (Aung-Din et al. 1981; Murray and Vatner 1981). It was also documented (Katz and Feinberg 1958; Khouri et al. 1965) that there are marked increases in myocardial oxygen demand due to sudden stress, which then leads to widening of the systolic time tension index. Thus, there may be both an increase in myocardial oxygen demand and a reduction in supply in this situation, which could result in myocardial ischemia. Such a paradigm would closely ἀt the situation of seizure patients. Many of the seizures, especially those that caused
112 Sudden Death in Epilepsy: Forensic and Clinical Issues
ischemic changes as evidenced by the electrocardiographic ST segment changes, occurred while the patients were asleep (Tigaran et al. 2003), which during normal NREM sleep, is a time of decreased sympathetic tone and increased parasympathetic activity, normally creating a state of reduced activity, and which, during REM sleep, is characterized by increased parasympathetic activity and variable sympathetic activity associated with increased activation of certain brain functions (Harris 2005; Yasue 1983). Furthermore, epileptic patients, especially those with tonic–clonic seizures, are known to have apnea during seizures (Nashef et al. 1996; So et al. 2000; Johnston et al. 1995). Thus, in addition to sudden exertion and the abnormalities in supply and demand described above, there are addiÂ�tional provocative stimuli, such as hypoxia for cardiac ischemia, in these patients. Moreover, as shown by Nei et al. (2000a), epilepsy patients may have impaired autonomic function, which, in the context of seizure-related rapid high catecholamine turnover, represents an additional facilitator for cardiac ischemia and arrhythmia. These ἀndings are consonant with the pathology of formation of cardiac contraction band necrosis as a result of massive catecholamine release, as shown in patients who died as a result of status epilepticus (Manno et al. 2005), along with ἀndings of perivascular interstitial ἀbrosis and myocyte vacuolization often found in patients with SUDEP (P-Codrea Tigaran et al. 2005). It is well known that increased amounts of ἀbrotic tissue in the heart strongly correlates with an increased incidence of atrial and ventricular tachyarrhythmias and sudden cardiac death (Ten Tusscher and Panἀlov 2007). These islands of necrosis found in the hearts of some persons with epilepsy could provide the substrate for the stimulation of malignant arrhythmias, such as ventricular tachycardia (Espinosa et al. 2009), and may represent the structural damage required to initiate ventricular arrhythmias through a functional re-entrant mechanism (El Sherif 1994).
7.5â•…In Vivo Evidence for an Arrhythmogenic Substrate in the Hearts of Epilepsy Patients at Risk for SUDEP A special electrocardiographic technique, known as signal-averaged electrocardiography, or ventricular late potentials, can be used to examine the presence of an arrhythmoÂ� genic substrate such as the patchy subendocardial ἀbrosis detected when the otherwise healthy hearts of the SUDEP victims have been autopsied. It should be noted that, even in patients with known heart disease and known ventricular ectopy, late potentials have a good negative predictive value but have an extremely poor positive predictive value. Today in clinical cardiology, signal-averaged electrocardiography is being supplanted by other techniques such as the microvolt T-wave alternans (TWA) test (Cambridge Heart, Bedford, MA) (Heart 2009), which monitors for minute beat-to-beat variations in the electrocardiographic T-wave during exercise stress. Even though the data presented in this chapter are unique in their application to a group of persons with epilepsy, there is obviously a need for additional studies using the more sophisticated newer techniques and a larger number of patients. Late potentials are produced by delayed or slowed conduction of the ventricular myocardium. When applied in coronary heart disease, late potentials have been shown to represent diseased myocardium with delayed depolarization, which may serve as the substrate for the re-entrant mechanism causing ventricular tachycardia and sudden cardiac death (El Sherif 1994).
Sudden Unexpected Death in Epilepsy
113
The prevalence of electrocardiographic late potentials is generally increased by the amount of scarring of the myocardium, as noted previously. The prevalence of late potentials is highest in patients with the most severely damaged myocardium, such as in patients with reduced left ventricular function due to previous myocardial infarctions (Christiansen et al. 1995). In autopsy studies of SUDEP victims, the ἀndings were represented by subendocardial patchy ἀbrosis, which would very likely not be visible on echocardiography or in a 12-lead electrocardiogram, but only detectable by the signal averaging electrocarÂ�dioÂ�graphic technique, namely the late potentials. Accordingly, in 1999 we were the ἀrst to employ this technique in both unmedicated and medicated epilepsy patients (Tigaran et al. 1999). Twenty-three patients were enrolled in the study. All the patients had normal 12-lead electrocardiograms and echocardiograms, as well as normal myocardial scintigraphy stress tests. The patients were used as their own controls. In the ἀrst phase, the patients were medicated when they underwent 15 min of raw electrocardiographic late potentials recordÂ� ings study. Before the ἀrst electrocardiogram, a blood sample was drawn to determine the antiepileptic drug concentration. Three of those were on monotherapy with lamotrigine, one on monotherapy with vigabatrin, and one on topiramate. The remaining eight received polypharmacy, with two (n = 5 patients) and three (n = 3 patients) drugs. Only one patient receiving polypharmacy was on carbamazepine, the others received topiramate (n = 5 patients), clobazam (n = 5 patients), lamotrigine (n = 1 patient), vigabatrin (n = 1 patient), gabapentine (n = 1 patient), and oxcarbazepine (n = 4 patients). Two of these drugs do not have sodium channel blocker properties (vigabatrine, gabapentine). In this ἀrst phase, 59% (13 out of 22 patients) were late potentials positive (8 men and 5€women). In one patient, the data could not be analyzed for technical reasons, due to the presence of a continuous electrocardiographic P–Q interval. For the second phase, namely the off-drugs phase, the investigation was not performed in the ἀrst ἀve patients. For the remainder of the patients undergoing this late potential electrocardiographic study, before the completion of the study, a blood sample was drawn to determine if any antiepileptic drugs could be detected in plasma. Thus, we detected that in two patients the antiepileptic drugs were within the therapeutic range when the investigation was conducted, leaving 15 patients with pertinent results after undergoing both on- and off-drugs late potentials electrocardiography study. Out of these 15 patients, there were initially 7 (47%) late potentials positive. With the withdrawal of all drugs, ἀve became late potentials negative, leaving only two with persistently positive results [2 out of 15 patients (13%)]. One was on monotherapy with lamotrigine, and one received a combination of topiramate with clobazam. Both patients received a drug with an action mechanism related to the inactivation of the sodium channels. Our results showed a clear correlation between male gender and positive longer signaled averÂ�aged electrocardiographic QRS complex, which correlates with the data across most of the SUDEP literature showing higher SUDEP fatalities among men. Females tended to€normalÂ�ize when antiepileptic medications and all the other drugs were stopped (see€Figure 7.1). Likewise, a high diastolic pressure at study entry was a signiἀcant predictor for poor late potentials normalization when drugs were withdrawn. Statistical work-up was considered to be nonrelevant due to the small numbers of the different subgroups. Our observations raised an important question concerning the background of the high prevalence of the late potential results (see Figure 7.2), which lead us to the following hypotheses:
114 Sudden Death in Epilepsy: Forensic and Clinical Issues 25 20 15 10 5 0 –5 –10 –15 –20 –25
Males Females
RMS
QRS
LPD
Figure 7.1╇ Average increase in measurements induced by stopping medication. LP tends to normalize in women [late potential duration (LPD) and the root mean square (RMS) voltage of the terminal at 40 mS] when AEDs were stopped; LP were considered positive when two parameters were abnormal: QRS > 120 mm, RMS40 < 25 μV, LPD > 40 mS. (From Tigaran, S., Acta Neurol Scand Suppl, 177, 9–32, 2002. With permission.)
1. The changes are due to subendocardial scarring present in the epilepsy patients’ myocardium. However, because of the discrete nature of ἀbrosis found postmortem in the hearts of the epilepsy patients, we may not be able to detect these abnormalities with sufficient sensitivity by means of the present technique. The author must admit that the results following the investigation of the ἀrst ἀve patients enrolled in the study, all of which exhibited positive late potentials, were surprising. Consequently, it was decided to repeat the investigation after the antiepileptic drugs were withdrawn (the patients did not receive any other drugs but antiepileptics), and simultaneously control the antiepileptic drug plasma concentration when investigating the rest of the patients, both in the medicated and in the unmedicated Positive *Vector Butterworth 40–250 Hz
Negative RMS40 : 10.2 µV RMS50 : 19.2 µV QRS : 140 mS
*Vector Butterworth 40–250 Hz
RMS40 : 25.3 µV RMS50 : 40.1 µV QRS : 101 mS
LPD : 46 mS
LPD : 24 mS
Noise : 0.4 µV
Noise : 0.3 µV
200 mm/s 10 µV/10 mm
200 mm/s 10 µV/10 mm
Figure 7.2╇ Example positive versus negative LP image. (From Tigaran, S., Acta Neurol Scand Suppl, 177, 9–32, 2002. With permission.)
Sudden Unexpected Death in Epilepsy
115
phase. Our ἀrst conclusion, coupled with the delayed depolarization of the left ventricle observed in 47% (positive late potentials) of our patients on drugs when compared with the off-drugs phase, led us to the second working hypothesis. 2. The changes are due to the antiepileptic drugs, thus generating the hypothesis that antiepileptics might also influence the electrical properties of the myocyte due to their electrophysiological effects on the conduction system and the myocardium. As previously shown, many antiepileptic drugs exert their effects by blocking sodium channels, which generally slow conduction. Several cardiac antiarrhythmic drugs also exert their effects by blocking this channel (Anderson et al. 1994). This relationÂ� ship has also been observed in other clinical studies of sodium channel blocker drugs. Antiepileptic drugs may thus, through their as yet unrecognized influence on the depolarization process (Freedman and Steinberg 1991), potentially increase the propensity for malignant arrhythmias. In a larger perspective, this could be a potential so-called proarrhythmic effect, which could precipitate cardiac arrhythmias. To the best of the author’s knowledge, there are no available data describing the relationship between the occurrence of late potentials and antiepileptic drugs. While not claiming to have found the ultimate explanation, the author would like to propose that although the two hypotheses are apparently discordant, both variants may be true. Likewise a combination of both hypotheses would also be a possibility, an idea supported by the ἀndings of the electrocardiographic positive ST segment and the positive late potentials. However, the interpretation of these ἀndings requires much caution, warranting further studies to verify the reproductibility of the described ἀndings (Tigaran et al. 2002). Future studies employing the magnetic resonance imaging (MRI) technique will help in clarifying the questions rained by these two hypotheses.
7.6â•…Evidence of Sinus Tachycardia Associated with Epileptic Seizures More than 25 years ago, Marshall et al. (1983) wrote that, “a seldom-recognized accompaniment of temporal lobe seizures is tachycardia.” They were the very ἀrst authors to document by simultaneous “electroencephalographic, electrocardiographic, and videotape monitoring” the presence of this phenomenon in 12 consecutive patients with spontaneous seizures. Several subsequent articles have described this phenomenon, and as a result of the analysis of more than 1500 seizures from more than 1000 epilepsy patients, all of them established without any doubt that, despite the origin of the epileptic seizure, sinus tachycardia is by far the most common cardiac phenomenon temporally associated with epileptic seizures, as one would expect as part of a normal response to stress. Some of the previous articles in the literature are lacking in details related to the exact brain origin of the seizure or the exact type of seizure, i.e., secondary generalization versus complex versus simple partial seizures. In the older studies, this inconsistency is due to the technical limitations of the imaging methods employed at the time of the study. Unfortunately, at times, the electroencephalographic onset of the seizure can be deceiving due to either rapid propagation of the seizure or inadequacy of the scalp EEG recording(s), as shown by studies using intracranial electrodes or magnetoencephalogram studies (Shibasaki et al. 2007). Overall, the heart rate is thought to be signiἀcantly higher with seizures arising from the temporal than from the frontal lobe (Galimberti et al. 1996; Schernthaner et al.
116 Sudden Death in Epilepsy: Forensic and Clinical Issues
130
1999; Garcia et al. 2001; Opherk et al. 2002; Tigaran et al. 2002; Leutmezer et al. 2003) and to occur earlier in patients whose seizures arise during sleep (Opherk et al. 2002). Of note, Tigaran et al. (2003) showed that epileptic seizures induce a rapid increase in heart rate from resting levels to more than 180 beats/min shortly before the onset of electrocardiographic seizures. This early increase in heart rate indicates that seizures can induce a turning on/off of very high levels of efferent neural cardiac sympathetic activity (see Figure 7.3). Such high levels of sympathetic activity (Tigaran et al. 2001) become toxic principally to the cardiac myocyte and could, in the long run, be a contributing factor to the scarring of the myocardium observed in SUDEP victims (see Figure 7.4) (P-Codrea Tigaran et al. 2005; Natelson et al. 1998; Falconer and Rajs 1976), as well as the formation of cardiac contraction bands (Manno et al. 2005). Moreover, Tigaran et al. (2003) have demonstrated the occurrence of myocardial ischeÂ� mia triggered by high heart rate values, as shown by the presence of electrocardiographic ST-segment depression, which is associated with an epileptic seizure (see Figure 7.5), and could represent an additional contributing factor to the pathologic changes of the myocardium, such as ἀbrotic scarring. Strikingly, the failure of the recorded heart rate to recover to the baseline level for as long as 1 h after seizure cessation can be a possible result of the impaired autonomic function (Ushijima et al. 2009) such as Nei et al. (2000a) have demonstrated to be present in some of their epilepsy patients. It is important to consider that, in epilepsy patients, tachycardia triggering cardiac ischemia may have even more serious consequences, especially in patients who already have cardiac disease. This suggests that methods of addressing it might be important and worthy of investigation, such as, for example, blunting the ischemic and heart rate response with beta-blockers. The observations and present hypothesis represent an exciting challenge with regard to experimental clinical testing. Salutary in this context are studies looking into the association between tachycardia and diverse types of ethnic groups. A pioneer in this ἀeld of research, Wilder-Smith
110 100 90 70
80
Average heart rate
120
No ST-segment change ST-segment change
0
10
20
30
40
50
60
Minutes relative to seizure
Figure 7.3╇ Average heart rate (HR) over time by ST-segment changes. 0 = max HR during seizure. (From Tigaran, S., Acta Neurol Scand Suppl, 177, 9–32, 2002. With permission.)
Sudden Unexpected Death in Epilepsy 9
1
2
117 1 2 3 4 5 6 7 8 9 10 11 12 13 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
8
3
10
4
7
5
6
11
(a)
X
1 2 3 4 5 6 7 8 9 10 11 12 13
8
3
10
4 5
(b)
9
1
2
7 6
11
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15
X X X
Figure 7.4╇ Comparison between the distribution of the fibrotic changes of the deep and sub-
endocardial myocardium in SUDEP versus control patients. (a) Control patients for fibrotic myocardial areas. (b) Fibrotic areas in the hearts of SUDEP patients. 1–15 (vertical), subject’s identification number; 1–11 (horizontal), sections from the transmural tissue blocks containing the deep and endocardial myocardium; 12, longitudinal tissue block from intermedial septum; 13, longitudinal tissue block from the papillary muscle of the left ventricle; X, presence of fibrotic changes in singular areas which are not present in the stylized figure. Light gray: slight fibrosis: 1 patient with fibrotic changes confined to 1 area. Darker gray, moderate fibrosis: 2 patients with fibrotic changes observed in the same area. Darkest gray, severe fibrosis: 3 patients with fibrotic changes observed in the same area. (From P-Codrea, Tigaran, S. et al., Am J Forensic Med Pathol, 26 (2), 99–105, 2005. With permission.)
(Wilder-Smith and Lim 2001), published a study concerning the changes in heart rate amongst non-Caucasian Singaporean patients. Notably, this study concluded that sinus tachycardia was considerably less frequent in non-Caucasian epilepsy patients. Despite being a very comprehensive review of SUDEP and its mechanism, the Nigerian Kwara State article lacked regional ethnic data that could have addressed this particular topic (Sanya 2005). By the same token, it is quite possible that the American melting pot, more than anywhere else, will claim its own speciἀc studies looking at the issue of racial and ethnic differences in epilepsy-related cardiac arrhythmias.
118 Sudden Death in Epilepsy: Forensic and Clinical Issues
00:49:13 Pre start of Event
01:03:57 Pre start of Event
00:49:47 Max. depress.
01:08:28 Max. depress.
00:51:33 Post end of Event
01:12:11 Post end of Event
Figure 7.5╇ Example from Patient 1 (left) and Patient 9 displaying dynamic ST-segment depression in relation to seizure with secondary generalization. (From Tigaran, S., Acta Neurol Scand Suppl, 177, 9–32, 2002. With permission.)
A conceptually different idea, outside of the direct association between heart rate variations and SUDEP, involves the epidemiology of obesity, which is thought to be a speciἀc important risk factor for occult cardiovascular disease. Thus, complications of obesity in epilepsy patients might influence even more the ability of the heart to adjust to abrupt, sudden variations in its rate and represent a contributory mechanism in SUDEP. Obesity is a chronic metabolic disorder associated with cardiovascular disease and increased morbidity and mortality. It is a widely acknowledged risk factor for developing coronary artery disease (Franzosi 2006). The number of deaths per year attributable to obesity is about 30,000 in the United Kingdom, a country that has produced a signiἀcant amount of SUDEP data. This number is 10 times higher in the United States, roughly about 300,000 deaths per year (Allison et al. 1999), where more than half of the adults are overweight (Flegal et al. 1998) and where obesity is thought to have overtaken smoking in 2005 as the main preventable cause of illness and premature death (Franzosi 2006). If we do death rate extrapolations for the United States for obesity, there will be 300,000 deaths per year, 25,000 deaths per month, 5769 deaths per week, 821 deaths per day, and 34 deaths per hour (WrongDiagnosis.com 2009). Moreover, we also have to keep in mind the speciἀc association between obesity and obstructive sleep apnea, which represents an aggravating and important contributing factor to the genesis of cardiovascular diseases (Hiestand et€al. 2006). Since apnea has already been identiἀed to be associated with epileptic seizures and SUDEP (Nashef et al. 1996; So et al. 2000), this association should prompt even more attention and many more research studies. Another notable association, which might be very signiἀcant for epilepsy and SUDEP, is the signiἀcant increase in the older population and the speciἀc increase of epilepsy prevalence in this age group (Velez and Selwa 2003). Accordingly, the speciἀc concurrent morbidities, such as stroke and cardiac diseases, present in this age category will prompt an even higher awareness of the cardiac complications in epilepsy.
Sudden Unexpected Death in Epilepsy
119
7.7â•…Bradycardia and Asystole Asystole and atrioventricular block are recognized as potentially malignant conduction abnormalities that can lead to ventricular ἀbrillation (Tigaran et al. 2002). Thus, bradyarrhythmia could be particularly risky in patients with coexistent, underlying ischemic heart diseases; this emphasizes the importance of recognizing these cases. Ictal bradycardia, cardiac asystole, and total atrioventricular block associated with epileptic seizures is to date a more seldom but noteworthy complication of epilepsy. This association is probably still underestimated because of the lack of recognition of cardiac complications in epilepsy, as mentioned before. Because of its implication in the pathophysiology of SUDEP, there were two earlier literature reviews on bradyarrhythmias and asystole as cardiac consequences of epileptic seizures (Devinsky et al. 1997; Tinuper et al. 2001). Several other case reports have been published since 2001 (Rocamora et al. 2003; Venugopalan et al. 2001; Mondon et al. 2002; Leutmezer et al. 2003; Toth et al. 2008; Carinci et al. 2007; Strzelczyk et al. 2008; Schuele et al. 2008; Ghearing et al. 2007; Almansori et al. 2006; Mascia et al. 2005; So and Sperling 2007; Rugg-Gunn et al. 2004a; Carvalho et al. 2004), adding valuable information about the occurrence of bradycardia in epilepsy. Of note, in this context, are recent studies from the Mayo Clinic (Britton et al. 2006), which showed no consistent hemispheric lateralization of seizure activity at the onset of bradycardia. Another study (Ghearing et al. 2007) found over a 14-year period that only 29 seizures were associated with ictal bradycardia in 13 patients. Out of the 29 bradycardia episodes, 7 patients had a total of 11 complex partial seizures that were associated with asystole. Despite the apparent multitude of published case reports, this association still seems to be infrequent. A feasible explanation of the paucity of data regarding the association between epilepsy and bradycardia may be an underestimation of this association due to the lack of adequate monitoring of the epilepsy patients, with concurrent electrocardiographic and intracranial electroencephalographic analysis (Leung et al. 2006). Important in this context, Rugg-Gunn et al. (2004b) developed a new monitoring strategy. Epilepsy patients were implanted with subcutaneous electrocardiogram loop recorders for an average of 18 months. Of the 19 patients, 4 (21%) developed bradycardia or asystole, for which a permanent pacemaker was deemed appropriate. Three of these episodes occurred at the time of a clinical seizure and one was not associated with a known clinical event. This study clearly showed how inadequate it is to simply record electroencephalograms and electrocardiograms for a few days or a few seizures. Thus, the ἀndings of Rugg-Gunn and colleagues (2004b) should be applauded. Other investigators should try to replicate these ἀndings in order to acquire more evidence-based data before we apply these ἀndings to the routine care of people with epilepsy (Hirsch and Hauser 2004).
7.8â•…Ictal Cardiac SPECT Imaging Supportive of a Cardiac Mechanism of SUDEP To the best of our knowledge, there is only one study illustrating focal myocardial perfusion defects concurrent with electrocardiographic ST-segment depression at the cessation of an epileptic seizure as an indicator for myocardial ischemia (see Figure 7.6) (Tigaran 2001; Dam et al. 2001). Notably, the criteria and the methods available for the detection of the myocardial ischemia with myocardial perfusion scintigraphy in this study were not
120 Sudden Death in Epilepsy: Forensic and Clinical Issues
Seizure
Rest
Perfusion defect during seizure
Patient 8
Figure 7.6╇ Perfusion defect during epileptic seizure.
used to determine if ischemia could occur globally in the myocardium. For future studies, the limitation of employing this type of imaging technique could be potentially addressed by the use of newer techniques, such as hybrid positron emission tomography/computerized tomography (PET/CT) or PET/magnetic resonance imaging systems, which would be able to detect more accurately any perfusion defects (Slomka et al. 2008). In data from an unpublished study conducted by the author of this chapter, 14 men and 9 women (age range 20–59 years, mean 42) with intractable focal epilepsy for 4 to 55 years (mean age 26 years) participated in this prospective study. All patients had normal baseline results on electrocardiography, Holter monitoring, echocardiography, myocardial scintigraphy at rest, and coronary angiography. Technetium 99m Cardiolite (DuPont Pharma, UK) was injected into 18 unmedicated patients during ictal events in which nine patients experienced secondarily generalized tonic–clonic seizures with a mean of maximum ictal heart rate of 133 beats/min. The other seven patients were injected in relation to complex partial seizures with an average maximal ictal heart rate of 108 beats/min. One patient received the tracer during a simple partial status epilepticus episode, during which the Holter recording was not available. Of the 18 myocardial perfusion studies, there were several ictal studies positive for focal myocardial perfusion defects (n = 3 or 16%). Unfortunately, only one was a positive ictal study in which the tracer was injected in direct relationship to a seizure where a 1-mm ST-segment depression, which is reflective of myocardial ischemia, was detected on the Holter monitor subsequent to a complex partial seizure without any motor phenomenon, recorded at 03:05 p.m. The maximum ictal heart rate during this seizure was 134 beats/min. This patient, a 56-year-old female with MRI-veriἀed right-sided hippocampus gliosis, had both infero- and anteroseptal reversible defects. This particular ἀnding may advocate for SUDEP being more frequent in women than was previously estimated (Walczak et al. 2001). The patient was moderately obese and had a normal 12-lead electrocardiogram, rest and stress test, and myocardial scintigraphy, as well as normal coronary angiography. Her baseline plasma norepinephrine was higher than normal, namely 1033 pg/mL. Her urine norepinephrine was 55,200 pg/mL
Sudden Unexpected Death in Epilepsy
121
or 135 μg per 24 h. Her baseline plasma epinephrine was also elevated above the normal reference interval, up to 87 pg/mL, and her urine norepinephrine was 13,800 pg/mL or 34€μg per 24€h (diuresis was 2450 mL for 24 h when the values were collected). Normal reference ranges are laboratory-speciἀc, vary according to methodology of testing, and differ between blood and urine samples. Supine (lying down): epinephrine less than 50 pg/ mL, norepinephrine less than 410 pg/mL; reference ranges for urine catecholamines are: epinephrine 0–20 μg per 24 h and norepinephrine 15–80 μg per 24 h (Answers.com 2009). The ἀndings in the above case concur with those of Nei et al. (2004), who suggests “. . . that patients with evidence of a great degree of change in autonomic tone during seizures might be at increased risk for SUDEP.” During the epileptic seizure, an almost threefold increase was noted in both plasma and urine catecholamines (plasma norepinephrine, 2891 pg/mL; plasma epinephrine, 296 pg/mL; urine norepinephrine, 121,300 pg/mL; and urine epinephrine, 29,700 pg/mL) for a total diuresis of 2400 mL. During the seizure, a drop in O2 saturation from 100% to 93% was recorded by the pulse oximeter, which did not represent any signiἀcant drop in the O2 saturation. The oxygen saturation dropped, but not below the limit of 90%. Most physicians would not be concerned when the oxygen saturation is above 90% (93% in this study). The imaging results from a small cohort of drug refractory epilepsy patients, whose antiepileptic drugs were withdrawn during the course of the study, and without any evidence of cardiovascular disease, substantiate the hypothesis that cardiac ischemic abnormalities may exist and could potentially provide some of the pathophysiologic explanation for SUDEP. The data also suggest that epileptic seizures of temporal origin may induce myocardial ischemia in the absence of coronary pathology, presumably by autonomicÂ�mediated vasospasm. This ἀnding points again toward an association between cardiac abnormalities in epilepsy and the sudden, large imbalance in cardiac efferent autonomic activity (Druschky et al. 2001) that may result in autonomic-mediated ischemia and, thus, possible fatal arrhythmia. Unfortunately, this study (Tigaran 2001) has several limitations. The tracer was simultaneously injected during the electrocardiographic detected myocardial ischemia as reflected by the ST-segment changes in one patient out of the 23 who were enrolled in the study. Studies related to the anatomical brain localization of the site of the seizure employing the subtraction ictal SPECT coregistered to MRI (SISCOM) method documented the importance of the timing for the tracer injection (O’Brien et al. 1998). Late injection of the radiotracer (>45 s) after the onset of the epileptic seizure was associated with a falsely localizing or nonlocalizing SISCOM study, a ἀnding that could be extrapolated to our epilepsy study. This might represent the explanation for why 15 of the 18 scans were negative myocardial perfusion studies.
7.9â•…Future Research Avenues for an Underlying Cardiac Mechanism of SUDEP: Epilepsy, Depression, and Cardiac Disease For centuries poets and folklore have asserted that there is a relationship between the mind and body in general, and human moods and the heart in particular. Almost 400 years ago Shakespeare wrote, “. . . My life being made of four, with two alone sinks down to death, oppress’d with melancholy . . . .” (Shakespeare). However, only in the past few years has this
122 Sudden Death in Epilepsy: Forensic and Clinical Issues
conviction been scientiἀcally tested (Glassman and Shapiro 1998). Indeed, it has also been proved that depression is the most frequent psychiatric disorder in patients with epilepsy and that it is more common in patients with partial seizure disorders of temporal or frontal lobe origin and among patients with poorly controlled seizures. In three communitybased studies, prevalence rates of depression ranged between 21% and 33% among patients with persistent seizures and between 4% and 6% among seizure-free patients (LaFrance et al. 2008). Ettinger et al. (2005) reported the results of a population-based survey that investigated a lifetime prevalence of depression, epilepsy, diabetes, and asthma in 185,000 households. Among the 2900 patients with epilepsy, 32% reported having experienced at least one episode of depression. This contrasted with an 8.6% prevalence among healthy respondents, 13% among patients with diabetes, and 16% among people with asthma. For a long time, people speculated about whether depression increases the risk of mortality only in individuals with established coronary disease, or if those without a history of heart disease are at increased risk as well. Glassman and Shapiro (1998) concluded that both groups are at risk, but the risk is higher in groups with established coronary artery disease. This conclusion was validated in a study by Penninx et al. (2001), which concluded that, regardless of the preexistence of coronary artery disease, the effects of depression result from the same mechanisms in both groups. Because sudden cardiac death accounts for most of the excess mortality in association with depression in patients with established coronary artery disease, one should search for proarrhythmic mechanisms associated with depression (Carney et al. 2001). Multiple possibilities exist. Heart rate variability is lower in depressed than in nondepressed patients with established coronary artery disease. In addition, plasma catecholamines, known provokers of arrhythmias and sudden cardiac death, are elevated in depressed patients (Carney et al. 2001). This is also the case in epilepsy patients (Tigaran et al. 2001; Lathers et al. 1984, 2008). Especially supportive of the altered autonomic tone in depression is the study of Sheline et al. (1996) who demonstrated that patients with a history of major depression had signiἀcantly smaller hippocampal volumes bilaterally when compared with matched control subjects. The decrement in hippocampal volume correlates with the cumulative lifetime duration of major depression, possibly as result of a progressive process mediated by glucocorticoid neurotoxicity (Carney et al. 2001). This process may be responsible for an increase in corticotropin-releasing factor secretory drive and may thereby contribute to the elevated hypothalamic–pituitary–adrenal axis activity observed in depression. Corticotropin-releasing factor is also a potent stimulus for sympathetic nervous system activation, which may account for the sympathetic hyperactivity observed in major depression (Carney et al. 1999, 2001) and in epilepsy patients (Nei et al. 2000a). In concert with the hippocampal ἀndings in depression, recent imaging studies in epilepsy patients revealed the existence of similar pathological ἀndings, namely those with right temporal lobe epilepsy and depression have hippocampal atrophy that cannot be explained by epilepsy alone (Shamim et al. 2009). In this context and supportive of this theory is the recent study of Bernhardt et al. (2009), which provides a unique quantitative assessment in patients with temporal lobe epilepsy. The study indicates that regions of the brain remote from the lobe from which the seizure originates may be adversely affected with signiἀcant changes in cerebral cortical structures that may be important in the development of comorbidities (Cascino 2009). Unfortunately, the sample size was too small to allow any conclusions regarding the left side hippocampus. Until now, there have been no studies looking into the association between the size of the hippocampal sclerosis, epilepsy, and depression in SUDEP patients. The ἀndings of
Sudden Unexpected Death in Epilepsy
123
this recent imaging study (Shamim et al. 2009) may open new research avenues for a better understanding of the SUDEP phenomenon, and a possible explanation of why not all epilepsy patients have an equal risk of dying of SUDEP. Finally, depression is associated with platelet activation and with inflammatory processes that may increase the risk of developing coronary artery disease or, in patients with established coronary artery disease or myocardial infarction (Carney et al. 2001), which might also be the case in epilepsy.
7.10â•…Evidence of Cardiac Arrhythmogenic Substrate for SUDEP: The Influence of Antiepileptic Drugs on the Heart Blumhardt et al. (1986) suggested that treated patients with epilepsy had lower mean rates of the ictal cardiac acceleration than the untreated patients, whereas Opherk et al. (2002) stated that antiepileptic drug regimes were mostly similar in seizure patients with and without cardiac abnormalities. However, due to the small number of patients studied, further conclusions concerning the possible protective effect of antiepileptic drugs were precluded. Others studies evaluated the role of heart rate, but did not specify the part played by antiepileptic drugs upon the heart rate. In contradistinction to the antiepileptic drug protective role theory, Devinsky et al. (1994) showed that patients with epilepsy have greater blood pressure and heart rate variability and reactivity than control patients, with those ἀndings partly attributable to carbamazepine. Conversely, by employing the technique of the electrocardiographic late potentials (see Figure 7.2) (Tigaran et al. 2002), it has been shown, with no preference for any of the antiepileptic drugs, that all may also influence the electrical properties of the myocytes, mostly through an inactivation of the sodium channels, thus potentially precipitating cardiac arrhythmias. The electrocardiographic late potential technique was shown to reveal the presence of diseased myocardium with delayed depolarization, which may serve as the substrate for reentrant arrhythmias causing ventricular tachycardia and sudden cardiac death (Tigaran et al. 2002). Further work is needed to determine whether techniques such as signal-averaged electrocardiography (SAECG) or other, newer techniques will be useful screening tools to identify whether some persons with epilepsy are at risk for SUDEP.
7.11â•…Summary and Clinical Perspectives The concept that abnormal electrical discharges in the brain trigger cardiac arrhythmias does not seem to be widely recognized by clinicians, although it has long been proposed in the neurological literature (Blumhardt et al. 1986; Mameli et al. 2006; Jallon 1997). Unfortunately, even now, electrocardiographic recordings are not always conducted or reviewed during epilepsy monitoring. Thus, the deἀnite relationship between epileptic seizures and cardiac abnormalities is still the subject of an ongoing debate. The diversity of the methods employed in the assessment of this relationship, in contrast to the use of only a single electrocardiogram rhythm monitoring channel that is usually a supplement to the EEG recordings, along with the infrequent use of simultaneous long-term EEG-Holter recordings, presents another limitation of this type of investigation.
124 Sudden Death in Epilepsy: Forensic and Clinical Issues
Of note is the consistent lack of respiratory recordings, which need to be conducted during assessments related to electroencephalographic investigations before epilepsy surgery or admittance for differential diagnosis purposes, since apnea and hypoxia clearly represent a major contributory mechanism to the occurrence of cardiac events (Schulz et al. 2006). Nonetheless, the variable results from studies seeking a relationship between epilepsy and the risk of potentially fatal cardiac events, as discussed in this chapter, support the need for different animal models (Lathers et al. 2008, 2010, Chapter 28) that would provide comparison with clinical study data from patients with epilepsy. Also, studies addressing the association between epilepsy, depression, and cardiac abnormalities and SUDEP are deemed to be of future research importance. We need to encourage cardiologists to exercise caution when concluding from Holter monitoring alone, especially in the setting of ambulatory recordings that presumed cardiogenic arrhythmias, even when they coincide with symptoms, are the primary cause of any patient’s complaints. Only prolonged monitoring, deἀned as at least 24 h of recordings of simultaneous EEG and ECG records, will improve the diagnostic yield and, consequently, optimize the treatment of the patients with seizure-related arrhythmias and also of persons with cardiogenic arrhythmias that can result in seizure like activity. Moreover, besides the determination of the genetic etiology of epilepsy and association with depression, it would be useful to conduct collaborative studies aimed at evaluating both the epileptogenic and the cardiologic aspect of the underlying substrate that may lead to increasing the chance of potentially fatal events. Only by making both doctors and patients aware of the presence of the potential for adverse symbiosis between neurological and cardiac abnormalities will the quality of preventive services, especially as relates to SUDEP, be improved. Only time, education, and interdisciplinary joint efforts will determine whether well-conducted research will be feasible in large population samples.
Acknowledgment For valuable criticism when reviewing this book chapter, I have to thank Allan S. Jaffe, MD, Mayo Clinic, Rochester, MN.
References Allison, D. B., K. R. Fontaine, J. E. Manson, J. Stevens, and T. B. VanItallie. 1999. Annual deaths attributable to obesity in the United States. JAMA 282 (16): 1530–1538. Almansori, M., M. Ijaz, and S. N. Ahmed. 2006. Cerebral arrhythmia influencing cardiac rhythm: a case of ictal bradycardia. Seizure 15 (6): 459–461. Anderson, J. L., E. V. Platia, A. Hallstrom, R. W. Henthorn, T. A. Buckingham, M. D. Carlson, and P. E. Carson. 1994. Interaction of baseline characteristics with the hazard of encainide, flecainide, and moricizine therapy in patients with myocardial infarction. A possible explanation for increased mortality in the Cardiac Arrhythmia Suppression Trial (CAST). Circulation 90 (6): 2843–2852. Answers.com. 2009. Catecholamines Tests: Normal Results. Available from http://www.answers╉ .com/catecholamines-tests-normal-results (accessed February 2009).
Sudden Unexpected Death in Epilepsy
125
Aung-Din, R., J. H. Mitchell, and J. C. Longhurst. 1981. Reflex alpha-adrenergic coronary vasoconstriction during hindlimb static exercise in dogs. Circ Res 48 (4): 502–509. Begun, J. W., J. Tornabeni, and K. R. White. 2006. Opportunities for improving patient care through lateral integration: the clinical nurse leader. J Healthc Manag 51 (1): 19–25. Beran, R. G. 2006. SUDEP—To discuss or not discuss: That is the question. Lancet Neurol 5 (6): 464–465. Bernhardt, B. C., K. J. Worsley, H. Kim, A. C. Evans, A. Bernasconi, and N. Bernasconi. 2009. Longitudinal and cross-sectional analysis of atrophy in pharmacoresistant temporal lobe epilepsy. Neurology 72 (20): 1747–1754. Blumhardt, L. D., P. E. Smith, and L. Owen. 1986. Electrocardiographic accompaniments of temporal lobe epileptic seizures. Lancet 1 (8489): 1051–1056. Brazier, J. R., and G. D. Buckberg. 1975. Effects of tachycardia on the adequacy of subendocardial oxygen delivery in experimental aortic stenosis. Am Heart J 90 (2): 222–230. Britton, J. W., G. R. Ghearing, E. E. Benarroch, and G. D. Cascino. 2006. The ictal bradycardia syndrome: localization and lateralization. Epilepsia 47 (4): 737–744. Carinci, V., G. Barbato, A. Baldrati, and G. Di Pasquale. 2007. Asystole induced by partial seizures: a rare cause of syncope. Pacing Clin Electrophysiol 30 (11): 1416–1419. Carney, R. M., K. E. Freedland, and A. S. Jaffe. 2001. Depression as a risk factor for coronary heart disease mortality. Arch Gen Psychiatry 58 (3): 229–230. Carney, R. M., K. E. Freedland, R. C. Veith, and A. S. Jaffe. 1999. Can treating depression reduce mortality after an acute myocardial infarction? Psychosom Med 61 (5): 666–675. Carvalho, K. S., V. Salanova, and O. N. Markand. 2004. Cardiac asystole during a temporal lobe seizure. Seizure 13 (8): 595–599. Cascino, G. D. 2009. Temporal lobe epilepsy is a progressive neurologic disorder: Time means neurons! Neurology 72 (20): 1718–1719. Chin, P. S., K. R. Branch, and K. J. Becker. 2004. Myocardial infarction following brief convulsive seizures. Neurology 63 (12): 2453–2454. Christiansen, E. H., L. Frost, H. Mlgaard, P. E. Thomsen, T. T. Nielsen, and A. K. Pedersen. 1995. The signal-averaged ECG becomes late potential-positive at low noise levels in healthy subjects. Eur Heart J 16 (11): 1731–1735. Dam, M., S. Tigaran, K. Rasmussen, M. Rehling, and H. Molgaard. 2001. Sudden unexpected death in epilepsy (SUDEP): Regional myocardial blood flow during seizure. Neurology 56 (S-3): A233. DeGiorgio, C. M., P. Miller, S. Meymandi, and J. A. Gornbein. 2008. n-3 fatty acids (ἀsh oil) for epilepsy, cardiac risk factors, and risk of SUDEP: Clues from a pilot, double-blind, exploratory study. Epilepsy Behav 13 (4): 681–684. Devinsky, O., K. Perrine, and W. H. Theodore. 1994. Interictal autonomic nervous system function in patients with epilepsy. Epilepsia 35 (1): 199–204. Devinsky, O., S. Pacia, and G. Tatambhotla. 1997. Bradycardia and asystole induced by partial seizures: a case report and literature review. Neurology 48 (6): 1712–1714. Druschky, A., M. J. Hilz, P. Hopp, G. Platsch, M. Radespiel-Troger, K. Druschky, T. Kuwert, H. Stefan, and B. Neundorfer. 2001. Interictal cardiac autonomic dysfunction in temporal lobe epilepsy demonstrated by [(123)I]metaiodobenzylguanidine-SPECT. Brain 124 (Pt 12): 2372–2382. Duncan, H. W., R. J. Barnard, G. K. Grimditch, J. Vinten-Johansen, and G. D. Buckberg. 1987. Cardiovascular response to sudden strenuous exercise. Basic Res Cardiol 82 (3): 226–232. El Sherif, N. 1994. Re-entrant mechanism in venticular arrhythmias. In Cardiac Electrophysiology: From Cell to Bedside, ed. D. Zipes and J. Jalife. Philadelphia, PA: W. B. Saunders. Espinosa, P. S., J. W. Lee, U. B. Tedrow, E. B. Bromἀeld, and B. A. Dworetzky. 2009. Sudden unexpected near death in epilepsy: Malignant arrhythmia from a partial seizure. Neurology 72 (19): 1702–1703. Ettinger, A. B., M. L. Reed, J. F. Goldberg, and R. M. Hirschfeld. 2005. Prevalence of bipolar symptoms in epilepsy vs other chronic health disorders. Neurology 65 (4): 535–540.
126 Sudden Death in Epilepsy: Forensic and Clinical Issues Falconer, B., and J. Rajs. 1976. Post-mortem ἀndings of cardiac lesions in epileptics: A preliminary report. Forensic Sci 8 (1): 63–71. Flegal, K. M., M. D. Carroll, R. J. Kuczmarski, and C. L. Johnson. 1998. Overweight and obesity in the United States: Prevalence and trends, 1960–1994. Int J Obes Relat Metab Disord 22 (1): 39–47. Foster, C., J. D. Anholm, C. K. Hellman, J. Carpenter, M. L. Pollock, and D. H. Schmidt. 1981. Left ventricular function during sudden strenuous exercise. Circulation 63 (3): 592–596. Foster, C., D. S. Dymond, J. Carpenter, and D. H. Schmidt. 1982. Effect of warm-up on left ventricular response to sudden strenuous exercise. J Appl Physiol 53 (2): 380–383. Franzosi, M. G. 2006. Should we continue to use BMI as a cardiovascular risk factor? Lancet 368 (9536): 624–625. Freedman, R. A., and J. S. Steinberg. 1991. Selective prolongation of QRS late potentials by sodium channel blocking antiarrhythmic drugs: Relation to slowing of ventricular tachycardia. Electrophysiologic Study Versus Electrocardiographic Monitoring Trial (ESVEM) Investigators. J Am Coll Cardiol 17 (5): 1017–1025. Galimberti, C. A., E. Marchioni, F. Barzizza, R. Manni, I. Sartori, and A. Tartara. 1996. Partial epileptic seizures of different origin variably affect cardiac rhythm. Epilepsia 37 (8): 742–747. Garcia, M., C. D’Giano, S. Estelles, R. Leiguarda, and A. Rabinowicz. 2001. Ictal tachycardia: Its discriminating potential between temporal and extratemporal seizure foci. Seizure 10 (6): 415–419. Ghearing, G. R., T. M. Munger, A. S. Jaffe, E. E. Benarroch, and J. W. Britton. 2007. Clinical cues for detecting ictal asystole. Clin Auton Res 17 (4): 221–226. Glassman, A. H., and P. A. Shapiro. 1998. Depression and the course of coronary artery disease. Am J Psychiatry 155 (1): 4–11. Hanna, J. 2007. Epilepsy and sudden death: A personal view. Epilepsia 38 (s11): S3–S5, doi: 10.1111/ j.1528-1157.1997.tb06121.x. Harris, C. D. 2005. Neurophysiology of sleep and wakefulness. Respir Care Clin N Am 11 (4): 567–586. Heart, Cambridge. 2009. T-Wave Alternans. Available from http://www.cambridgeheart.com. Hiestand, D. M., P. Britz, M. Goldman, and B. Phillips. 2006. Prevalence of symptoms and risk of sleep apnea in the US population: Results from the national sleep foundation sleep in America 2005 poll. Chest 130 (3): 780–786. Hirsch, L. J., and W. A. Hauser. 2004. Can sudden unexplained death in epilepsy be prevented? Lancet 364 (9452): 2157–2158. Ho, R. T., T. Wicks, D. Wyeth, and M. Nei. 2006. Generalized tonic–clonic seizures detected by implantable loop recorder devices: Diagnosing more than cardiac arrhythmias. Heart Rhythm 3 (7): 857–861. Hoffman, J. I., and G. D. Buckberg. 1975. Pathophysiology of subendocardial ischaemia. Br Med J 1€(5949): 76–79. Jallon, P. 1997. Epilepsy and the heart. Rev Neurol (Paris) 153 (3): 173–184. Johnston, S. C., J. K. Horn, J. Valente, and R. P. Simon. 1995. The role of hypoventilation in a sheep model of epileptic sudden death. Ann Neurol 37 (4): 531–537. Katz, L. N., and H. Feinberg. 1958. The relation of cardiac effort to myocardial oxygen consumption and coronary flow. Circ Res 6 (5): 656–669. Khouri, E. M., D. E. Gregg, and C. R. Rayford. 1965. Effect of exercise on cardiac output, left coronary flow and myocardial metabolism in the unanesthetized dog. Circ Res 17 (5): 427–437. LaFrance, W. C., Jr., A. M. Kanner, and B. Hermann. 2008. Psychiatric comorbidities in epilepsy. Int Rev Neurobiol 83: 347–383. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008. The mystery of sudden death: Mechanisms for risks. Epilepsy Behav 12 (1): 3–24. Lathers, C. M., P. L. Schraeder, and S. B. Carnel. 1984. Neural mechanisms in cardiac arrhythmias associated with epileptogenic activity: The effect of phenobarbital in the cat. Life Sci 34 (20): 1919–1936.
Sudden Unexpected Death in Epilepsy
127
Lathers, C. M., and P. L. Schraeder. 2010. SUDEP animal models. Ch. 28 in Sudden Death in Epilepsy: Forensic and Clinical Issues. Boca Raton: CRC Press. Leung, H., P. Kwan, and C. E. Elger. 2006. Finding the missing link between ictal bradyarrhythmia, ictal asystole, and sudden unexpected death in epilepsy. Epilepsy Behav 9 (1): 19–30. Leutmezer, F., C. Schernthaner, S. Lurger, K. Potzelberger, and C. Baumgartner. 2003. ElectroÂ� cardiographic changes at the onset of epileptic seizures. Epilepsia 44 (3): 348–354. Mameli, O., M. A. Caria, A. Pintus, G. Padua, and S. Mameli. 2006. Sudden death in epilepsy: an experimental animal model. Seizure 15 (5): 275–287. Manno, E. M., E. A. Pfeifer, G. D. Cascino, K. H. Noe, and E. F. Wijdicks. 2005. Cardiac pathology in status epilepticus. Ann Neurol 58 (6): 954–957. Marshall, D. W., B. F. Westmoreland, and F. W. Sharbrough. 1983. Ictal tachycardia during temporal lobe seizures. Mayo Clin Proc 58 (7): 443–446. Mascia, A., P. P. Quarato, A. Sparano, V. Esposito, F. Sebastiano, G. Occhiogrosso, and G. Di Gennaro. 2005. Cardiac asystole during right frontal lobe seizures: A case report. Neurol Sci 26 (5): 340–343. Mondon, K., B. Charbonnier, C. Hommet, P. Corcia, A. Autret, and B. de Toffol. 2002. Ictal bradycardia followed by cardiac asystole: A case report. Epileptic Disord 4 (4): 261–264. Murray, P. A., and S. F. Vatner. 1981. Carotid sinus baroreceptor control of right coronary circulation in normal, hypertrophied, and failing right ventricles of conscious dogs. Circ Res 49 (6): 1339–1349. Nashef, L., F. Walker, P. Allen, J. W. Sander, S. D. Shorvon, and D. R. Fish. 1996. Apnoea and bradycardia during epileptic seizures: Relation to sudden death in epilepsy. J Neurol Neurosurg Psychiatry 60 (3): 297–300. Natelson, B. H., R. V. Suarez, C. F. Terrence, and R. Turizo. 1998. Patients with epilepsy who die suddenly have cardiac disease. Arch Neurol 55 (6): 857–860. Nei, M., R. T. Ho, M. R. Sperling. 2000. EKG abnormalities during partial seizures in refractory epilepsy. Epilepsia May;41(5): 542–548. Nei, M., R. T. Ho, B. W. Abou-Khalil, F. W. Drislane, J. Liporace, A. Romeo, and M. R. Sperling. 2004. EEG and ECG in sudden unexplained death in epilepsy. Epilepsia 45 (4): 338–345. O’Brien, T. J., E. L. So, B. P. Mullan, M. F. Hauser, B. H. Brinkmann, N. I. Bohnen, D. Hanson, G. D. Cascino, C. R. Jack Jr., and F. W. Sharbrough. 1998. Subtraction ictal SPECT co-registered to MRI improves clinical usefulness of SPECT in localizing the surgical seizure focus. Neurology 50 (2): 445–454. Opherk, C., J. Coromilas, and L. J. Hirsch. 2002. Heart rate and EKG changes in 102 seizures: Analysis of influencing factors. Epilepsy Res 52 (2): 117–127. P-Codrea Tigaran, S., S. Dalager-Pedersen, U. Baandrup, M. Dam, and A. Vesterby-Charles. 2005. Sudden unexpected death in epilepsy: Is death by seizures a cardiac disease? Am J Forensic Med Pathol 26 (2): 99–105. Pedley, T. A., and W. A. Hauser. 2002. Sudden death in epilepsy: A wake-up call for management. Lancet 359 (9320): 1790–1791. Penninx, B. W., A. T. Beekman, A. Honig, D. J. Deeg, R. A. Schoevers, J. T. van Eijk, and W. van Tilburg. 2001. Depression and cardiac mortality: Results from a community-based longitudinal study. Arch Gen Psychiatry 58 (3): 221–227. Rocamora, R., M. Kurthen, L. Lickfett, J. Von Oertzen, and C. E. Elger. 2003. Cardiac asystole in epilepsy: Clinical and neurophysiologic features. Epilepsia 44 (2): 179–185. Rugg-Gunn, F. J., R. J. Simister, M. Squirrell, D. R. Holdright, and J. S. Duncan. 2004a. Cardiac arrhythmias in focal epilepsy: A prospective long-term study. Lancet 364 (9452): 2212–2219. Rugg-Gunn, F. J., R. J. Simister, M. Squirrell, D. R. Holdright, and J. S. Duncan. 2004b. Cardiac arrhythmias in focal epilepsy: A prospective long-term study. Lancet 364 (9452): 2212–2219. Sanya, E. O. 2005. Increasing awareness about sudden unexplained death in epilepsy—A review. Afr J Med Med Sci 34 (4): 323–327.
128 Sudden Death in Epilepsy: Forensic and Clinical Issues Schernthaner, C., G. Lindinger, K. Potzelberger, K. Zeiler, and C. Baumgartner. 1999. Autonomic epilepsy—The influence of epileptic discharges on heart rate and rhythm. Wien Klin Wochenschr 111 (10): 392–401. Schuele, S. U., A. C. Bermeo, E. Locatelli, R. C. Burgess, and H. O. Luders. 2008. Ictal asystole: A benign condition? Epilepsia 49 (1): 168–171. Schulz, R., M. Grebe, H. J. Eisele, K. Mayer, N. Weissmann, and W. Seeger. 2006. Obstructive sleep apnea-related cardiovascular disease. Med Klin (Munich) 101 (4): 321–327. Scorza, F. A., D. B. Colugnati, A. P. Pansani, E. Y. Sonoda, R. M. Arida, and E. A. Cavalheiro. 2008. Preventing tomorrow’s sudden cardiac death in epilepsy today: what should physicians know about this? Clinics (Sao Paulo) 63 (3): 389–94 LID-S1807-593220. Shakespeare, W. Sonnet 45. Available from http://www.shakespeare-online.com/sonnets/45.html. Shamim, S., G. Hasler, C. Liew, S. Sato, and W. H. Theodore. 2009. Temporal lobe epilepsy, depression, and hippocampal volume. Epilepsia 50 (5): 1067–1071. Sheline, Y. I., P. W. Wang, M. H. Gado, J. G. Csernansky, and M. W. Vannier. 1996. Hippocampal atrophy in recurrent major depression. Proc Natl Acad Sci U S A 93 (9): 3908–3913. Shibasaki, H., A. Ikeda, and T. Nagamine. 2007. Use of magnetoencephalography in the presurgical evaluation of epilepsy patients. Clin Neurophysiol 118 (7): 1438–1448. Slomka, P. J., D. S. Berman, and G. Germano. 2008. Applications and software techniques for integrated cardiac multimodality imaging. Expert Rev Cardiovasc Ther 6 (1): 27–41. So, E. L., M. C. Sam, and T. L. Lagerlund. 2000. Postictal central apnea as a cause of SUDEP: evidence from near-SUDEP incident. Epilepsia 41 (11): 1494–1497. So, N. K., and M. R. Sperling. 2007. Ictal asystole and SUDEP. Neurology 69 (5): 423–424. Spratling, W. P. 1902. The cause and manner of death in epilepsy. Med News 80: 1225–1227. Strzelczyk, A., S. Bauer, S. Knake, W. H. Oertel, H. M. Hamer, and F. Rosenow. 2008. Ictal asystole in temporal lobe epilepsy before and after pacemaker implantation. Epileptic Disord 10 (1): 39–44. Ten Tusscher, K. H., and A. V. Panἀlov. 2007. Influence of diffuse ἀbrosis on wave propagation in human ventricular tissue. Europace 9 (Suppl 6): vi38–vi45. Tigaran, S. 2001. Regional myocardial blood flow during seizures. Paper read at the American Academy of Neurology Annual Meeting in Philadelphia, on May 9, 2001 during session no. 32. Tigaran, S. 2002. Cardiac abnormalities in patients with refractory epilepsy. Acta Neurol Scand Suppl 177: 9–32. Tigaran, S., F. Andreasen, and M. Dam. 2001. Changes in plasma catecholamines after epileptic seizures. Possible explanation of SUDEP. Epilepsia 42 (S-2): 158. Tigaran, S., H. Molgaard, and M. Dam. 1999. Detection of myocardial ἀbrosis by ECG technique in epilepsy patients—Further evidence for cardiac pathogenesis of SUDEP. Epilepsia 40 (S-7): 105. Tigaran, S., H. Molgaard, and M. Dam. 2002. Atrio-ventricular block: A possible explanation of sudden unexpected death in epilepsy. Acta Neurol Scand 106 (4): 229–233. Tigaran, S., H. Molgaard, R. McClelland, M. Dam, and A. S. Jaffe. 2003. Evidence of cardiac ischemia during seizures in drug refractory epilepsy patients. Neurology 60 (3): 492–495. Tinuper, P., F. Bisulli, A. Cerullo, R. Carcangiu, C. Marini, G. Pierangeli, and P. Cortelli. 2001. Ictal bradycardia in partial epileptic seizures: Autonomic investigation in three cases and literature review. Brain 124 (Pt 12): 2361–2371. Toth, V., L. Hejjel, Z. Kalmar, A. Fogarasi, T. Auer, C. Gyimesi, A. Szucs, and J. Janszky. 2008. Effect of epileptic seizures on the heart rate. Ideggyogy Sz 61 (5–6): 155–161. Ushijima, A., N. Fukuma, Y. Kato, N. Aisu, and K. Mizuno. 2009. Sympathetic excitation during exercise as a cause of attenuated heart rate recovery in patients with myocardial infarction. J€Nippon€Med Sch 76 (2): 76–83. Velez, L., and L. M. Selwa. 2003. Seizure disorders in the elderly. Am Fam Physician 67 (2): 325–332. Venugopalan, P., P. M. Nair, and R. L. Koul. 2001. An infant with seizure-related bradycardia and asystole. J Paediatr Child Health 37 (1): 96–97.
Sudden Unexpected Death in Epilepsy
129
Walczak, T. S., I. E. Leppik, M. D’Amelio, J. Rarick, E. So, P. Ahman, K. Ruggles, G. D. Cascino, J. F. Annegers, and W. A. Hauser. 2001. Incidence and risk factors in sudden unexpected death in epilepsy: A prospective cohort study. Neurology 56 (4): 519–525. WHO. 2009. Epilepsy. 2009/01/01. Available from http://www.who.int/mediacentre/factsheets/ fs999/en/index.html (accessed February 2009). Wilder-Smith, E., and S. H. Lim. 2001. Heart rate changes during partial seizures: A study amongst Singaporean patients. BMC Neurol 1: 5. Willams, B., and A. Richens. 1998. Epilepsy and sudden death. UK winter 1998 Epilepsy Toronto: EA updates. London: Epilepsy Research Foundation. WrongDiagnosis.com. 2009. Deaths from obesity. Available from http://www.wrongdiagnosis╉ .com/o/obesity/deaths.htm. Yasue, H. 1983. Role of autonomic nervous system in the pathogenesis of angina pectoris. Arch Mal Coeur Vaiss 76 Spec No: 3–6. Zijlmans, M., D. Flanagan, and J. Gotman. 2002. Heart rate changes and ECG abnormalities during epileptic seizures: Prevalence and deἀnition of an objective clinical sign. Epilepsia 43 (8): 847–854.
Forensic Postmortem Examination of Victims of Sudden Unexpected Death in Epilepsy
8
Claire M. Lathers Paul L. Schraeder Steven A. Koehler Cyril H. Wecht
Contents 8.1 Introduction 8.2 Hypothesis and Future Retrospective Studies 8.3 Speciἀc Aims 8.3.1 Year One 8.3.2 Year Two 8.3.3 Year Three 8.4 Questions for Retroprospective Postmortem Studies References
131 135 135 136 136 136 137 139
8.1â•…Introduction Evaluation of all potential cardiac risks for sudden death needs to start with detailed cardiac postmortem examinations. Detailed postmortem examinations of hearts obtained from patients with epilepsy who experienced sudden and unexpected death (SUDEP) will be helpful in identifying associated cardiac risk factors in persons with epilepsy, and also family members that could be predisposed to sudden death. A proἀle of representative pathology associated with sudden death is found in Table 8.1. Research work in the areas of SUDEP suggests that changes in autonomic peripheral and central mechanisms involved in the control and regulation of blood pressure, heart rate, and rhythm may contribute to sudden death. More speciἀcally, changes in postganglionic cardiac sympathetic discharges, which result in nonuniform neural discharges associated with epileptiform discharges, may be part of the mechanism of risk. Another major risk factor seems to be noncompliance with antiepileptic drug use. A national survey of coroners and medical examiners throughout the United States was conducted to determine their depth of understanding of causes of death in persons with epilepsy and, in particular, the phenomenon of sudden death (Schraeder et al. 2006, 2009). The survey concluded that, while there is a valid classiἀcation of SUDEP, it is not routinely used in autopsy reports of patients with known seizures who die suddenly and unexpectedly with no cause of death found on postmortem examination. Instead, the autopsy reports emphasized the negative ἀndings, i.e., that the death might have been 131
132 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 8.1â•… Pathological Findings in Victims of Sudden Death Victims of Sudden Death Victims of stress-related death (Selye 1958) 51 SUDEP cases non-East Asian subjects including indigenous Saudis, 1/1995 to 6/1995; most subcontinent Indians (43%) (Elfawal 2000) Autopsies of sudden death cases in Japan, 5/1994 to 2/1998 Of 271 cases, 176 patients (20 to 59 years old) were sudden death (Owada et al. 1999) 200 cases of sudden death in persons younger than 35 years in Veneto region, Italy – Unexplained deaths occurred in 12 cases (6%) – More than 1 in 20 cases in sudden death not explained by structural risk factors (Basso et al. 1999)
Cardiac Pathology Microscopic myoἀbrillar degeneration or myocytolysis Identical in hearts of patients dying subarachnoid hemorÂ� rhage and other acute strokes Autopsies on 22 victims 7 mild to moderate cardiac hypertrophy and 2 mild to moderate coronary stenosis 4 similar degrees of coronary narrowing but no myocardial hypertorphy Of the sudden death cases, 29 (31.9%) were due to coronary artery disease 18 (19.8%) acute cardiac dysfunction 6 (6.6%) other cardiac diseases 4 (4.4%) acute aortic dissection 163 cases (81.5%) due to cardiovascular etiologies
Obstructive coronary atherosclerosis, 23%; arrhythmogenic right ventricular cardiomyopathy, 12.5%; mitral valve prolapse 10%; conduction system abnormalities, 10%; congenital coronary artery anomalies, 8.5%; myo�carditis, 7.5%; hyper�trophic cardiomyopathy 5.5%; aortic rupture, 5.5%; dilated cardiomyopathy, 5%; nonatherosclerotic-acquired coronary artery disease, 3.5%; postoperative congenial heart disease, 13%; aortic stenosis, 2%
Pulmonary Pathology
Cerebral Pathology
Other
18 of 22 with severe pulmonary congestion and alveolar hemorrhage
10 cases (5%) due to respiratory causes
4 (4.4%) due to cardiovascular disease
30 (32.9%) due to other diseases
15 cases (7.5%) due to cerebral causes
Other causes (2%)
Pulmonary embolism, 2%
caused by a seizure disorder when there was no pathological ἀnding. Two important questions remain: 1. How do we determine if the death of a person is a sudden unexpected death? 2. How do we establish a true prevalence of the phenomenon of SUDEP?
Forensic Postmortem Examination of Victims of SUDEP
133
In addition to the need for establishing the true prevalence of the phenomenon of SUDEP is the importance of looking for evidence of the roles of the brain and the heart in the cause of death when conducting an autopsy on a person with epilepsy who has died suddenly. SUDEP refers to sudden death of an individual with a clinical history of epilepsy, in whom a postmortem examination fails to uncover a gross anatomic, toxicological, or environmental cause of death. Evidence of terminal seizure activity may not be present. In 2002, Shields et al. reported that 1–2% of natural deaths certified by the medical–legal death investigators in the United States are attributed to epilepsy and that increased microscopic examination of the brain postmortem has allowed identification of structural changes representative of epileptogenic foci. They examined 70 death cases, all with known clinical history of seizures, and classified them as: 1. Individuals who lacked a gross brain lesion 2. Those with a brain lesion demonstrable at autopsy 3. Those who lacked neuropathological evaluation because of decomposition so that only an external examination was done. Microscopic ἀndings include neuronal clusters, increased perivascular oligodendrogÂ� lia, gliosis, cystic gliotic lesions, decreased myelin, cerebellar Bergmann’s gliosis, and folial atrophy were found to be present in a higher percentage of the brains of SUDEP victims, when compared to brains from age- and sex-matched control subjects. Additional autopsy results are needed to clarify the role of changes in the heart in SUDEP. Insight into the mechanism of death in persons with epilepsy who die unexpectedly is not much greater than what it was when the ἀrst book (Lathers and Schraeder 1990b) addressed the topic of epilepsy and sudden death in 1990. This chapter emphasizes the need for clinical studies to focus on the contribution of cardiac autonomic dysfunction and/or antiepileptic drug use, with or without other drugs, to the development of cardiac abnormalities to gain an understanding of the mechanism of death in these persons. While most investigators agree that disturbance in the function of the autonomic nervous system may be a contributory cause (Han and Moe 1964; Randall et al. 1968; Lathers 1975; Lathers 1980a, 1980b; Lathers and Roberts 1985; Lathers and Spivey 1987; Spivey and Lathers 1985; Lathers et al. 1977a, 1977b, 1978; Lathers and Schraeder 1982; Lathers and Roberts 1985; Lathers et al. 1986; Lipka et al. 1988), how disruption of autonomic function contributes to the risk of death is not known. There are some clues from clinical observations. For example, the occurrence of seizures is often associated with measurable changes in cardiac conduction and rhythm. Two recent papers are relevant. The ἀrst, by Chin et al. (2004), reports myocardial infarction following brief convulsive seizures. The second paper, also by Chin et al. (2005), describes the occurrence of “postictal neurogenic stunned myocardium,” resulting from the consequence of seizures. A reversible multifocal ventricular dysfunction, developed in a nonvascular pattern, is thought to be the result of a high sympathetic tone. The initiating factor(s) for a fatal outcome in some at-risk individuals has not been deἀned. Experimental evidence indicates that cortical epileptiform activity can affect cardiac autonomic regulatory function (Lathers and Schraeder 1982; Lathers et al. 1987; Lathers and Schraeder 1990a, 1995, 2002; Lathers et al. 2003a; Lathers and Schraeder 1983, 1989, 1995, 2006, 2009; Lathers et al. 1984, 1988,
134 Sudden Death in Epilepsy: Forensic and Clinical Issues
1989, 1993, 2008a; Scorza et al. 2008; Carnel et al. 1985; Kraras et al. 1987; Stauffer et al. 1989, 1990; Suter and Lathers 1984; Tumer et al. 1985) and the integrity of pulmonary vasculature function (Simon et al. 1982; Johnston et al. 1995, 1997). In young adults with epilepsy, there is an increased risk for sudden death, often, but not always, as a function of the severity of their seizure disorder. Why there is an increased risk of presumed cardiac arrhythmia in this group is not known. Many investigators assume that death in these patients is a function of neurogenically induced cardiac arrhythmias since, in most cases, no gross pathological explanations are found on postmortem examination. However, there is a small body of literature that suggests that microscopic changes in the subendocardial region of the heart may be a contributory factor to increased risk of death in this population. Natelson et al. (1998) found irreversible pathological changes in the form of subendocardial perivascular and interstitial ἀbrosis in four of seven hearts from persons with epilepsy who died suddenly and unexpectedly. These ἀndings support the premise that patients with epilepsy who die suddenly and unexpectedly have subtle microscopic cardiac pathological conditions that may be responsible for increased risk of neurogenically induced arrhythmias. A series of questions must be addressed to focus on the issue of whether drugs are a beneἀt or a risk for SUDEP (Lathers 2002, 2003; Lathers and Schraeder 1995, 2002; Lathers et al. 2003, 2008a, 2008b; Scorza et al. 2008; Leestma et al. 1997; Schraeder and Lathers 1995). The ἀrst question is: “Do cardiac changes induced by antiepileptic drugs contribute to the risk of sudden death in persons with epilepsy?” A second question is: “Are particular combinations of antiepileptic drugs more likely to be associated with an increased risk of sudden death?” A third question to be addressed is: “Does a combination of antiepileptic drugs with other drugs, i.e., psychotropics, increase the risk of dying in a sudden, unexpected manner?” The FDA recognizes the importance of addressing this series of questions related to the use of pharmacological agents in that most of the new antiepileptic drugs have to be evaluated for the risk of SUDEP. As such, the FDA requires a statement in the package insert addressing the relative risk of occurrence of SUDEP with use of the drug. It is important for postmortem protocols to address the details of types of drugs and dosage schedules and possible adverse interactions as contributing to SUDEP. Speculation as to risk factors for SUDEP and/or contributory causes of SUDEP include the following:
1. Autonomic neurohumoral dysfunction 2. Autonomic cardiac neural dysfunction 3. Cardiac changes of subendocardial perivascular and interstitial ἀbrosis 4. Other cardiac changes (e.g., coronary heart disease, cardiomyopathy, aortic valvular stenosis, right ventricular dysplasia, postictal neurogenic stunned myocardium, coronary artery thrombosis, and postmyocardial infarction ἀbrosis 5. Cardiac changes possibly induced by antiepileptic drugs 6. The likelihood of cardiac changes being induced by particular combinations of antiepileptic drugs and associated with an increased risk of SUDEP 7. Whether a combination of antiepileptic drugs and nonantiepileptic drugs are more likely to increase the risk of dying in SUDEP (nonantiepileptic drugs are deἀned as therapeutic drugs and do include drugs of abuse)
Forensic Postmortem Examination of Victims of SUDEP
135
8. Whether an inherited predisposition to increased risk of cardiac arrhythmias (e.g., long QT and Brugada syndromes) could also be an additional risk factor in persons with epilepsy
8.2â•…Hypothesis and Future Retrospective Studies Autonomic neurohumoral and autonomic cardiac neural dysfunction, in combination with susceptibility associated with cardiac pathological changes, are hypothesized to be risk factors for the development of circumstances that predispose a person with epilepsy to sudden death. The potential risk factors of antiepileptic drug use versus nonantiepileptic drug use also must be examined. Study design should evaluate and differentiate the contribution of intrinsic parameters of autonomic dysfunction and/or cardiac pathological changes from the extrinsic parameter of therapeutic pharmacological agents (antiepileptic drugs and/or nonantiepileptic drugs). Microscopic pathological cardiac markers manifest in the heart in association with autonomic catecholamine-mediated arrhythmias and cardiac damage and/or by the administration of drugs (antiepileptic drugs and nonantiepileptic drugs should be examined). It could be assumed that catecholamine toxicity at the local level in the myocardium is a contributory factor to the development of microἀbrotic changes thought to be a predisposing risk factor for cardiac arrhythmias. Another contributory factor to cardiac arrhythmias and/or sudden death is abnormal cardiac postganglionic discharge. It is theorized that the combination of nonuniform postganglionic cardiac discharge due to abnormal anatomy of the postganglionic nerves in combination with catecholamine toxicity at the local level in the myocardium, possibly in combination with a genetically determined cardiac predisposition, are risk factors that combine to contribute to arrhythmias culminating in a fatal sudden death event. It is unclear whether or not the use of certain antiepileptic drugs such as carbamazepine compound diminish the physiologic risk factors for SUDEP (Devinsky 2004). The role of genetics in epilepsy needs to be considered when evaluating risk factors for SUDEP and/or the role of sodium channel dysfunction. The reader is referred to the following references and chapters discussing the genetics of epilepsy in this book: Chioza et al. (2001, 2002a, 2002b, 2002c), Sisodiya et al. (2007), Hindocha et al. (2008), Helbig et al. (2009), Mullen and Scheffer (2009), Herreros (2010), Ghali and Nashef (2010), and Lathers et al. (2010 Chapter 1).
8.3â•…Specific Aims Study designs should examine the potential contributory role of the following parameters to the risk of SUDEP to determine if: 1. Consistent microscopic, cardiac changes of subendocardial, perivascular, and interstitial ἀbrosis are present and may have contributed to the SUDEP. 2. Changes in postganglionic cardiac sympathetic nerves may be present. 3. Cardiac changes are induced by speciἀc antiepileptic drugs that could contribute to the risk of SUDEP.
136 Sudden Death in Epilepsy: Forensic and Clinical Issues
4. Particular combinations of antiepileptic drugs are associated with an increased risk of SUDEP. 5. A combination of antiepileptic and nonantiepileptic drugs is likely to increase the risk of SUDEP. Nonantiepileptic drugs are deἀned as therapeutic agents and will not include drugs of abuse. 6. Controls for the retrospective and prospective arms of the studies will consist of matched persons without a history of epilepsy who have died. See the chapter by Ghali and Nashef (2010) for a discussion of what genetic issues should be considered. To determine the validity of the proposed hypothesis that autonomic neurohumoral and autonomic neural dysfunction, in combination with susceptibility to cardiac pathological changes and/or the use of antiepileptic or nonantiepileptic drugs, are risk factors for the development of circumstances that predispose a person with epilepsy to sudden death, the following timeline and methodology could be used by those designing retrospective postmortem studies. 8.3.1â•…Year One During the ἀrst year, study should be devoted to analyzing retrospectively the frozen samples of heart tissue obtained from victims of SUDEP in order to determine the optimal parameters of analysis of samples obtained from the prospective arm of the study. Collection of prospectively obtained samples of cardiac tissue and preparations for postmortem examination of cardiac postganglionic innervations, using the method of Druschky et al. (2001), in persons who have died suddenly and unexpectedly should be initiated during year one. Likewise, methods should be utilized to determine the presence or absence of genetic defects at the Na+ channel level (Mullen and Scheffer 2009; Herreros 2010; Lathers and Schraeder 2010). 8.3.2â•…Year Two During the second year, the retrospective analysis should be completed and the prospective acquisition of samples should be completed. 8.3.3â•…Year Three During the third year, analysis of the pathological materials should be completed. The following analyses should be done: • Microscopic histopathology of the heart, especially the conduction system and subendocardial tissue. • Transmission electron microscopy, scanning transmission electron microscopy, scanning electron microscopy, and laser scanning fluorescence confocal microscopy. • Use 123I-metaiodobenzylguanidine-SPECT to look for sympathetic changes in the postganglionic cardiac sympathetic innervation in patients with chronic temporal lobe epilepsy, since the study of Druschky et al. (2001) suggested that altered
Forensic Postmortem Examination of Victims of SUDEP
137
postganglionic cardiac sympathetic innervation may increase the risk of cardiac abnormalities and/or SUDEP.
8.4â•…Questions for Retroprospective Postmortem Studies
1. What was the gender of the victim? 2. What was the victim’s age? 3. Did the victim of sudden, unexpected death have a known seizure disorder? 4. Was the victim witnessed exhibiting seizure(s) at the time of death? If so, what type of seizure was observed? 5. What was the actual date of death? How does the date of death for this victim compare with the date of the last known seizure? 6. Was any other cause of death found upon autopsy for any of these patients, such as cardiomyopathy and glial tumor? Did the victim have a terminal illness or any known associated illnesses? 7. What was the extent of postmortems? Were microscopic examinations done of the heart, lungs, brain, and other organs? 8. What was the microscopic pathology of the lungs and the hearts? 9. How did you interpret ἀndings of “heavy lungs” and data from hearts obtained in the postmortem autopsy? What do these ἀndings mean in terms of mechanism and signiἀcance (see Terrence 1990)? 10. Did the autopsy conduct postmortem examination of postganglionic cardiac sympathetic innervation of the heart? 11. Were quantitative antiepileptic drug levels found in the toxicological screen conducted postmortem? What assay method was used? 12. What were the actual antiepileptic drug levels postmortem? Were they within the therapeutic range or were they subtherapeutic? Were any levels below the lower level of quantiἀcation of the assay method? 13. Did the postmortem examine tears and aqueous humor or just aqueous humor for antiepileptic drug levels? 14. Were hair samples obtained to examine antiepileptic drugs? 15. Was the patient considered to be a compliant patient prior to death? 16. Was any genetic testing for entities that predispose an individual to cardiac arrhythmias done on the victim and/or the victim’s family prior to death? 17. How can the diagnosis of a seizure-induced death be differentiated from a diagnosis of a SUDEP death? 18. Was there any prior history of cardiac rhythm irregularities? 19. Was there any family history of cardiac rhythm irregularities or any history of sudden deaths?
Sympathetic changes in the postganglionic cardiac sympathetic innervation in patients with chronic temporal lobe epilepsy suggest that altered postganglionic cardiac sympathetic innervation may increase the risk of cardiac abnormalities and/or SUDEP (Druschky et al. 2001). Developmental and regulatory mechanisms determining density and pattern of cardiac sympathetic innervation are still unclear. Likewise, the exact role of innervation
138 Sudden Death in Epilepsy: Forensic and Clinical Issues
in arrhythmogenesis is unclear. The clinical study of Druschky et al. (2001) conἀrms the animal studies conducted by Lathers and colleagues (Lathers 1975, 1980a, 1980b; Lathers and Roberts 1985; Lathers and Spivey 1987; Spivey and Lathers 1985; Lathers et al. 1977a, 1977b, 1978; Lathers et al. 1986; Lathers and Schraeder 1982, 1983, 1987, 1989, 1990a, 2002; Lathers et al. 1984, 1987, 2003a, 1989, 1993, 2008a; Scorza et al. 2008; Lathers et al 2008b) in which postganglionic cardiac sympathetic neural discharge was monitored before and as arrhythmias developed. When considering likely mechanisms of SUDEP, it is important to consider whether there is any underlying, undeἀned genetic predisposition to arrhythmias and, thus, the mechanism of sudden death. Obviously, genetic predisposition to arrhythmias varies from patient to patient. The status of any subtle symptomatic disease present at the time of death will also vary from patient to patient and emphasize the importance of a genetic component to the autopsy. Animal data (Lathers et al. 1987; Staufferet al. 1989, 1990; O’Rourke and Lathers 1990; Dodd-O and Lathers 1990) demonstrated the lockstep phenomenon, i.e., postganglionic cardiac sympathetic discharge time locked to cortical epileptiform activity. The lockstep phenomenon may explain propagation of electrical impulses to autonomic nervous system regulatory centers, thus initiating arrhythmogenic potentials. During the lockstep phenomenon, cardiac postganglionic sympathetic and vagal discharges were synchronized with both ictal and interictal discharges and premature ventricular contractions, ST/T changes, and conduction blocks occurring concurrent with interictal spikes at a time when nonuniform cardiac sympathetic and vagal discharges were also observed. These experimental observations suggest that altered cardiac sympathetic innervation of hearts in patients who die suddenly and unexpectedly may contribute to nonuniform neural discharge, arrhythmias, and/or death. Detailed microscopic pathologic examination of cardiac autonomic nerves should be part of an autopsy study of SUDEP. A regulatory response, resulting from increased awareness of SUDEP, occurred in 1993 when the FDA focused the attention of practitioners and pharmaceutical manufacturers on the question of whether the use of anticonvulsant drugs contributes to or prevents sudden unexpected death in epileptic persons (Lathers 2002, 2003; Lathers and Schraeder 1995, 2002; Lathers et al. 2008a, 2008b; Scorza et al. 2008; Leestma et al. 1997; Schraeder and Lathers 1995). The FDA-convened panel of scientists considered the prevalence of sudden unexpected death in patients involved in studies associated with developing new anticonvulsant drugs and reviewed data on the risk of sudden unexpected death in patients taking lamotrigine. The risk of SUDEP was no different from that found in the young epilepsy population in general. Estimated SUDEP rates in patients receiving the new anticonvulsant drugs lamotrigine, gabapentin, topiramate, tigabine, and zonisamide were found to be similar to those in patients receiving standard anticonvulsant drugs, suggesting that SUDEP rates reflect population rates and not a speciἀc drug effect. The FDA requires warning labels on the risk of SUDEP in association with the use of each of the above-mentioned drugs. However, little data is available on the relative risk associated with the older, commonly prescribed antiepileptic drugs. The reader is referred to the chapters by Lathers and Schraeder (2010) and by Lathers, Schraeder, and Claycamp (Lathers et al. 2010) in this book for an in-depth discussion of the possible role of antiepileptic drugs in the cause and/or prevention of SUDEP. Widdes-Walsh and Devinsky (2007) discuss drug-resistant epilepsy, stating that it is a prevalent problem in spite of the fact that multiple ADE drug options are available. Mimics of drug-resistant epilepsy exist and cause diagnostic confusion. Fortunately, advances in epilepsy research and pharmacogenomics
Forensic Postmortem Examination of Victims of SUDEP
139
prove that new understandings of the mechanisms of drug resistance and tolerance allow rational antiepileptic drug strategies to prevent drug resistance. A different question regarding the clinical pharmacology of SUDEP has been raised by Tigaran and coauthors (Tigaran et al. 1997; Tigaran 2002; Tigaran et al. 2002; Tigaran et al. 2003). The question to be addressed is whether some persons with severe drug-resistant epilepsy, and without any indication of previous cardiac disease, may experience a beneἀcial effect of prophylactic treatment with cardioactive drugs to reduce the risk of sudden death (Tigaran et al. 1997). These investigators found ECG changes and ST-segment depression—many of which were closely related to the occurrence of epileptic seizures— that were suggestive of myocardial ischemia in the patients with severe drug-resistant epilepsy and no previous indication of cardiac disease. Of twelve patients with medically intractable epilepsy in studies with both ECG and EEG recordings, the ECG recording found in one person with chest pain minor yet morphologically conspicuous changes in the ECG, suggestive of myocardial infarction. This person with epilepsy died in cardiac arrest. In two publications in 2002, these authors reported atrio-ventricular block occurring as a life threatening cardiac arrhythmia complicating epileptic seizures in one person with medically intractable epilepsy (Tigaran et al. 2002) and cardiac abnormalities in patients with refractory epilepsy (Tigaran 2002). In another study, Tigaran et al. (2003b) examined 23 patients with drug-refractory epilepsy and found ST-segment depression in 40% of the patients and this was associated with a higher maximum heart rate during seizures, indicative of myocardial ischemia occurring in these individuals. These studies emphasize the importance of conducting both EEG and ECG in persons with severe drug-resistant epilepsy and the necessity of evaluating whether these patients would beneἀt from prophylactic treatment with cardioactive drugs to reduce the risk of sudden death. This chapter focuses on the need for retrospective forensic postmortem examination of not only the brains but also the hearts, myocardial autonomic innervations, and antiepileptic drug levels obtained from patients with epilepsy who die suddenly. A recent series of publications has addressed the multiple risk factors for sudden death in cardiac patients and in persons with epilepsy who have died suddenly and unexpectedly (Lathers and Schraeder 2010; Lathers et al. 2008a, 2008b; Scorza et al. 2008; (Herreros 2010). An evaluation of all potential risks for sudden death requires that risk assessments be done (Lathers 2002). These risk assessment efforts will aid all working in clinical and research ἀelds as they work to unravel the mystery of SUDEP. We recommend that retrospective postmortem examinations, including genetic determinations, be done using hearts and, of course, brains, obtained from patients who have died suddenly and unexpectedly. In addition, an effort should be made to obtain data on preexisting diatheses for cardiac arrhythmias in SUDEP victims and family members. The ἀndings from these rÂ�etrospective studies will allow prospective identiἀcation of persons in families of patients with epilepsy who have died suddenly. Finally, in the event that a physical autopsy was not conducted, the value of verbal autopsies must be determined as a relative substitute (Aspray 2005; Nashef et al. 1998; Lathers and Schraeder 2009; Nashef and Sahloldt 2010; Schraeder et al. 2010).
References Aspray, T. J. 2005. The use of verbal autopsy in attributing cause of death from epilepsy. Epilepsia 46 (Suppl 11): 15–17.
140 Sudden Death in Epilepsy: Forensic and Clinical Issues Carnel, S. B., P. L. Schraeder, and C. M. Lathers. 1985. Effect of phenobarbital pretreatment on cardiac neural discharge and pentylenetetrazol-induced epileptogenic activity in the cat. Pharmacology 30 (4): 225–240. Chin, P. S., K. R. Branch, and K. J. Becker. 2004. Myocardial infarction following brief convulsive seizures. Neurology 63 (12): 2453–2454. Chin, P. S., K. R. Branch, and K. J. Becker. 2005. Postictal neurogenic stunned myocardium. Neurology 64 (11): 1977–1978. Chioza, B., H. Wilkie, L. Nashef, J. Blower, D. McCormick, P. Sham, P. Asherson, and A. J. Makoff. 2001. Association between the alpha(1a) calcium channel gene CACNA1A and idiopathic generalized epilepsy. Neurology 56 (9): 1245–1246. Chioza, B., A. Osei-Lah, H. Wilkie, L. Nashef, D. McCormick, P. Asherson, and A. J. Makoff. 2002a. Suggestive evidence for association of two potassium channel genes with different idiopathic generalised epilepsy syndromes. Epilepsy Res 52 (2): 107–116. Chioza, B., A. Osei-Lah, L. Nashef, B. Suarez-Merino, H. Wilkie, P. Sham, J. Knight, P. Asherson, and A. J. Makoff. 2002b. Haplotype and linkage disequilibrium analysis to characterise a region in the calcium channel gene CACNA1A associated with idiopathic generalised epilepsy. Eur J Hum Genet 10 (12): 857–864. Chioza, B., L. Nashef, P. Asherson, and A. Makoff. 2002c. CACNA1A and P/Q-type calcium channels in epilepsy. Lancet 359 (9302): 258. Devinsky, O. 2004. Effects of seizures on autonomic and cardiovascular function. Epilepsy Curr 4 (2): 43–46. Dodd-O, J. H., and C. M. Lathers. 1990. A characterization of the lockstep phenomenon in pÂ�henobarbital-pretreated cats. In Epilepsy and Sudden Death, Chapter 13. New York, NY: Marcel Dekker. Druschky, A., M. J. Hilz, P. Hopp, G. Platsch, M. Radespiel-Troger, K. Druschky, T. Kuwert, H. Stefan, and B. Neundorfer. 2001. Interictal cardiac autonomic dysfunction in temporal lobe epilepsy demonstrated by [(123)I]metaiodobenzylguanidine-SPECT. Brain 124 (Pt 12): 2372–2382. Ghali, N., and L. Nashef. 2010. Genetics of sudden death in epilepsy. In Sudden Death in Epilepsy: Forensic and Clinical Issues, Chapter 18. ed. C. M. Lathers, P. Schraeder, M. Bungo, and J. Leestma. Boca Raton: CRC Press. Han, J., and G. K. Moe. 1964. Nonuniform recovery of excitability in ventricular muscle. Circ Res 14: 44–60. Helbig, I., H. C. Mefford, A. J. Sharp, M. Guipponi, M. Fichera, A. Franke, H. Muhle et al. 2009. 15q13.3 microdeletions increase risk of idiopathic generalized epilepsy. Nat Genet 41 (2): 160–162. Herreros, B. 2010. Cardiac channelopathies and sudden death. In Sudden Death in Epilepsy: Forensic and Clinical Issues, Chapter 19. ed. C. M. Lathers, P. Schraeder, M. Bungo, and J. Leestma. Boca Raton: CRC Press. Hindocha, N., L. Nashef, F. Elmslie, R. Birch, S. Zuberi, A. Al-Chalabi, L. Crotti, P. J. Schwartz, and A. Makoff. 2008. Two cases of sudden unexpected death in epilepsy in a GEFS+ family with an SCN1A mutation. Epilepsia 49 (2): 360–365. Johnston, S. C., J. K. Horn, J. Valente, and R. P. Simon. 1995. The role of hypoventilation in a sheep model of epileptic sudden death. Ann Neurol 37 (4): 531–537. Johnston, S. C., R. Siedenberg, J. K. Min, E. H. Jerome, and K. D. Laxer. 1997. Central apnea and acute cardiac ischemia in a sheep model of epileptic sudden death. Ann Neurol 42 (4): 588–594. Kraras, C. M., N. Tumer, and C. M. Lathers. 1987. The role of enkephalins in the production of epileptogenic activity and autonomic dysfunction: Origin of arrhythmia and sudden death in the epileptic patient? Med Hypotheses 23 (1): 19–31. Lathers, C. M. 1975. Effect of practolol and stalol on ouabrain-induced nonuniform adrenergic nerve activity. Pharmacologist 34: 745. Lathers, C. M. 1980a. Effect of timolol on autonomic neural discharge associated with ouabaininduced arrhythmia. Eur J Pharmacol 64 (2–3): 95–106.
Forensic Postmortem Examination of Victims of SUDEP
141
Lathers, C. M. 1980b. The effect of metoprolol on coronary occlusion-induced arrhythmia and autonomic neural discharge. Fed Proc 39: 771. Lathers, C. M. 2002. Risk assessment in regulatory policy making for human and veterinary public health. J Clin Pharmacol 42 (8): 846–866. Lathers, C. M. 2003. Challenges and opportunities in animal drug development: A regulatory perspective. Nat Rev Drug Discov 2 (11): 915–918. Lathers, C. M., and J. Roberts. 1985. Are the sympathetic neural effects of digoxin and quinidine involved in their action on cardiac rhythm? J Cardiovasc Pharmacol 7 (2): 350–360. Lathers, C. M., and P. L. Schraeder. 1982. Autonomic dysfunction in epilepsy: Characterization of autonomic cardiac neural discharge associated with pentylenetetrazol-induced epileptogenic activity. Epilepsia 23 (6): 633–647. Lathers, C. M., and P. L. Schraeder. 1987. Review of autonomic dysfunction, cardiac arrhythmias, and epileptogenic activity. J Clin Pharmacol 27 (5): 346–356. Lathers, C. M., and P. L. Schraeder. 1990a. Arrhythmias associated with epileptogenic activity elicited by penicillin. In Epilepsy and Sudden Death., ed. C. M. Lathers and P. Schraeder, Chapter€9. New York, NY: Marcel Dekker. Lathers, C. M., and P. L. Schraeder, eds. 1990b. Epilepsy and Sudden Death. New York, NY: Marcel Dekker. Lathers, C. M., and P. L. Schraeder. 1995. Experience-based teaching of therapeutics and clinical pharmacology of antiepileptic drugs. Sudden unexplained death in epilepsy: Do antiepileptic drugs have a role? J Clin Pharmacol 35 (6): 573–586; quiz 586–587. Lathers, C. M., and P. L. Schraeder. 2002. Clinical pharmacology: Drugs as a beneἀt and/or risk in sudden unexpected death in epilepsy? J Clin Pharmacol 42 (2): 123–136. Lathers, C. M., and P. L. Schraeder. 2006. Stress and sudden death. Epilepsy Behav 9 (2): 236–242. Lathers, C. M., and P. L. Schraeder. 2009. Verbal autopsies. Epilepsy Behav 14: 573–576. Lathers, C. M., and P. L. Schraeder. 2010. Antiepileptic drugs beneἀt/risk clinical pharmacology: Possible role in cause and/or prevention of SUDEP. In Sudden Death in Epilepsy: Forensic and Clinical Issues, Chapter 47. ed. C. M. Lathers, S. P. L., M. W. Bungo, and J. Leestma. Boca Raton: CRC Press. Lathers, C. M., and W. H. Spivey. 1987. The effect of beta blockers on cardiac neural discharge associated with coronary occlusion in the cat. J Clin Pharmacol 27 (8): 582–592. Lathers, C. M., K. M. Keller, J. Roberts, and A. B. Beasley. 1977a. Role of the adrenergic nervous system in arrhythmia produced by acute coronary artery occlusion. In Pathophysiology and Therapeutics of Myocardial Ischemia, ed. L. A., G. J. Kelliher, and M. Rovetto, Chapter 5. New York, NY: Spectrum. Lathers, C. M., J. Roberts, and G. J. Kelliher. 1977b. Correlation of ouabain-induced arrhythmia and nonuniformity in the histamine-evoked discharge of cardiac sympathetic nerves. J Pharmacol Exp Ther 203 (2): 467–479. Lathers, C. M., G. J. Kelliher, J. Roberts, and A. B. Beasley. 1978. Nonuniform cardiac sympathetic nerve discharge: Mechanism for coronary occlusion and digitalis-induced arrhythmia. Circulation 57 (6): 1058–1065. Lathers, C. M., P. L. Schraeder, and S. B. Carnel. 1984. Neural mechanisms in cardiac arrhythmias associated with epileptogenic activity: The effect of phenobarbital in the cat. Life Sci 34 (20): 1919–1936. Lathers, C. M., W. H. Spivey, L. E. Suter, J. P. Lerner, N. Tumer, and R. M. Levin. 1986. The effect of acute and chronic administration of timolol on cardiac sympathetic neural discharge, arrhythmia, and beta adrenergic receptor density associated with coronary occlusion in the cat. Life Sci 39 (22): 2121–2141. Lathers, C. M., P. L. Schraeder, and F. L. Weiner. 1987. Synchronization of cardiac autonomic neural discharge with epileptogenic activity: The lockstep phenomenon. Electroencephalogr Clin Neurophysiol 67 (3): 247–259.
142 Sudden Death in Epilepsy: Forensic and Clinical Issues Lathers, C. M., L. J. Lipka, and H. Klions. 1988. Digitalis glycosides: A discussion of the similarities and differences in actions and existing controversies. Rev Clin Basic Pharm 7 (1-4): 1–108. Lathers, C. M., A. Z. Stauffer, N. Tumer, C. M. Kraras, and B. D. Goldman. 1989. Anticonvulsant and antiarrhythmic actions of the beta blocking agent timolol. Epilepsy Res 4 (1): 42–54. Lathers, C. M., P. L. Schraeder, and N. Tumer. 1993. The effect of phenobarbital on autonomic function and epileptogenic activity induced by the hippocampal injection of penicillin in cats. J Clin Pharmacol 33 (9): 837–844. Lathers, C. M., P. L. Schraeder, and H. G. Claycamp. 2003a. Clinical pharmacology of topiramate versus lamotrigine versus phenobarbital: Comparison of efficacy and side effects using odds ratios. J Clin Pharmacol 43 (5): 491–503. Lathers, C. M., S. A. Koehler, C. H. Wecht, and P. L. Schraeder. 2003b. Forensic antiepileptic drug levels in 2001 autopsy cases of sudden, unexpected deaths in persons with epilepsy in Allegheny County Pennsylvania. Paper read at the Annual Meeting of American College of Clinical Pharmacology, September, Orlando, FL. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008a. The mystery of sudden death: Mechanisms for risks. Epilepsy Behav 12 (1): 3–24. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2008b. Sudden death: Neurocardiologic mystery. In Psychological Factors and Cardiovascular Disorders, ed. L. Sher, Chapter 13. Hauppauge, NY: Nova Science. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2010. Sodium channel dysfunction: Common pathophysiologic mechanism associated with sudden death ECG abnormalities in Brugada Syndrome and some types of epilepsy. Case histories. In Sudden Death in Epilepsy: Forensic and Clinical Issues, Chapter 20. ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma. Boca Raton: CRC Press. Leestma, J. E., J. F. Annegers, M. J. Brodie, S. Brown, P. Schraeder, D. Siscovick, B. B. Wannamaker, P. S. Tennis, M. A. Cierpial, and N. L. Earl. 1997. Sudden unexplained death in epilepsy: Observations from a large clinical development program. Epilepsia 38 (1): 47–55. Lipka, L. J., C. M. Lathers, and J. Roberts. 1988. Does chlorpromazine produce cardiac arrhythmia via the central nervous system? J Clin Pharmacol 28 (11): 968–983. Mullen, S. A., and I. E. Scheffer. 2009. Translational research in epilepsy genetics: Sodium channels in man to interneuronopathy in mouse. Arch Neurol 66 (1): 21–26. Nashef, L., and L. Sahloldt. 2010. Bereavement and sudden unexpected death in epilepsy. In Sudden Death in Epilepsy: Forensic and Clinical Issues, Chapter 58. ed. C. M. Lathers, P.€Schraeder, M. W. Bungo, and J. Leestma. Boca Raton: CRC Press. Nashef, L., S. Garner, J. W. Sander, D. R. Fish, and S. D. Shorvon. 1998. Circumstances of death in sudden death in epilepsy: Interviews of bereaved relatives. J Neurol Neurosurg Psychiatry 64€(3): 349–352. Natelson, B. H., R. V. Suarez, C. F. Terrence, and R. Turizo. 1998. Patients with epilepsy who die suddenly have cardiac disease. Arch Neurol 55 (6): 857–860. O’Rourke, D. K., and C. M. Lathers. 1990. Interspike interval histogram characterization of synchronized cardiac sympathetic neural discharge and epileptogenic activity in the electrocorticogram of the cat. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. Schraeder, Chapter 15. New York, NY: Marcel Dekker. Randall, W. C., M. Szentivanyi, J. B. Pace, J. S. Wechsler, and M. P. Kaye. 1968. Patterns of sympathetic nerve projections onto the canine heart. Circ Res 22 (3): 315–323. Schraeder, P. L., and C. M. Lathers. 1983. Cardiac neural discharge and epileptogenic activity in the cat: An animal model for unexplained death. Life Sci 32 (12): 1371–1382. Schraeder, P. L., and C. M. Lathers. 1989. Paroxysmal autonomic dysfunction, epileptogenic activity and sudden death. Epilepsy Res 3 (1): 55–62. Schraeder, P. L., and C. M. Lathers. 1995. Clinical pharmacology of antiepileptic drug use: Clinical pearls about the perils of patty. J Clin Pharmacol 35 (12): 1120–1135.
Forensic Postmortem Examination of Victims of SUDEP
143
Schraeder, P. L., K. Delin, R. L. McClelland, and E. L. So. 2006. Coroner and medical examiner documentation of sudden unexplained deaths in epilepsy. Epilepsy Res 68 (2): 137–143. Schraeder, P. L., K. Delin, R. L. McClelland, and E. L. So. 2009. A nationwide survey of the extent of autopsy in sudden unexplained death in epilepsy. Am J Forensic Med Pathol 30 (2): 123–126. Schraeder, P. L., E. L. So, and C. M. Lathers. 2010. Forensic case identiἀcation. In Sudden Death in Epilepsy: Forensic and Clinical Issues, Chapter 6. ed. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma. Boca Raton: CRC Press. Scorza, F. A., R. M. Arida, and E. A. Cavalheiro. 2008. Preventive measures for sudden cardiac death in epilepsy beyond therapies. Epilepsy Behav 13 (1): 263–264; author reply 265. Shields, L. B., D. M. Hunsaker, 3rd, J. C. Hunsaker, and J. C. Parker Jr. 2002. Sudden unexpected death in epilepsy: Neuropathologic ἀndings. Am J Forensic Med Pathol 23 (4): 307–314. Simon, R. P., L. L. Bayne, R. F. Tranbaugh, and F. R. Lewis. 1982. Elevated pulmonary lymph flow and protein content during status epilepticus in sheep. J Appl Physiol 52 (1): 91–95. Sisodiya, S., J. H. Cross, I. Blumcke, D. Chadwick, J. Craig, P. B. Crino, P. Debenham et al. 2007. Genetics of epilepsy: Epilepsy research foundation workshop report. Epileptic Disord 9 (2): 194–236. Spivey, W. H., and C. M. Lathers. 1985. Effect of timolol on the sympathetic nervous system in coronary occlusion in cats. Ann Emerg Med 14 (10): 939–944. Stauffer, A. Z., J. Dodd-O, and C. M. Lathers. 1989. The relationship of the lock-step phenomenon and precipitous changes in mean arterial blood pressure. Electroencephalogr Clin Neurophysiol 72 (4): 340–345. Stauffer, A. Z., J. Dodd-O, and C. M. Lathers. 1990. Relationship of the lockstep phenomenon and precipitous changes in blood pressure. In Epilepsy and Sudden Death, Chapter 14. New York, NY: Marcel Dekker. Suter, L. E., and C. M. Lathers. 1984. Modulation of presynaptic gamma aminobutyric acid release by prostaglandin E2: Explanation for epileptogenic activity and dysfunction in autonomic cardiac neural discharge leading to arrhythmias? Med Hypotheses 15 (1): 15–30. Terrence, C. F. 1990. Unexpected, unexplained death of epileptic persons: clinical correlation including pulmonary changes. In Epilepsy and Sudden Death, ed. C. Lather and P. Schraeder, Chapter€6. New York, NY: Marcel Dekker. Tigaran, S. 2002. Cardiac abnormalities in patients with refractory epilepsy. Acta Neurol Scand Suppl 177: 9–32. Tigaran, S., V. Rasmussen, M. Dam, S. Pedersen, H. Hogenhaven, and B. Friberg. 1997. ECG changes in epilepsy patients. Acta Neurol Scand 96 (2): 72–75. Tigaran, S., H. Molgaard, and M. Dam. 2002. Atrio-ventricular block: A possible explanation of sudden unexpected death in epilepsy. Acta Neurol Scand 106 (4): 229–233. Tigaran, S., A. Cascino Fuglsang-Frederiksen, and G. D. Cascino. 2003a. Temporal distribution of partial seizures during the sleep–wake cycle: possible signiἀcance for sudden unexpected death. Epilepsia 44: 123. Tigaran, S., H. Molgaard, R. McClelland, M. Dam, and A. S. Jaffe. 2003b. Evidence of cardiac ischeÂ� mia during seizures in drug-refractory epilepsy patients. Neurology 60 (3): 492–495. Tumer, N., P. L. Schraeder, and C. M. Lathers. 1985. The effect of phenobarbital upon autonomic function and epileptogenic activity induced by hippocampal injection of penicillin in cats. Epilepsia 26: 520. Widdess-Walsh, P., and O. Devinsky. 2007. Antiepileptic drug resistance and tolerance in epilepsy. Rev Neurol Dis 4 (4): 194–202.
One-Year Postmortem Forensic Analysis of Deaths in Persons with Epilepsy
9
Steven A. Koehler Paul L. Schraeder Claire M. Lathers Cyril H. Wecht
Contents 9.1 Introduction 9.2 Methods 9.3 Results 9.4 Discussion Acknowledgments References
145 148 148 155 158 158
9.1â•…Introduction Individuals with epilepsy can die from the progression of the primary underlying brain process, status epileptics, trauma, drowning precipitated by a seizure, or causes totally unrelated to the epilepsy (Earnest et al. 1992). The medical literature reports sudden, unexpected and unexplained deaths among individuals with epilepsy (Earnest et al. 1992). This disorder has been termed sudden unexpected death in epilepsy (SUDEP). SUDEP has been deἀned as a sudden, unexpected, witnessed or unwitnessed death, nontraumatic and nondrowning, in patients with epilepsy, with or without evidence of a seizure, excluding documented status epileptics, in whom postmortem examination does not reveal an anatomical or toxicological cause of death (Nashef and Shorvon 1997). SUDEP occurs most frequently among young individuals with a history of generalized tonic-clonic seizures. SUDEP has been reported in the literature to be responsible for 1.7–17% of all deaths among individuals with epilepsy (Ficker et al. 1998; Ficker 2000). However, these prior studies to ascertain the incidence of SUDEP suffered from selection bias and methodological limitations resulting in a tenfold difference between the various studies. Populationbased and forensic (medical examiner or coroner’s office) studies are few. Postmortem examinations of victims of SUDEP fail to establish the cause of death and toxicological analysis reveals subtherapeutic antiepileptic drug blood levels (Earnest et al. 1992). Some of the commonly reported features of SUDEP are highlighted in Table 9.1. Previous postmortem-based studies have reported the following changes. The brains in these series showed increased weight. The cerebral hemispheres were anemic and congested, and there were signs of hypoxia in the hippocampal regions. The hearts showed 145
146 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 9.1â•… Characteristics of SUDEP Characteristics History of epilepsy Age Sex Race Seizure event Death Location found dead Postmortem ἀndings Toxicological ἀndings
Features of SUDEP Victims 8–17% of deaths Average age is 28–35 years, rare in children Number of male victims is twice the number of female victims More frequent among blacks Witnesses to the seizure event are rare Occurred within minutes Bed Autopsies do not reveal a cause of death Heavier than normal weights of the heart, lungs, and liver Postmortem antiepileptic drug (AED) levels were either subtherapeutic or absent
ἀbrosis localized in the conductive system around the atrioventriclular bundle, edema of the conductive tissue, perivascular and interstitial ἀbrosis, and reversible myocyte vacuolization. The lungs showed increased weight, mild to moderate pulmonary edema, and alveolar hemorrhage (Leestma et al. 1989; Terrence et al. 1981; Jallon 1999; So 2008). The livers showed increased weight and venous congestion (Leestma et al. 1989). Leestma stated that the degree of passive congestion in both the liver and lungs, as well as the edema in the lungs, suggests some element of acute backward cardiac failure in SUDEP cases (Leestma 1990). The true incidence of SUDEP is not known and the estimates vary greatly. Possible reasons for this may be linked to the fact that SUDEP is not a diagnosis as such, since it is assigned when all other possible diagnoses have been eliminated, making it a default label. Another may be the general lack of understanding by medical examiners and coroner’s office personnel of what deἀnes a SUDEP death and when they should list it on the death certiἀcate. One method of investigating the protocol used within a medical examiner’s or coroner’s office regarding SUDEP deaths is to examine the death scene investigation, the autopsy and toxicology results, and the resulting death certiἀcate. In addition, by examining all the deaths at the medical examiner’s or coroner’s office and calculating the number of deaths that conform to the SUDEP deἀnition, an approximate incidence rate of SUDEP can be ascertained. All deaths that are sudden, unexpected, and unexplained by past medical history are investigated by the medical examiner or coroner’s offices. They typically conduct a detailed death scene investigation, a forensic autopsy, and a toxicological analysis of the body fluids. The level of investigation and the anatomical and toxicological data collected by the medical examiner or coroner’s office offer investigators studying SUDEP a wealth of information. The Allegheny County Coroner’s Office was selected for several reasons. First, it was the site of a previous examination of SUDEP death and, second, the forensic examination of these types of deaths involves a thorough death scene investigation, complete postmortem examination, and a comprehensive toxicological analysis of body fluids. The ἀrst study to examine SUDEP deaths at the Allegheny County Coroner’s Office was a retrospective study conducted in 1981 (Terrence et al. 1981). The study examined SUDEP cases that occurred between January 1, 1978 and December 31, 1979 and located a total of 8 cases: 4 male, 4 female, 4 white, and 4 black, ranging in age from 9 to 31 years. The pathological ἀndings at autopsy are shown in Table 9.2 (Terrence et al. 1981). While, the
One-Year Postmortem Forensic Analysis of Deaths in Persons with Epilepsy
147
Table 9.2â•… Pathological Findings Heart Weight Normal Weight Range (250–350 g)
Combined Lung Weight Normal Weight Range (650–1140 g)
1 2 3 4 5
275 400 360 370 200
1090 850 800 1250 755
6 7 8
374 300 110
1325 930 350
Patient Number
Neuropathological Findings None Cerebral edema None None Old contusion of L temporal pole, olfactory bulb, and orbitofrontal surfaces None None Cerebral edema
Source: Terrence, C. F., Rao, G. R., and Perper, J. A., Ann Neurol, 9 (5), 458–464, 1981.
normal heart weight by sex could not be calculated, using the overall range of 250–350€g as the normal heart weight, 50% of the cases had an enlarged heart (Cotran et al. 1994). No signiἀcant abnormalities in the brain were noted. Using the range of 650–1140 g as a normal weight range of the combined lung weight, 25% of the cases had heavy lungs. The type, number of prescription medications, and the postmortem blood levels are shown in Table 9.3 (Terrence et al. 1981). Phenytoin and phenobarbital was prescribed to all 8€patients,€primidone prescribed to 4, and carbamazepine, valproic acid, and mephenytoin prescribed to one patient. Toxicological analysis revealed subtherapeutic or absent blood levels of phenytoin in 7 cases and phenobarbital in 4 out of the 8 cases. Levels for carbaÂ� mazepine, valproic acid, and mephenytoin were also measured postmortem. The purpose of the current study was to present an overview of all deaths examined at the Allegheny County Coroner’s Office among individuals with epilepsy in AlÂ�Â� legheny County during 2001, to describe epidemiological, anatomical, pathological, and Table 9.3â•… Prescribed Medications and the Postmortem Drug Levels Patient Number 1 2 3 4 5 6 7 8
Postmortem Drug Levels Drug Prescribed Phenytoin, phenobarbital Phenytoin, phenobarbital, primidone Phenytoin, phenobarbital, primidone Phenytoin, phenobarbital, primidone Phenytoin, phenobarbital, primidone Phenytoin, phenobarbital Phenytoin, phenobarbital Phenytoin, phenobarbital, carbamazepine, valproic acid, mephenytoin
Phenytoin
Phenobarbital
Other
None detected None detected
None detected None detected
None detected None detected
None detected
Therapeutic
None detected
Subtherapeutic
Therapeutic
None detected
Therapeutic
Therapeutic
None detected
None detected Subtherapeutic None detected
None detected Subtherapeutic Therapeutic
None detected None detected None detected
Source: Terrence, C. F., Rao, G. R., and Perper, J. A., Ann Neurol, 9 (5), 458–464, 1981.
148 Sudden Death in Epilepsy: Forensic and Clinical Issues
toxicological features of each SUDEP case, and to determine if SUDEP is present on the death certiἀcates issued by the coroner’s office.
9.2â•…Methods The Allegheny County Coroner’s Office has jurisdiction to investigate all deaths within Allegheny County, which is located in western Pennsylvania and encompasses a population of ~1.2 million individuals. All deaths investigated by the Allegheny County Coroner’s Office were reviewed from January 1, 2001 to December 31, 2001. This office investigates more than 6000 cases and conducts more than 1200 autopsies annually. All cases were identiἀed by conducting a computer and hand search of all the case reports by the Chief Forensic Epidemiologist (SAK) for all deaths with the words “seizure disorders,” “epilepsy,” or “SUDEP” appearing in Part I or Part II of the death certiἀcate. The following epidemiological information was collected: age, sex, race, time and date last seen alive, and the time and date of death. Seizure-related information collected included past medical€ history, prescribed medications, and who witnessed the event. Pathological information collected included the weights of the internal organs obtained from the forensic autopsy report. The normal weight parameters of the internal organs are based on published data and, where possible, separated by age and sex. Toxicological analysis was conducted on the blood, bile, urine, and eye fluid recovered during the autopsy. The blood used for the toxicological analysis was collected from the heart during the autopsy. The number and level of drugs detected in the body fluids were obtained from the toxicological report. The data was entered and analyzed by Statistical Package for the Social Sciences® (11.0 Chicago, IL). The anatomical and toxicological data for all deaths with a diagnosis of epilepsy were summarized. Based upon the summarized data, the cases that meet the classiἀcation criteria for SUDEP were determined.
9.3â•…Results A total of 12 deaths were identiἀed in which seizure disorder was listed as either the immediate cause of death or contributed to the death during the study period. Epidemiological characteristics are shown in Table 9.4. Among the 12 cases, 58.3% were male, 41.7% were female, and all cases were white. All cases were between the ages of 38 and 54 years old with the mean age of the males being slightly higher than that of the females. Overall, more than 90% of the seizures were unwitnessed events. The only witnessed seizure was that of a 42-year-old female. She was in her residence when she had a sudden seizure and became unresponsive. She was pronounced dead at the emergency room one hour after the seizure. Among the males, four were found in their bathroom and three in bed. Among the females, all were found in their residence (one on the kitchen floor, one on the bed, one in a chair, and one outside on the rear deck). Deaths were most frequent in January among the males and in September for the females. According to information contained within the death investigation report, all 12 cases had a past medical history for either a diagnosis of seizures or epilepsy. All cases would be considered as having a seizure disorder. A complete postmortem examination was conducted on all but one case, due to an advanced level of decomposition.
One-Year Postmortem Forensic Analysis of Deaths in Persons with Epilepsy
149
Table 9.4â•… Epidemiological Characteristics: Age, Sex, Race, Seizure Events, Month of Event, Medical History, and Type of Postmortem Examination Epidemiological Characteristics Total number of cases (all were Caucasian) Age range (mean) Seizure event witnessed Month of seizure
Medical history of seizures disorder or epilepsy Manner of death Type of postmortem examination a
Males
Females
7 38–50 (x = 45.4) Yes: 0 No: 7 January: 3 February: 1 March: 1 August: 1 October: 1 Yes: 7
5 39–54 (x = 44.8) Yes: 1 No: 4 June: 1 July: 1 August: 1 September: 2
Natural: 6 Accident: 1 Complete: 6 External only: 1a
Natural: 5
Yes: 5
Complete: 5 External only: 0
Decomposed.
An examination of the information contained on Part I or Part II of the death certiἀcate by sex is shown in Tables 9.5 and 9.6. The immediate cause of death is the event that directly and immediately resulted in the death. The contributory cause of death consists of conditions that play a role in causing the death, but do not cause immediate death. The section criteria for this study included any death where seizure disorder appeared on the death certiἀcate. Seizure disorder was listed as the immediate cause of death in 83.3% of the cases (6 males and 4 females), cardiomyopathy was listed in one male case, and a glial brain tumor was listed in one female case (Tables 9.5 and 9.6). Among males, seizure disorder was the immediate cause of death among 6 of the 7 deaths. In Male Case #7, the seizure disorder was considered by the forensic pathologist conducting the examination to have played a signiἀcant role in contributing to the death. The manner of death was ruled natural in six cases (85.7%) and accidental in one (14.3%). Among the females, seizure disorder Table 9.5â•…Immediate and Contributory Causes of Death for Males Death Certiἀcate Part I Immediate cause of death
Part II Contributory cause of death
Case No. 1
2
3
Seizure Seizure Seizure disorder disorder disorder (clinical)
4 Seizure disorder
5 Seizure disorder
6 Seizure disorder
Chronic Liver Liver Chronic cirrhosis cirrhosis obstructive obstructive disease pulmonary pulmonary disease disease
7 Dilated cardiomyopathy with arteriosclerotic cardiovascular disease, acute pneumonia, emphysema Seizure disorder
150 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 9.6â•…Immediate and Contributory Causes of Death for Females Case No.
Death Certiἀcate Part I Immediate cause of death
1
2
Seizure disorder
Seizure disorder (clinical)
3
4 Seizure disorder with hypertensive and arteriosclerotic cardiovascular disease
Seizure disorder (clinical) with arteriosclerotic cardiovascular disease
5 Convulsive seizure developed from grade II glial tumor
Part II Contributory cause of death
was the immediate cause of death among four of the ἀve deaths. In one case, the immediate cause of death was a convulsive seizure that developed in association with a grade II glial tumor. The manner of death was ruled natural in all ἀve cases. Overall, the incidence of death in persons with a history of seizures in which no cause of death was found on postmortem was 0.83% (10 in 1200 autopsies). The 2001 Allegheny County Coroner’s data found 0.833% (10 of 1200) of the autopsy cases met SUDEP criteria. Among the 12 cases, 85.7% (six of all males) and 80% (four of all females) represented SUDEP deaths. Autopsies were performed on all ἀve females and six of the seven males. The weights of the internal organs were available in 92% of the cases. The weights of the hearts, thicknesses of the left ventricles, lungs, and brains, and brain pathologies by sex are shown Table 9.7â•…Observed and Normal Organ Weights of the Heart, Lungs, and Brain by Sex
Sex
Weight (lb)
Heart Weight (g) (Normal Weight)a
Left Ventricle Thickness (cm)
Combined Lung Weight (g)b
Brain Weight (g)c
Male
118
310 (281)
1.2
1440
1070
121 131 145 240
445 (292) 360 (302) 400 (317) 455 (406)
1.4 1.2 1.2 1.5
1095 1200 1510 955
1240 1275 1760 1570
268 99.5 108 160 226
575 (432) 300 (230) 345 (243) 445 (284) 395 (329)
1.6 1.5 1.2 1.7 1.2
2065 915 550 1055 975
1760 1215 1205 1450 920
300
400 (371)
1.4
970
1365
Female
a b c
Normal heart range (mean expected heart weight based on body weight and sex). Normal combined weights of lungs: males, 720–1140 g; females: 650–960 g. Normal brain weights: males, 1100–1700 g; females: 1050–1550 g.
Brain Pathology Craniotomy, patchy subarachnoid hemorrhage Normal Slight swelling Normal Congestion, periventricular white matter Normal Chronic mild swelling Normal Normal Small crowded gyri, w/o atrophy Congested, mild swelling
One-Year Postmortem Forensic Analysis of Deaths in Persons with Epilepsy
151
700 600 500 400
Actual
300
Normal
200 100 0 1
2
3
4
5
6
Figure 9.1╇ Normal and actual heart weight (g) among males.
in Table 9.7. The normal ranges of the internal organs are also shown in Table 9.7. The observed weight of the heart was above the expected mean weight based on body weight and sex in all cases. Figures 9.1 and 9.2 show the normal and actual heart weights among males and females, respectively. The normal range was based on the weight and sex of the subjects. The weight of the heart was above the expected weight, after adjusting for body weight and sex in all cases. Left-ventricle hypertrophy was seen in two cases. The combined weight of the right and left lungs showed that more than 66% of the male and 60% of the female lungs exceeded normal parameters. The normal range of combined lung weights was based on sex. The mean weight for all the female lungs was normal (449.2 g), while that of the males was elevated (688.75 g). Figures 9.3 and 9.4 show the weight of the normal and actual combined lung weights by sex. Among males, the combined lung weight exceeds the upper limits of normal in four cases. Among females, the combined lung weight exceeds the upper limits of normal in three cases and dropped below the lower limits in one case. Examinations of the brains of the males showed that 33% were above normal limits, 50% were within normal limits, and 16% were below. The normal range of brain weights was based on sex. Examinations of the brains of the females showed that 80% were within
500 450 400 350 300
Actual
250
Normal
200 150 100 50 0 1
2
3
4
Figure 9.2╇ Normal and actual heart weight (g) among females.
5
152 Sudden Death in Epilepsy: Forensic and Clinical Issues 2500 2000 Actual
1500
Lower Limit Upper Limit
1000 500 0 1
2
3
4
5
6
Figure 9.3╇ Actual and normal upper and lower ranges of the combined weight of lungs (g) among males.
normal limits and 16% were below. Figures 9.5 and 9.6 show the normal and actual brain weight by sex. In the male group, the past medical history, prescribed medications, drugs identiἀed by the toxicology screen, level of postmortem compounds, and pathological factors are shown in Table 9.8. All seven had a history of seizures or epilepsy disorder. In ἀve cases (71%), antiepileptic drugs were prescribed (clonazepam, phenytoin). The death scene investigation failed to ascertain a list of prescription medications in two deaths. Toxicological analysis revealed that AED medications were detected in 57% of the cases, with phenytoin the most frequently detected. All the detected AED were at subtherapeutic levels. In only one case was the toxicological analysis negative. The bodies in three of the cases were in varying stages of decomposition. In the female group, the past medical history, prescribed medications, drugs identiἀed by the toxicology screen, level of postmortem compounds, and pathological factors are shown in Table 9.9. All cases had a past medical history of seizures. In two cases (40%), medications for seizures were prescribed (Dilantin, Lamotrigine, Tegretol). The death 1200 1000 800
Actual Lower Limit
600
Upper Limit
400 200 0 1
2
3
4
5
Figure 9.4╇ Actual and normal upper and lower ranges of the combined weight of lungs (g) among females.
One-Year Postmortem Forensic Analysis of Deaths in Persons with Epilepsy
153
2000 1800 1600 Male
1400
Lower Upper
1200 1000 800
118
121
131
145
240
268
Figure 9.5╇ Actual and normal upper and lower ranges of brain weight (g) among males by body weight (lb).
scene investigation failed to ascertain a list of prescription medications in one death. Toxicological analysis revealed that AED medications were detected in 60% of the cases, with phenytoin the most frequently detected. Toxicological analysis showed that the AED medications were at therapeutic levels in three, subtherapeutic in one, and above the therapeutic level in one case. Even though all the female cases had a diagnosis of seizure disorder, no information was collected as to why three of them were not taking any antiepileptic medications. This omission is one of the pitfalls of a retrospective study. This category of information (i.e., why a person with a diagnosis of epilepsy is not on medication) should be a speciἀc issue addressed in future studies.
1600 1500 1400 1300
Female
1200
Lower
1100
Upper
1000 900 800
99.5
108
160
226
300
Figure 9.6╇ Actual and normal upper and lower ranges of brain weight (g) among females by body weight (lb).
154 Sudden Death in Epilepsy: Forensic and Clinical Issues Table 9.8â•… Medical History, Prescribed Medication, Toxicology Screen, and Pathological Features among Males
Medical History
Prescribed Medications
Drugs Identiἀed (with Levels) in Toxicology Screen (AED Drugs in€Bold)
Seizures
Dilantin
Acetone (6 mg%) Alcohol (5 mg%)
Seizures
Prinvil Clonazepam K-Dur Oramorph Depo Medrol Provential inhaler
Doxylamine (0.014 mg%) Benzodiazepines: ╇ Nordiazepam (0.01€mg%) ╇ Chlordiazepoxide (0.013 mg%) ╇ Demoxepam (0.023 mg%) ╇ Oxazepam (0.010 mg%) ╇ Clonazepam (too low to quantify) Morphine (0.087 μg/mL) Dextromethorphanpositive Ibuprofen-positive Diphenhydraminepositive Phenytoin (8.31 μg/mL)
Seizures
Dilantin
DVT, seizures, alcoholism
Dilantin Keflex
None detected
Seizures, alcoholism
Celexa Neurontin Phenytoin Indomethacin Unknown
Ethanol (0.04%) Phenytoin (1.05 μg/mL)
HIV, seizures, chronic lung disease Bipolar depression Epilepsy, depression
Unknown
Citalopram-positive Desmethylcitaloprampositive Ethanol (0.02%) Phenytoin (2.45 μg/mL) Olanzapine (0.041 mg%) Sertraline (0.021 mg%) Valproic acid (TDX) (8.99 μg/mL)
Levels of Postmortem Compounds — —
Above therapeutic levels Therapeutic level Subtherapeutic level — Subtherapeutic level — Subtherapeutic level — — — Subtherapeutic level —
— Subtherapeutic level — — — Subtherapeutic level Above therapeutic level Therapeutic level Subtherapeutic level
Pathological Features Alive: 1/7/01 Found dead: 1/11/01 12:30 p.m. Body moderately decomposed Alive: 1/17/01 4:30€p.m. Dead: 1/18/01 12:30 p.m.
Alive: 1/18/01 7:30€a.m. Found dead: 1/18/01 4:50 p.m. Alive: 2/11/01 1:00€a.m. Found dead: 8:00€p.m. Decomposed
Putriἀcation
Alive: 10/16/01 11:00 p.m. Found dead: 10/16/01 12:00€p.m.
One-Year Postmortem Forensic Analysis of Deaths in Persons with Epilepsy
155
Table 9.9â•… Medical History, Prescribed Medication, Toxicology Screen, and Pathological Features among Females
Medical History
Prescribed Medications
Drugs Identiἀed in Toxicology Screen (AED Drugs in Bold)
Level of Postmortem Compounds Subtherapeutic level Therapeutic level Subtherapeutic level Above therapeutic level
Hysterectomy, seizures
Dilantin Lamotrigine
Phenytoin (5.36 μg/mL) Lamotrigine (0.79 mg%) Ibuprofen (0.81 mg%)
Seizures
Neurontin Tegretol Dilantin
Clonazepram (8.37 μg/ mL)
Amyotrophic lateral sclerosis, depression, seizures
Bupropion Ditropanxl Zanaflex Baclofen Rilutek Unknown
Bupropion (0.006 mg%) Threoaminobupropionpositive
Therapeutic level —
Trazodone (0.296 mg%) Venlfaxine (0.175 mg%) O-Desmethylvenlafaxine (0.025 mg%) Carbamazepine (4.56 μg/mL) Phenytoin (14.68 μg/ mL) Butalbital (0.246 mg%) Acetaminophen (14.05 mg%)
Therapeutic level Therapeutic level —
Diabetes, ╇ seizures, ╇ hypertension, ╇ asthma Hypertension, ╇ seizures, TMJ, ╇ osteoporosis, ╇ cervical fusion ╇ psychiatric history
Prempro Gybutynin Butslbitalapac-caff-tap
Therapeutic level Therapeutic level Subtherapeutic level Nearly toxic
Pathological Features Alive: 6/7/01 evening Found dead: 6/8/01 3:30 p.m. Alive: 7/6/01 12:20€a.m. Found dead: 7/6/01 12:21 a.m. Witnesses to seizure Alive: Unknown Found dead: 8/7/01 5:37 p.m. Moderate putriἀcation Alive: 9/28/01 11:30€p.m. Found dead: 9/29/01 9:31 a.m. Alive: 9/4/01 2:30€p.m. Found dead: 9/5/01 11:32 p.m.
9.4â•…Discussion The sudden and unexpected deaths among individuals with a history of epilepsy are cases that fall under the jurisdiction of the medical examiner or coroner’s office for a forensic investigation. These investigations involve a detailed review of the victims’ past medical history, a list of current medications with dosage levels, and a determination of the events immediately surrounding the time of death. The body, in most cases, also undergoes a complete forensic autopsy and toxicological analysis. All these factors can provide a fairly accurate representation of the events at the time of death, including any anatomical or disease processes that might have contributed to the death and the circulating blood levels of any medications or other compounds at the time of death. Therefore, those studying SUDEP via forensic data will be provided with not only the circumstances surrounding the death, but the weights and state of the internal organs, and a detailed toxicological analysis of the body fluids. The difficulty is locating these types of cases within the medical examiners’ or coroners’ ἀles. When medical examiner’s or coroner’s offices are confronted with a death where the autopsy and toxicological analyses fail to identify a speciἀc cause of death, and that individual has a well-documented history of seizures, the cause of death on the death certiἀcate would be listed as seizure disorder and not as SUDEP. A lack of any other
156 Sudden Death in Epilepsy: Forensic and Clinical Issues
explanation for the cause of death indicates that these victims should be considered more appropriately as having a deἀnite classiἀcation of SUDEP. However, some authors have highlighted concerns with the death certiἀcate generated from the medical examiner and coroner data. If the diagnosis of epilepsy and/or seizure disorder is not stated on death certiἀcates with accuracy, many SUDEP deaths will go undetected. Coyle et al. (1994) examined 40 cases of SUDEP identiἀed in the United Kingdom in 1992. Postmortem reports and witness statements were examined to look at the accuracy of the coroners’ diagnoses. In 70% of those cases, the type of seizure either was not known or was not referred to. The review also found inconsistent reports of the position of the victim’s body, examination of the organs, especially the brain, details of the medication history, and the toxicology examinations conducted. Epilepsy or seizure disorder as an attributed cause of death was used in less than half of the cases even though the victims had a history consistent with this diagnosis. All of these ἀndings raise issues of the quality of data included in postmortem reports. Within the United States, the majority of medical examiners’ and coroners’ offices traditionally list such deaths as seizure disorders rather than epilepsy. This practice of not using the diagnosis of SUDEP on the death certiἀcate is not due to a lack of understanding or acknowledgment of SUDEP as a valid classiἀcation of the cause of death. The lack of utilization of SUDEP as a ἀnal diagnosis in appropriate cases is in agreement with data obtained in a recent nationwide survey (Schraeder et al. 2006) that found most medical examiners and coroners did not use the diagnosis of SUDEP when entering the cause of death on the death certiἀcate in those seizure disorder cases where no cause of death was identiἀed on postmortem. This lack of use of SUDEP on the death certiἀcates results in an underreporting of SUDEP and overreporting of deaths from seizure disorder. This study highlights the increased need to educate medical examiners’ and coroners’ offices regarding when the category of SUDEP should be used. Forensic pathologists face their greatest challenge when attempting to determine causes of death that rely on exclusion criteria, such as in SUDEP. In these types of cases it is important for the examination to attempt to rule out other possible causes before classifying the death as SUDEP on the death certiἀcate. In a case that is likely to be SUDEP, the following should be part of the standard protocol. First, conduct a detailed death scene investigation with an emphasis on collecting prescription medicines at the residence. Second, obtain a detailed past medical history with a thorough review of the medical history. Third, conduct a meticulous forensic autopsy with a comprehensive examination of the heart and its conductive system. Finally, review the results of the toxicological analysis of the body fluids with special attention to the postmortem levels of AED medications. When comparing the results of the study conducted in 1981 (Terrence et al. 1981) with our data, there were some similarities and some differences. Enlarged hearts were reported in 50% of the victims in the earlier study; our study reported that all victims had an enlarged heart. However, a retrospective case control study in a medical examiner’s population by Davis and McGwin (2004) found no difference in mean heart mass between the two groups. With increasing age, they did ἀnd competing causes of death in patients with epilepsy. Their ἀndings support the concept that SUDEP occurs in young adults. Opeskin et al. (2000) conducted cardiac pathology exams in 10 victims of SUDEP and in 10 controls. They found no abnormalities in the conduction system nor in the other cardiac pathological parameters studied. In contrast, the ἀndings in our study showed above-normal heart weights. Other studies found cardiac pathological changes obtained
One-Year Postmortem Forensic Analysis of Deaths in Persons with Epilepsy
157
Table 9.10â•… Questions to Be Asked by Death Investigators Relating to Possible Seizure-â•›Related Deaths Questions 1 2 3 4 5 6 7 8 9 10
Was the deceased diagnosed with a seizure disorder? At what age was the deceased diagnosed with a seizure disorder? Was the deceased taking any antiepileptic drugs? Do you have a list of the deceased’s antiepileptic drugs? Was the deceased compliant with taking his/her medication? What was the date of the deceased’s last seizure? Were the deceased’s seizures well-controlled? Is there a family history of seizures in the deceased’s family? When was the last time the deceased took his/her antiepileptic drugs? Do you have the name of the deceased’s treating physician?
from SUDEP victims. George and Davis (1998) looked at the pathology of arrhythmogenic right ventriclular cardiomyopathy/dysplasia. Inflammatory inἀltrates (i.e., lymphocytes) were observed in 60% of cases while myocyte necrosis was found in only one case. In the current study, 63% of the deaths had above-normal lungs weights while the earlier data reported that only 25% had heavy lungs. Both studies showed that the levels of AED medications detected during toxicological analysis were typically at the subtherapeutic level, or absent entirely. In this study, 7 of the 12 deaths were determined to have occurred in patients who had been prescribed anticonvulsant medications. Based on the postmortem analysis for antiepileptic drugs, ἀve were at subtheraputic levels, one was within the therapeutic range, one was€above therapeutic levels, and ἀve were totally absent of antiepileptic drugs. Based on these results and supported by the Terrence et al. (1981) study, a high percentage were either due to individuals being noncompliant with their medications or the detection methods of the antiepileptic drugs; levels in postmortem samples were below the lower limit of quantiἀcation of the assay method. The issue of using postmortem blood to estimate the circulating blood level in the living due to the phenomena of redistribution is a concern in forensic€toxicology. In this study, all the analyses were conducted on blood collected from the chambers of the heart. This blood typically shows a higher concentration of the drug than does peripheral blood. Therefore, the recoded levels of the antiepileptic drugs were lower in the circulating blood, meaning that the individuals with subtherapeutic heart blood levels have an even lower level of the drug in their circulating blood. The current observation of increased lung weights has also been reported to be present in SUDEP by other investigators. Noncompliance of anticonvulsants has been suggested as a risk factor for neurogenic pulmonary edema and the ἀnding of pulmonary edema is thought to be associated with an adrenergic component in the death event (Lathers and Schraeder 2002; Tomson et al. 2005; Hughes 2009). For future studies, there is a need to have more detailed data collection, for example, about seizure types, the premorbid antiepileptic drug levels, the general level of compliance, and any stressful circumstances preceding death. In essence, the need for detailed information could be obtained with oral autopsy data (Lathers and Schraeder 2009). Finally, there is a need to emphasize the importance of prospective data collection. Those investigating a possible death related to a seizure-related medical history should obtain a detailed description of the events leading up to the death from the next of kin and obtain all medical records and a complete list of prescription
158 Sudden Death in Epilepsy: Forensic and Clinical Issues
medications. To ensure that the important information is ascertained, Table 9.10 lists the key questions.
Acknowledgments The authors thank Shaum Ladham, MD, Leon Rozin, MD, Abdulrezak Shakir, MD, and Joseph Dominick, RN, LFD, for technical support in the data collection process.
References Cotran, R. S., V. Kumar, S. L. Robbins, and F. J. Schoen. 1994. Robbins Pathological Basis of Disease, 5th ed. Philadelphia, PA: W. B. Saunders. Coyle, H. P., N. Baker-Brian, and S. W. Brown. 1994. Coroners’ autopsy reporting of sudden unexplained death in epilepsy (SUDEP) in the UK. Seizure 3 (4): 247–254. Davis, G. G., and G. McGwin Jr. 2004. Comparison of heart mass in seizure patients dying of sudden unexplained death in epilepsy to sudden death due to some other cause. Am J Forensic Med Pathol 25 (1): 23–28. Earnest, M. P., G. E. Thomas, R. A. Eden, and K. F. Hossack. 1992. The sudden unexplained death syndrome in epilepsy: Demographic, clinical, and postmortem features. Epilepsia 33 (2): 310–316. Ficker, D. M. 2000. Sudden unexplained death and injury in epilepsy. Epilepsia 41 (Suppl 2): S7–S12. Ficker, D. M., E. L. So, W. K. Shen, J. F. Annegers, P. C. O’Brien, G. D. Cascino, and P. G. Belau. 1998. Population-based study of the incidence of sudden unexplained death in epilepsy. Neurology 51 (5): 1270–1274. George, J. R., and G. G. Davis. 1998. Comparison of anti-epileptic drug levels in different cases of sudden death. J Forensic Sci 43 (3): 598–603. Hughes, J. R. 2009. A review of sudden unexpected death in epilepsy: Prediction of patients at risk. Epilepsy Behav 14 (2): 280–287. Jallon, P. 1999. Sudden death of epileptic patients. Presse Med 28 (11): 605–611. Lathers, C. M., and P. L. Schraeder. 2002. Clinical pharmacology: Drugs as a beneἀt and/or risk in sudden unexpected death in epilepsy? J Clin Pharmacol 42 (2): 123–136. Lathers, C. M., and P. L. Schraeder. 2009. Verbal autopsies. Epilepsy Behav 14: 573–576. Leestma, J. E. 1990. Sudden unexpected death associated with seizures: A pathological review. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. L. Schraeder. New York, NY: Marcel Dekker. Leestma, J. E., T. Walczak, J. R. Hughes, M. B. Kalelkar, and S. S. Teas. 1989. A prospective study on sudden unexpected death in epilepsy. Ann Neurol 26 (2): 195–203. Nashef, L., and S. D. Shorvon. 1997. Mortality in epilepsy. Epilepsia 38 (10):1059–1061. Opeskin, K., A. Thomas, and S. F. Berkovic. 2000. Does cardiac conduction pathology contribute to sudden unexpected death in epilepsy? Epilepsy Res 40 (1): 17–24. Schraeder, P. L., K. Delin, R. L. McClelland, and E. L. So. 2006. Coroner and medical examiner documentation of sudden unexplained deaths in epilepsy. Epilepsy Res 68 (2): 137–143. So, E. L. 2008. What is known about the mechanisms underlying SUDEP? Epilepsia 49 (Suppl 9): 93–98. Terrence, C. F., G. R. Rao, and J. A. Perper. 1981. Neurogenic pulmonary edema in unexpected, unexplained death of epileptic patients. Ann Neurol 9 (5): 458–464. Tomson, T., T. Walczak, M. Sillanpaa, and J. W. Sander. 2005. Sudden unexpected death in epilepsy: A review of incidence and risk factors. Epilepsia 46 (Suppl 11): 54–61.
Drug Abuse and SUDEP Steven B. Karch
10
Contents 10.1 Introduction 10.2 Channelopathies and Abused Drugs 10.2.1 QT Interval Prolongation 10.2.2 QT Shortening 10.3 QT Dispersion 10.4 Abnormal Catecholamine Metabolism References
159 161 161 164 164 165 165
10.1â•…Introduction Nearly a quarter century ago, Leestma et al. (1985) described the ἀndings seen at autopsies of 66 epileptics who had died unexpectedly during or just after experiencing a seizure. The autopsy ἀndings were insufficient to explain the cause of death in any of the cases. The syndrome of sudden death during or immediately after a seizure has come to be called sudden unexplained death in epilepsy (SUDEP). Over a 10-year period, the mean age of epileptics with SUDEP in Leestma’s studies was 31.4 years. Of these, 37% were found dead in bed, 49% were black males, 25% were white males, 11% were black females, and 15% were white females ranging in age from 10 months to 60 years (mean age, 28 years); nearly half of the decedents were found “dead in bed,” a description that applies equally well to deaths from long QT syndrome (LQTS), an entity due to heritable channelopathies (Ackerman et al. 2001), or to diabetes with hypoglycemia (Rothenbuhler et al. 2008; Tu et al. 2008). By convention, the abbreviation sudden unexplained death syndrome (SUDS) is used to describe the death of anyone older than 2 years who dies in this fashion, whereas for children 2 years and younger, the diagnosis that is used is sudden infant death syndrome (SIDS). More recently, a similar syndrome has been recognized in young diabetics (Gill et al. 2009). As with SUDEP, the cause of death is not apparent in any of these disorders, although it seems probable that an explanation is to be found only at the molecular level. One popular hypothesis holds that SUDEP victims may have died because of QT interval prolongation (QTd) and that SUDEP is just another variety of LQTS. The presence of prolonged QT intervals reflects delayed cardiac repolarization. It can be caused by a variety of different abnormalities, including acute hypoglycemia, superimposed upon the presence of cardiac autonomic neuropathy (Tu et al. 2008). This process may account for the death of young diabetics as noted above, although why the QT interval in young diabetics should be prolonged has never really been explained. Other factors, such as channelopathies and cardiomyocyte membrane abnormalities, may also be involved. The notion that the same abnormality might account for both SUDEP and LQTS (Aurlien et al. 2009) has the potential to open up new areas of research. 159
160 Sudden Death in Epilepsy: Forensic and Clinical Issues
Numerous risk factors for SUDEP have been proposed and a few have been consistently identiἀed, including young age, early seizure onset, refractory seizures, generalized tonic clonic seizures, and male gender. Studies have found that many of these individuals are in bed, presumably asleep, at the time of death, that anticonvulsant blood levels are subtherapeutic, and that a structural brain lesion often can be identiἀed (Leestma et al. 1985). The current consensus seems to be that SUDEP is primarily a seizure-related cause of death, but the mechanisms underlying SUDEP are unknown (Jehi and Najm 2008; Hughes 2009). Most SUDEP victims are found alone in a room at home and only rarely have they been vigorously exercising. A recent meta-analysis, which included a review of the Cochrane database (Monte et al. 2007), found that patients were more likely to be discovered asleep or, at least, in their beds. Subtherapeutic concentrations of antiseizure medications were found in nearly 70% of Leestma’s cases, many of the decedents having no medications detectable at all. Signiἀcant but nonprogressive brain abnormalities were present in more €than half the decedents. Leestma et al. (1985) estimated the prevalence of seizureassociated SUDEP was between 1:525 and 1:2100 epileptics (Tellez-Zenteno et al. 2005). Other retrospective studies have reported both slightly higher and slightly lower incidence rates (Tellez-Zenteno et al. 2005; Hughes 2009), but the fact remains that SUDEP is the most common cause of death in persons with epilepsy. SUDEP is rare in those who have only recently been diagnosed with epilepsy, and it is equally uncommon in those who are in remission. Many theories accounting for the etiology of SUDEP have been proposed (Kloster and Engelskjon 1999; Lathers and Schraeder 2006; So and Sperling 2007; Aurlien et al. 2009). Most involve cardiac arrhythmias, mediated by sympathetic autonomic events, which are thought to occur during the seizures. The possibility of heritable channelopathy is receiving much closer scrutiny than in the past. Some candidate genes make the QT interval longer and some make it shorter, but both abnormalities are associated with a sudden arrhythmia-related death. These changes are important not only because they have been identiἀed in epileptics (Akalin et al. 2003), but also because they are associated with the use of some abused drugs, in particular cocaine and alcohol (Gamouras et al. 2000; Karle and Kiehn 2002; Uyarel et al. 2005; Yap et al. 2009). The possibility that genetic polymorphisms may be responsible for SIDS, SUDS, and even SUDEP cannot be ignored, but neither can the process known as myocardial remodeling, which causes the QT interval to be longer in some parts of the heart than in others. This phenomenon is referred to as QT interval dispersion; if the difference between the longest and shortest QT interval measured in a 12-lead electrocardiogram exceeds 80 ms, a state of QT dispersion (QTd) is said to exist (Anderson 2003). QTd has the same strong association with sudden cardiac death as interstitial ἀbrosis and channelopathy (Cuddy et al. 2009). The process of myocardial remodeling has received relatively little attention from neurologists, but is increasingly recognized as a cause of sudden death by cardiologists and electrophysiologists (Fischer et al. 2007). Stimulant drugs initiate the same remodeling process as seen in states of chronic catecholamine excess, and such a state can be said to exist during recurrent seizure activity (Meierkord et al. 1994; Henning and Cuevas 2006). Hypertension (Haider et al. 1998), catecholamine excess (Rona 1985), and stimulant drug abuse (Karch et al. 1998 1999) always lead to myocardial ἀbrosis and left ventricular hypertrophy (i.e., myocardial remodeling). Either or both of these processes can provide
Drug Abuse and SUDEP
161
the substrate for sudden arrhythmia death (John et al. 2004; Haider et al. 1998). Ventricular hypertrophy and ἀbrosis are both common ἀndings in SUDEP victims (P-Codrea Tigaran et al. 2005) and it may well be that QTd is responsible for some cases of SUDEP.
10.2â•…Channelopathies and Abused Drugs 10.2.1â•…QT Interval Prolongation Ackerman and others have proposed that perturbations of the hERG channels (“rapid delayed repolarizing channel”) can confer a susceptibility for seizures themselves or, alternatively, cause QT prolongation, resulting in syncopal episodes that trigger seizures (Johnson et al. 2009; Nemec et al. 2009). This is not an unreasonable theory given that many patients who have seizures and QT prolongation are often confused with patients suffering from primary seizure disorders, and are treated with antiepileptic drugs instead of the internal deἀbrillators they really need (Lathers et al. 2010). In a recently published controlled case study, seizure phenotype was recorded in 98 of 343 (29%) patients who were randomly checked for the most common channelopathies. A seizure phenotype was more common in individuals with LQT2 (36 of 77 or 47%) than those with LQT1 (16 of 72 or 22%, p < 0.002) and LQT3 (7 of 28 or 25%, p < 0.05, not signiἀcant). LQT1 and LQT3 combined cohorts did not differ signiἀcantly from the expected background rates of a seizure phenotype, but a personal history of seizures was much more commonly found in those individuals with LQT2 (30 of 77 or 39%) than all other subtypes of LQTS (11 of 106 or 10%, p < 0.001) (Johnson et al. 2009). If this connection can be proven in other studies, the observation is potentially very signiἀcant. The gene, KCNH2, is responsible for LQT2. The KCNH2 channel was cloned originally from the hippocampus; it encodes a potassium channel active in hippocampal astrocytes and in the heart (Zehelein et al. 2004). Not only can this channel interact with some antiepileptic medications, e.g., phentoyin, phenobarbital, toprimate, and flunariÂ� zine (Danielsson et al. 2003; Trepakova et al. 2006; Yang et al. 2008), but it also interacts with abused drugs such as cocaine, methamphetamine, methadone, anabolic steroids, and even alcohol. This observation suggests that, in some cases of SUDEP, drug abuse may be the cause of death. That this observation has not yet been recorded in the literature only reflects the fact that full toxicology screening for abused drugs is not part of the routine investigation of SUDEP. Indeed, the autopsy is often performed even before a history of epilepsy is established (Kloster and Engelskjon 1999). Lathers et al. (1990) suggest, “… since both cocaine and epilepsy alone are associated with sudden unexpected death and since both are capable of modifying cardiac sympathetic neural discharge to produce changes in heart rate and rhythm, the question of whether the use of cocaine in the epileptic person places this individual at risk for sudden death must be raised.” It is also known that alcohol use is associated with an increased risk of autonomic dysfunction, seizure, and sudden death (Chan et al. 1990). It is clear that no single neurochemical system can adequately explain the complex nature of epileptic seizures. The same can be said for the neurochemical mechanisms that underlie alcohol withdrawal reactions in that there are complex, dynamic interactions among the neurotransmitters and neuromodulator systems in the brain. Another complicating factor is that
162 Sudden Death in Epilepsy: Forensic and Clinical Issues
occurrence of withdrawal seizures is only one component of the withdrawal syndrome. The challenge is to separate the neurochemical changes that may trigger seizures from those that are actually the result of the seizures themselves, or some other complication of the withdrawal reaction. Some of these factors include the individual’s genetic makeup, seizure threshold, health status, malnutrition, polydrug abuse, a history of epilepsy, prior alcohol withdrawal seizures, and trauma. Despite the difficulties associated with interpreting the neurochemical changes associated with ethanol withdrawal, there do appear to be similarities between the abnormalities observed in alcoholics and those postulated to be involved in the mechanism of epileptic seizures (Lathers et al. 1990). Twenty years have lapsed since Lathers et al. (1990) and Chan et al. (1990) discussed the possible interactions of cocaine and alcohol and SUDEP. The time is long overdue for us to answer these questions. The results of very recent discoveries make the effort to answer these questions even more worthwhile. When genome-wide data from ἀve different population-based cohorts, composed of 15,842 individuals of European ancestry, were analyzed, a total of 10 loci associated with the occurrence of LQTS were identiἀed. Four of these loci map near the monogenic LQTS genes: KCNQ1, KCNH2, SCN5A, and KCNJ2. Two other loci, ATP1B1 and PLN, have already been shown to be genes with established electrophysiological functions, whereas three of the newly discovered genes map to RNF207, near LITAF and within the NDRG4–GINS3–SETD6–CNOT1 complex, respectively. Until this study was undertaken, not a single one of these genes was thought to have anything to do with cardiac function (Newton-Cheh et al. 2009; Pfeufer et al. 2009). Any one of these genes could be responsible for LQTS, torsades de pointes, and sudden cardiac death (Pfeufer et al. 2009). The most striking thing about this new discovery is that it was replicated within the same week by another group of scientists who came up with exactly the same results (Newton-Cheh et al. 2009). If this sequence of events were to occur in a person with epilepsy, it would be called SUDEP, since the genetic component would not be detected by the medical examiner.€Even though these new discoveries very strongly suggest a nexus between SUDEP, channelopathies, and drug abuse, further understanding of the pathophysiology is required. Associations between LQT2 and epilepsy that had not previously been suspected are now known to exist. This raises the possibility that LQT2 perturbations in the KCNH2-encoded potassium channel may confer susceptibility for recurrent seizure activity (Johnson et al. 2009). When a cardiomyocyte depolarizes, the rapid component of the delayed rectiἀer K+ current, abbreviated as IKr, plays a key role in cell repolarization. During the plateau phase of the depolarization and repolarization cycle, the current generated through the IKr channel is small. As repolarization proceeds, a transient increase in the IKr outward current occurs due to fast recovery from inactivation and slow deactivation, ultimately leading to repolarization of the cardiac cell. The LQTII or hERG gene controls the IKr channel (Thomas et al. 2006). In congenital forms of LQTII syndrome, flow through the channel is slowed because the structure of the potassium pore itself is abnormal. As a consequence, the action potential is prolonged. This leads to the occurrence of early after depolarization currents that, in turn, can lead to lethal arrhythmias (torsades de pointes, literally “twisting of the points,” a form of ventricular tachycardia). However, LQTS can occur even in someone with a perfectly normal hERG gene because so many drugs, both licit and illicit, such as ἀrst and second generation antidepressants, interact with the channel (Sala et al. 2006). Since the
Drug Abuse and SUDEP
163
majority of antiepileptic drugs block voltage-dependent sodium and calcium channels, enhance GABAergic transmission, and/or antagonize glutamate receptors, it only seems reasonable to assume that an epileptic who abuses drugs is at far greater risk for arrhythmia, even if the effects of their antiseizure medications predominate. Although there is nothing in the literature to suggest that any of the commonly used anti-seizure medications cause QT prolongation, there is ample evidence that some abused drugs do. Cocaine, alcohol, and cocaethylene (a cocaine metabolite that is formed only in the presence of signiἀcant amounts of alcohol) all block the hERG potassium channel, effectively producing an acquired form of LQTII (Karle and Kiehn 2002). Whether they interact with any of the other recently discovered channels is not known. When hERG currents are measured in vitro using the patch-clamp technique, cocaethylene (the only metabolite of cocaine that is psychoactive) increases the QT interval and causes torsades de pointes (Ferreira et al. 2001; O’Leary 2002). Other studies have shown cocaethylene accelerates the inactivation of hERG current without affecting recovery from inactivation. Depending on the molecular conἀguration of an ion pore, there are several different ways to disrupt normal IKr function. Cocaine and its metabolite, cocaethylene, produce what is called open channel block, which prevents the channel closing by putting a “foot in the door” (Wang et al. 2000). Much the same mechanism has been proposed for quaternary ammonium compounds. Study of cocaethylene is particularly important because the IKr current is found to be altered, even at realistic plasma drug concentrations (O’Leary 2002). hERG K+ channels have also been found in neurons, putatively contributing to the neuropsychological behavior of individuals who have been drinking alcohol and/or using cocaine. Methamphetamine abuse also causes QT prolongation, even though it does not interact with the hERG channel (or any other known cardiac channel) (Haning and Goebert 2007). This somewhat perplexing result may be a consequence of catecholamine toxicity, as it is well established that epinephrine induces LQTS (Urao et al. 2004), and methamphetamine usage causes catecholamine release from synaptic vesicles, thereby increasing circulating levels of catecholamines (Stuerenburg et al. 2002). Central sympathetic stimulation, such as occurs during seizures, also causes release of catecholamines and could provide a plausible explanation for this phenomena (Eckard et al. 1999). Clinical studies show that cerebral infarction causes various cardiovascular and electrocardiographic abnormalities, depending on the location and the size of the infarct. The two most frequently encountered abnormalities in patients with stroke are QT interval prolongation and widening of the QRS complex. Disease of the insular cortex seems to be very important for activation of the sympathetic nervous system. Patients with brain stem infarction have substantially higher mean plasma norepinephrine levels than patients with hemispheric infarction; on the other hand, hemispheric lesions are associated with a signiἀcantly higher incidence of cardiac arrhythmias when compared to patients with brain stem infarction (Klingelhofer and Sander 1997). Whether any of these changes can be related to the mechanism that causes arrhythmias in epileptics is not known. Methadone has recently been added to the list of drugs shown to produce QT prolongation, arrhythmias, and sudden death. It has been known for several years that highdose methadone can induce QT prolongation (Kornick et al. 2003) by hERG inhibition. However, new evidence shows that QT prolongation can occur at much lower doses of methadone, even when the drug is not given intravenously. Methadone is a chiral€drug, but only (R)-methadone provides any pain relief. Laboratory experiments have shown that
164 Sudden Death in Epilepsy: Forensic and Clinical Issues
(S)-methadone, which does not bind the mu receptor or provide pain relief, blocks the hERG current three-and-a-half times more potently than (R)-methadone. If an individual is a CYP2B6 slow metabolizer (SM), they can still metabolize (R)-methadone normally, but they cannot metabolize the (S) form. Concentrations of the (S) form of methadone will continue to rise, eventually leading to hERG blockade and, potentially, torsades de pointes (Eap et al. 2007). 10.2.2â•…QT Shortening Pathologic reduction in the QT interval is much less common than prolongation but it is also associated with sudden death. Brugada et al. (2004) linked SQTS to a KCNH2 gene mutation, the same gene responsible for QT prolongation. This disorder is characterized by a corrected QT (QTc) interval that is shorter than normal (QTc ≤€320 ms), and it is often associated with atrial ἀbrillation, syncopal episodes, and/or sudden cardiac death in patients who are said to have no anatomic evidence of heart disease (Zareba and Cygankiewicz 2008). While there is general agreement about what constitutes a prolonged QT interval, the deἀnition of short QT (SQTS) remains somewhat controversial, though most accept that the lower boundary of normal is on the order of 320 ms. Unlike the mutations in LQTS, which result in loss of function, mutations in SQTS cause an increase in function with rapid repolarization; cardiac arrest may be the ἀrst symptom (Giustetto et al. 2006). The recent discovery that anabolic steroid abuse is associated with a reduction in the QT interval (Bigi et al. 2009) is most provocative, given the repeated observation that abnormalities of reproductive endocrine hormones are more often found in men with epilepsy than in the general population (Roste et al. 2005). There is an ongoing debate whether this increased risk in males can be attributed to the use of antiepileptic drugs or the epilepsy itself. The corrected QT interval in proven anabolic steroid abusers is signiἀcantly shorter than the QT interval of drug-free bodybuilders and that of sedentary men. In this recently study, sedentary men were found to have a QTc interval of 418 ± 23.6 ms, drug-free bodybuilders had a QTc interval of 422 ± 24.5 ms, and steroid abusing bodybuilders had a QTc interval of 367 ± 17.1 ms (p < 0.01). In fact, the correlation between steroid abuse and QT interval is so strong that some have recommended EKG screening as a method of detecting steroid abusers (Bigi et al. 2009). Similar ἀndings have been produced by the administration of anabolic steroids to experimental animals (Fulop et al. 2006; Liu et al. 2003).
10.3╅QT Dispersion Animal studies suggest that hippocampal norepinephrine transporters are downregulated when chronically exposed to cocaine (Kitayama et al. 2006), and human studies have shown a decrease in dopamine and serotonin transporters in the same areas (Mash et al. 2000). It should not be forgotten that all local anesthetics are Na channel blockers, both in the brain and the heart, and cocaine is a local anesthetic. Thus, it might be reasonable to postulate that some drug abusers who also have epilepsy, of which there appear to be more than a few (Opeskin et al. 2000),€die as a consequence of the drug abuse acting in synergy with their primary disease to cause seizure-related death.
Drug Abuse and SUDEP
165
10.4â•…Abnormal Catecholamine Metabolism Disruption of postganglionic reuptake is thought to be the mechanism that leads to bradyarrhythmia or even asystole during epileptic seizures. In the heart, as opposed to the brain, the action of norepinephrine is terminated primarily by reuptake (Kloner et al. 1992; Schafers et al. 1998) by the actions of catechol-O-methyl transferase (COMT). Recent studies of epileptics who have experienced bradyarrhythmia or asystole have shown that these individuals have dramatically abnormal postganglionic cardiac norepinephrine uptake (Kerling et al. 2009), suggesting impaired sympathetic cardiac innervation, resulting in a limited ability to adjust and modulate heart rate, or even cause asystole. A large number of commonly abused drugs (cocaine, methamphetamine, and 3,4-methylenedioxymethamphetamine) profoundly disrupt catecholamine metabolism, and their use may well be responsible for the death of an occasional drug abuser who also has epilepsy. However, the most current studies suggest variations in COMT activity are more likely due to genetic polymorphisms and, no doubt, more work will be done in this area in the near future (Haile et al. 2009).
References Ackerman, M. J., D. J. Tester, and D. J. Driscoll. 2001. Molecular autopsy of sudden unexplained death in the young. Am J Forensic Med Pathol 22 (2): 105–111. Akalin, F., A. Tirtir, and Y. Yilmaz. 2003. Increased QT dispersion in epileptic children. Acta Paediatr 92 (8): 916–920. Anderson, K. P. 2003. Sympathetic nervous system activity and ventricular tachyarrhythmias: Recent advances. Ann Noninvasive Electrocardiol 8 (1): 75–89. Aurlien, D., T. P. Leren, E. Tauboll, and L. Gjerstad. 2009. New SCN5A mutation in a SUDEP victim with idiopathic epilepsy. Seizure 18 (2): 158–160. Bigi, M. A., A. Aslani, and A. Aslani. 2009. Short QT interval: A novel predictor of androgen abuse in strength trained athletes. Ann Noninvasive Electrocardiol 14 (1): 35–39. Brugada, R., K. Hong, R. Dumaine, J. Cordeiro, F. Gaita, M. Borggrefe, T. M. Menendez et al. 2004. Sudden death associated with short-QT syndrome linked to mutations in HERG. Circulation 109 (1): 30–35. Chan, A. W. K., C. M. Lathers, and J. E. Leestma. 1990. Chapter 19. Alcohol, arrhythmias, seizures, and sudden death. In Epilepsy and Sudden Death, ed. C. Lathers and P. Schraeder. New York, NY: Marcel Dekker. Cuddy, T. E., P. S. Halli, and R. B. Tate. 2009. QT dispersion and heart rate predict the risk of sudden unexpected cardiac death in men: The Manitoba Follow-Up Study. Prev Cardiol 12 (1): 27–33. Danielsson, B. R., K. Lansdell, L. Patmore, and T. Tomson. 2003. Phenytoin and phenobarbital inhibit human HERG potassium channels. Epilepsy Res 55 (1–2): 147–157. Eap, C. B., S. Crettol, J. S. Rougier, J. Schlapfer, L. Sintra Grilo, J. J. Deglon, J. Besson, M. CroquetteKrokar, P. A. Carrupt, and H. Abriel. 2007. Stereoselective block of hERG channel by (S)-methadone and QT interval prolongation in CYP2B6 slow metabolizers. Clin Pharmacol Ther 81 (5): 719–728. Eckardt, M., L. Gerlach, and F. L. Welter. 1999. Prolongation of the frequency-corrected QT dispersion following cerebral strokes with involvement of the insula of Reil. Eur Neurol 42 (4): 190–193. Ferreira, S., W. J. Crumb Jr., C. G. Carlton, and C. W. Clarkson. 2001. Effects of cocaine and its major metabolites on the HERG-encoded potassium channel. J Pharmacol Exp Ther 299 (1): 220–226.
166 Sudden Death in Epilepsy: Forensic and Clinical Issues Fischer, R., R. Dechend, A. Gapelyuk, E. Shagdarsuren, K. Gruner, A. Gruner, P. Gratze et al. 2007. Angiotensin II-induced sudden arrhythmic death and electrical remodeling. Am J Physiol Heart Circ Physiol 293 (2): H1242–H1253. Fulop, L., T. Banyasz, G. Szabo, I. B. Toth, T. Biro, I. Lorincz, A. Balogh, K. Peto, I. Miko, and P. P. Nanasi. 2006. Effects of sex hormones on ECG parameters and expression of cardiac ion channels in dogs. Acta Physiol (Oxf) 188 (3–4): 163–171. Gamouras, G. A., G. Monir, K. Plunkitt, S. Gursoy, and L. S. Dreifus. 2000. Cocaine abuse: Repolarization abnormalities and ventricular arrhythmias. Am J Med Sci 320 (1): 9–12. Gill, G. V., A. Woodward, I. F. Casson, and P. J. Weston. 2009. Cardiac arrhythmia and nocturnal hypoglycaemia in type 1 diabetes—The ‘dead in bed’ syndrome revisited. Diabetologia 52 (1): 42–45. Giustetto, C., F. Di Monte, C. Wolpert, M. Borggrefe, R. Schimpf, P. Sbragia, G. Leone et al. 2006. Short QT syndrome: Clinical ἀndings and diagnostic–therapeutic implications. Eur Heart J 27€(20): 2440–2447. Haider, A. W., M. G. Larson, E. J. Benjamin, and D. Levy. 1998. Increased left ventricular mass and hypertrophy are associated with increased risk for sudden death. J Am Coll Cardiol 32 (5): 1454–1459. Haile, C. N., T. R. Kosten, and T. A. Kosten. 2009. Pharmacogenetic treatments for drug addiction: Cocaine, amphetamine and methamphetamine. Am J Drug Alcohol Abuse 35 (3): 161–177. Haning, W., and D. Goebert. 2007. Electrocardiographic abnormalities in methamphetamine abusers. Addiction 102 (Suppl 1): 70–75. Henning, R. J., and J. Cuevas. 2006. Cocaine activates calcium/calmodulin kinase II and causes cardiomyocyte hypertrophy. J Cardiovasc Pharmacol 48 (1): 802–813. Hughes, J. R. 2009. A review of sudden unexpected death in epilepsy: Prediction of patients at risk. Epilepsy Behav 14 (2): 280–287. Jehi, L., and I. M. Najm. 2008. Sudden unexpected death in epilepsy: Impact, mechanisms, and prevention. Cleve Clin J Med 75 (Suppl 2): S66–S70. John, B. T., B. K. Tamarappoo, J. L. Titus, W. D. Edwards, W. K. Shen, and S. S. Chugh. 2004. Global remodeling of the ventricular interstitium in idiopathic myocardial ἀbrosis and sudden cardiac death. Heart Rhythm 1 (2): 141–149. Johnson, J. N., N. Hofman, C. M. Haglund, G. D. Cascino, A. A. Wilde, and M. J. Ackerman. 2009. Identiἀcation of a possible pathogenic link between congenital long QT syndrome and epilepsy. Neurology 72 (3): 224–231. Karch, S. B., B. G. Stephens, and C. H. Ho. 1999. Methamphetamine-related deaths in San Francisco: Demographic, pathologic, and toxicologic proἀles. J Forensic Sci 44 (2): 359–368. Karch, S. B., B. Stephens, and C. H. Ho. 1998. Relating cocaine blood concentrations to toxicity—An autopsy study of 99 cases. J Forensic Sci 43 (1): 41–45. Karle, C. A., and J. Kiehn. 2002. An ion channel ‘addicted’ to ether, alcohol and cocaine: The HERG potassium channel. Cardiovasc Res 53 (1): 6–8. Kerling, F., M. Dutsch, R. Linke, T. Kuwert, H. Stefan, and M. J. Hilz. 2009. Relation between ictal asystole and cardiac sympathetic dysfunction shown by MIBG-SPECT. Acta Neurol Scand 120€(2): 123–129. Kitayama, T., L. Song, K. Morita, N. Morioka, and T. Dohi. 2006. Down-regulation of norepinephrine transporter function induced by chronic administration of desipramine linking to the alteration of sensitivity of local-anesthetics–induced convulsions and the counteraction by coadministration with local anesthetic. Brain Res 1096 (1): 97–103. Klingelhofer, J., and D. Sander. 1997. Cardiovascular consequences of clinical stroke. Baillieres Clin Neurol 6 (2): 309–335. Kloner, R. A., S. Hale, K. Alker, and S. Rezkalla. 1992. The effects of acute and chronic cocaine use on the heart. Circulation 85 (2): 407–419. Kloster, R., and T. Engelskjon. 1999. Sudden unexpected death in epilepsy (SUDEP): A clinical perspective and a search for risk factors. J Neurol Neurosurg Psychiatry 67 (4): 439–444.
Drug Abuse and SUDEP
167
Kornick, C. A., M. J. Kilborn, J. Santiago-Palma, G. Schulman, H. T. Thaler, D. L. Keefe, A. N. Katchman et al. 2003. QTc interval prolongation associated with intravenous methadone. Pain 105 (3): 499–506. Lathers, C. M., and P. L. Schraeder. 2006. Stress and sudden death. Epilepsy Behav 9 (2): 236–242. Lathers, C. M., P. L. Schraeder, and M. W. Bungo. 2010. Neurocardiologic mechanistic risk factors in sudden unexpected death in epilepsy. Ch. 1 in Sudden Death in Epilepsy: Forensic and Clinical Issues, eds. C. M. Lathers, P. L. Schraeder, M. W. Bungo, and J. E. Leestma. Boca Raton: CRC Press. Lathers, C. M., M. M. Spino, I. Agarwal, L. S. Y. Tyau, and W. B. Pickworth. 1990. Chapter 27. Cocaine-induced seizures, arrhythmias, and sudden death. In Epilepsy and Sudden Death, ed. C. M. Lathers and P. Schraeder. New York, NY: Marcel Dekker. Leestma, J. E., J. R. Hughes, S. S. Teas, and M. B. Kalelkar. 1985. Sudden epilepsy deaths and the forensic pathologist. Am J Forensic Med Pathol 6 (3): 215–218. Liu, X. K., A. Katchman, B. H. Whitἀeld, G. Wan, E. M. Janowski, R. L. Woosley, and S. N. Ebert. 2003. In€vivo androgen treatment shortens the QT interval and increases the densities of inward and delayed rectiἀer potassium currents in orchiectomized male rabbits. Cardiovasc Res 57 (1): 28–36. Mash, D. C., J. K. Staley, S. Izenwasser, M. Basile, and A. J. Ruttenber. 2000. Serotonin transporters upregulate with chronic cocaine use. J Chem Neuroanat 20 (3–4): 271–280. Meierkord, H., S. Shorvon, and S. L. Lightman. 1994. Plasma concentrations of prolactin, noradrenaline, vasopressin and oxytocin during and after a prolonged epileptic seizure. Acta Neurol Scand 90 (2): 73–77. Monte, C. P., J. B. Arends, I. Y. Tan, A. P. Aldenkamp, M. Limburg, and M. C. de Krom. 2007. Sudden unexpected death in epilepsy patients: Risk factors. A systematic review. Seizure 16 (1): 1–7. Nemec, J., M. Buncova, V. Shusterman, B. Winter, W. K. Shen, and M. J. Ackerman. 2009. QT interval variability and adaptation to heart rate changes in patients with long QT syndrome. Pacing Clin Electrophysiol 32 (1): 72–81. Newton-Cheh, C., M. Eijgelsheim, K. M. Rice, P. I. de Bakker, X. Yin, K. Estrada, J. C. Bis et al. 2009. Common variants at ten loci influence QT interval duration in the QTGEN Study. Nat Genet 41 (4): 399–406. O’Leary, M. E. 2002. Inhibition of HERG potassium channels by cocaethylene: A metabolite of cocaine and ethanol. Cardiovasc Res 53 (1): 59–67. Opeskin, K., A. S. Harvey, S. M. Cordner, and S. F. Berkovic. 2000. Sudden unexpected death in epilepsy in Victoria. J Clin Neurosci 7 (1): 34–37. P-Codrea Tigaran, S., S. Dalager-Pedersen, U. Baandrup, M. Dam, and A. Vesterby-Charles. 2005. Sudden unexpected death in epilepsy: Is death by seizures a cardiac disease? Am J Forensic Med Pathol 26 (2): 99–105. Pfeufer, A., S. Sanna, D. E. Arking, M. Muller, V. Gateva, C. Fuchsberger, G. B. Ehret et al. 2009. Common variants at ten loci modulate the QT interval duration in the QTSCD Study. Nat Genet 41 (4): 407–414. Rona, G. 1985. Catecholamine cardiotoxicity. J Mol Cell Cardiol 17 (4): 291–306. Roste, L. S., E. Tauboll, L. Morkrid, T. Bjornenak, E. R. Saetre, T. Morland, and L. Gjerstad. 2005. Antiepileptic drugs alter reproductive endocrine hormones in men with epilepsy. Eur J Neurol 12 (2): 118–124. Rothenbuhler, A., C. P. Bibal, S. Le Fur, and P. Bougneres. 2008. Effects of a controlled hypoglycaemia test on QTc in adolescents with Type 1 diabetes. Diabet Med 25 (12): 1483–1485. Sala, M., F. Coppa, C. Cappucciati, P. Brambilla, G. d’Allio, E. Caverzasi, F. Barale, and G. M. De Ferrari. 2006. Antidepressants: Their effects on cardiac channels, QT prolongation and Torsade de Pointes. Curr Opin Investig Drugs 7 (3): 256–263. Schafers, M., D. Dutka, C. G. Rhodes, A. A. Lammertsma, F. Hermansen, O. Schober, and P. G. Camici. 1998. Myocardial presynaptic and postsynaptic autonomic dysfunction in hypertrophic cardiomyopathy. Circ Res 82 (1): 57–62. So, N. K., and M. R. Sperling. 2007. Ictal asystole and SUDEP. Neurology 69 (5): 423–424.
168 Sudden Death in Epilepsy: Forensic and Clinical Issues Stuerenburg, H. J., K. Petersen, T. Baumer, M. Rosenkranz, C. Buhmann, and R. Thomasius. 2002. Plasma concentrations of 5-HT, 5-HIAA, norepinephrine, epinephrine and dopamine in ecstasy users. Neuro Endocrinol Lett 23 (3): 259–261. Tellez-Zenteno, J. F., L. H. Ronquillo, and S. Wiebe. 2005. Sudden unexpected death in epilepsy: Evidence-based analysis of incidence and risk factors. Epilepsy Res 65 (1–2): 101–115. Thomas, D., C. A. Karle, and J. Kiehn. 2006. The cardiac hERG/IKr potassium channel as pharmaÂ� cological target: Structure, function, regulation, and clinical applications. Curr Pharm Des 12€(18): 2271–2283. Trepakova, E. S., S. J. Dech, and J. J. Salata. 2006. Flunarizine is a highly potent inhibitor of cardiac hERG potassium current. J Cardiovasc Pharmacol 47 (2): 211–220. Tu, E., S. M. Twigg, and C. Semsarian. 2008. Sudden death in type 1 diabetes: The mystery of the ‘dead in bed’ syndrome. Int J Cardiol. Urao, N., H. Shiraishi, K. Ishibashi, M. Hyogo, M. Tsukamoto, N. Keira, S. Hirasaki, T. Shirayama, and M. Nakagawa. 2004. Idiopathic long QT syndrome with early after depolarization induced by epinephrine. A case report. Circ J 68 (6): 587–591. Uyarel, H., C. Ozdol, A. M. Gencer, E. Okmen, and N. Cam. 2005. Acute alcohol intake and QT dispersion in healthy subjects. J Stud Alcohol 66 (4): 555–558. Wang, J., C. D. Myers, and G. A. Robertson. 2000. Dynamic control of deactivation gating by a soluble amino-terminal domain in HERG K(+) channels. J Gen Physiol 115 (6): 749–758. Yang, Z. Q., J. C. Barrow, W. D. Shipe, K. A. Schlegel, Y. Shu, F. V. Yang, C. W. Lindsley et al. 2008. Discovery of 1,4-substituted piperidines as potent and selective inhibitors of T-type calcium channels. J Med Chem 51 (20): 6471–6477. Yap, Y. G., E. R. Behr, and A. J. Camm. 2009. Drug-induced Brugada syndrome. Europace 11 (8): 989–994. Zareba, W., and I. Cygankiewicz. 2008. Long QT syndrome and short QT syndrome. Prog Cardiovasc Dis 51 (3): 264–278. Zehelein, J., D. Thomas, M. Khalil, A. B. Wimmer, M. Koenen, M. Licka, K. Wu et al. 2004. Identiἀcation and characterisation of a novel KCNQ1 mutation in a family with Romano–Ward syndrome. Biochim Biophys Acta 1690 (3): 185–192.
Cocaine-Induced Seizures, Arrhythmias, and Sudden Death
11
Claire M. Lathers Michelle M. Spino Isha Agarwal Laurie S. Y. Tyau Wallace B. Pickworth
Contents 11.1 Introduction 11.2 Mechanisms of Action of Cocaine 11.3 Cocaine-Induced Sudden Death 11.3.1 Cocaine-Induced Changes in Mean Arterial Blood Pressure and Heart Rate 11.3.2 Cocaine-Induced Myocardial Ischemia, Infarction, Arrhythmia, and Cardiomyopathies 11.3.3 Cocaine-Induced Changes in Postganglionic Cardiac Sympathetic Neural Function 11.3.4 Central Actions of Cocaine 11.3.5 Cocaine-Induced Seizures 11.4 Treatment of Cocaine-Induced Arrhythmias and Seizures 11.5 Use of Cocaine in Persons with Epilepsy 11.6 Summary References
169 170 172 172 174 176 176 179 180 181 181 182
11.1â•…Introduction The presence of coca leaves in the tombs of South American Indian mummies suggests that cocaine was used as early as a .d. 600. The use of cocaine is prevalent in modern society. Cregler and Mark (1986a) reviewed the demographics of current cocaine users and found that approximately 1 out of every 10 Americans, have used cocaine at least once (Cregler and Mark 1987). The fallacy that cocaine is a benign, nonaddicting substance may be part of the reason for the alarming rise in abuse (Cregler and Mark 1986b). Although cocaine has been found to be a cardiotoxin, the pathogenesis of this toxicity is not well deἀned (Cregler and Mark 1987). Cocaine use has also been linked to the occurrence of subarachnoid hemorrhage, hypertension, ventricular arrhythmia, tachycardia, acute myocardial infarction, seizure, and sudden death (Lichtenfeld et al. 1984; Nahas et al. 1985; Tazelaar et al. 1987; Young and Glauber 1947). Persons with epilepsy have been shown to manifest autonomic dysfunctions similar to those manifested by cocaine users, 169
170 Sudden Death in Epilepsy: Forensic and Clinical Issues
including changes in blood pressure and heart rate and rhythm, phenomena that may be contributory to sudden unexpected death (Leestma et al. 1984; Penἀeld and Erickson 1941; Phizackerly et al. 1954; Walsh et al. 1968). Thus, one must ask whether the use of cocaine in individuals with epilepsy places these individuals at risk of dying in a sudden unexplained manner.
11.2â•…Mechanisms of Action of Cocaine Cocaine (Figure 11.1), extracted from the leaves of Erythroxylon coca, is a potent local anesthetic agent (Cregler and Mark 1986a; Gould et al. 1985) possessing membrane-stabilizing effects at low plasma levels (Tazelaar et al. 1987). It is also a sympathomimetic agent at higher plasma concentrations (Benchimol et al. 1978; Duke 1986). Cocaine ampliἀes the effect of catecholamines by blocking the reuptake at the synaptic junctions, causing a local excess of norepinephrine at the synaptic cleft. As a result of the excess of norepinephrine at the nerve terminal, there is a prolongation and potentiation of the activity of norepinephrine (Weiss 1986). Norepinephrine is the primary neurotransmitter of the sympathetic nervous system. Excitation of the sympathetic nervous system produces physiological characteristics, such as mobilization of adrenal catecholamines, causing an increase in blood pressure and the heart rate, dilatation of the pupils, a rise in blood sugar levels, vasoconstriction of vessels in the brain and muscles, tightening of the sphincters, and an elevation of body temperature. The intense peripheral vasoconstriction retards reabsorption. Drug effects include intense euphoria and elation, garrulousness, excitability, and irritability; with repeated administration, paranoid ideation, delirium, and assaultiveness occur. Table 11.1 summarizes the actions of cocaine on the cardiovascular, respiratory, and central nervous system (Gay 1982). Cocaine as a hydrochloride salt is brought into the United States with purity ranging up to 95% (Gay 1982). The purity is decreased to 25–90% of its original state through the addition of diluents and adulterants such as procaine, lidocaine (Cregler and Mark 1986b), caffeine, benzocaine, amphetamines, heroin, quinine, talc, and phencyclidine. All adulterants contribute to the toxicity of cocaine. Finally, it is combined with sugars such as mannitol, lactose, and glucose to attain a ἀnal volume and weight (Gay 1982). The resulting cocaine street product can be administered by various routes, including intravenous and subcutaneous injections, intranasal inhalation (snorting), and the current vogue of smoking a “freebase” form of cocaine (crack). Freebase smoking or intravenous injections of
CH3 N
COOCH3
OOCC6H5 H
Figure 11.1╇ Structure of cocaine (C17 H 21NO4).
Cocaine-Induced Seizures, Arrhythmias, and Sudden Death
171
Table 11.1â•… The Cocaine Reaction Phase I: Early stimulation
II: Advanced stimulation
III: Depressive
Central Nervous System
Cardiovascular System
Euphoria: stated feelings of “soaring,” well-being Elation, expansive good humor, laughing, mydriasis Talkative, garrulous Excited, flighty, emotionally unstable Restless, irritable, apprehensive, unable to sit still Stereotyped movements (such as “picking” or “stroking”), bruxism Nausea, vomiting, vertigo Sudden headache Cold sweats Tremor (nonintentional) Twitching of small muscles, especially of the face, ἀngers, and feet Tics, generalized Preconvulsive, tonic and clonic jerks Possible psychosis, hallucinations Core body temperature rises Verbalization of impending doom (precedes imminent total collapse) Unresponsive to voice; decreased responsiveness to all stimuli Increased deep tendon reflexes Generalized hyperreflexia Convulsions: tonic and clonic Status epilepticus Incontinence Malignant encephalopathy possible
Pulse vanes at ἀrst, may immediately slow because of reflex vagal effect; will increase 30% to 50% above normal with system absorption of 25 mg of cocaine Blood pressure usually elevates 15% to 20% above normal with similar dosages as noted above Skin pallor caused by vasoconstriction Premature ventricular contractions
Increased respiratory rate and depth Dyspnea
Increased pulse and blood pressure: high output failure possible Blood pressure falls as ventricular dysrhythmias supervene and inefficient cardiac output results Pulse becomes rapid, weak, and irregular Peripheral, then central cyanosis Ventricular ἀbrillation Circulation failure Ashen gray cyanosis No palpable pulse Cardiac arrest Paralysis of medullary brain center Exitus
Gasping, rapid, or irregular respiration (Chevne–Stokes)
Flaccid paralysis of muscles Coma Pupils ἀxed and dilated Loss of reflexes Loss of vital support functions Paralysis of medullary brain center Exitus
Respiratory System
Agonal gasps Respiratory failure Gross pulmonary edema Paralysis of medullary brain center Exitus
cocaine cause a euphoric or “rush” experience, which occurs within 45 s and is associated with a rapid increase in plasma cocaine concentrations. The effect lasts for approximately 20 min. In contrast, intranasal administration results in euphoria occurring within 3 to 5 min of administration and lasts for 1 to 1.5 h (Van Dyke and Byck 1983). Regardless of the route of administration, accounts of cocaine-induced sudden death have become common.
172 Sudden Death in Epilepsy: Forensic and Clinical Issues
11.3â•…Cocaine-Induced Sudden Death Sudden death has been shown to be induced by cocaine (Amon et al. 1986; Estroff and Gold 1986; Mittleman and Welti 1987; Welti and Fishbain 1985). Reports indicate 1.2 g to be a lethal dose; however, severe toxic effects have been reported with doses as low as 20 mg (Estroff and Gold 1986). Because it is so sudden, medical personnel do not ordinarily witness cocaineinduced death; victims usually collapse and die before resuscitation efforts can begin. Confusion or convulsions precede death induced by cocaine. Estroff and Gold (1986) reported seven cases of sudden death associated with the use of cocaine, in whom a state of excited delirium was the fatal symptom. The initial symptom was intense paranoia, followed by bizarre and violent behavior necessitating the use of force to restrain the patient. The unexpected outbursts of strength were associated with hyperthermia, which was thought to be due to a direct effect of cocaine on the central nervous system center for temperature regulation, and due to peripheral vasoconstriction, with resultant reduction in heat (Ritchie and Greene 1980). Status epilepticus, respiratory paralysis, or cardiac arrhythmias genrally precede sudden death induced by cocaine. Abramowicz (1986) suggested that most sudden deaths associated with cocaine use are caused by seizures leading to anoxia. Recent clinical data have been correlated with pathological ἀndings, generating several hypotheses that attempt to deἀne forensically the pathological mechanisms of cocaine-induced sudden death. 11.3.1â•…Cocaine-Induced Changes in Mean Arterial Blood Pressure and Heart Rate The circulatory effects of cocaine are believed to be of both central and peripherally induced vasoconstriction and cardioacceleration (Young and Glauber 1947). Change in heart rate is a sensitive measure of cocaine-induced cardiovascular effect (Fischman et al. 1976). Cocaine results in dose-related changes in heart rate (Javiad et al. 1978), with small doses decreasing heart rate via central vagal action and moderate doses increasing heart rate via atrial and peripheral sympathetic stimulation (Benchimol et al. 1978). Extremely high intravenous doses have direct toxic effects on the heart and cause immediate death (Nanji and Filipenko 1984; Young and Glauber 1947). The duration of the cardiovascular action is dependent on the dose of cocaine. Fischman et al. (1976) showed that an increase in heart rate was evident after intravenous injections of varying doses of cocaine; the increase began 2–5 min after infusion, peaked at 10 min, and rapidly returned to baseline (Figure 11.2). Cocaine also increased blood pressure in a dose-related manner, but more variability is seen in this measure. In one study (Pitts et al. 1987), cocaine was administered intravenously and evoked a rapid, transient, dose-dependent rise in mean arterial pressures (Figure 11.3). Jain et al. (1987) reported that the administration of cocaine (0.25 mg/kg, i.v.) to anesthetized cats increased systolic and diastolic blood pressure by 33 ± 11 and 31 ± 7 mm Hg, respectively. The dose also enhanced the pressor responses to intravenous norepinephrine and to bilateral carotid occlusion. Doses of 0.5 and 1.0 mg/kg (i.v.) also caused an increase in blood pressure and responses to intravenous norepinephrine but did not increase the blood pressure response to bilateral carotid occlusion. Higher doses had no additive effect on the blood pressure, but rather slowed the heart rate, attenuated blood pressure responses to norepinephrine, prolonged the QRS duration, and decreased tidal volumes. All effects
Mean heart rate (beats/min)
Cocaine-Induced Seizures, Arrhythmias, and Sudden Death 120 115 110 105 100 95 90 85 80 75 70 65 60 55 50
173 4 mg 8 mg 16 mg 32 mg Saline
Pre-drug
0
8
16
24
32
40
48
56
Time since drug injection (min)
Figure 11.2╇ Mean heart rate as a function over time after cocaine is injected. 40 20 (a)
0 –20 –40 –60
Mean percent change
40 20 (b)
0 –20 –40 –60 40 20
(c)
0 –20 –40 –60
0
M 1
2
3
5 10 15 30
(min)
Figure 11.3╇ Time course for the cardiovascular and respiratory effects of three different doses of
cocaine: 0.312, 1.25, and 5 mg/kg (i.v.) depicted in (a) (N = 6), (b) (N = 5), and (c) (N = 4), respectively. The ordinate scale is percentage of change and the abscissa scale is time in minutes. M€= period during maximal pressor response. Squares represent mean values for arterial pressure. Vertical lines represent standard error of the mean. All animals were anesthetized with pentobarbital (6.5 mg/kg, i.p.). (From Pitts, D.K., Udom, C.E., and Marwah, J., Life Sci., 40, 1099–1111, 1987.)
174 Sudden Death in Epilepsy: Forensic and Clinical Issues
were increased after a dose of 4 mg/kg or greater of cocaine i.v., with arrhythmias occurring with 4 and 8 mg/kg. Doses as low as 0.25 mg/kg (i.v.) evoked substantial cardiovascular responses and lethal responses of apnea. In another study, the administration of cocaine intravenously to conscious rats increased arterial blood pressure (Rockhold et al. 1987). The heart rate was elevated initially but subsequently was decreased. With the onset of cocaine-induced seizures, a further elevation in heart rate and blood pressure occurred, ultimately progressing to cardiovascular collapse and death. Preliminary studies utilizing intravenous administration of cocaine to anesthetized dogs elicited a dose-dependent increase in blood pressure and heart rate and alterations in the ST segment (Tackett and Jones 1987). These changes were associated with elevated cerebrospinal fluid levels of norepinephrine and dopamine, ἀndings that suggest a role for central catecholaminergic mechanisms in the cardiovascular actions of cocaine. Therefore, as cocaine raises the blood pressure and heart rate to excessively high levels, there is an increased risk of aneurism, arteriovenous malformation, and stroke or hemorrhage from ruptures of cerebral arteries weakened by drug-related arteritis. 11.3.2â•…Cocaine-Induced Myocardial Ischemia, Infarction, Arrhythmia, and Cardiomyopathies There has been a recent and dramatic increase in cardiac abnormalities among cocaine users (Duke 1986; Wiener and Putnam 1987; Wiener et al. 1986) that has raised questions concerning the effect of cocaine on the cardiovascular system. Indeed, cocaine is clearly cardiotoxic, being temporally linked to myocardial ischemia, arrhythmias, and many cardiomyopathies. Cocaine use in the presence of preexisting coronary artery disease may predispose the individual to the development of angina, arrhythmias, or myocardial infarction (Coleman et al. 1982; Young and Glauber 1947). It is possible that a patient with hypercholesterolemia who is using cocaine may be further increasing the likelihood of coronary artery spasm (Rosendorff et al. 1981), leading to myocardial ischemia and necrosis. Numerous cases of suspected cocaine-induced myocardial ischemias and infarctions have been reported (Isner et al. 1985, 1986; Kassowsky and Lyon 1984; Mathias 1986; Rod and Zucker 1987; Rollingher et al. 1986; Schachne et al. 1984; Simpson and Edwards 1986). Simpson and Edwards (1986) reported a case of a 21-year-old man with a history of recreational intravenous cocaine abuse who developed chest pain within 1 min and cardiopulmonary collapse within 1 h after injection of cocaine. Postmortem ἀndings revealed severe coronary obstructive lesions and acute platelet thrombosis, with secondary chronic and acute myocardial ischemic lesions, focal endothelial injury, and platelet aggregations being observed. The author proposed that coronary artery spasm induced by cocaine caused the endothelial lesions and favored platelet adherence and aggregation. The chronic obstructions that were also found may have resulted from a similar mechanism. According to Weiss (1986), ἀxed coronary atherosclerotic lesions play a permissive role in the induction of coronary vasospasm. It has been proposed that the ability of both intrinsic atherosclerotic plaques and cocaine-induced norepinephrine uptake blockade increases local levels of catecholamine, producing coronary vasospasms. Furthermore, preexisting coronary artery disease sensitizes the vascular smooth muscle to norepinephrine-induced vasoconstriction, predisposing the cocaine user to life-threatening ischemia (Gould et al. 1985; Weiss 1986). Also, with chronic cocaine abuse, the excessive accumulation of norepinephrine may prime the myocardium for a fatal arrhythmia (Tazelaar et al. 1987).
Cocaine-Induced Seizures, Arrhythmias, and Sudden Death
175
Cocaine increases the local concentrations of catecholamines from blocked adrenergic nerve endings to other cell receptors by inhibiting the neuronal uptake of norepinephrine. Thus the adrenergic response in susceptible organs is increased, leading to the development of catecholamine supersensitivity (Benchimol et al. 1978; Trendelenburg 1968). Therefore, cocaine is capable of eliciting both an inhibitory and an excitatory response of sympathetically innervated structures to endogenous and exogenous catecholamines (Pitts et al. 1987). It has also been suggested that cocaine accentuates the action of norepinephrine on beta receptors in the heart (Nanji and Filipenko 1984) by increasing the concentration of norepinephrine at the synaptic cleft. Beta stimulation increases automaticity, heart rate, and the conduction velocity of the His–Purkinje system and decreases atrioventricular nodal refractoriness (Tazelaar et al. 1987). Tazelaar et al. (1987) characterized cocaine-induced pathophysiology in a postmortem study of 30 cocaine-related deaths. Morphologic characteristics of acute ischemia were observed in 93% of the cases. These involved the formation of myocardial contraction bands in association with polymorphonucleocytes in the initial 12–24 h; they were replaced with lymphocytes by 24–48 h. The formation of contraction bands and myocardial interstitial ἀbrosis may be one pathogenic mechanism for fatal arrhythmias. These contraction bands may also represent an anatomical route for reentrant mechanism, thus priming the heart for fatal arrhythmias. It is quite possible that arrhythmias may be generated by cocaine through a decrease in the refractoriness of the myocardial ἀbers, accumulation of excess norepinephrine, formation of contraction bands, and production of interstitial ἀbrosis. Cocaine causes myocardial ischemia by direct and indirect actions (Vitullo et al. 1987). Direct effects are the stimulation of the sinoatrial node, with an increase in heart rate, contractility, and wall tension. Indirectly, the effects can be due to the sympathetic vasoconstriction of the peripheral smooth muscle vasculature. Arterial vasoconstriction leads to an increase in afterload and blood pressure, which, in turn, increases the work that the heart must pump against. Both the direct and the indirect actions increase the oxygen consumption of the myocardium, with an ischemic event occurring when the demand for oxygen supersedes the supply (Tyau and Lathers 1988). Pasternack et al. (1985) reported three male patients in their middle to late thirties who were referred for coronary angiography after having angina pectoris and/or an acute myocardial infarction, coincident with an increase in the frequency of cocaine abuse. The onset of angina and acute myocardial infarctions may have been caused by a cocaineinduced potentiation of the activities of the central nervous system resulting in systemic hypertension and tachycardia. Isner et al. (1986) reported a temporal relationship between cocaine and cardiac sequelae in seven nonintravenous cocaine abusers. It was concluded that cocaine may precipitate fatal arrhythmias, myocarditis, acute infarctions, and possible sudden death in patients with either anatomically normal or abnormal coronary arteries. In these cases there was a temporal relationship between the administration of cocaine and the onset of a myocardial ischemia and/or infarction. Because of many other medical factors involved, it is difficult to discern the actual etiological mechanisms of the infarctions. However, in a case report by Howard et al. (1985), a young woman with normal coronary arteries, blood glucose, and lipid levels and no history of cardiovascular disease or smoking was admitted to the hospital for loss of consciousness and epigastric pain; 5€h earlier, she had inhaled 1.5 g of cocaine. On admission, an ECG showed precordial ST segment elevation and a loss of R waves. On the day following admission, an echocardiography revealed akinesis and dyskinesis of the left ventricle apex and septum. In this
176 Sudden Death in Epilepsy: Forensic and Clinical Issues
healthy individual with no coronary risk factors or demonstrable coronary artery disease, infarction occurred. This ἀnding suggests that cocaine-induced myocardial infarctions should be considered when examining individuals who may not appear to be vulnerable. The cardiovascular events produced through cocaine abuse can be seen to involve a range of pathological responses, including coronary vasospasm, arrhythmia, myocardial ischeÂ� mia, infarction, and cardiomyopathies. Therapeutic use of cocaine is not without risk. For example, Chiu et al. (1986) reported a patient who was anesthesized for a closed reduction of a nasal fracture by spraying 2 ml of 1% cocaine solution into the nasal airways. The patient complained of an acute onset of chest pain and shortness of breath. An electrocardiogram indicated ST-T wave changes in the precordial leads, suggestive of an acute coronary ischemic event. The rise in the MB creatine kinase fraction and reversed LDH isoenzyme fractional values were consistent with a small nontransmural myocardial infarction. The published accounts of cardiovascular events, myocardial infarction, and mortality related to cocaine use as described here and consist mostly of case reports (Loveys 1987). Experimental research looking into the cardiovascular effects of cocaine is warranted. 11.3.3â•…Cocaine-Induced Changes in Postganglionic Cardiac Sympathetic Neural Function Cocaine potentiates the ganglionic blocking action of norepinephrine (Christ et al. 1982). In the isolated hamster stellate ganglia preparation, cocaine exaggerated the inhibitory action of exogenously applied norepinephrine. In pithed rats, cocaine potentiated the pressor effect of norepinephrine more than it potentiated the pressor effect of sympathetic stimulation (Bayorh et al. 1983). Cocaine increased plasma norepinephrine levels and extended the inotropic and chronotropic responses to sympathetic neural stimulation in anesthetized dogs (Matsuda et al. 1980). These actions were attributed to the inhibition of the neuronal catecholamine uptake by cocaine (Matsuda et al. 1980). It is possible that cocaine-induced exaggeration of sympathetic discharge may enhance the arrhythmias experimentally caused by ouabain (Lathers et al. 1977), coronary occlusion (Lathers et al. 1978), and seizures (Lathers and Schraeder 1982; Schraeder and Lathers 1983). Experimental arrhythmias are hypothesized to be a useful model to study possible mechanisms of sudden death associated with myocardial infarctions (Lathers et al. 1986) and epilepsy (Lathers and Schraeder 1987; Schraeder and Lathers 1989). Consequently, any changes induced by cocaine in cardiac sympathetic neural discharge may well augment the development of arrhythmias and/or sudden death. On the other hand, Dart et al. (1983) demonstrated that stimulation of postganglionic cardiac sympathetic nerves in a Langendorff rat–isolated heart preparation produced a stimulation frequency-dependent overflow of endogenous norepinephrine into the venous effluent with an increase in the heart rate. Cocaine signiἀcantly reduced the norepinephrine outflow while the heart rate continued to increase. 11.3.4â•…Central Actions of Cocaine Many of the effects of cocaine result from actions in the central nervous system. Cocaineinduced euphoria, for example, was among the ἀrst effects described (Freud 1884) and is the most well-known central effect. Generalized convulsions, which often precede
Cocaine-Induced Seizures, Arrhythmias, and Sudden Death
177
cocaine-induced death, unfortunately are less well-known outside the medical community. It has been shown that seizures are a major determinant of cocaine-induced death (Catravas and Waters 1981; Catravas et al. 1978). The common concomitants of generalized seizures, including hyperthermia, acidosis, increased blood pressure, cardiac arrhythmia, and hypoventilation, may be responsible for the lethality. In animal studies, many of the effects of cocaine have been localized to limbic structures. For example, Castellani et al. (1983) found that cocaine initiated high-voltage spindles that began in the amygdala 5–25 s after the injection of cocaine (Figure 11.4) and spread within seconds to other olfactory sites in synchronous bursts. Cocaine induced an increase in spindle frequency in the olfactory bulb and amygdala that was inhibited by atropine administration. Yasuda et al. (1984) reported that low concentrations of cocaine potentiated a norepinephrine-induced increase in spike amplitude of hippocampal splices. The authors concluded that the action was due to the inhibition of catecholamine uptake based on the observation that other inhibitors had the same effect. Lesse and Collins (1979) found that cocaine increased the speed at which epileptiform discharges spread to the amygdala and hippocampus. They postulated that subconvulsive doses of cocaine have an excitatory effect on limbic structures, which increases their sensitivity to repetitive discharges from distant foci. Matsuzaki (1978) reported that chronic high doses of cocaine in the rhesus monkey engendered persistent behavioral depression, with cortical and limbic slowing of EEG. They concluded that it was the action of cocaine on limbic structures that played an important role in the persistence of these effects. Overall, the evidence indicates that cocaine enhances the propagation of limbic seizures. Since such activity has been associated with cardiac arrhythmia (Lathers and Schraeder 1982; Schraeder and Lathers 1983), it is quite possible that cocaine-induced seizures could be a factor in the deaths of persons using the drug. The cortical EEG effects of cocaine in humans were among the earliest documented effects of the drug (Berger 1937). Cocaine increases power in the fast frequency (beta bands) of the resting EEG after subcutaneous, intravenous, or oral administration (Berger 1937; Herning et al. 1985). Four-hour intravenous infusions of high doses of cocaine in humans sustains the increase in EEG beta power (Pickworth et al. 1986). The increase of power in
1 min after injection
7th week after cocaine initiation
µV/mm 15
L OLF BULB
7.5
R OLF BULB
7.5
L AMYG
15
R AMYG
10
L OLF TUB
7.5
L ACCUMB 1s
10 mm
Figure 11.4╇ Electrographic amygdala–olfactory spindling and spike response to 5 mg/kg (i.v.) cocaine during preseizure behaviors.
178 Sudden Death in Epilepsy: Forensic and Clinical Issues
the fast EEG frequency bands is ordinarily associated with increased attention, vigilance, or arousal. Pickworth et al. (1986) measured subjective, cardiovascular, and EEG effects of large (60 mg) intravenous doses of cocaine in human volunteers. Although the subjective report of “rush” lasted for only a few moments, the pressor effect and tachycardia persisted for up to 60 min (Figure 11.5). The rush, or intense cocaine-induced euphoria, is the effect for which the drug is self-administered. It is quite probable that inadvertent overdosage may occur when subjects readminister cocaine at a time when the cardiovascular and central nervous systems are at jeopardy. In reviewing the effect of cocaine on the electrophysiology of the central monoaminergic neurons, Pitts and Marwah (1986) found that intravenous cocaine activated cerebellar Purkinje neurons and inhibited serotonergic dorsal raphe and noradrenergic locus coeruÂ� leus neurons. The authors concluded that cocaine-induced increases in the mean arterial blood pressure were correlated with changes in the discharge of the central neurons. Pitts and Marwah (1987) also found that reserpine pretreatment diminished the inhibitory effects of intravenous cocaine on neuronal discharges in the locus coeruleus and dorsal raphe as well as the excitatory action of cocaine on the cerebellar Purkinje neurons. Thus, although stimulation of the inhibitory locus coeruleus afferent input to the cerebellar Purkinje neurons can reduce the activity of the Purkinje neurons via a betaadrenoceptor mechanism, intravenous cocaine (1 mg/kg) did not precipitate the inhibitory actions of locus coeruleus stimulation on cerebellar Purkinje neurons. This dose of cocaine also did not potentiate the inhibitory effects of iontophoretically applied norepinephrine or GABA on cerebellar Purkinje neurons. Locus coeruleous neurons were inhibited by intravenous cocaine (1 mg/kg) in conscious animals paralyzed with gallamine. It was proposed that intravenous cocaine (1 mg/kg) reduced impulse flow in locus coeruleus neurons, possibly through an alpha2-autoreceptor mechanism, without augmenting the effect
Systolic pressure (mm Hg)
4
120
160
105
150
90
140
2
75
130
1
60
120
0
Heart rate (beats/min) “Rush”
–30
–15
0 Cocaine
15
30
45
60
75
3
90
105
120
135
150
Time (min)
Figure 11.5╇ Effects of intravenous cocaine (60 mg) in seven drug-experienced volunteers. The high dose caused a transient “rush” (drug-induced euphoria) but prolonged increases in blood pressure and heart rate.
Cocaine-Induced Seizures, Arrhythmias, and Sudden Death
179
of norepinephrine at the level of the noradrenergic terminals impinging on postsynaptic cerebellar Purkinje neurons. The action of cocaine on norepinephrine-containing locus coeruleus neurons was also evaluated in freely moving, unanesthetized cats (Trulson and Trulson 1987). Cocaine eÂ�licited a dose-dependent reduction in the activity of the neurons, which was suppressed by a prior administration of an alpha2 antagonist, piperoxane. Also, the activity of the locus coeruleus remained unchanged by the administration of the structurally related local anesthetic agent procaine. It was concluded that the local anesthetic actions of cocaine were not the inhibitory factor in its effect on the activity of norepinephrine-containing nÂ�eurons. Nevertheless, as Yasuda et al. (1984) stated, “It is remarkable that its effects upon the electrophysiological activity of the brain remain virtually unknown.” Whether cocaineiÂ�nduced changes in the activity of central neurons contributes to sudden death remains to be determined. 11.3.5â•…Cocaine-Induced Seizures Seizures have been shown to play an essential role in the pathophysiology of cocaine toxicity. A major determinant of lethality in cocaine-treated dogs was the presence of seizures (Catravas and Waters 1981; Catravas et al. 1978). Cocaine infusions produced prolonged seizures that led to lactic acidosis and hyperthermia prior to death while cardiac output, systemic vascular resistance, respiration, and oxygenation were stable just prior to death. Seizures and death could have been prevented with pretreatment using diazepam, highdose chlorpromazine, or neuromuscular blockade with pancuronium (Antelman et al. 1981; Fekete and Borsy 1971). The use of diazepam is particularly important since it also counteracts the sympathomimetic action of cocaine on the heart. Treatment of acidosis alone did not prevent death, unless the animals were maintained in a hypothermic state. Jonsson et al. (1983) reported one patient who, as a result of cocaine intoxication, showed combined metabolic and respiratory acidosis consequent to seizures and hypoventilation. Improved ventilation and the administration of bicarbonate reversed the hypotension and accelerated idioventricular rhythm to sinus rhythm. Blood pH increased from 6.33 to normal and the pCO2 decreased from 70 to 46 mm Hg. Jonsson et al. concluded that respiratory arrest compounded the acidosis in patients intoxicated with cocaine and may have contributed signiἀcantly to their deaths. Acidosis has a particularly negative effect on myocardial contractility (Fabiato and Fabiato 1978; Spivey et al. 1985) and acidosis can heighten the effects of catecholamines on the heart (Ford et al. 1968; Lathers et al. 1988; Spivey et al. 1985), and thereby contribute to the initiation of arrhythmias by cocaine. Carbamazepine is an antiepileptic drug that seems to be particularly effective in treating limbic system seizures. In experimental studies, repeated high doses of cocaine produce a convulsive response classiἀed as pharmacologic kindling. Weiss et al. (1987) reported that chronic carbamazepine administration inhibited the development of lidocaine- or cocaine-kindled seizures and lethality. Chronic, but not acute, pretreatment with carbaÂ� mazepine inhibited the high-dose cocaine seizures. It was suggested that carbamazepine may interact with local anesthetic mechanisms mediating the progressive development of seizures and that the effects of this antiepileptic drug at the level of the sodium channels should be further explored since both carbamazepine and the local anesthetics are believed to interact at this site. Investigation of the mechanism responsible for this effect should be undertaken, as it may prove clinically useful in preventing cocaine toxicity.
180 Sudden Death in Epilepsy: Forensic and Clinical Issues
11.4â•…Treatment of Cocaine-Induced Arrhythmias and Seizures Treatment of cocaine toxicity must ultimately involve deconditioning therapy to reduce drug craving and drug-seeking behavior (Kumor et al. 1988). Tricyclic antidepressants, bromocriptine, amantadine, methylphenidate, and lithium may decrease cocaine selfmedication. The hypertension and tachycardia that follow administration of cocaine are mediated by both alpha-adrenergic and beta-adrenergic receptors to induce vasoconstriction and an increase in heart rate and cardiac output, respectively (Olsen et al. 1983). One clinical management procedure of the adrenergic cocaine crisis involves the judicious use of intravenous propranolol, given in doses of 1 mg at 1-min intervals to a total of up to 6€mg (Gay 1982). Although intervention calms the excitable patient and decreases tachyÂ� arrhythmias, the efficacy of propranolol is limited by its receptor sensitivity. It has been argued that although propranolol effectively blocks beta receptors to decrease heart rate, it leaves the alpha-adrenergic receptors unopposed (Olsen et al. 1983). Thus stimulation of the alpha1-adrenergic receptors in the smooth muscle vasculature results in a worsening of vasoconstriction with resultant dangerous hypertension. Olsen et al. (1983) propose the use of phentolamine or nitroprusside to effect rapid vasodilatation. However, Gay (1983) argues that the nonselective alpha-adrenergic blockade properties of phentolamine may, in fact, further aggravate matters. Indeed, phentolamine will block alpha1 postsynaptic receptors to decrease vasoconstriction, but it will also block alpha2 presynaptic receptors. This blocks the normal regulatory control of the catecholamines, resulting in an increase in synthesis and output of norepinephrine, and may even spur a reflex sympathetic response to the heart. One agent recently used to treat cocaine toxicity is labetalol, which possesses both alpha- and beta-blocking capabilities. Thus the establishment of the alpha blockade counters the cocaine-induced vasoconstriction and hypertension while the beta blockade decreases the tachyarrhythmias (Gay and Loper 1988). The use of chlorpromazine and haloperidol to calm the hyperkinetic state is contraindicated in the cocaine user as they can lower seizure threshold activity and cause cardiac arrhythmias and/or sudden death (Lathers and Lipka 1986, 1987; Lipka and Lathers 1987). Instead, an effective means of quieting the stimulatory phase of cocaine intoxication is the use of diazepam, 15–20 mg orally every 8 h. Antelman et al. (1981) serendipitously found that amytriptiline, a tricyclic antidepressant, protected against sudden cardiac death due to cocaine intoxication in animals. Amytriptiline, 10 mg/kg, administered experimentally in animals 1 h before intraperitoneal injection of cocaine (35 mg/kg) resulted in no protection against sudden death. However, 24-h pretreatment with a single injection of amytriptiline markedly increased survival, while 10-day pretreatment conferred complete protection against sudden death. The mechanism of action, to date, has not been deἀned. However, pretreatment is not a useful tool in the management of clinical toxicity associated with cocaine use. It has recently been suggested that Ca2+ channel blockers may be a useful antidote for cocaine toxicity (Duke 1986; Mittleman and Welti 1987; Trouve and Nahas 1986). Ca2+ channel blockers inhibit the vasoconstrictive effects of norepinephrine by blocking the release of Ca2+ into the smooth muscle of the vasculature. Trouve and Nah